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 Abstract 
 
This thesis describes the application of compartmental modelling techniques to data 
from human intervention studies with the objective of studying the absorption and 
metabolism of minerals (iron, copper, calcium) and vitamins (folate, carotenoids, 
riboflavin) labelled with stable isotopes. Compartmental modelling is a mathematical 
tool that uses differential equations to describe a dynamic process, such as nutrient 
metabolism, by adjusting the parameters of the equations until the model is a good fit 
to the real experimental data. 
 A single compartment model was developed that can be used to estimate the quantity 
of absorbed (unlabelled) iron from a test drink containing a minimum of 10mg iron. 
Studies on copper demonstrated that approximately 74% of the absorbed dose is 
sequestered by the liver on “first-pass” and that large quantities of copper (2.4mg/d) 
are lost via the bile. Data from a calcium intervention trial was evaluated using a 
multi-compartment model and indicated that a moderately high salt intake (11.2g/d) 
was associated with a significantly negative bone calcium balance with a high calcium 
(1284mg/d) compared to a low calcium (518mg/d) diet (P=0.024). Modelling the 
initial metabolism of an absorbed dose of 13C-labelled folic acid resulted in the 
finding that it is not metabolised in the mucosal cells but (probably) in the liver. The 
absorptive efficiency of carotenoids was investigated by isolating the triglyceride rich 
lipoprotein fraction in plasma and a simple model was used to estimate β-carotene and 
lutein bioavailability. Results from the first stable isotope labelled riboflavin study 
indicated that the bioavailability of riboflavin from spinach (60±30%) was not 
significantly different to the bioavailability of riboflavin derived from milk (67±21%). 
The thesis has shown how compartmental modelling, in conjunction with stable 
isotope labelling, can reveal new insights into human mineral and vitamin 
metabolism, especially in the study of nutrient bioavailability. 
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 1. Introduction 
 
 
Organisation and Aim of the Thesis 
The thesis begins with an introduction of the definition and historical use of stable 
isotopes and compartmental modelling. This is followed by a critical analysis of the 
development of the submitted publications (see Appendix B) and their impact on the 
field of human nutrition. It is divided into six sections that describe the work 
undertaken on a particular mineral or vitamin and demonstrates the author’s unique 
contribution, to each area. The aim of the thesis is to show how compartmental 
modelling, in conjunction with stable isotope labelling, can reveal new insights into 
human mineral and vitamin metabolism, especially in the study of nutrient 
bioavailability. 
  
Stable Isotopes 
Most minerals have several, naturally occurring stable isotopes, all with a fixed 
abundance in nature. Vitamins are compounds that are made from several elements 
but they also have a fixed molecular mass (abundance).To study the in vivo 
metabolism of a mineral or vitamin, it is necessary to ingest it in an altered form so 
that it can be distinguished from the naturally occurring nutrient. The form of a 
mineral can be altered by enriching one of its low abundance isotopes. The alteration 
in the mass of a vitamin is more complex and involves changing one or more of its 
naturally occurring elements, from the higher to the lower abundance isotope (e.g. 12C 
to 13C). Whilst carbon is a popular choice for alteration, hydrogen (1H to 2H), nitrogen 
(14N to 15N) and oxygen (16O to 18O) are also good candidates. The “new” form of the 
mineral or vitamin is known as a “tracer” or “label” and can be injected and/or taken 
orally. The concept of a tracer is important in isotope work. A true tracer is one that 
does not perturb the system it is investigating. Only radioisotopes can be called true 
tracers since they are administered in extremely small quantities. The term “label” is 
more appropriate for stable isotopes because they are usually given in quantities 
equivalent to the amount received in the normal diet. The word “tracer” is, however, 
still used in some stable isotope studies with the implicit understanding that it will 
almost certainly perturb the system under investigation. The underlying assumption in 
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 this type of work is that the label (or tracer) behaves in the same kinetic way as the 
naturally abundant nutrient (sometimes called the tracee), otherwise the use of labels 
to mimic the behaviour of the native mineral or vitamin is invalid. There must be no 
discrimination by the body between the two forms of the nutrient. 
 
The use of tracers (labels) allows the nutrient to be monitored in the plasma, urine and 
faeces over several days or weeks depending on the “enrichment” in vivo and the 
precision of the mass spectrometer that is measuring the study samples. Enrichment is 
another important concept in stable isotope experiments. There is a large, endogenous 
background concentration of most elements in plasma, urine and faeces and the dose 
of tracer needs to be of a sufficient quantity that the mass spectrometer can detect it 
with good precision against the “natural” background. Enrichment can be defined as 
the ratio of the quantity of tracer (or label) to quantity of naturally abundant nutrient, 
in the measured sample. Good mass spectrometer measurement quality is vital for the 
accuracy and precision of the resultant model and the measurement precision needs to 
be known before the experiment is designed so that an effective dose size can be 
ascertained. Depending on the nutritional hypothesis that is being investigated, 
designing an experiment that takes samples for days, rather than hours, usually reveals 
more features of the underlying metabolism. It is, therefore, very important to 
simulate the combination of dose size, mass spectrometer precision and different 
sampling times to achieve the optimal (theoretical), experimental design. In designing 
a study, it is important to avoid administering a nutrient dose that would exceed the 
reference nutrient intake (RNI), as the subsequent metabolism of the absorbed nutrient 
might be different from that of a dose in the “normal” range and the results of the 
study could not be generalised to the wider population. Simulated mass spectrometer 
data can also be generated from a compartmental model. Random variation 
(sometimes called, “noise”) can be added to this data from knowledge of the precision 
(RSD) of the instrument that will measure the real samples. This allows investigators 
to simulate when the potential limit of detection (LOD), and limit of quantification 
(LOQ), may occur, in the sampling procedure. Knowledge of the time required to 
reach the LOQ and LOD should prevent unnecessary extra plasma, faecal or urine 
collection, which would be unethical, as well as a waste of resources. 
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 Although stable isotopes were the first tracers to be used in nutritional science 
(Schoenheimer & Rittenburg, 1935), radioisotopes quickly became the standard 
amongst researchers after the Second World War. Cyanocobalamin (vitamin B12) 
was one of the first vitamins to be labelled with a radioisotope (Chaiet et al, 1950) and 
a radioisotope of calcium was used at a similar time (Harrison & Harrison, 1950). 
Mineral and vitamin stable isotope studies started to be published in the early 1960’s 
(iron - Lowman & Krivit, 1963; B12 - Ekins et al, 1967). The first studies using 
calcium (McPherson, 1965) and chromium (Donaldson et al, 1968) followed shortly 
afterwards and the late 1970’s saw the first zinc and copper stable isotope studies 
performed (King et al, 1978). Human studies using stable isotope labelled folic acid 
(Gregory & Toth, 1988) and beta-carotene (Dueker et al, 1994) appeared more than 
ten years later. Stable isotope labelled riboflavin was not used in a human study until 
2007 (Dainty et al, paper [13]). A combination of advances in mass spectrometry, and 
concern about exposure to ionising radiation, led to a growing number of researchers 
switching to stable isotope tracers in the 1980’s. Several reviews and guides on the 
use of stable isotopes in nutrition have been written (Buckley, 1988; Turnlund, 1989; 
Turnlund, 1991; Turnlund, 1994; Mellon & Sandstrom, 1996; Lowe & Jackson, 
2001). The isotopic labels are normally incorporated in food, either intrinsically 
(Janghorbani et al, 1981; Weaver, 1985; Fox et al, 1991; Hart et al, 2006), or 
extrinsically (Janghorbani et al, 1982; Christensen et al, 1983; Johnson & Lykken, 
1988; Weaver, 1988). An intrinsic label is one in which the stable isotope is 
incorporated biosynthetically into a plant or animal, whereas an extrinsic label is 
simply added to the food, prior to ingestion. 
 
Compartmental Modelling 
The advances in mathematical modelling in nutrition, since the 1980’s, have been 
described in conferences and workshops (Canolty & Cain, 1985; Hoover-Plow & 
Chandra, 1988; Abumrad, 1991; Siva Subramanian & Wastney, 1995; Coburn & 
Townsend, 1996; Clifford & Muller, 1998; Novotny et al, 2003). The vast majority of 
the work published from those meetings was concerned with compartmental and 
empirical modelling. A comprehensive literature exists on this type of modelling and 
it is well grounded, theoretically (Atkins, 1969; Shipley & Clark, 1972; Anderson, 
1983; Carson et al, 1983; Green & Green, 1990; Wolfe, 1992; Jacquez, 1996; 
Wastney et al, 1999). Dedicated software tools such as SAAMII (1997) allow non-
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 mathematicians to set up compartmental and empirical models, without the need to 
define the differential equations that underpin them.  
 
 Before describing why models are useful tools for gaining insight into human 
nutrition, some definitions must be given to clarify the terminology. A compartment is 
a theoretical construct that may combine material from several different physical 
spaces. It is defined as an amount of material that acts as though it is well mixed and 
kinetically homogeneous and a compartmental model consists of a finite number of 
compartments with specified interconnections between them. The interconnections 
are a representation of the flux of material that is transported from one location to 
another. By defining a compartmental model in this way, the researcher can reduce a 
complex metabolic system into a small number of pathways and compartments. The 
outputs from such a model include the quantity of mineral or vitamin stored in certain 
body pools, the rate and extent to which the nutrient moves from one pool to another 
and how long it will remain in the body before being excreted. This can inform the 
approach of the nutritionist about status, daily requirements and retention and, only 
through modelling, can this type of information be obtained from humans in a non-
invasive way. As an example, consider the 2-compartment model shown in the figure 
below. 
 
The circles represent compartments and the arrows are pathways showing the 
direction of transfer of material. Associated with each pathway is a rate constant, 
which is conventionally written as k (i,j) that denotes transfer of material, from 
compartment “j”, to compartment “i”, per unit time. The type of compartment models 
which are usually found in nutrition are described by constant coefficient, ordinary, 
first-order differential equations. The basis of these equations is that the rate constants 
do not alter over the course of the experiment and, by applying The Conservation Of 
 8
 Mass to the system under study, it is possible to solve the resultant series of equations. 
If the mass of material in compartment 1 is denoted as P (for plasma) and that in 
compartment 2 as E (the “rest” of the body), the system can be described by: 
P)k(k-Ek
dt
dP
0,12,11,2 ⋅+⋅=  
Ek - Pk
dt
dE
1,22,1 ⋅⋅=  
To solve these equations, one of the two compartments needs to be sampled 
(measured) so that the parameters (k0,1, k1,2 and k2,1) can be fitted to the resultant, 
measurement data. It is often the case that the only compartment that can be sampled 
is the plasma. This limits the number of “other” compartments that can be used in the 
model, if the parameters are to be identified, uniquely.  This is called a priori 
identifiability and is used to identify, given noise-free data, the number of 
compartments a model may have in order that all its parameters will have a single 
solution. Often investigators have an in-depth knowledge of the metabolism of a 
particular nutrient, and want to include many compartments, but this can lead to 
uncertainty in the value of the subsequent parameters. Any model that is not a priori 
identifiable must be carefully evaluated and the results from it used cautiously. The 
fitted parameters from a model should always be quoted with their calculated 
precision so that an assessment of the quality of the model can be made. This is called 
a posteriori identifiability and plays an important part in drawing nutritional 
conclusions from the modelling of real data. The a posteriori identifiability is 
dependent on good quality data and the correct choice of model structure for the 
system under investigation. The 2-compartment model is a priori identifiable. If the 
data from the plasma samples are of sufficient quality and they support a 2-
compartment rather than, say, a one or three compartment structure then the model 
should be a posteriori identifiable. A compartment model is, therefore, constrained by 
the type of data collected, the location it is collected from and the statistical 
considerations involved in fitting experimental data to models. 
 
Closely linked with compartmental modelling is empirical modelling. This is usually 
applied to data generated by multiple sampling of the plasma, over a few hours, after 
an intravenous (IV) label has been administered. The disadvantage of empirical 
models is that they cannot inform the researcher about mineral or vitamin absorption, 
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 endogenous losses or bioavailability. This type of modelling also makes the 
assumption that the nutrient introduced into the plasma, via an IV injection, behaves 
in the same kinetic way as the nutrient that appears in the plasma from the oral route. 
It cannot be assumed that a mineral or vitamin introduced into the body by different 
methods will be transported in the plasma in the same way. This can lead to the 
subsequent kinetics being “route dependent”. In modelling a nutritional system, the 
oral route of label administration is preferable because this is how minerals and 
vitamins enter the body from food. Due to these considerations, compartmental 
approaches are more widely used than empirical and this is reflected in the models 
described in the Critical Analysis section of this thesis. 
 
The remaining text focuses on the human metabolism of copper, calcium, iron, 
folates, carotenoids and riboflavin. All the work is “whole body” in the sense that 
plasma, urine or faecal samples are taken from volunteers after the ingestion of a 
stable isotope labelled test meal or drink. 
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 2. Critical Analysis 
 
2.1 Minerals 
 
2.1.1 Iron 
Compartmental modelling has been applied extensively to a number of studies on iron 
metabolism (Franzone et al, 1982; Nathanson et al, 1985; McLaren et al, 1995; Lao & 
Kamei, 2006). All of these previous papers attempt very detailed analysis of the 
kinetics of iron and require several compartments and rate constants to describe the 
system under study. The models developed in papers [2] and [10] were simpler 
because only one aspect of iron metabolism was being investigated, namely, 
bioavailability.  The original motivation to use compartmental modelling to estimate 
bioavailability was to avoid the problems associated with existing methods that 
measured iron absorption. 
 
Methods to estimate iron absorption, using isotopic labels 
Since the 1980’s, safety concerns have prevented the use of radioisotopes and whole 
body counting in the UK and researchers have switched to stable isotope labels to 
measure iron absorption using one of three main methods:  
 
(1) faecal monitoring (Janghorbani et al, 1980)  
(2) dual isotope (plasma) method (Werner et al, 1983a) 
(3) erythrocyte incorporation (Dyer & Brill, 1972)  
 
The first of these (faecal monitoring) is no longer a method of choice as it was 
recognised that it overestimated absorption, probably due to losses of isotope during 
collection and processing (Van den Heuvel et al, 1997). The dual isotope method is 
considered to be very accurate (it has been validated against the “gold standard” 
technique of whole body counting (Werner et al, 1983b)) but an intravenous (IV) dose 
of labelled iron has to be administered at the same time as an oral dose. Erythrocyte 
incorporation is the third method that is widely used and usually requires only a single 
(oral) stable isotope label to estimate iron absorption. It is assumed that a large 
fraction (usually, 80%) of newly absorbed iron is eventually incorporated into 
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 erythrocytes, reaching a “peak” of enrichment approximately 14 days (post-dose) 
after which a single blood sample can be taken to determine absorption.  
 
Problems with existing, stable isotope methods to measure iron bioavailability 
The assumption that 80% of newly absorbed iron is taken up by red cells is based on 
studies that measured erythrocyte incorporation of labelled iron from intravenous 
doses (e.g. Hosain et al, 1967; Barrett et al, 1992; Van den Heuvel et al, 1998; Roe et 
al, 2007). This has led to most, subsequent iron bioavailability studies administering 
an oral label to volunteers and assuming a fixed value of 80% red cell incorporation 
of the newly absorbed iron. However, on closer inspection, the papers mentioned 
above also showed that individuals varied markedly (62% - 99%) in their 
incorporation of iron into red cells. This would suggest that an intravenous dose of 
labelled iron should be given with the oral dose if an accurate determination of iron 
absorption is required for an individual, or a small group comparison study. 
 
The need for an intravenous dose with the dual isotope, or erythrocyte incorporation 
methods, is inconvenient but not insurmountable. The real motivation for the 
development of compartmental models were the other, more intractable problems 
associated with using these methods to measure iron absorption in mixed meals (meat 
and vegetables) and in food fortified with iron (powder).  
 
First, it is often assumed by researchers that the iron found naturally in food is 
absorbed to the same extent as an added, extrinsic stable isotope label. Extrinsically 
labelled non-haem iron is thought to enter a “common pool” which means that native 
iron in a food will be absorbed to the same extent as extrinsically labelled iron 
(Bothwell, 1979). However, there is evidence that this is not always true as at least 
one, intrinsic/extrinsic label comparison study has shown that retention of an intrinsic 
label was significantly lower in rats compared to extrinsic labels (Boza et al, 1995). 
Also, a review listed several publications that highlighted problems with extrinsically 
labelled iron not fully exchanging with native iron (Van Campen & Glahn, 1999).  
 
The second problem is that iron is found in two main forms in foods, haem and non-
haem, which are absorbed by independent pathways (Sharp, 2004). Extrinsic labels 
cannot be used to measure haem iron absorption and intrinsically labelling meat is 
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 expensive (Weaver, 1985). Also, iron absorption can vary from day-to-day; any study 
hoping to estimate absorption from a multitude of iron sources in a meal (e.g. meat, 
vegetables and drinks) should ideally be performed on the same day. Another 
limitation is that there are only three, relatively low abundance stable isotopes of iron, 
so only three iron sources could be quantified in the same experiment.  
 
Third, to combat iron deficiency in developing countries, different iron fortification 
methods have been trialled to assess the extent of the iron absorption of the various 
compounds, but the evidence of their efficacy is inconsistent (Hurrell, 2002). This 
paper acknowledges that the physicochemical characteristics of the commercial iron 
powders that influence bioavailability (e.g. particle size, porosity, solubility and 
chemical form) cannot easily be reproduced with an extrinsic or intrinsic label of iron 
and, therefore, the absorption results from stable isotope labelled fortificant studies 
may not be accurate, especially if they involve an iron powder. A possible resolution 
to these problems is to use intrinsically labelled iron products but the cost is 
prohibitive (Weaver, 1985) and reproducing commercial iron fortificants of the right 
particle size and porosity is extremely difficult. 
 
Compartmental modelling 
An alterative, novel solution is to measure the absorption of the iron that is naturally 
present in the food or fortificant without recourse to adding stable isotope labels. The 
measurement of this “natural”, unlabelled iron in a biological sample (e.g. plasma) is 
straightforward but to distinguish the iron in a sample whose origin is exogenous (e.g. 
from the last meal) compared to iron whose origin is endogenous is more of a 
challenge as they cannot be differentiated, analytically. 
 
The following section will outline how compartmental modelling can be used to 
estimate iron absorption from the plasma appearance of newly absorbed iron. It will 
provide more detail of the modelling process than the critical analysis of the other 
minerals and vitamins. This will avoid repetition of modelling description in other 
sections where similar analysis was undertaken but will serve as an in-depth 
illustration of the process of modelling changes in the plasma concentration over time.  
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 It is known from pharmacokinetic studies, that the bioavailability of certain drugs can 
be estimated from their appearance in the plasma, over the first few hours post-
ingestion (Gabrielsson & Weiner, 2000). In an analogous way, the study described in 
paper [2] was designed to test the hypothesis that a compartmental model could 
accurately predict the absorption of a dose of unlabelled iron, by assuming that certain 
key features of iron and drug absorption are shared and, that the plasma appearance of 
newly absorbed iron, would be measurable. 
 
The initial problem in this type of study is the measurement of new, “dietary” iron, 
against the natural background concentration of endogenous iron, already in the 
plasma. The plasma needs to be perturbed, sufficiently, to enable accurate 
quantification of absorption, by the model. Simulations, performed prior to the study 
design, indicated that a dose of 10mg of iron (as ferrous sulphate) would be sufficient 
to ensure a large perturbation in the plasma iron concentration. The simulation, with a 
10mg dose, suggested that the change in concentration (from baseline) would be large 
enough for good measurement precision for up to eight hours (post-dose), using a 
Ferrozine kit (total iron diagnostic kit; Sigma, Poole, Dorset, UK). This simulation 
also had to take account of the diurnal variation in serum iron concentration, which is 
known to increase from early morning (8am), when the volunteers would start the 
study (Statland et al, 1976; Dale et al, 2002).  
 
This introduced two other issues that are very important for modelling of this type: (i) 
the duration of the experiment and (ii) the number of blood samples required to ensure 
that all the relevant iron kinetics are captured. The work performed by Gonzalez et al 
(2001) had indicated that 360 minutes (post-dose) was an optimal time to allow an 
estimate of the rate of disappearance of iron from plasma. This is a vital parameter for 
the model because the underlying mathematics (differential equations) depend on the 
principle of mass balance – the rate of change in the plasma iron concentration is 
equal to the rate of iron absorption minus the rate of removal of iron from the plasma 
for utilisation and storage. So, the estimation of rate of iron removal is very important 
if the absorption is to be estimated correctly. Intensive blood sampling was carried out 
in this first study (paper [2]) to ensure that the peak in plasma concentration was not 
missed and the changes in iron concentration were fully characterised. Simulation of 
ten sampling times, equally spaced over 360 minutes, indicated that there would be 
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 enough degrees of freedom to estimate all the model parameters “a priori” from a one 
or two compartment model, given noise free data. This is an important part of the 
modelling process and must be performed to ensure that a model is theoretically 
possible, given the experimental design. The number of parameters that need to be 
estimated in the one compartment model are the quantity of iron absorbed, the rate of 
iron loss from the plasma and the time period during which absorption is taking place. 
The same parameters would be estimated from a two compartment model, as well as 
the rate of re-appearance of iron from the second compartment (rest of body). 
 
Modelling work from other researchers had suggested the need for more complicated 
models (i.e. more than two compartments) for iron metabolism but they had sampled 
the plasma for days, rather than hours, which allows far more details of the kinetics to 
be estimated (e.g. McLaren et al, 1995). In developing a model whose only function is 
the estimation of iron absorption, sampling for days is unnecessary because the 
absorptive process takes place over a few hours. 
 
It became possible to decide which of the two competing models (one or two 
compartment) was the most appropriate after the human study was performed and the 
data were collected. This was carried out in SAAMII (SAAM Institute Inc, Seattle, 
WA) by looking at the residual plots, examining the uncertainty on the parameters and 
using the model comparison parameters called Akaike's information criterion, AIC 
(Akaike, 1974) and Bayesian information criterion, BIC (Schwarz, 1978). When 
comparing two or more model structures, the one with the lowest AIC (or BIC) is 
preferred, because these parameters measure the goodness of fit of the model and also 
take into account the number of parameters that are used in fitting it. If two models 
have a comparable goodness of fit to the data, the simplest model (one with the least 
parameters) is preferred. 
 
Figure 1 in paper [2] illustrates the final model which is a single compartment. It is 
assumed that mass, M, of the iron dose, is absorbed from the small intestine, into the 
plasma, at a constant rate, R, for a time, T. This is known as “zero-order” absorption 
and equates to a constant infusion of iron from the gut into the plasma, which is, of 
course, a simplification, as the true process is more likely to be first-order (time-
varying) in nature (Schumann et al, 1999). A first-order absorptive process had been 
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 examined as part of the model development but it did not improve the absorption 
predictions and also required the estimation of an additional parameter. Therefore, by 
applying the Principle of Parsimony, the simpler process of zero-order absorption was 
preferred. Had the labelled iron been mixed with solid food instead of a liquid test 
drink, a first-order absorptive process would almost certainly have been preferable. 
 
By fitting equations 2 and 3 in paper [2] to the plasma concentration data (C) for 
either labelled or unlabelled iron, it is possible to estimate the mass of iron absorbed 
(M), the period of time when absorption has taken place (T) and the rate constant of 
elimination from the plasma (k). All fitting can be performed in Excel (Microsoft 
Corporation, 2002) or SAAMII but the latter is preferable as it gives statistics that 
indicate how good the fit is. Initially, the volume of distribution (V) was estimated 
from the model and was found to be, approximately, equal to the plasma volume. It 
was decided to use plasma volume estimates rather than model fits in the published 
work because it meant that fewer parameters had to be estimated in the model. Plasma 
volume was calculated from nomograms by knowledge of the volunteer’s age and 
weight (Lentner, 1984). The fractional iron absorption can then be calculated by 
knowledge of the mass of iron (M) appearing in plasma, divided by the mass of the 
dose of iron. 
 
When the plasma data were fitted to the model, it was necessary to baseline subtract 
the measured values of iron concentration so that the model examined the change in 
plasma iron concentration due solely to the unlabelled iron absorbed from the test 
dose. There is some uncertainty associated with this baseline correction, because the 
value that is subtracted is the measurement at time=0 minutes (just before the dose is 
given). It is known that unlabelled plasma iron concentration is subject to a diurnal 
variation, which means that the “true” baseline plasma iron concentration at 360 
minutes post-dose is likely to be higher than that at time=0 (Dale et al, 2002). Some 
account was taken of this variation by adding more uncertainty to the plasma iron 
concentration at the later time points, compared to those at the beginning. Modellers 
refer to this as “weighting” the data. The literature suggests that the diurnal variation 
causes a maximum 10% change in iron concentration, in the period from 8am to 2pm 
(Statland et al, 1976; Dale et al, 2002). Simulations indicate that not taking account of 
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 the diurnal variation will lead to a 2% (approximate) overestimation of the quantity of 
iron absorbed. 
 
The experimental design of paper [2] consisted of five volunteers receiving 10mg of 
iron (as ferrous sulphate) in a drink of water, followed by regular (25mL) blood 
sampling at 0, 20, 40, 60, 80, 100, 120, 150, 180, 210, 240, 300 and 360 minutes. In 
order to validate the results from the unlabelled iron study, a labelled iron experiment 
was performed at the same time. Hence, a dual isotope study was carried out with the 
same volunteers and 1mg of highly enriched Fe-57 (as ferrous sulphate) was given 
orally, in a drink, and 0.225mg of Fe-58 (as ferrous citrate) was given intravenously, 
in order to estimate absorption using the well validated, area under the (plasma) curve 
(AUC) method (Barrett et al, 1994). When the results of the model (unlabelled iron 
geometric mean absorption = 19%, -1SD=12%, +1SD=28%) were compared to those 
using the AUC dual isotope method (labelled iron geometric mean absorption = 17%, 
-1SD=10%, +1SD=29%), there was no significant difference in the results. In 
addition, the model estimated the quantity of iron absorbed from the labelled iron’s 
plasma appearance and found it to be 16% (geometric mean). This demonstrated that 
there was no significant difference in the estimates of unlabelled iron absorption from 
the model, compared to the AUC method for the labelled appearance of iron.  
 
Another study examined some of the modelling assumptions in more detail (paper 
[10]). IV doses of 0.2mg of highly enriched Fe-58 were infused slowly into nine, 
female volunteers and the resultant plasma appearance was modelled using a single 
compartment model. If the model is accurate, it should predict the quantity of the 
known IV dose (approx. 0.20mg). The model estimated the IV dose to be 95% of its 
true value (0.19mg) but this was found to be a non-significant difference. 
  
There is, therefore, independent evidence from two data sets (papers [2, 10]) that the 
model accurately estimates the quantity of iron that has been absorbed or infused 
despite initial concerns that the single compartment structure might be too simple, or 
that the diurnal variation in serum iron concentration might cause the method to be 
inaccurate. 
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 Other Methods to Estimate Iron absorption from unlabelled test meals 
Previous authors have used the plasma appearance of newly absorbed iron to assess 
bioavailability. This work can be broadly categorised as either, (a) relating the (post 
test meal) peak change in serum iron concentration to iron absorption (Ekenved et al, 
1976; Heinrich & Fischer, 1982; Werner et al, 1983b; Gonzalez et al, 2001; Hoppe & 
Hulthen, 2006; Conway et al, 2006) or, (b) relating the (post-test meal) area under the 
serum iron concentration (versus time) curve (AUC) to iron absorption (Ekenved et 
al, 1976; Werner et al, 1983b; Gonzalez et al, 2001; Hoppe et al, 2004; Conway et al, 
2006). Method (b) is sometimes called the iron tolerance test (ITT). Both of these 
methods lead to regression equations of the form y = mx + c, where “y” is the fraction 
or percent of iron absorbed and “x” is the peak increase in serum iron or the AUC 
(“m” and “c” are estimated constants). The drawback to this type of analysis is that it 
is only valid for the range of iron absorption that led to the development of the 
equation (i.e. it should not be used for extrapolation) and it can only be used for the 
particular iron compound that the original data/equation was constructed for. It is, 
therefore, a very restrictive method and probably explains why it has not become 
popular as a technique for measuring iron absorption. Only the work by Gonzalez et 
al (2001) attempted something more flexible but this required the administration of a 
labelled IV dose as well as measuring the AUC (or peak change in serum iron). This 
paper does not fully describe the method that was used to quantify absorption and, 
therefore, it is impossible to reproduce. The work described in papers [2, 10] has an 
obvious advantage over these “regression” methods, in that it will measure the 
absorption of any form of iron. Whether it can measure low quantities of absorbed, 
unlabelled iron remains to be demonstrated but that is a problem with any serum-
based method, as the change in iron concentration (post-test meal) must be large 
enough to allow accurate quantification, against the background of endogenous 
diurnal changes in plasma concentration. 
 
Conclusions 
The impact of the work in papers [2, 10] is, firstly, that there is no need to give an 
intravenous dose of iron in future, labelled studies that estimate absorption from 
plasma appearance. This is an improvement because it reduces the invasiveness for 
the volunteers. It also reduces the cost of the study and improves the overall safety as, 
injecting any substance, carries a slight risk of an adverse event. Secondly (and more 
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 importantly), it allows the possibility to estimate absorption of unlabelled iron, which 
was successfully demonstrated in paper [2] with 10mg ferrous sulphate in a liquid 
carrier. If it is to become a really valuable tool for future bioavailability work, the 
model needs to be tested with different forms of unlabelled iron at lower doses in real 
food systems. If substantiated, it does hold out the promise to be the first technique 
that will accurately measure the total iron absorption in a meal containing both haem 
and non-haem iron. It also has the potential to measure the unlabelled iron absorption 
from commercial iron powders which is something that no method, to date, has been 
able to achieve. This should help policy makers to decide which iron fortification 
product is the most bioavailable. 
 
Limitations and future work 
The drawbacks to the technique are threefold, but not insurmountable. First, using a 
Ferrozine kit to analyse unlabelled iron, requires quite a large overall blood volume to 
be taken; this makes it unlikely to be used in cross-over studies in the same 6 month 
period, as the limit on blood volume withdrawal is 450ml. This problem would be 
overcome if the samples were analysed using a mass spectrometer (e.g. ICP-MS) as 
the method would then require a much smaller blood volume, for each sample. 
Second, the experimental protocol is quite invasive and inconvenient for volunteers. 
However, unpublished results from our work (J Dainty, unpublished) show that it is 
possible to accurately estimate iron absorption, from the model, using a single blood 
sample at 120 minutes. Further work is necessary before we could validate this. If that 
could be accomplished, it raises the possibility of a cheap and fast clinical technique 
for assessing iron absorption. The third and final drawback is the diurnal variation in 
plasma iron concentration which could make estimates of unlabelled iron 
concentration less accurate, the longer blood is sampled for. If the model could be 
reduced to one blood sample at 120 minutes, this problem should be reduced. More 
work is needed to assess the implications of diurnal changes in the serum iron 
concentration on the accuracy of the model estimates of iron absorption. 
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 2.1.2 Copper 
Copper is an essential element in the human diet and is involved as a cofactor in a 
number of enzymes (Linder, 1991). There is homeostatic control over copper 
absorption and endogenous excretion and this requires human bioavailability trials to 
measure both absorption and retention (Turnlund, 1998). Copper bioavailability 
studies are problematic because the element only has two isotopes (63Cu, 65Cu). 
Consequently, dual tracer experiments cannot be performed and only, either, 
absorption (using oral isotope administration and faecal monitoring) or, retention 
(using intravenous isotope administration and faecal monitoring) can be investigated 
in any one study. This has led researchers to design expensive, separate trials (an oral 
study and an IV study) on the same volunteers to quantify both absorption and 
endogenous losses.  
 
New Method to Estimate Endogenous loss of Copper 
Reducing the time and cost of this type of experiment was the motivation for the first 
human trial that is outlined here (paper [1]). This work presents a technique that 
allows an estimate of the absorption and endogenous loss of copper, from a single, 
stable isotope-labelled, study. Ten volunteers were given a variety of test meals (on 
separate study days) containing between 1-3mg of highly enriched Cu-65 (for details, 
see Table 2 in paper [1]) and faeces were collected for 10 days, post-dose. This gives 
sufficient time for the last few faecal samples to contain only labelled copper that has 
been absorbed and then excreted (henceforth, called “labelled, endogenous copper”) 
(see Figures 1 and 2 in paper [1]). There is a linear relationship between the mole 
fraction of the labelled, endogenous copper and (post-dose) time (Figure 3 in paper 
[1]). From the linear equation that describes this relationship, an estimate can be made 
of the mole fraction (and quantity) of the endogenous, labelled copper in the earlier 
stools that also contain unabsorbed, labelled copper. Therefore, a mathematical 
correction can be made in these earlier stools and this allows the calculation of the 
endogenous loss as well as the true absorption of copper from the oral dose. This is 
validated by examining Figures 5 and 6 in paper [1] (wrongly labelled as the data for 
volunteer 230 when, in fact, it is the entire volunteer set). Figure 5 illustrates the 
relationship between labelled, faecal copper and the faecal appearance of the rare 
earth element, holmium, which is assumed to have the same excretory pattern as 
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 copper. Theoretically, the data should fall on the y=x line (slope=1.00) but the slope is 
0.84, indicating that the two elements do not have the same excretory pattern and that 
copper travels through the GI tract faster than holmium. However, if the labelled 
faecal copper is corrected for endogenous losses and the data are plotted again, the 
slope is estimated to be 0.99 and the data does lie, approximately, on the y=x line 
(Figure 6). 
 
Further validation of this method was carried out in paper [8] using a cross-over 
design. Volunteers were given an oral dose of Cu-65 on one study day and an 
intravenous dose of the same isotope, some weeks later. Faecal samples were 
collected for 14 days (post-dose) on both occasions. The results from six volunteers 
indicated that there was no significant difference between the two methods 
(endogenous loss from IV label=32% of dose; from oral label=35% of dose). A final 
validation is the finding that this quantity of endogenous loss is similar to that 
reported previously, using radioisotope labels (Bush et al, 1955; Weber et al, 1969). 
 
This new method for estimating endogenous loss was used in another study (paper 
[4]) that examined the effect on absorption and retention of consuming a high, 
medium and low copper diet. Twelve male volunteers completed a longitudinal cross-
over trial in which they were assigned to consume either 6.0mg/d Cu (high), 1.6mg/d 
Cu (medium) or 0.7mg/d Cu (low) for six weeks each, with a minimum four-week 
washout period after each intervention. Before and after each intervention, the 
volunteers were given a stable isotope labelled copper dose of Cu-65 (3mg), and 
complete faecal collections were carried out for 14 days, to allow an estimation of the 
copper absorption and endogenous loss. The results indicated that absorption of 
copper did not change between diets, but there were differences in endogenous loss, 
with significantly higher excretion on the high, compared to the medium (P=0.001) 
and low copper diet (P<0.001). A similar study had been performed in the US 
(Turnlund et al, 1989), but the strength of the work in paper [4] was that both 
absorption and endogenous loss were estimated from the faecal appearance of copper 
from the oral dose, whereas the study by Turnlund et al had used an oral and IV dose 
in separate experiments. 
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 In paper [1], a linear equation (y=mx+c) was used to describe the temporal 
appearance of the labelled, endogenous copper but there was no attempt to examine 
whether there was a better, mathematical description. In paper [4] there was an 
opportunity to examine different equations to describe the pattern of endogenous loss. 
The effect on the estimation of endogenous loss was compared using linear, mono-
exponential and bi-exponential formulae (see Figure 2 and Table 7 in paper [4]). The 
figure in the paper is slightly misleading as it shows that the bi-exponential model is 
the best fit to the data for this particular example, but was found to be incorrect for the 
whole data set, for which the linear expression was the only model that could be 
justified from the data. Other researchers (Owen, 1982; Linder et al, 1986) have 
shown, in rats, that the endogenous loss of copper from the body follows a biphasic 
pattern.  
 
The underlying pattern of endogenous excretion, in humans, is probably more 
complex than has been proposed in papers [1, 4] but only a simple linear model could 
be justified from the data generated by these studies. More precise measurement of 
the quantity of labelled copper in these final faecal samples is required before a 
complicated excretion model could be proposed. It can be seen from Table 7 (paper 
[4]) that the effect of a bi-exponential fit to the data is to increase the estimates of 
copper absorption and excretion. The isotope enrichment in these samples was close 
to the limit of detection of the mass spectrometer. A larger isotopic dose could 
increase the enrichment but the quantity of copper used in paper [4] was above the 
UK RNI (1.2mg). Increasing it further could prevent the study results being 
generalised to the wider population. 
 
New Method to Estimate Absorption of Copper 
Prior to 2005, faecal monitoring was the only method available to calculate copper 
absorption. Paper [8] describes a study that estimates copper absorption from plasma 
appearance in an analogous way to the iron studies contained in papers [2, 10]. A 
single compartment model was deemed to be the most appropriate choice after 
assessing the goodness of fit and suitability (via AIC and BIC) of two and three 
compartment alternatives. Again, the movement of copper, from the GI tract into the 
plasma compartment, was modelled as a constant rate infusion (zero order process). 
The volume of distribution of copper was more difficult to estimate, compared to that 
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 of iron, and some unpublished data was used (N Lowe, personal communication) to 
calculate a value. This volume is the “apparent” space that the mineral occupies in the 
sampled compartment (blood). For iron, it had been found that this is equal to the 
plasma volume which is dependent on a subject’s age and weight (Lentner, 1984). 
The estimate for the copper volume of distribution (5 litres) was higher than the 
plasma volume (less than three litres for a typical subject). The model estimated that 
copper absorption from a 3mg labelled dose was 8±2%, but the faecal monitoring 
method found the absorption to be 48±5%. Even allowing for the fact that faecal 
monitoring can sometimes overestimate absorption, the model is clearly not fit for 
purpose.  
 
The reason for this became apparent when a full compartmental model of copper 
metabolism was analysed. The copper that is absorbed across the mucosal cells, is 
carried, mainly, by albumin (Venelinov et al, 2007) in the portal vein to the liver, 
where a large proportion of it is removed. This is known as the first-pass effect 
(Gabrielsson & Weiner, 2000). It is particularly marked in copper metabolism 
because most newly absorbed copper, although initially transported on albumin, has 
to be repackaged into ceruloplasmin by the liver. This “new” form of copper is slowly 
released into the general circulation over a period of 4-5 days (Figure 2A, paper [8]). 
This means that only a small fraction of the absorbed copper appears, immediately, in 
the plasma and explains why the simple, one compartment model grossly 
underestimated the absorption of copper from the test dose. Whilst this invalidates the 
use of the model for predicting the quantity of copper absorbed from a meal/dose, it 
does allow the estimation of relative bioavailability. To date, no such studies have 
taken place. It would be useful if the bioavailability of unlabelled copper could be 
assessed using the model, with the proviso that it would only be possible to measure 
relative bioavailability. 
 
Detailed compartmental model 
Whilst parts of the work from paper [8] have already been mentioned, additional 
insights into copper metabolism were obtained from the full compartmental model 
(Figure 1 in paper [8]). Before describing our model, it is important to highlight 
previous work in this area so that the novel aspects of paper [8] can be understood in 
the right context. 
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 The first compartmental model of human copper metabolism was developed by 
Cartwright & Wintrobe (1964), but was unconventional because no experiment was 
performed to gather data for the model. Instead, literature values were used for serum 
and urinary copper values and autopsy data were utilised for total copper in specific 
body parts. These data, together with the current knowledge of copper metabolism, 
allowed a simple compartmental model to be built, which had albumin as the main 
copper transporter to other tissues. It is now known that this is incorrect because 
ceruloplasmin is the main copper transporter in plasma, but the model stimulated 
debate and led to a study, in rats, that was designed to generate data for 
compartmental modelling (Hazelrig et al, 1966). For this trial, the radioisotope 64Cu 
was injected into ten rats, and bile, blood and liver was sampled over the next five 
hours. This resulted in a detailed model of copper liver metabolism and reinforced the 
view that biliary excretion was important in copper homeostasis. This model was 
viewed as definitive over the next 25 years and was extended to allow for simulations 
of copper metabolism in man (Blincoe, 1992; 1993) although, again, no human 
experimental data were generated. 
 
Dunn et al (1991) performed a detailed experiment that injected doses of 64Cu in 33 
rats and sampled various tissue sites over three days to generate data for 
compartmental modelling. This study used the Hazelrig et al (1966) model as a basis, 
but included many other tissue compartments, for the first time. Like the Cartwright 
& Wintrobe (1964) model, it concluded that the tissues are not supplied with copper 
transported by ceruloplasmin but by another (unknown) carrier. As mentioned 
previously, this is not correct in the human but is, perhaps, a good example of why the 
results from animal studies must be viewed with caution when trying to extrapolate 
their findings to human metabolism. One of the interesting points to note in the 
development of these copper metabolism models is that, until the early 1990’s, there 
were no papers published describing a compartmental model that used data generated 
from a human study. This is probably due to ethical reasons, as there are dangers 
associated with the ionising radiation from a 64Cu dose. 
 
It was not until 1994 when a study was finally published on human copper 
metabolism, using stable isotope data (Scott & Turnlund, 1994). The study was 
originally designed to examine the absorption and retention of labelled copper, during 
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 and after three periods of (unlabelled) copper intervention using low, medium and 
high copper diets (Turnlund et al, 1989). As such, the data were not ideal for 
developing a compartmental model, as the blood was not sampled regularly enough 
after oral dose administration to permit an accurate model fit to the plasma 
appearance of labelled copper. Nevertheless, this was the first model to correctly 
identify that ceruloplasmin is the protein that transports copper to body tissues, but it 
underestimated the percentage of copper in the plasma that is bound to ceruloplasmin 
(62-72%) in comparison to the model in paper [8] (mean=99%).  
 
The detail of our model (paper [8]) was such that it gave a good representation of 
most of the copper storage sites and estimated the quantity of liver copper more 
accurately (2.4mg)  than Scott & Turnlund’s work (88.8mg) when compared to the 
reference value (9.9mg) from autopsy work (Linder, 1991). This autopsy data also 
suggest that the average human has 110mg of copper stored in the body, but at least 
60mg of this is in the skeleton. The study in paper [8] was too short in duration to 
estimate the size of the skeletal pool, but this could be possible in a longer study, 
assuming that the enrichment of labelled copper in plasma was measurable for more 
than the estimated 30 days that would be needed in such an experiment. 
An interesting finding was the large quantity of copper that is lost through the bile. 
Previous work had suggested that this is the primary mechanism of copper 
homeostasis, since loss through the urine is negligible (Cartwright & Wintrobe, 1964). 
Post-mortem examinations have indicated that large quantities of copper are stored in 
the bile duct (Cartwright & Wintrobe, 1964) and evidence for copper excretion via 
bile has been demonstrated with radio and stable isotopes (Bush et al, 1955; Turnlund 
et al, 1998). 
 
In paper [8], a large, first-pass effect for copper was quantified as 74% of the 
absorbed dose. This is the first report of a copper first-pass effect in humans; the Scott 
& Turnlund (1994) paper failed to recognise that newly absorbed copper enters the 
liver before being circulated to other tissues. The quantity of copper removed on first-
pass is, unexpectedly large, but the reasons for this are unclear. We speculate that it 
could be connected with the repackaging of newly absorbed copper, from albumin, 
into ceruloplasmin but there might also be a need to store newly absorbed copper for 
subsequent release to maintain fasting plasma levels, which are quite tightly 
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 controlled and generally not thought to be linked with status (Medeiros et al, 1991; 
Milne, 1994) although a recent systematic review concluded that plasma copper 
concentrations may reflect dietary intake under some circumstances (Harvey et al, 
2009). Another explanation for the first-pass effect could be the liver’s role in 
maintaining homeostatic control over retention, by excreting excess copper via the 
bile. The liver is clearly at the centre of copper metabolism, and this is reflected in its 
predominant role in the model (Figure 1, paper [8]). 
 
Conclusion and future work 
The model developed in paper [8] is only the second of its kind to be published, and is 
the most detailed and accurate representation of copper metabolism, in humans. Extra 
detail would be forthcoming if an experiment could be designed that took samples 
over a longer period, but this might not be possible with a physiological dose of Cu-
65, since the determination of accurate copper ratios, in plasma, are currently not 
feasible with ICP-MS after about 14 days (post-dose), due to insufficient enrichment.
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 2.1.3 Calcium 
The structure of bone is highly dynamic and about 10% of the skeleton is undergoing 
constant “remodelling”. Osteoporosis is a bone disease that can lead to increased risk 
of fracture and the underlying cause of this is more bone being broken down (bone 
resorption), than is made (bone formation). Bone resorption releases calcium, whereas 
formation requires it, but although skeletal integrity is important, the main 
homeostatic driver for calcium is the maintenance of the calcium plasma 
concentration, within very tight tolerances. This is because calcium has an important 
role in intracellular signalling, neurotransmission, muscle contraction and many other 
functions. These vital processes take precedent over maintaining a healthy skeleton 
and therefore calcium will be released from bone to ensure that they are preserved. 
Therefore, there is greater risk of developing osteoporosis when (over a prolonged 
period) the daily quantity of absorbed (dietary) calcium is less than the daily 
endogenous calcium excretion because more bone will be resorbed in order to 
maintain the “correct” plasma concentration (Heaney et al, 1977). 
 
Objective 
High salt intake is considered to be a risk factor for osteoporosis because urinary 
calcium excretion (calciuria) is increased by diets high in sodium (Teucher & 
Fairweather-Tait, 2003). However, many previous studies that investigated this 
hypothesis used intervention diets that contained salt levels far in excess of those 
commonly consumed. The objective of the study presented in paper [14] was to 
clarify the effects of salt (and calcium) on calcium metabolism at normal dietary 
levels. 
 
Calcium Balance 
Calculations from earlier studies have indicated that the average additional body loss 
of calcium is 40mg for every 2290mg of sodium consumed (Zarkadas et al, 1989). 
The increased urinary loss of calcium must be compensated for by increased 
absorption, or increased calcium intake, otherwise there is the potential for the 
skeleton to lose 10% of its calcium within a decade. Measurements of calcium 
“balance” are crucial in assessing the loss of calcium from the skeleton (so-called 
negative balance), and at what rate. This measure of balance can be achieved by the 
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 use of compartmental modelling because, in conjunction with stable isotope labelling, 
the major calcium fluxes can be quantified either directly (calcium used in bone 
formation, calcium excretion), or indirectly (calcium lost in bone resorption). This is 
particularly useful when studying calcium metabolism as the vast majority (>99%) is 
stored in bone, which turns over too slowly to allow its size to be measured. 
 
 The study that is described here (paper [14]) is a 4-way cross-over that attempts to 
examine the effect of salt and calcium on overall calcium balance. Eleven 
postmenopausal women completed a randomised cross-over trial consisting of four 
successive, five week periods of controlled dietary intervention, each separated by a 
minimum 4 week washout. Moderately low and high calcium (518mg versus 1284mg) 
and salt (3.9g versus 11.2g) diets, reflecting lower and upper intakes in 
postmenopausal women consuming a Western-style diet, were provided. On the 
morning of day 30 (at the end of each intervention period), subjects consumed a drink 
of water containing an extrinsically labelled dose (20mg) of Ca-42 (as CaCl2) with a 
standard breakfast that contained 183mg of unlabelled calcium. Approximately 30 
minutes later, a solution of Ca-43 (4.5mg as CaCl2) was infused over 20 minutes 
through a cannula. Blood was sampled intensively over the first six hours and then at 
days 1, 4, 8 and 10 post-dosing. In addition, 24-hour urine and faecal samples were 
collected for 10 days post-dose. Compartmental modelling was used to estimate 
calcium absorption, excretion and bone calcium balance. Biochemical markers of 
bone formation and resorption were also measured in blood and urine. 
 
Compartmental Model 
Arriving at the final two-compartment model (Figure 1 in paper [14]) was a process of 
trial and error. Prior to data collection, it was thought that a three-compartment model 
would be optimal as several other studies had used this approach (Neer et al, 1967; 
O’Brien et al, 1998; Wastney et al, 1996, 2000).  The model should attempt to reflect 
the known physiology but must also be the simplest that fits the data (Principle of 
Parsimony). After extensive model comparison and goodness of fit tests, it was found 
that a two-compartment model best represented the data. The uncertainty estimates for 
the rate constants were quite low for modelling of this type with a typical coefficient 
of variation being less than 10%. This was due to the large data set that was collected 
and the unique way it was used by the model fitting program (SAAMII). The program 
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 has a facility that allows both the oral and the IV data to be fitted simultaneously to 
the same model, thereby doubling the degrees of freedom that are used. Typically, the 
model was attempting to estimate seven parameters, but there were approximately 
sixty data points with which to do so (thirty from each isotope “source”), and this 
meant that the parameters could be estimated with good precision. 
 
Compartment 1 represents the blood and compartment 2 is probably a combination of 
soft tissue pools (see Figure1, paper [14]). The rate of whole body calcium loss or 
gain (balance, Vbal) was estimated from the principles of mass balance (= rate of 
calcium into system – rate of calcium out of system, i.e. Vbal = Va – Vu – Vf). This 
requires a knowledge of the rate of calcium absorbed (Va), and the rate of calcium 
excreted via urine (Vu) and into faeces (endogenous Ca loss, Vf). It is also useful to 
estimate the rate of calcium loss (V0-) and gain (V0+) to bone. The gain to bone (V0+) 
can be measured directly from the compartmental model but the loss (V0-) cannot, and 
has to be estimated by difference (V0- = V0+ - Va + Vu + Vf). The reason that V0- 
cannot be estimated directly is that labelled calcium, taken up into bone from the oral 
dose, will not be broken down and returned to the plasma within the timeframe (10 
days) of the experiment. 
 
The results of the study demonstrated that a moderately high salt intake (11.2g/d) 
elicited a significant increase in urinary calcium excretion (p < 0.001) and 
significantly affected bone calcium balance with the high calcium diet (p = 0.024). 
Efficiency of calcium absorption was higher following a period of moderately low 
calcium intake (p < 0.05) but was unaffected by salt intake. Salt was responsible for a 
significant change in bone calcium balance, from positive to negative, when 
consumed as part of a high calcium diet. With a low calcium intake, the bone calcium 
balance was negative with both high and low salt diets (see Table 2 in paper [14]). 
 
The strengths of this study were that the volunteers acted as their own controls which 
eliminated the confounding effects of genotype that are known to be strongly related 
to the probability of developing osteoporosis (Parfitt, 1997). An additional strength of 
the design was the use of a range of salt levels that are commonly consumed in the 
UK. This allows the conclusions of the study to be applied more widely than if higher 
(or lower) levels had been used. A potential weakness was that the study gave the 
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 same calcium load for the test breakfast on day 30, irrespective of which calcium diet 
(high or low) the volunteers were on. It is known that absorption is influenced by 
calcium load (Heaney et al, 1989) as well as by physiological requirements and the 
test breakfast should have been tailored to the level of calcium that the volunteers 
were consuming at breakfast over the 30 days of the intervention diet. The 183mg of 
calcium that was fed would have been appropriate for the low calcium diet but it 
would have been preferable to have given about 450mg of calcium at breakfast on the 
test days for the high calcium diet. 
 
The standard deviations for the estimated, mean calcium balances are worth 
examining in more detail. For each individual set of data, the compartmental 
modelling estimated the model parameters (rate constants) with good precision. 
However, the means of the two model parameters for calcium excretion (Vf and Vu) 
had large uncertainties associated with them (see Table 2 in paper [14]). This is due to 
the large, inter-individual variation in excretion and is explained by certain volunteers 
being “non-responders”, described as the fact that some people do not alter calcium 
excretion in response to salt challenges (Shortt et al, 1988; Leitz et al, 1998). Vf and 
Vu were used in the derivation of calcium balance (Vbal) and this partly explains why 
the parameter has a large uncertainty associated with its mean. Another reason is that, 
on adding or subtracting one quantity from another, the errors in these quantities 
propagate to form larger uncertainties in the derived parameter (Vbal). The fact that the 
calcium balance was estimated with such large uncertainty explains why some of the 
findings did not reach statistical significance, even though a trend was evident. Other 
studies that derive calcium balance in this way have suffered from similarly large 
uncertainties (e.g Wastney et al, 2000; Bryant et al, 2003). This highlights the need 
for a larger study with possibly even longer adaptation to the intervention diets before 
clear conclusions can be reached. 
 
Comparison of findings to other studies 
On comparing the work carried out in paper [14] to other studies, several points 
emerge. First, as has been mentioned earlier, other authors have used an extra 
compartment to model their data (e.g. Wastney et al, 1996). This was found 
unnecessary with the data generated in paper [14] and the resulting model parameters 
were estimated with similar precision to other work. The model parameter values 
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 were also similar, so there was no perceived loss of accuracy by having one less 
compartment.  
Second, some previous studies did not collect faeces but still managed to estimate 
endogenous loss in the faeces, with reasonable precision (O’Brien et al, 1998; 
Kerstetter et al, 2005). This is somewhat surprising given that others estimate this 
parameter with less precision, having collected faecal samples. Some preliminary 
work was performed with the data in Paper [14] to examine the effect of not fitting the 
faecal data, but the parameter estimates were badly affected and the faecal data was 
subsequently included in all analysis. The other advantage of including faecal data is 
its use in absorption estimates.  
A third point that arose in comparing paper [14] with other work, was the lack of 
controlled diets and small sample sizes in previous papers (e.g. Smith et al, 1996). 
Even though the study in paper [14] had controlled diets and eleven volunteers it was 
still under-powered to detect significant changes between some of the dietary 
interventions. Power calculations performed prior to the study design had indicated 
that 16 volunteers would be needed but, due to the invasive and time consuming 
nature of the study, five volunteers dropped out. 
 
Conclusions 
Paper [14] presents a model that estimates the calcium flux from bone and therefore 
allows an estimation of bone calcium balance after four intervention diets in the same 
subjects. Although the parameters (rate constants) of the model are estimated with 
good precision, the calcium balance has a large uncertainty associated with it because 
of the combined effect of error propagation, and its derivation from the calcium 
excretion parameters (Vu and Vf), which are subject to large inter-individual variation. 
There is a significant difference (P=0.024) of bone calcium balance between the low 
salt (Vbal=90±46 mg/d) and high salt (Vbal=-12±84 mg/d) regimen on the high calcium 
diet. 
 
Future work 
A larger study is warranted that has a longer adaptation period to each diet.
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 2.2 Vitamins 
 
2.2.1 Folate 
Folate is the generic name for the members of a family of water soluble B-group 
vitamins. They are primarily comprised of reduced methyl and formyl 
folylpolyglutamates that have similar chemical structures to folic acid (a 
monoglutamate), the synthetic form of the vitamin. There is considerable interest in 
folates because of their involvement in 1-carbon metabolism which is crucial for 
nucleotide biosynthesis (Stover, 2009). In addition, low folate status has been 
implicated in neural tube defects and higher risks of cardiovascular disease and stroke 
(McNulty et al, 2007). 
 
Plasma Appearance of Labelled Folate 
The rationale for the initial work (paper [3]), was to compare the bioavailability of 
three forms of folate by observing their appearance, in plasma, as 5-
methyltetrahydrofolate (5-methylTHF) in human volunteers. At the time of 
publication (2003), other researchers were using folic acid as a reference dose because 
14C labelled folate studies had shown that about 90% of a dose of folic acid was 
absorbed (Clifford et al, 1998). Stable isotope labelled folates were generally not 
available so folate bioavailability studies were designed with unlabelled folate doses 
in conjunction with sampling of the plasma for a few hours to quantify the area under 
the (plasma concentration) curve (AUC). These were “relative absorption” studies as 
an unlabelled dose of folic acid was usually given and its AUC compared to that of 
the other folates, with the assumption being that folic acid absorption was of the order 
of 90-100% (Pietrzik et al, 1990; Prinz-Langenohl et al, 1999). 
Paper [3] is an account of one of the first experiments to use stable isotope labelled 
folates and the study it describes was designed to replicate the protocol of previous, 
unlabelled folate studies, in order to test the validity of the labelled “tracer” approach. 
The experimental protocol employed two groups of volunteers receiving either 285µg 
of 13C-labelled folic acid (n=12) or 200-230µg of 13C-labelled 5-
formyltetrahydrofolate (n=12). The study was performed after an overnight fast and 
serial blood samples were taken regularly for 8 hours post-dose. It is well known that 
the main form of folate in the plasma is 5-methylTHF and the first task, after 
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 measuring the plasma samples by LC-MS, was to quantify the labelled plasma portion 
of the 5-methylTHF (from the doses) from the total 5-methylTHF. The calculations 
for this are shown in Appendix 1 of paper [3].  
The results indicated that the plasma profile had perturbations of labelled and 
unlabelled folate (Figure 1 in paper [3]). This was unexpected because only a labelled 
dose had been given to the volunteers and it was concluded that the origin of the 
unlabelled folate was endogenous. A similar finding has subsequently been found for 
vitamin C (Bluck et al, 2005) which could indicate that all water-soluble vitamins 
have a similar mechanism. Paper [3] speculated that the original site or store of this 
displaced, unlabelled folate was the liver. The amounts of displaced folate varied 
widely between volunteers as evidenced by the far bigger error bars on the “total” 5-
methylTHF compared to the “labelled” 5-methylTHF (Figure 1, paper [3]) but there 
was no significant difference in the AUC of the displaced, unlabelled 5-methylTHF 
generated after the folic acid dose compared to that after the 5-formyltetrahydrofolate 
(5-formylTHF) dose. 
 
Unexpected Findings  
The reason why the unexpected displacement of endogenous folates is an important 
finding, is that previous researchers had given unlabelled folate doses and measured 
the appearance of folate in the plasma to ascertain the “relative” bioavailability of the 
dose (Konings et al, 2002; Pentieva et al, 2004). This assumed that the change in 
plasma folate was all due to the dose, an assumption which our results indicate is not 
true. This finding invalidates these earlier, unlabelled folate studies, and leads to the 
conclusion that only labelled-tracer studies can be used to assess folate bioavailability. 
A second, unexpected finding was the difference in plasma profile of the labelled 5-
methylTHF from the folic acid dose compared to profile from the 5-formylTHF dose. 
There is a long delay in the peak appearance of 5-methylTHF derived from folic acid 
(Tmax=173 minutes) compared to that derived from the 5-formylTHF dose (Tmax=41 
minutes). This was the first time such a discrepancy in plasma profiles had been 
observed, and appeared to suggest that folic acid and 5-formylTHF are handled very 
differently by the body. The folic acid had been given as a capsule, and an adjustment 
in the Tmax was required to reflect the delayed breakdown of the capsule. This delay 
was taken into account in a later paper (paper [7]) and reduced the “absorption time” 
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 of folic acid by approximately 35 minutes so the “true” Tmax is probably about 140 
minutes. 
The third unexpected finding from paper [3] was that the (dose corrected) AUC of 
labelled 5-methylTHF was significantly smaller (P<0.001) after the folic acid dose 
compared to the 5-formylTHF dose. This meant that the relative absorption of the 
dose of 5-formylTHF was 221% compared to that of folic acid (assumed to be 100%) 
which led to two possible conclusions with regard to folic acid metabolism:  
(1) Previous papers are incorrect when they suggest that a dose of folic acid is almost 
completely (90-100%) absorbed, or, 
(2) Folic acid is metabolised in a different way to 5-formylTHF. 
 It is safe to dismiss conclusion (1) as the previous papers that found ~90% 
absorption, had used state-of-the-art measurement techniques with 14C-labelled folic 
acid doses. 
 
Initial Site of Metabolism of Folic Acid 
Conclusion (2) deserves more scrutiny, especially when the evidence of the apparent 
low absorption of folic acid is added to the finding of a delay in the peak appearance 
of labelled 5-methylTHF after a labelled folic acid dose. It had been argued for some 
time in reviews of folate metabolism, that all forms of folate were metabolised by the 
mucosal cells before being transported in the portal vein as 5-methylTHF to the liver 
(e.g. Gregory & Quinlivan, 2002). The problem with this theory, for folic acid, is that 
it originates from studies performed on rats which were then extrapolated to humans 
(Tani & Iwai, 1983). In fact, there was evidence before 1983 to show that folic acid 
entered the portal vein intact (Whitehead & Cooper, 1967; Melikian et al, 1971) but 
these papers were dismissed because the folic acid dose was deemed to be too large 
(non-physiological) even though the Melikian study had given just 500µg of folic 
acid. This earlier work by Whitehead & Cooper (1967) and Melikian et al (1971) and 
the results of paper [3] began to lead us to speculate that the site of reduction of folic 
acid had to be the liver, not the mucosal cells. 
 
Whilst the site of initial metabolism may be different for folic acid compared to other 
folates, this hypothesis isn’t enough to explain the findings of paper [3]. It wasn’t 
until the publication of paper [7] that the reasons for the apparent, low folic acid 
absorption were revealed. Paper [7] presents the modelling approach (the Critical 
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 Analysis of paper [5] will provide the overall modelling detail) and uses the data set 
from paper [3], plus additional data from that study which was not analysed at the 
time paper [3] was in press. It includes the data from an intrinsically labelled (15N) 
spinach meal (n=14) as well as the full data set from the (13C) 5-formylTHF dose 
(n=16) and (13C) folic acid dose (n=14). The folate in the spinach was predominantly 
5-methylTHF and the labelled dose was approximately 264µg of folate. This 
experiment was originally designed as a cross-over but very few of the volunteers 
managed to complete more than one of the interventions, so the data are presented and 
analysed as independent observations. The intrinsically labelled spinach has a 5-
methylTHF plasma appearance similar to that seen after the 5-formyl labelled drink 
but quite different to the labelled folic acid (Figure 2, paper [7]). The labelled 5-
methylTHF from the folic acid dose had a significantly (P<0.001) delayed appearance 
in the plasma (Tmax = 171±9 minutes) in comparison to that from the 5-formylTHF 
(Tmax = 54±10 minutes) and the spinach derived 5-methylTHF (Tmax = 60±13 
minutes). Here were further results that the folic acid was being handled differently by 
the body, contrary to what had been reported consistently since 1983. Additional 
evidence was apparent when the results from the modelling were examined. The 
model predicted that the apparent absorption of the folic acid dose (24±2%) was 
significantly lower (P<0.05) than that from the 5-formyl (38±6%) and the spinach 
(44±6%). Taking the apparent absorption of folic acid as the reference dose (i.e. 
absorbed at 100%, as many papers have done by using AUC (e.g. Konings et al, 
2002)), it was concluded that 5-formyl is absorbed at 158% and the spinach folate at 
183% of the quantity in the dose. This is clearly incorrect but was the first time that 
anomalous absorption results had been published using folic acid as a reference dose. 
 
First-pass effect 
 It is speculated that the reason for the low, apparent absorption of folic acid is that, 
all newly absorbed folates are subject to a first-pass effect of the liver (Steinberg et al, 
1979) and, that the liver has a higher affinity for folic acid than other folate forms 
(Steinberg et al, 1979; Selhub, 1989; Zhao et al, 2009). When these two vital pieces of 
information are added to the hypothesis that folic acid, uniquely amongst the folates, 
is transported intact to the liver, the reason for the relatively, low apparent absorption 
of folic acid becomes clear. The Steinberg et al (1979) paper used rats to demonstrate 
the first-pass effect and the work in paper [7] is the first to confirm it in humans. The 
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 liver must be “removing” a larger fraction of the absorbed folic acid dose in 
comparison to other folates (on first-pass) if the results from papers [3, 7] are to be 
reconciled with previous work that reports high absorption (~90%) of folic acid. By 
assuming that the absorption of all three folate doses was 90%, an estimate can be 
made of the first-pass effect for each folate. The folic acid dose (73±2%) had a 
significantly higher (P<0.05) fraction of the absorbed dose removed by the liver on 
first-pass than did 5-formyl (58±6%) and spinach folate (52±6%). Interestingly, Table 
2 of paper [7] contains data on the correlation coefficients of percentage first-pass 
effect versus fasting plasma folate concentrations which shows that there is a 
significant inverse (wrongly assigned in paper as being positive) correlation for folic 
acid (r=-0.703, P=0.005) and 5-formyl (r=-0.770, P<0.001) and a borderline inverse 
correlation with spinach folate (r=-0.507, P=0.054).  
 
Homeostatic control 
This suggests that the quantity of folate the liver removes on first-pass is under 
homeostatic control to ensure that the fasting plasma concentration of folate is 
maintained. Folate is a water soluble vitamin and cannot, therefore, be stored in lipid 
tissue. However, the finding from paper [3] that a large quantity of endogenous folate 
appears in the plasma after a meal does suggest that the liver has a short-term storage 
capacity. This observation, in conjunction with the inverse correlations seen in paper 
[7], lead to the conclusion that the liver sequestrates a certain fraction of newly 
absorbed folate to maintain fasting levels of 5-methylTHF. The biological 
mechanisms for this homeostatic control are unknown but warrant further 
investigation. It was originally speculated in paper [3] that the mechanism was the 
enterohepatic recirculation of folate. In hindsight, this overstated the role of 
enterohepatic recirculation in maintaining a fasting level of 5-methylTHF, as it is a 
process that happens infrequently, namely when the gall bladder is emptied following 
a meal, and therefore cannot be expected to contribute significantly to the overall 
plasma concentration.  
 
Explanation for delay in plasma appearance of folic acid derived folate  
Paper [3] also suggested that enterohepatic recirculation could explain the delay in 
appearance of labelled 5-methylTHF from a folic acid dose in comparison to that 
from other folate forms. A much more plausible theory for this phenomenon was put 
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 forward in a recent paper by Bailey & Ayling (2009). All forms of dietary folate are 
metabolised to 5-methylTHF by an enzyme called dihydrofolate reductase (DHFR). 
The Bailey & Ayling paper has shown that humans have a reduced capacity (more 
than 50-fold) to metabolise folic acid by DHFR compared to rats. That paper predicts 
that the absorption of a folic acid dose of 400µg would be metabolised by DHFR (in 
humans) in about an hour after peak absorption which would explain the delayed peak 
appearance of labelled 5-methylTHF, after the folic acid dose in papers [3, 7]. 
 
Paper [7] adds evidence to support the proposal that folic acid is handled differently to 
other folates by the human body. Until its publication, researchers had used the 
plasma appearance of unlabelled folic acid as a “reference” dose (usually presented as 
an AUC) as a standard against which to compare the relative bioavailability of other 
forms of folate. The work in papers [3, 7] has shown that this is invalid for two 
reasons. Firstly, large quantities of endogenous 5-methylTHF appear in the plasma 
after an oral dose of folates and there is no method of distinguishing this from the 
newly absorbed folate (paper [3]). Secondly, folic acid appears to be handled in a 
different way, compared to other forms of folate (paper [7]), which makes it 
unsuitable to use as a reference. 
  
The results from papers [3, 7], in conjunction with the work by Whitehead & Cooper 
(1967), Melikian et al (1971), Steinberg et al (1979) and Bailey & Ayling (2009) have 
explained why folic acid is handled differently, by humans, in comparison to other 
folates. The conclusion from all these studies is that human folate bioavailability can 
only be assessed properly by the use of labelled folates in combination with 
mathematical modelling. 
 
Collaborative work (I) 
Paper [5] provided details of a novel modelling approach to estimating bioavailability 
using labelled folate doses. Five volunteers were given two simultaneous oral doses of 
folic acid (13C and 2H labelled) and serial blood samples were collected for 8 hours 
(post-dose). The 13C-folic acid (dose=224µg) was in the form of a capsule and 2H-
folic acid (dose=207µg) was a drink. We took a similar modelling approach to the one 
that had been taken with iron (see papers [2, 10] and earlier discussion in the Iron 
section of the Critical Analysis). A priori identifiability suggested that a one or two 
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 compartment model would be feasible to estimate the absorbed mass of folate, from 
the plasma appearance of 5-methylTHF, over a minimum of 6 hours post-dose, using 
the same assumptions of zero-order absorption. It was thought to be more difficult to 
estimate folate bioavailability as compared to iron, since it was reported (in rats) that 
a significant fraction of newly absorbed folate did not appear in the plasma due to 
some of the folate being sequestered by the liver as a first-pass effect (Steinberg et al, 
1979; Steinberg, 1984). No attempt had ever been made to quantify this in humans. In 
addition, the volume of distribution of folate was not the plasma volume but was, in 
fact, a far larger space which Loew et al (1987) had estimated to be 387ml/kg body 
weight. After much preliminary work on model comparison (using AIC and BIC 
parameters), with the data generated from the study, it was decided that the one-
compartment model was preferable in terms of goodness of fit and simplicity. 
For paper [5], we focussed on estimating the first-pass effect and just assumed the 
fractional absorption of folic acid to be 90%, based on previous findings (89% - 
Clifford et al, 1998; 90% - Butterworth et al, 1969; 92% - Krumdieck et al, 1978). A 
large fraction of the absorbed folate was removed on first-pass (72±10%) which 
compared favourably to an estimate we made of work by Clifford et al (1998) that 
used accelerator mass spectrometry to measure the plasma appearance of a 14C-
labelled dose of folic acid. That paper had reported the most detailed study to date on 
human folic acid metabolism and, although it hadn’t estimated the liver first-pass 
effect, it was possible to quantify it from the data in the paper, to be about 65% 
(Finglas et al, 2002). The equivalent value of 72% in paper [5] is almost certainly an 
overestimate since non-metabolised folic acid was detected in the plasma (see Figure 
3a in paper [5]) but this wasn’t corrected for in the model (the model assumed that the 
entire labelled dose of folic acid had been converted to labelled 5-methylTHF). This 
“free” folic acid was a manifestation of the drawback in the design of this study 
(paper [5]) because the combined dose of folic acid from the capsule and the drink 
was 431µg which is above the known folic acid dose threshold (~300µg) when intact 
folic acid will appear in the plasma (Kelly et al, 1997). More reliability can be placed 
on the other data presented in the paper such as the absorption time (T), which is 
defined as:  
 
T=time for labelled folate plasma concentration to reach a maximum after test dose 
(Tmax) – time for labelled folate concentration to be detectable after test dose (Tlag) 
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 The absorption time (T) for folic acid from the capsule (T=146±38 minutes, 
Tmax=182 mins, Tlag=36 mins) was larger than that from the drink (T=122±21 
minutes, Tmax=122 mins, Tlag=0 mins). This compares with a Tmax of 173 minutes for 
the peak appearance of labelled 5-methylTHF from the folic acid capsules reported in 
paper [3]. 
 
Collaborative work (II) 
The combined methodology of stable isotope labelled folate and compartmental 
modelling was used successfully in two more studies [9, 11]. In paper [9] an attempt 
was made to estimate the “true” absorption of folic acid by taking account of the first-
pass effect. The study comprised 12 young (<30y) and 12 middle-aged (>50y) 
volunteers who were randomized into two groups to receive daily supplementation 
with 400µg of folic acid or 5-methylTHF for five weeks. Before and after 
supplementation, an oral test dose of 202µg 2H-folic acid was given to the volunteers 
to estimate their absorption and metabolism of folate. Leaving aside the post-
supplementation results, it is worth examining the data from the two age groups 
before supplementation (n=12 in each group). Folic acid apparent absorption was 
significantly higher (P=0.031) in the young (39±12%) compared to the middle aged 
adults (29±7%). This was an unexpected finding, and hadn’t been reported before. 
After supplementation with 5-methylTHF, the apparent absorption was lower and the 
differences between age groups less marked (33±10%; <30y and 28±11%; >50y). 
After supplementation with folic acid, the apparent absorption was higher for the 
young adults but about the same for the middle aged adults (43±8%; <30y and 
28±14%; >50y). It is difficult to interpret the “after supplementation” results as the 
group sizes were small (n=6) and a larger study would be needed to assess any 
differences in folate absorption after different supplements, but there is clearly a trend 
for younger adults to absorb more folate than middle aged adults. 
 
The first-pass effect was set to be a constant fraction (fraction of absorbed dose that is 
removed by liver = 0.65) of the absorption for all volunteers in both supplementation 
regimen based on previous work (Finglas et al, 2002). This figure would appear to be 
too high for the young volunteers (<30 y) as the estimated true absorption values are, 
on average, above 100%. The absorption values for the older volunteers appear to be 
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 more realistic (absorption=80 to 90%, approximately) so it is possible that the first-
pass effect is age dependent and that a range of 0.50-0.70 rather than a fixed, 0.65, is 
more appropriate. However, if the first-pass effect remains constant then a declining 
fractional absorption of folic acid with advancing age would explain the difference in 
relative absorption between the two age groups. This effect has been reported before 
for other micronutrients (e.g. calcium – Ebeling et al, 1992), and has important 
implications for the provision of nutritional advice for the over-50s age group. 
 
Collaborative work (III) 
Paper [11] uses compartmental modelling to estimate the apparent absorption of folate 
from unlabelled test foods and capsules containing either 5-methylTHF or folic acid. 
This paper also used ileostomists as subjects so that the predicted bioavailability from 
the modelling could be verified. Faecal balance in normal subjects cannot be used to 
assess bioavailability because the gut microflora can degrade folate. Nine ileostomy 
volunteers were recruited to the study; they each consumed the same seven test foods 
on different days and had serial blood samples taken for 10 hours (post-dose) on each 
occasion. The bioavailability of folic acid and 5-methylTHF were estimated from both 
the AUC and a model developed from previous work (papers [5, 7]). The volunteers 
also collected all their ileostomy effluent over the same 10 hour period, enabling an 
assessment of the quantity of non-absorbed folate to be calculated. To try and ensure 
that all volunteers had the same folate status prior to the test days, each consumed a 
daily capsule of 960µg folic acid. This is the so-called “presaturation” protocol that 
other unlabelled folate studies have used (Tamura & Stokstad, 1973). 
 
A single compartment model was sufficient to fit the plasma appearance data from all 
the test foods except for the bread, where two compartments were required. The 
second compartment was equivalent to modelling the absorption as a first order 
process. This results in a model that equates to the Bateman function (Equation 3, 
paper [11]). The apparent absorptions (median) of folate from the test doses were as 
follows: fermented milk 86%, fermented milk with folate binding protein (FBP) 62%, 
fermented milk pasteurised with FBP 55%, bread 74%, yeast crème 80%. Previous 
research (paper [3]) had found that the plasma response would consist of newly 
absorbed as well as endogenous folates. However, it was reasoned that the 
comparison of the results for each test meal would be easily interpretable because the 
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 nine volunteers had each of the test meals (randomised) in a cross-over design. 
Having established that endogenous folates would form part of the plasma response, 
one of the aims of pre-saturation was to minimise this and, also, to minimise any first-
pass effect. This probably explains why the apparent absorption values were higher 
than those seen in previous work (papers [7, 9]) using the same method. The excretion 
of 5-methylTHF as measured from the effluent samples is shown in Table 4 of paper 
[11].  
 
Paper [13] contains a summation of our work on modelling folate metabolism. The 
two main findings from papers [3, 5, 7, 9, 11] are, firstly, that folic acid appears to be 
absorbed to a lesser extent than other folate forms. This was surprising because many 
previous studies had demonstrated that about 90% of the dose is absorbed. The 
observation can be explained by assuming that folic acid is metabolised in the liver 
and all other folate forms are metabolised in the mucosal cells. The liver has a higher 
affinity for folic acid than other forms of folate and therefore it sequesters a higher 
fraction of absorbed folic acid, on first-pass, than it would if it were 5-methylTHF. 
The second important finding is that the 5-methylTHF peak appearance in plasma 
(after a folic acid dose) is about 80 minutes later than other forms of folate. This delay 
in plasma appearance after a folic acid dose is important because it had not been 
observed before with unlabelled folate doses and confirms the finding that the human, 
almost uniquely, has very low capacity to metabolise a folic acid dose to 5-
methylTHF.  A recent paper in PNAS (Bailey & Ayling, 2009) has demonstrated that 
the human DHFR activity is 50 fold lower than that of the rat. Their data suggest that 
a 400µg dose of folic acid will take about 60 minutes to be metabolised to 5-
methylTHF after peak absorption has occurred, which, for a liquid test dose, would 
happen about 40 minutes after ingestion of the dose. This suggests that the plasma 
peak in 5-methylTHF appearance, after a folic acid dose of 400µg, should be 
approximately 100 minutes. Paper [5] reported the time of maximum 5-methylTHF 
concentration (Tmax) to be 122±21 minutes, for a 207µg dose. Although paper [9] did 
not report the Tmax for the 202µg dose of folic acid, it was 119±39 minutes (J Dainty, 
unpublished). After correcting for the time taken for capsule dissolution 
(approximately 30 minutes), paper [7] reported a Tmax of about 140 minutes for a 
285µg dose of folic acid. These peak times to convert folic acid to 5-methylTHF are 
all longer than predicted by Bailey & Ayling (2009) but of the right order of 
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 magnitude. This suggests that the in vitro data overestimate the activity of in vivo 
DHFR by about 50% but further work is needed to clarify this. 
 
Paper [13] hypothesises that the reason many people living in the US have folic acid 
circulating in their plasma is that this form of folate is metabolised in the liver, not in 
the mucosal cells. The constant exposure of the liver to folic acid fortified products, 
coupled with its low DHFR activity, should lead to some folic acid appearing in the 
plasma. Evidence to corroborate this hypothesis has come from a large study in the 
US (Troen et al, 2006) that found 78% of 105 postmenopausal women had 
measurable fasting concentrations of folic acid in their plasma. This paper also 
showed a significant relationship between reduced natural killer (NK) cell toxicity 
and elevated levels of folic acid in plasma, which suggests that “free” folic acid 
compromises the immune function in some way. Other papers have suggested a link 
between high intake of folic acid and risk of colorectal neoplasia (Van Guelpen, 2005; 
Cole et al, 2007) and breast cancer (Stolzenberg-Solomon, 2006). These findings are 
particularly pertinent for the US which has had a mandatory folic acid fortification 
policy since 1998 and intakes of more than 1.0mg/d are not uncommon 
(Choumenkovitch et al, 2002; Quinlivan & Gregory, 2003). As the threshold dose for 
folic acid appearing in the plasma is about 0.3mg, it would not be surprising if a 
significant proportion of the US population have detectable concentrations of folic 
acid in their plasma. 
 
Conclusions 
Studies using labelled folates have led to the observation that (1) large quantities of 
endogenous folate appear in the plasma after a labelled folate dose, (2) folic acid is 
metabolised more slowly to 5-methylTHF and, is absorbed to a lesser extent, in 
comparison to test doses of 5-formylTHF and spinach folate. Mathematical modelling 
has helped to explain finding (2) by showing that more folic acid is removed on first-
pass through the liver than other folates. This indicates that folic acid is metabolised 
by the liver and other folates are metabolised by the mucosal cells. 
 
Future work 
The portal vein connects the GI tract to the liver and all newly absorbed folate must 
pass through it. By sampling this vein after a folic acid test meal, it would be possible 
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 to identify the folate form that enters the liver. In addition, in vitro studies predict an 
earlier plasma peak of 5-methylTHF, after a folic acid dose, than is observed from in 
vivo work. Modelling the enzyme kinetics of the conversion (by DHFR) of folic acid 
to 5-methylTHF could help to pinpoint why these differences arise. 
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 2.2.2 Carotenoids 
Epidemiological studies indicate that the consumption of foods rich in carotenoids is 
associated with a reduced risk for certain types of cancer and cardiovascular disease 
(e.g. Gey et al, 1993; van Poppel, 1993). There is controversy over the effectiveness 
of carotenoids to prevent disease because several studies have concluded that they are 
poorly absorbed (O’Neill & Thurnham, 1998; Castenmiller et al, 1999). These studies 
examined the plasma response after a test meal and found little or no change in the 
carotenoid concentration. However, another study hypothesised that, in fact, the 
absorption was quite high (greater than 50%) but the clearance from the plasma was 
so rapid that very little of the absorbed carotenoid could be observed (Faulks et al, 
1997). Paper [6] describes an experiment that tests this hypothesis. 
 
Methods used to assess carotenoid absorption 
There are four techniques that have been commonly used to assess bioavailability: 
1) Appearance of unlabelled carotenoids in plasma after a test meal (Brown et al, 
1989). 
2) Appearance of unlabelled carotenoids in the triglyceride rich lipoprotein 
(TRL) fraction in plasma after a test meal (van Vliet et al, 1995). 
3) Appearance of stable isotope labelled carotenoids in plasma after a test meal 
(Novotny et al, 1995). 
4) Appearance of radio isotope labelled carotenoids in faeces after a test meal 
(Dueker et al, 2000). 
 
Approach (1) has been discredited because it is not sensitive enough and requires 
pharmacological doses before any plasma response is observed (van den Berg, 2000). 
Techniques (3) and (4) are sensitive and selective for the absorbed dose but they are 
expensive and may require intrinsic labelling of the food under study for valid results. 
Approach (2) is relatively inexpensive and can be used with any food containing a 
relatively high concentration of carotenoid. At the time of publication of paper [6], 
approach (2) had been used by other groups but they had concluded that carotenoid 
absorption was quite low (van Vliet et al, 1995 - absorption=11%; O’Neill & 
Thurnham, 1998 – absorption=4%). The models used in these papers appear to 
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 calculate a low absorption because of an underestimation in the rate of clearance of 
carotenoid from the plasma. 
 
Novelty of study design 
Newly absorbed carotenoids are found in the triglyceride rich lipoprotein (TRL) 
fraction and these can be isolated from blood samples (Goodman et al, 1966). The 
TRL fraction consists of chylomicrons and chylomicron remnants (e.g. VLDL). The 
papers of van Vliet et al (1995) and O’Neill & Thurnham (1998) had measured 
carotenoid from the TRL and then estimated absorption with the assumption that the 
half-life of newly absorbed carotenoids in plasma was 11.5 minutes (mean of reported 
half-lives for chylomicron remnants). The study in paper [6] hypothesised that the 
true half-life of newly absorbed carotenoids is less than 11.5 minutes as the TRL 
contains a mixture of chylomicrons (Grundy & Mok, 1976: T1/2=2-5 minutes) and 
chylomicron remnants. To allow for individual variation, paper [6] estimates the half-
life of newly absorbed carotenoids for each subject in the study.  
 
To validate the modelling approach in paper [6], we recruited ileostomy subjects in 
order to collect their non-absorbed carotenoid. The carotenoid had not been degraded 
by colonic bacteria as it had only passed through part of the small intestine. This 
allowed a comparison of estimated absorption (by modelling plasma appearance of 
carotenoid) with actual absorption (measurement of unabsorbed carotenoid in the 
volunteers’ effluent, collected via the stoma).  
 
Some previous studies had used β-carotene capsules to test bioavailability (e.g. Traber 
et al, 1994), but the study reported in paper [6] examined the plasma response using a 
real food. Spinach was selected as the test meal as it was known to contain two types 
of carotenoid (lutein and β-carotene) in relatively large amounts. Nutrition advice is 
based on the consumption of food and it is important to clarify the bioavailability of 
carotenoids from commonly consumed meals, rather than supplements.  
 
Initial metabolism of carotenoids 
During the absorptive process, a variable fraction of the β-carotene is metabolised to 
retinyl ester in the enterocyte (Goodman et al, 1966; Parker et al, 1996) followed by 
both species being packaged into chylomicrons and transported out of the enterocyte. 
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 At the time of publication of paper [6], very little was known about the initial 
metabolism of absorbed lutein and it was assumed that it was carried in the 
chylomicrons, in an identical way to that of β-carotene. 
 
Modelling approach 
Carotenoids are absorbed into the enterocyte, incorporated into chylomicrons and 
secreted into lymph before appearing in the plasma. This will lead to a delay in their 
peak plasma appearance and, coupled with an expected slower absorption linked to 
the need to break down the food structures in the gut, it was decided to sample the 
plasma every two hours over a 12-hour period. Due to the expected variation in the 
measurements and possibility that the appearance of carotenoid would be limited, a 
very simplistic view of the TRL kinetics was taken and it was assumed that the 
plasma clearance would be acceptably modelled as a single compartment. The 
modelling strategy was to measure the area under the curve (AUC) of the carotenoid 
plasma TRL response over time, and then calculate a clearance rate constant (k), so 
that the model estimated fractional absorption was similar to that based on the 
recovery of carotenoid in the ileostomy effluent. The carotenoid half-life (T1/2) in 
plasma is related to the clearance rate constant (k) by the simple expression, 
T1/2=loge2 / k. The requirements for this approach to work are: (1) the carotenoid 
plasma concentration (in the TRL fraction) must return to baseline within the 
timeframe of the experiment, (2) that a single compartment is adequate 
(mathematically) to model the change in plasma appearance of carotenoids, (3) all of 
the absorbed carotenoid (β-carotene or lutein) is contained in the TRL and, (4) no 
significant cleavage of the absorbed β-carotene and lutein takes place in the 
enterocyte prior to them being packaged into chylomicron (we only measured the 
quantity of β-carotene and lutein in the TRL, not the retinyl ester). 
 
Summary of results 
Whole or chopped-leaf cooked spinach (in 150g portions) were fed to volunteers 
(n=7, paired), with vegetable oil in yoghurt. The quantity of lutein was approximately 
15mg in each spinach portion and there was approximately 10mg of β-carotene, in the 
same portion. The results of the study were slightly disappointing. As other studies 
had reported, none of the volunteers had measurable carotenoid plasma concentrations 
(e.g. van Vliet, 1995). The isolated TRL fraction did have measurable carotenoid 
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 concentrations for three (out of six) volunteers but only in two of these did the 
concentration return to baseline by the end of the 12 hour study period. Volunteers 
with the highest absorption (C and F) did not show any plasma TRL response.  
 
Table 2 (in paper [6]) details the results for the two volunteers whose temporal plasma 
concentration data was applicable for modelling. The Table shows the estimated 
absorption of carotenoid for six different half lives of TRL clearance. We expected 
there to be a “common” half-live, for each volunteer, that would allow the model to 
correctly estimate both lutein and β-carotene absorption in whole and chopped leaf 
spinach. Comparison of Tables 1 and 2 (paper [6]) suggest that the model 
underestimated the lutein and β-carotene absorption from whole leaf spinach in three 
out of the four instances where data was obtained. Lutein and β-carotene absorption 
from chopped leaf spinach was more successfully estimated by the model, with the 
same plasma TRL half-life for volunteer B (T1/2=8 minutes for lutein and β-carotene 
clearance) and approximately the same for volunteer G (T1/2=~3 minutes for lutein 
and β-carotene clearance). 
 
Limitations of the study 
There are several limitations to the study design that affect the ability of the model to 
accurately predict the quantity of β-carotene and lutein that has been absorbed from 
the spinach. 
First, previous studies of initial lutein (post-absorption) kinetics, have found that it 
peaks in plasma later (Kostic et al, 1995 – 16 hours; Yao et al, 2000 – 16 hours; 
Kurilich et al, 2003 – 11 hours; Burri & Clifford, 2004 – 11 hours) than an equivalent 
β-carotene dose (6-8 hours). This suggests that β-carotene and lutein are transported 
and cleared from the plasma in different ways. Therefore, some of the absorbed lutein 
may not have appeared in the plasma TRL fraction but could have been transported in 
plasma by another, unmeasured carrier. This will lead to an underestimation of lutein 
absorption and could explain why half the volunteers had no measurable lutein in 
their TRL. 
Second, a large fraction of the absorbed β-carotene will, potentially, be converted to 
retinyl esters in the enterocytes. This fraction has been estimated to be more than 50% 
of the total 14C-label from a β-carotene test meal (Lemke et al, 2003; Burri & Clifford, 
2004; Ho et al, 2009). Interestingly, Burri & Clifford (2004) also show data to suggest 
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 that only 70% of the total 14C plasma concentration peak at 6-hours (post 14C-labelled 
β-carotene dose) is accounted for by the sum of the contribution from labelled β-
carotene and retinyl esters. The consequence of this for the study reported in paper [6] 
would be that the majority of the absorbed spinach β-carotene was not measured. 
Again, this will lead to an underestimation of β-carotene absorption and could explain 
why half the volunteers had no measurable β-carotene in their TRL. 
Third, the isolated TRL fraction contains two entities with different half-lives in 
plasma (chylomicrons, T1/2 ~2-5 minutes; chylomicron remnants (VLDL), T1/2~11 
minutes). There is no way of distinguishing the two different components and, 
therefore, no mechanism of modelling their different kinetics. Without the validation 
from the measurement of non-absorbed carotenoid in the ileostomy effluent, it would 
have been impossible to choose the “correct” half-life for carotenoid clearance. 
 
Conclusions 
When the half-life of the TRL in the plasma is set in a range between 2-11 minutes, 
the predicted model absorption for lutein and β-carotene from chopped leaf spinach is 
similar to that estimated by analysis of ileostomy effluent. Only three of the six 
volunteers had measurable carotenoid concentrations in their plasma TRL fraction 
even though “true” absorption was reasonably high. The model is not a reliable 
method for the estimation of carotenoid absorption. 
 
Future work 
The use of labelled carotenoid studies appears to be the only reliable way to assess 
absorption, other than using ileostomists. Stable isotope labelled carotenoids can be 
measured accurately in plasma and urine, but not in faeces. This makes absorption 
estimates difficult but stable isotope labels are useful for tracing the metabolic fate of 
ingested carotenoids. Extremely small doses of 14C labelled carotenoid can be traced 
in plasma and faeces for over 100 days using AMS. Future bioavailability work 
should focus on 14C labelled studies.
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 2.2.3 Riboflavin 
Riboflavin is a B vitamin that is the central component in the co-factors flavin adenine 
dinucleotide (FAD) and flavin mononucleotide (FMN) and is, therefore, vital in a 
wide variety of cell processes. Green leafy vegetables, meat and milk are all good 
sources of riboflavin but very little is known about the bioavailability from food. The 
study in paper [12] was designed to measure the absorption of riboflavin from 
commonly consumed foods. 
 
Requirement for bioavailability studies 
At the time of publication of paper [12], the scientific literature did not contain any 
studies that had investigated the human bioavailability of riboflavin from food. 
Although this was unexpected, it was probably related to the apparent consensus that 
riboflavin deficiency was not a significant problem. Influential studies by Sauberlich 
et al (1972) and Boisvert et al (1993) had demonstrated that the measurement of the 
erythrocyte glutathione reductase activity coefficient (EGRAC) was a reliable 
indicator of riboflavin deficiency. From these studies, it appeared that a dietary intake 
of 1.2mg/d was adequate for most people to remain below the EGRAC cut-off for 
deficiency (=1.4). However, recently, the National Diet and Nutrition Survey of 
British Adults (Henderson et al, 2003) reported biochemical riboflavin deficiency in 
between 54% and 80% of the population, and the National Diet and Nutrition Survey 
of Young People aged 4–18 y (Gregory & Lowe, 2000) reported biochemical 
riboflavin deficiency in 95% of adolescent girls. On examining the riboflavin intakes 
from these studies, it became clear that the populations with riboflavin deficiency 
were consuming the recommended daily amounts of riboflavin. This led to our 
hypothesis that the foods being consumed by the deficient individuals, had low 
riboflavin bioavailability. To test this, we designed a study that fed two stable isotope 
labelled foods (milk and spinach) to female volunteers and collected blood and urine 
to estimate absorption by mathematical modelling (paper [12]). 
 
Novelty of study design 
There are a number of original features of the experimental design in study [12]. It 
was the first riboflavin study to administer stable isotope labels to volunteers and it 
was the first to estimate the quantity of riboflavin absorbed from food. Riboflavin was 
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 synthesised with different labels (milk: 13C-ribolflavin as an extrinsic label; spinach: 
15N-riboflavin as an intrinsic label). A 13C labelled intravenous dose of riboflavin was 
also synthesised, which was administered with the test meals. It is well known in trace 
element work that this type of “dual” stable isotope method can estimate the 
absorption of a labelled dose from plasma and/or urine samples (Turnlund, 1991). The 
labelling of the spinach and milk meant that the labelled riboflavin from these meals 
would be handled identically, in vivo, to the unlabelled vitamin. The two foodstuffs 
were chosen because they have completely different food matrices and this made it 
possible to investigate whether riboflavin absorption is matrix dependent. In addition, 
milk contains ‘free’ riboflavin bound to specific binding proteins, in contrast to most 
foodstuffs (e.g. spinach) that contain predominantly FAD and riboflavin phosphate, 
tightly bound to enzymes. These different “forms” of riboflavin would be labelled 
within the foods and their metabolic fate could be traced in plasma and urine to 
extract more detailed kinetic information. 
 
Compartment model 
The kinetics of riboflavin had been investigated before (Zempleni et al, 1996), but 
that study used very high, non-physiological doses of riboflavin, up to 60 times higher 
in quantity than the RNI. It also used unlabelled doses which made it difficult to 
distinguish between newly absorbed and endogenous riboflavin.  
The study in paper [12] required extensive mathematical modelling to estimate a 
number of important kinetic parameters including the riboflavin pool size, volume of 
distribution and rate of elimination from the plasma. A two compartment model was 
deemed most appropriate to represent the plasma appearance of riboflavin from a 
labelled meal. This decision was taken after extensive “goodness of fit” tests, both 
before and after data collection. The movement of absorbed, labelled riboflavin into 
the plasma volume is modelled as a zero order process as was the case with previous 
work on iron (papers [2, 10]) and folate (papers [5, 7, 9]). 
 
Study design 
The study used a cross-over design, with a sample comprising 20 female volunteers 
randomly assigned to consume either 734µg riboflavin (334µg unlabelled, 400µg 
labelled) in whole milk or 642µg riboflavin (334µg unlabelled, 308µg labelled) in 
spinach soup. An intravenous dose of 200µg of free riboflavin (labelled) was 
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 administered as a bolus whilst the volunteers consumed their test meals. Four weeks 
later, the study was repeated with the other test meal. Serial blood samples were 
collected for up to 7 hours on the test day. 24h urine samples were collected for 3 
days over the study period, starting at 24h before the test meals.  
 
Novel findings 
Results in Figures 2 and 4 of paper [12] indicate that the riboflavin in the milk and 
spinach appeared as “free” riboflavin in the plasma, not FMN or FAD (no labelled 
FMN or FAD was detected in the plasma for any volunteer).  The peak in plasma 
appearance for riboflavin from the milk (24±13 minutes) was slightly earlier than that 
from the spinach (35±12 minutes) which may reflect the fact that riboflavin from milk 
is in the free form and did not have to undergo any conversion before appearing in the 
plasma. The riboflavin from spinach is largely FMN and had to undergo conversion to 
free riboflavin. This may also account for the differences in the rate constants from 
the model (see Table 4 in paper [12]). The apparent absorption of riboflavin from 
milk (23±21%) was not significantly different from that of spinach (20±11%). These 
estimates were obtained using the plasma appearance of absorbed, labelled riboflavin 
in conjunction with the 2-compartment model. The true absorption of riboflavin from 
milk (67±21%) was not significantly different from that of spinach (60±30%). These 
estimates were obtained using the dose corrected ratio of urinary appearance of 
labelled riboflavin from the oral and intravenous doses, over the 48h period post 
dosing. The intravenous dose was also used to quantify the apparent volume of 
distribution of riboflavin in the sampled compartment, and it was found to be 
549±71ml/kg body weight. 
 
It is speculated that the large discrepancy between true and apparent absorption is due 
to the liver sequestering a large fraction of the absorbed riboflavin from the portal 
vein before its appearance in the general circulation. We estimate this first-pass effect 
to be something of the order of 60% of the absorbed dose. This is similar to the 
findings with folate (papers [3, 5, 7, 9]) and is probably common to all water soluble 
vitamins in order for the body to maintain stores and to prevent the fasting 
concentration becoming too low. It is also interesting to note that there appears to be 
no difference in absorption between riboflavin from milk and that from spinach. Both 
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 are quite well absorbed and validate the analysis used to set the dietary reference 
values for riboflavin (Department of Health, 1991). 
 
Conclusions 
The model predicted a large first-pass effect in line with previous work on other water 
soluble vitamins (folate - paper [7]; vitamin C - Bates et al, 2004; Bluck et al, 2005). 
This means that the compartmental model cannot be used to assess true absorption by 
plasma appearance but could be useful in measuring relative absorption of several 
sources of riboflavin. True absorption of riboflavin can be estimated by urinary 
monitoring of the appearance of oral and IV labelled riboflavin. 
The study makes a useful contribution to the knowledge of riboflavin bioavailability 
and leads towards a conclusion that the perceived problem of riboflavin deficiency, as 
indicated by biochemical indices, may need to be reassessed. The threshold for 
deficiency (EGRAC > 1.4) could be changed depending on the outcome of future 
work (see below). 
 
Future work 
It would be interesting to repeat the study with a larger sample size and different 
foods. The volunteers would need to be better characterised in terms of biochemical 
indices of riboflavin deficiency (e.g. EGRAC) and food diaries kept for a month to 
determine dietary intake. This would enable a clear link to be made between daily 
quantity of riboflavin absorbed and riboflavin status. 
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 3. Conclusions 
It has been demonstrated that stable isotope labels, in conjunction with compartmental 
modelling, can make useful contributions to the study of human mineral and vitamin 
metabolism. In particular, significant progress has been made in studying the 
bioavailability of iron and folate. It is now possible to quantify the absorption of iron 
from an unlabelled dose which should benefit those areas of research where iron 
particle size or chemical species is a factor in determining what quantity of iron can 
pass across the mucosa. Labelled folate studies have demonstrated for the first time 
that folic acid is handled very differently from other forms of folate, in vivo. This has 
major implications for countries where folic acid is used as a food fortificant, since 
we hypothesise that it is metabolised in the liver, not in the mucosa. The biological 
implications of this finding are beyond the critical review but it warrants further 
investigation, especially as many people living in the US have detectable levels of 
folic acid circulating in their plasma. The modelling of the plasma appearance of 
newly absorbed, labelled folate has also allowed an estimate of its bioavailability after 
assumptions are made regarding the volume of distribution, and fraction removed on 
first-pass through the liver. This technique has been successfully applied in many 
other folate studies and also in the first stable isotope labelled riboflavin study. An 
unlabelled carotenoid study used modelling to estimate the absorption of β-carotene 
and lutein from whole and chopped leaf spinach. It was concluded that the assessment 
of carotenoid bioavailability was more accurately estimated using isotopic labels. 
New insights into the kinetics of calcium and copper have been obtained from the 
papers outlined in this thesis. A moderately high salt intake significantly affects bone 
calcium balance with a high calcium diet in comparison to a low calcium diet.  
Finally, the copper compartmental model is the most detailed of its kind to be 
developed. The higher than expected endogenous losses and large liver first-pass 
effect are new insights into the way this mineral behaves in vivo.
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Holmium as a faecal marker for copper
absorption studies in adults
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A B S T R A C T
The objective of the present study was to investigate the validity of using holmium as a faecal
marker in a copper absorption study using a highly enriched 65Cu stable isotope label. Ten
volunteers (nine female, one male) aged 24–55 years were recruited from the Norwich area to
take part in a free-living study. The study was conducted in the Human Nutrition Unit at the
Institute of Food Research, Norwich, U.K., and involved feeding breakfast test meals containing
foods labelled intrinsically or extrinsically with a highly enriched 65Cu stable isotope label. A
1 mg oral dose of the rare earth element holmiumwas administered to volunteers simultaneously
with an oral dose of highly enriched 65Cu stable isotope as a label in the breakfast test meal.
Complete faecal collections were made for 10 days after dosing, and the mean percentage
holmium recovery (‡S.D.) was 105‡15%. After correcting for re-excreted copper label, the
labelled copper and holmium had similar excretory profiles. It was concluded that holmium is a
valid faecal marker in adult human copper absorption studies using stable isotopes.
INTRODUCTION
Copper homoeostasis in the human body is maintained
by changes in both the absorptive efficiency in the gut
and biliary copper excretion. Therefore an estimate of
endogenous copper losses is essential in order to measure
true copper absorption. Assessments of copper absorp-
tion in human studies have traditionally relied solely on
the use of the faecal monitoring technique using stable
isotopes. In order to accurately determine true copper
absorption using the faecal monitoring technique, it is
essential that complete faecal collections are made for
at least 10 days and that the quantity of re-excreted
copper label is estimated [1]. Faecal monitoring is time-
consuming and unpleasant, which may result in volunteer
non-compliance. Therefore it is important to have an
accurate method for determining completeness of faecal
Key words: adults, copper absorption, holmium, rare earth element, stable isotope.
Abbreviations: AAS, atomic absorption spectrometry; ICP-MS, inductively coupled plasma MS.
Correspondence: Dr Linda Harvey (e-mail linda.harvey!bbsrc.ac.uk).
collection. An ideal faecal marker would have an identical
excretory profile to that of copper, be completely non-
absorbable and allow the delineation of non-absorbed
copper stable isotope excretion from that which is due
purely to re-excretion. In addition, any such marker must
be of naturally low abundance in the diet and easily
quantifiable.
The rare earth elements are a group of 14 inert elements
(lanthanides) that are found in trace amounts in the diet,
are absorbed in negligible quantities by the mammalian
gastrointestinal tract [2–4] and are non-toxic [5].
Hutcheson et al. [3] suggested that rare earth elements
could be used to monitor various nutrients without
monitoring food intake directly, as the rare earth element
content of food was found to be negligible. Several
workers have suggested the use of rare earth elements as
faecal markers in mineral absorption studies involving
# 2002 The Biochemical Society and the Medical Research Society
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stable isotopes, but published data are somewhat limited.
In particular, there is a lack of satisfactory studies on the
validity of using holmium for this purpose in copper
absorption studies.
In the present paper we report data from a study
undertaken to evaluate the usefulness of the rare earth
element holmium as a non-absorbable faecal marker in
copper isotope absorption studies. The holmium data
also allow the re-excretion of the label to be accurately
quantified. All data presented here formed part of a larger
study investigating copper absorption from a variety of
foods labelled either intrinsically or extrinsically with a
highly enriched ’&Cu label. The absorption data will be
published separately.
METHODS
Subjects
Volunteers were recruited through advertisements placed
in the Norwich area. Ten healthy adult volunteers (nine
female, one male) were recruited to take part in the study;
subject characteristics are given in Table 1. A 10 ml blood
sample was taken from each volunteer for clinical
screening to ensure that biochemical indices and haemato-
logical measurements (MD 8 Coulter Counter), including
haemoglobin, haematocrit and mean red cell volume,
were within the normal range. Other exclusion criteria
included chronic illness, the taking of medication or
nutritional supplements, and smoking. The study proto-
cols were explained to the volunteers and written,
informed consent was obtained. The research was carried
out in accordance with the Declaration of Helsinki (1989)
of the World Medical Association and the protocol was
approved by the Norwich District Ethics Committee.
Study design
The study involved the measurement of copper ab-
sorption from a range of test meals consisting of foods
labelled either intrinsically or extrinsically with a maxi-
mum of 3 mg of highly enriched (99.6%) ’&Cu stable
isotope or from a 3 mg reference dose in a diet cola drink
(data to be published elsewhere). Details of the com-
position of the test meals are given in Table 2. Following
Table 1 Subject characteristics
Data are for 10 subjects (nine female, one male).
Parameter Mean (S.D.) Range
Age (years) 37 (9) 24–55
Height (m) 1.71 (0.06) 1.63–1.83
Weight (kg) 75.4 (17.8) 60.0–120.6
Body mass index (kg/m2) 25.6 (4.4) 20.8–36.0
an overnight fast, test meals were administered in the
Human Nutrition Unit, with a minimum interval of 4
weeks between meals. A 1 mg oral dose of holmium was
given with the test meal, either incorporated into the test
food or in a diet cola drink with the meal. Volunteers
refrained from eating for a period of 4 h after dosing.
Radio-opaque faecal markers were given with each test
meal and also with breakfast on the subsequent three
consecutive mornings (a total of 40 markers). Complete
faecal collections were made for 10 days following the
test meal plus a baseline sample. Complete recovery of all
radio-opaque markers in the faecal samples confirmed
volunteer compliance. All subjects consumed their ha-
bitual diet during the course of the study.
Dose preparation
Isotopically enriched copper chloride (’&CuCl
#
) was
prepared from elemental ’&Cu (Europa Scientific Ltd,
Crewe, U.K.) by dissolving the metal in 10 ml of
concentrated HNO
$
(BDH, Poole, Dorset, U.K. ; Aristar
grade) and evaporating to virtual dryness. The sample
was then taken up in 25 ml of 0.1 M HCl (BDH; Aristar
grade) and again evaporated almost to dryness ; this stage
was then repeated twice more, and finally the sample was
taken up in an appropriate volume of 0.1 M HCl. The
solution was divided into individual doses and stored in
plastic vials at fi20 °C until required. The concentration
was determined accurately by atomic absorption spec-
trometry (AAS).
The holmium oral doses were prepared by dissolving
holmium chloride (Avocado Research Chemicals Ltd,
Heysham, Lancs., U.K.) in demineralized, purified water
(Elga, Cambridge, U.K.) to a concentration of approx.
0.5 mg}ml. The solution was divided into individual
1 mg doses and stored in plastic vials at fi20 °C until
required. The concentration was determined accurately
by inductively coupled plasma MS (ICP-MS).
Production of intrinsically labelled food
Sunflower (Helianthus annuus) seeds and soya beans
(Glycine max) were intrinsically labelled with the highly
enriched ’&Cu stable isotope by cultivating the plants
using hydroponic techniques [6]. Copper concentrations
and isotope enrichments were determined by AAS and
ICP-MS respectively.
Sample preparation and analysis
Faecal samples were autoclaved, freeze-dried, ground to
a fine powder in a mortar and pestle and sub-sampled.
The number of radio-opaque markers in each sample was
recorded. Two 0.5 g replicates of each powdered faecal
sample were microwave-digested until a clear solution
was obtained. For quantitative analysis of copper and
holmium, 1 ml of the acid digest was diluted to 10 ml
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Table 2 Details of test meals administered
Test meal
No. of
subjects Meal details
Reference dose 10 3 mg of 65Cu and 1 mg of Ho in a 125 ml diet cola drink
Red wine 10 3 mg of 65Cu and 1 mg of Ho in 125 ml of red wine (1996 Co# tes du Rho# ne)
Extrinsically labelled mushrooms 10 3 mg of 65Cu and 1 mg of Ho added to a mushroom soup (350 g of mushrooms blended with 6.5 g of
butter, 143 g of demineralized water and seasoning)
Extrinsically labelled sunflower seeds 8 1 mg of 65Cu in 37.5 g of sunflower seed butter (25 g of finely chopped sunflower seeds with 12.5 g of
butter) served on 35 g of toasted white bread ; 1 mg of Ho was given simultaneously in 125 ml of diet cola
Intrinsically labelled sunflower seeds 8 1 mg of 65Cu in 75 g of sunflower seed butter (50 g of finely chopped intrinsically labelled sunflower seeds
with 25 g of butter) served on 70 g of toasted white bread ; 1 mg of Ho was given simultaneously in 125 ml
of diet cola
Extrinsically labelled soya beans 5 3 mg of 65Cu and 1 mg of Ho in 450 g of cooked and homogenized soya beans
Intrinsically labelled soya beans 9 0.3 mg of 65Cu and 1 mg of Ho in 450 g of cooked and homogenized soya beans
Table 3 Typical ICP-MS operating conditions
RF, radio frequency ; AMU, atomic mass unit.
Parameter Value
RF power (W) 1350
Gas flow (litres/min)
Coolant 14.0
Auxiliary 0.7
Nebulizer 0.80
Spray chamber temperature (°C) 4
Dwell time (ls) 320
Mass range for scan (AMU) 110–239
No. of channels per AMU 19
No. of runs per sample 3
Holmium internal standard Bismuth
using purified water. The remaining digest solution was
used for isotope ratio analysis by ICP-MS after sep-
aration of bivalent cations, including copper, from
univalent cations and other contaminants, using ion-
exchange chromatography. The precision of the
’$Cu}’&Cu ratios was 0.46%. Analysis of GBW 07605
certified reference material tea (Cu 17.3‡3 lg}g) for
copper gave a mean value of 16.2‡1.0 lg}g (n fl 4).
Samples were analysed quantitatively for copper by AAS
using a Thermo-Unicam Solaar 969 atomic absorption
spectrophotometer, which had been calibrated with
standards prepared from 1000 mg}l SpectrosoL (BDH)
stock solution. Measurements were made as described
previously [7]. Holmium was quantified by ICP-MS
using a VG PQ2› instrument (VG Elemental, Winsford,
Cheshire, U.K.). Typical operating conditions are given
in Table 3.
Mathematical analysis
Some calculations are necessary in order to estimate the
quantity of recovered copper label that has been re-
excreted. Firstly, the mole fraction of labelled copper in a
stool is defined as the quantity of recovered copper label
divided by the quantity of recovered total copper (all
corrected for differences in molecular mass). The cal-
culation of this is shown in the Appendix. Assuming that
all subsequent stools after the complete collection of
holmium only contain re-excreted labelled copper, it is
possible to plot the mole fraction of labelled copper
against time for these latter stools, fit a straight line
through the points (in the form y fl mx›c) and ex-
trapolate back to the time of dose administration. This
allows the calculation of the mole fraction of re-excreted
labelled copper in the earlier stools. Knowledge of this,
along with the measured total copper content in those
stools, permits calculation of the quantity of re-excreted
copper label in each stool, which can be applied as a
correction to estimate the true absorption of the labelled
copper dose.
All data are expressed as means (‡S.D.). Correlation
analysis was used to compare the excretory patterns of
labelled copper and holmium.
RESULTS
A mean percentage faecal recovery (‡S.D.) of 105‡15%
was obtained for the holmium dose; the baseline faecal
sample for each volunteer contained only negligible
amounts of holmium. In all cases, the unabsorbed copper
label and the holmium had very similar excretory
patterns, and there was also no difference in holmium
recoveries between the different test meals. Individual
transit times of the volunteers varied; however, the ma-
jority of the holmium was generally recovered in the
faeces within 6 days after dosing. There was no difference
in the excretory profile of either copper or holmium
when the copper dose was given as an intrinsic or an
extrinsic label.
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Figure 1 Examples of excretory patterns of the rare earth
element holmium (points) and a highly enriched 65Cu stable
isotope label (bars)
Excretory patterns were recorded following a reference dose test meal (top panel ;
volunteer 230), (b) a mushroom test meal (middle panel ; volunteer 540) and (c)
a red wine test meal (bottom panel ; volunteer 507)
Figure 2 Example of the recovery (in lg) of re-excreted
label following complete collection of the holmium dose
(volunteer 230)
Figure 1 (top panel) and Figures 2–4 represent data
from one subject following a single test meal, and are
shown to illustrate the general trend of results among the
group of volunteers. Examples of excretory patterns of
holmium and copper label following different test meals
Figure 3 Example of the recovery (in mole fraction) of re-
excreted label following complete collection of the holmium
dose (volunteer 230)
For definition of mole fraction, see the Mathematical analysis section in the text.
Figure 4 Example of the calculation of mole fraction of re-
excreted copper label (volunteer 230)
are illustrated in Figure 1. The holmium was completely
recovered within 3–6 days after dosing, and at this point
it was assumed that all subsequent stools contained re-
excreted labelled copper. Figure 2 displays the recovered
re-excreted label against time for the same volunteer as in
Figure 1 (top panel). The excretory pattern appears to be
a random series of recoveries. By converting the same
data into the mole fraction of recovered, re-excreted label
against time (Figure 3), a trend emerges. A straight line of
the form y fl mx›c was fitted through these points,
which allowed an extrapolation back to the time of dose
administration, thus giving an estimate of the mole
fraction of re-excreted label in the earlier stools. For each
stool, the quantity of labelled, re-excreted copper can be
estimated from the mole fraction and the quantity of total
copper in the stool (see Appendix for details). Figure 4
shows how the estimated quantity of labelled, re-excreted
(endogenous) copper varies with time. The quantity of
re-excreted label in each stool is used to correct the
amount of recovered labelled copper. An estimate can
then be made of the unabsorbed copper from the
administered dose. The total recovery of rare earth and
label (corrected and uncorrected) can be calculated by
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Figure 5 Relationship between copper label (uncorrected
for endogenous loss) and holmium in individual stools
(volunteer 230)
The broken line represents the line yfl x. The solid line represents the linear best
fit through the data points.
Figure 6 Relationship between copper label (corrected for
endogenous loss) and holmium in individual stools (volunteer
230)
The broken line (overlaid by the solid line) represents the line yfl x. The solid
line represents the linear best fit through the data points.
summing all the holmium and labelled copper (corrected
and uncorrected for re-excreted label) in the volunteer’s
stools. If the individual stool recoveries are then divided
by total recoveries, the fractions of holmium and label
in each stool can be calculated. These are plotted against
each other in Figure 5 (uncorrected label recovery) and
Figure 6 (corrected label recovery). The slope (‡S.E.M.)
of the line in Figure 5 is 0.84‡0.01, and that in Figure 6
is 0.99‡0.01. A slope equal to 1 would indicate that the
copper and holmium share identical excretory patterns.
DISCUSSION
Copper absorption can be described as a three-stage
process, consisting of uptake from the gastrointestinal
lumen by the mucosal cells, intra-enterocyte transfer and
serosal transport into the systemic circulation. Copper
that has not been transported into the body, but is lost
through mucosal cell exfoliation, is usually not classified
as absorbed. When copper is absorbed into the circulation
it is transported rapidly to the liver as a complex bound to
serum albumin, amino acids and possibly transcuprein
[8,9], where it is incorporated into the long-term trans-
port protein caeruloplasmin. Copper excretion from the
body is achieved via the secretion of bile and other
intestinal secretions such as pancreatic juice [8]. Copper
homoeostasis in the human body is maintained by
changes in both the absorptive efficiency in the gut and
biliary copper excretion. When measuring absorption,
the difference between labelled copper intake and ex-
cretion in faeces (i.e. luminal disappearance) is defined as
apparent absorption. However, when an allowance is
made for the re-excreted copper, the term true absorption
is used. Previous studies have used rare earth elements as
non-absorbable faecal markers to delineate the excretion
of unabsorbed isotope from endogenous secretion, and
also to correct for completeness of collection [10,11]. To
date, however, there has been no validation of the
reliability of using the rare earth element holmium as a
faecal marker in ’&Cu stable isotope studies.
In order for rare earth elements to be valid markers in
mineral absorption studies, it is essential that they are
completely non-absorbed and have similar temporal
patterns of excretion. If both criteria are met, it is then
possible to use rare earth element methodology to reduce
the period of faecal collection to a few days if only
apparent absorption data are required. For the estimation
of endogenous losses of copper, it is still essential to
collect individual stools for about 10 days. It should be
noted that a complete recovery coupled with dissimilar
excretory patterns only permits the use of rare earth
elements as markers of complete faecal collection by the
subject.
Previous studies have evaluated the use of various rare
earth elements as faecal markers in human stable isotope
studies. Dysprosium has been used as a quantitative
faecal marker in human mineral absorption studies, where
the excretion kinetics were found to parallel those of zinc
and magnesium, but not copper [10]. However, in all
cases dysprosium recovery from the faeces was complete.
A more recent study has supported these earlier findings,
concluding that dysprosium does not share the same
excretory pattern as copper and therefore is not a valid
faecal marker [12]. However, in that study, faecal samples
were collected for only 4 days post-dosing in three
volunteers and for 14 days in a fourth volunteer, which
meant that complete recovery of the dysprosium dose
was only achieved in the last volunteer. In order to verify
the validity of rare earth elements it is essential to attempt
complete recovery of the dose and, therefore, only limited
conclusions can be drawn from these data. The complete
recovery of the rare earth elements samarium and
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ytterbium has been reported previously in human studies
[11,13,14]. In one of the studies, samarium was adminis-
tered with iron as a highly enriched &(Fe label, ytterbium
with a highly enriched &)Fe label and dysprosium with a
highly enriched &%Fe label [11]. In each case there was
complete recovery of the rare earth element, and the
excretory patterns of the iron isotopes and the rare earth
elements were very similar. As a result, predicted values
of iron absorption from the first 4 days of pooled faeces
using rare earth element recovery data were in close
agreement with the measured values.
The holmium used in the present study was found to
be virtually unabsorbed in the gastrointestinal tract, as
demonstrated by its complete recovery. In addition, the
negligible holmium content of the baseline faecal samples
demonstrated that the habitual diets of the volunteers
contained only trace amounts of holmium. Any
significant contribution of holmium from either the test
meals or the habitual diets of the volunteers would have
caused an increase in faecal holmium recovery. Therefore
all holmium recovered in the faeces originated from
the holmium dose. The strong correlation between the
excretory patterns of holmium and unabsorbed copper
label demonstrates the validity of using holmium as a
predictor of apparent copper absorption. This could be
achieved by measuring the holmium content of all the
stools and the copper label content of any of the first
three. All the other stools could then have their copper
content estimated from the pattern of holmium recovery.
In order to calculate true copper absorption, it is
necessary to quantify the endogenous copper losses. This
can only be achieved by collecting individual stools for
approx. 10 days and analysing each sample for copper
and holmium. The first recovered stool that does not
contain holmium indicates that any copper label found in
that, and subsequent, stools has been absorbed previously
(Figure 1). Figure 2 shows how the quantity of this re-
excreted labelled copper varies with time.
In order to correct content in preceding stools for
endogenous losses, an estimate needs to be made of re-
excreted copper isotope. There are several potential ways
to do this. One method is to fit a line to the re-excreted
labelled copper against time data (Figure 2) and ex-
trapolate it back to the point of label administration. It
can be seen from Figure 2 that this approach is not valid,
because the quantity of copper in these stools is de-
pendent not just on the amount of re-excretion but also
on the quantity of the stool material collected. This will
vary in a random manner, as can be seen clearly in Figure
2. The variation with time of the mole fraction of re-
excreted labelled copper (Figure 3) appears to avoid these
random fluctuations. This was consistent for the majority
of the volunteers. By fitting a line to these data and
extrapolating back to the times of previous collections,
the mole fraction of the labelled re-excreted copper was
calculated for the earlier stools. The Methods section
describes how the quantity of labelled endogenous
copper loss over the time course of the experiment was
calculated, and an example is shown in Figure 4. When
this correction was applied to the labelled copper in each
appropriate stool, the quantity of unabsorbed labelled
copper could be calculated, which provides an estimate of
the true copper absorption of the volunteer. Examination
of Figures 5 and 6 provides compelling evidence that
holmium and copper share a common excretory pattern
once endogenous losses have been taken into account. A
slope equal to 1.0 would indicate identical patterns. It
also gives a strong validation of the technique to estimate
endogenous losses by fitting an equation to the copper
data from the last few stool samples.
It can be concluded that the rare earth element
holmium used in the present study was found to be
virtually unabsorbed in the gastrointestinal tract, as
demonstrated by its complete recovery. The strong
correlation between the excretory patterns of holmium
and the copper label demonstrates the validity of using
holmium as a predictor of copper absorption.
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APPENDIX
There are two possible sources of copper in our biological
samples : the tracer (the oral dose of copper that was
highly enriched in ’&Cu) and the tracee (naturally
abundant copper). The mass spectrometer response for
any particular isotope, say ’&Cu, will depend on the
number of ’&Cu atoms present in the sample that have
come from the two sources. Examining each source
separately, the number of ’&Cu atoms in the sample that
have come from the tracer (defined as ’&Cu
sampletracer
) is
proportional to the number of moles of the tracer present
in the sample (defined as mol
tracer
) and the percentage of
the tracer that is actually made up from ’&Cu (defined as
’&Cu
tracer
). Therefore :
’&Cu
sampletracer
£ ’&Cu
tracer
[ mol
tracer
In a similar fashion, the number of atoms of ’&Cu in the
sample that have been derived from the tracee (naturally
abundant) source is :
’&Cu
sampletracee
£ ’&Cu
tracee
[ mol
tracee
The overall contribution from the two sources to the
total number of ’&Cu atoms will be a linear combination
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of the two equations above, and is defined as ’&Cu
sample
.
Therefore the number of atoms of ’&Cu in the sample that
have been derived from the tracer and tracee (naturally
abundant) source is :
’&Cu
sample
£ ’&Cu
tracer
[ mol
tracer
›’&Cu
tracee
[ mol
tracee
(1)
Similarly for ’$Cu
sample
:
’$Cu
sample
£ ’$Cu
tracer
[ mol
tracer
›’$Cu
tracee
[ mol
tracee
(2)
On dividing eqn (2) by eqn (1) :
’$Cu
sample
}’&Cu
sample
fl (’$Cu
tracer
[ mol
tracer
›’$Cu
tracee
[ mol
tracee
)}
(’&Cu
tracer
[ mol
tracer
›’&Cu
tracee
[ mol
tracee
) (3)
The ratio ’$Cu
sample
}’&Cu
sample
is equal to the mass
spectrometer ratio of the sample, ’$/’&R (once any
corrections for mass discrimination have been accounted
for). Therefore :
’$/’&R fl (’$Cu
tracer
[ mol
tracer
›’$Cu
tracee
[ mol
tracee
)}
(’&Cu
tracer
[ mol
tracer
›’&Cu
tracee
[ mol
tracee
) (4)
Similarly for the ’&Cu
sample
}’&Cu
sample
ratio :
’&/’&R fl (’&Cu
tracer
[ mol
tracer
›’&Cu
tracee
[ mol
tracee
)}
(’&Cu
tracer
[ mol
tracer
›’&Cu
tracee
[ mol
tracee
) (5)
If we set the denominator in eqns (4) and (5) to be equal
to 1}k, then:
1}k fl ’&Cu
tracer
[ mol
tracer
›’&Cu
tracee
[ mol
tracee
(6)
Eqns (4) and (5) can now be rewritten:
’$/’&R fl ’$Cu
tracer
[ k [ mol
tracer
›’$Cu
tracee
[ k [ mol
tracee
(7)
’&/’&R fl ’&Cu
tracer
[ k [ mol
tracer
›’&Cu
tracee
[ k [ mol
tracee
(8)
Eqns (7) and (8) can be represented in matrix notation:
A
B
’$/’&R
’&/’&R
C
D
fl
A
B
’$Cu
tracer
’$Cu
tracee
’&Cu
tracer
’&Cu
tracee
C
D
[
A
B
k [ mol
tracer
k [ mol
tracee
C
D
(9)
or :
R fl A [ x (10)
Solving for x:
x fl A−" [ R (11)
where :
x fl
A
B
k [ mol
tracer
k [ mol
tracee
C
D
In terms of mole fractions :
Mole fraction of tracer fl Cu
fractiontracer
fl k [ mol
tracer
}(k [ mol
tracer
›k [ mol
tracee
) (12)
Mole fraction of tracee fl Cu
fractiontracee
fl k [ mol
tracee
}(k [ mol
tracer
›k [ mol
tracee
) (13)
It is now a simple task to calculate the quantity of tracer
or tracee in any biological sample, because the total
copper (defined as Cu
total
) in the sample is known from
an AAS measurement. Care must be taken to take account
of the molecular masses of the tracer (defined as
MW
tracer
) and tracee (defined as MW
tracee
).
Quantity of tracer fl
Cu
fractiontracer
[ Cu
total
[ MW
tracer
Cu
fractiontracer
[ MW
tracer
›Cu
fractiontracee
[ MW
tracee
(14)
Quantity of tracee fl
Cu
fractiontracee
[ Cu
total
[ MW
tracee
Cu
fractiontracer
[ MW
tracer
›Cu
fractiontracee
[ MW
tracee
(15)
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Short communication
Quantification of unlabelled non-haem iron absorption in human
subjects: a pilot study
Jack R. Dainty*, Mark A. Roe, Birgit Teucher, John Eagles and Susan J. Fairweather-Tait
Institute of Food Research, Colney Lane, Norwich NR4 7UA, UK
(Received 15 November 2002 – Revised 17 April 2003 – Accepted 10 May 2003)
A method for measuring unlabelled Fe absorption has been investigated in a pilot study using a simple mathematical model. The metab-
olism of newly absorbed Fe can be approximated as a single-compartment model with the sampled compartment being the plasma pool.
Five female volunteers (aged 30–55 years) were recruited to participate in the pilot study. After a 10 mg oral dose of unlabelled ferrous
sulfate, the change in plasma Fe concentration over the following 6 h was used to estimate the quantity of absorbed Fe from the math-
ematical model. To assess the accuracy of the new technique, a 1 mg oral dose of 57Fe-labelled iron sulfate was given simultaneously
with a 225mg intravenous dose of 58Fe as iron citrate. The plasma appearance of the labelled Fe was used to estimate the absorption
of the oral label from the traditional area under the curve method. There was no significant difference (P¼0·61) between the geometric
mean absorption of the unlabelled (19 (21 SD 12, þ1 SD 28) %) and the labelled Fe (17 (21 SD 10, þ1 SD 29) %). These initial results are
encouraging, but further work needs to be undertaken with smaller doses, as typically found in meals. The effect of diurnal variation in
serum Fe concentration on the estimation of unlabelled Fe absorption needs further assessment.
Iron: Mathematical models: Kinetics
Fe absorption has traditionally been measured from the
appearance of radio- or stable-isotope-labelled Fe doses
in either blood or faecal samples. Newly absorbed labelled
Fe is incorporated into erythrocytes and a single blood
sample taken 14 d after the oral dose is sufficient to
enable an estimate of Fe absorption to be made. Alterna-
tively, a complete faecal collection can be undertaken
for approximately 10 d and the unabsorbed label measured
directly. Both of these techniques require radio- or stable-
isotope-labelled Fe in the test meal because the unlabelled
Fe that naturally occurs in foods cannot be distinguished
from endogenous Fe once it is inside the body or in
faeces. Almost all non-haem Fe bioavailability studies
have used extrinsic labels, based on the assumption that
the Fe from the label will form a common pool in the
gut with non-haem Fe from unlabelled dietary sources
and be absorbed identically. Generally, the UK diet con-
tains a mixture of haem (10 to 15 %) and non-haem Fe
(85 to 90 %) and to quantify dietary Fe absorption, a
method is required that can measure the absorption of
both forms simultaneously. If this method can be applied
to single meals with an Fe content of about 5 mg then
the total quantity of unlabelled Fe absorbed from a meal
can be determined without the need to use extrinsic or
intrinsic isotope labels.
Previous authors (Gonzalez et al. 2001) have attempted
to use the increase in serum Fe concentration to estimate
unlabelled Fe absorption. The present paper is the first,
however, to describe the development of a method for esti-
mating unlabelled non-haem Fe absorption with the use of
a simple compartmental model. Compartmental modelling
is a well-established technique for estimating fluxes and
pool sizes without the need for invasive sampling of
body tissues (Jacquez, 1996). Its use in Fe metabolism is
based on radioisotope work, published mainly in the
1960s, which resulted in the development of complicated
multicompartmental models (for example, Pollycove &
Mortimer, 1961). In the present study a simpler compart-
mental approach has been taken that attempts to model
the short-term metabolism of Fe following a single
unlabelled dose of ferrous sulfate. The techniques
employed are similar to pharmacokinetic drug trials
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where single-compartment models are often the best
method for the approximate estimation of parameters
such as drug half-life, turnover time and fractional absorp-
tion (Fox et al. 1993). A technique for measuring labelled
Fe absorption, the plasma area under the curve (AUC)
method (Barrett et al. 1994), is used to evaluate the poten-
tial of the compartmental approach.
Materials and methods
Subjects
Five female volunteers aged 30–55 years took part in the
study. All were in apparent good health as assessed by bio-
chemical screening (full blood count, urea, electrolytes,
liver enzymes, glucose and cholesterol) and were Fe
replete (haemoglobin .120 g/l). All subjects gave written
informed consent and the Norwich District Ethics Commit-
tee approved the study.
Preparation and administration of iron solutions for oral
and intravenous use
Labelled ferrous sulfate for oral use was prepared from
elemental 57Fe (95 % 57Fe; AEA Technology, Didcot,
Oxon, UK) using a previously developed method (Fox
et al. 1998). Iron citrate for intravenous (iv) use was pre-
pared by dissolving 22 mg 58Fe (92 % 58Fe; Isotec, Saint-
Quentin Fallavier, France) in 5 ml concentrated HCl
(12 M) in a silica crucible and heating until almost dry.
Sodium citrate (20 ml of 0·5 M) was added to the iron chlor-
ide, giving a citrate:Fe molar ratio in excess of 20:1, which
is required to convert iron chloride to iron citrate. The pH
was adjusted to 7·0 with 0·1 M-sodium carbonate and the
solution was diluted to 250 ml with water for injection.
Iron citrate portions for iv use were checked for sterility
by the Norfolk and Norwich Hospital Pharmacy.
Experimental protocol
The five subjects were each given 10 mg Fe as sulfate and
20 mg ascorbic acid. In all subjects, following a 12 h over-
night fast, a dose of 225mg 58Fe as citrate was infused and
5 min later the subject was given 300 ml cola drink contain-
ing the 1 mg oral dose of 57Fe and 10 mg unlabelled Fe,
both as sulfate. For the duration of the study the subjects
were only allowed drinking water. Blood samples (25 ml)
were taken at 0, 20, 40, 60, 80, 100, 120, 150, 180, 240,
300 and 360 min after the ingestion of the oral doses and
collected into trace element-free vacutainers.
Sample analysis
Total serum Fe was measured in duplicate using Ferrozine
(total iron diagnostic kit; Sigma, Poole, Dorset, UK). The
manufacturer’s stated single measurement precision (CV)
is approximately 7 %, which was calculated from a group
of four serum pool preparations (range of serum Fe con-
centration 510–2220m/l) assayed on eight occasions.
According to our calculations, duplicate analysis of a
sample should provide a standard error of the mean of
about 40mg/l for a mean of 1000mg/l. Recovery of a set
of Fe standards (Fe concentrations of 2000, 3000 and
4000mg/l) were 100, 98 and 101 % respectively. Isotope
ratios of 57Fe:56Fe and 58Fe:56Fe were measured by thermal
ionisation quadrupole MS (Finnegan MAT, GmbH,
Bremen, Germany). The measured precision (% relative
SD) for these ratios is approximately 1 % and the method
has been described previously (Fairweather-Tait et al.
1995). A baseline blood sample was also analysed for
plasma ferritin using an in-house ELISA with WHO-certi-
fied reference standards.
Calculations
Plasma concentrations of the 57Fe oral dose and the 58Fe iv
dose were calculated by solving a set of simultaneous
equations generated from the mass spectrometer ratios.
The AUC was calculated for appearance of the oral and
iv doses in plasma using the trapezoidal method.
With reference to Fig. 1, changes in plasma concen-
tration of Fe after an oral dose (doseoral) can be approxi-
mated as a single-compartment model provided the
measurement period is between 3 and 6 h. This length of
time allows for the completion of the absorptive process
and a good characterisation of the decay of the plasma con-
centration. The plasma appearance of Fe from the oral dose
is assumed to approximate that of an infusion of rate R
over time T. The definition of R is:
R ¼ mass of dose that is absorbed
time period for absorption
¼ M
T
ð1Þ
If V is the apparent volume of distribution and k is the rate
constant of elimination from the compartment, then the Fe
concentration in the compartment (C) can be approximated
as:
C ¼ M
V:T:k
· ð12 e2k:tÞ ð0 , t , TÞ ð2Þ
C ¼ M
V:T:k
· ð12 e2k:TÞ :e2kðt2TÞ ðT , tÞ ð3Þ
By fitting equations 2 and 3 to the plasma concentration
data, M, T and k can be calculated. All fitting was per-
formed in Excel (Microsoft Corporation, 2002) using a
standard desktop personal computer. Plasma volume, V,
Fig. 1. Schematic overview of the compartmental model.
J. R. Dainty et al.504
PAPER 2
is estimated from nomograms by knowledge of the volun-
teer’s age and weight (Lentner, 1984).
The fractional absorption can then be calculated accord-
ing to the equation:
Fractional absorption ¼ M
doseoral
: ð4Þ
Results and discussion
Table 1 compares calculated percentage Fe absorption,
from measurements of plasma appearance of isotopically
enriched oral and iv doses (AUC), with serum appearance
of orally administered unlabelled Fe, as calculated by the
model. Geometric mean absorption measured by plasma
appearance of 57Fe using the AUC method (17 (21 SD
10, þ1 SD 29) %) was not significantly different
(P¼0·61, as calculated by two-tailed, paired, Student’s
t test) from unlabelled Fe absorption calculated using the
model (19 (21 SD 12, þ1 SD 28) %).
There are several criticisms of this new method. The first
is the potential error introduced by reliance on an estimate
of the plasma volume. The plasma volume estimates were
calculated according to the nomograms published in the
Geigy tables (Lentner, 1984), and depended on weight,
age and sex of the volunteer. An underestimation of
plasma volume would lead to an underestimation of the
Fe absorption as calculated by the model. For comparison,
a different plasma volume method was tried, which was
based on body surface area (Hurley, 1975). There was no
significant difference between the estimates, and whilst
this does not imply that the estimation of plasma volume
is accurate, it gives no grounds on which to say that it is
not. This remains as a possible small source of error in
the model estimate of Fe absorption.
A second source of error is encountered in assuming that
a single-compartment model adequately describes the kin-
etics of newly absorbed Fe. The modelling process can be
broken down into two distinct parts: absorption of Fe;
plasma Fe kinetics. The absorption process is modelled
by assuming that the plasma appearance of newly absorbed
Fe has come from the gut via a constant infusion, with a
sharply defined start and endpoint. This is a simplification
of how Fe is transported across the enterocytes, since the
rate of absorption will depend on the quantity of Fe
presented to the absorptive cells and the rate of systemic
delivery. It would probably be better modelled as a first-
order process and this will be investigated in future
work. However, as a first approximation, the flux of Fe
entering the blood appears to be adequately described as
a zero-order process. Any remaining modelling error will
be due to the assumptions made concerning Fe kinetics
in the plasma. Previous studies have shown that a two-
or three-compartment model best describes plasma Fe kin-
etics in ‘normal’ subjects studied over a few days (Sharney
et al. 1965). By simplifying this to a single compartment, it
was predicted that the calculation of the elimination rate
constant, k, would potentially underestimate the true
value. This is due to the Fe ‘reflux’ from extravascular tis-
sues, which causes Fe, once removed from the plasma, to
be returned, thereby increasing the plasma Fe concen-
tration. Since the present study was performed over 6 h,
it was thought that the inherent error of assuming a
single compartment would be quite small.
A simulation was performed in order to assess whether
this technique is sensitive enough to measure small differ-
ences in Fe absorption. The modelling program SAAMII
(version 1.1.1; SAAM Institute Inc., Seattle, WA, USA)
was used to generate a set of simulated Fe serum concen-
tration data over 360 min. The input conditions for the
simulation were that 20·0 % of a 10 mg oral dose of Fe
was absorbed into a single compartment of 3000 ml
volume (V) over 100 min (T) and the rate of elimination
(k) was 0·002/min. These input variables are approxi-
mately what were estimated from our volunteers. The
simulated output data (serum Fe concentration over
360 min) were then ‘overlaid’ with an approximate diurnal
variation in measured baseline serum Fe concentration
estimated from the data of twenty volunteers (Dale et al.
2002) by the use of a polynomial function. These output
data were processed through our model and it was found
that the absorption was now 18·9 %, so the diurnal vari-
ation affected the accuracy and led to a systematic error
(underestimate) in the ‘real’ absorption by 5 % of its
value (18·9 compared with 20·0 %). No attempt has been
made to quantify how random error in the diurnal variation
would affect the precision of the absorption estimate but
crossover studies are designed to test the same volunteer
on more than 1 d and, if the diurnal variation did not
remain constant, the precision as well as the accuracy of
the estimated absorption would be altered. This has impli-
cations for resolving differences in absorption between two
or more test meals and will have to be dealt with in a
future, more in-depth study.
Finally, using Monte Carlo techniques, random measure-
ment error was added to the data to account for the theor-
etical variability in the Sigma kit used to measure total
serum Fe. The resulting data with randomised error were
then generated several times (n 25) and the simulated
absorption calculated for each data set using the model
described earlier. The average absorption was found to
be 19·0 (SD 1·8)% compared with the noise-free simulation
of 18·9 % absorption for the simulated data overlaid with a
diurnal variation. Two conclusions can be drawn from this
Table 1. Comparison of methods used to measure iron absorp-
tion from a 1 mg 57Fe-labelled dose and 10 mg unlabelled dose of
ferrous sulfate
Fe absorption (%)
Volunteer no.
Labelled
(AUC)
Unlabelled
(Model)
Serum ferritin
(mg/l)
1 21 16 16
2 7 10 35
3 28 22 19
4 19 29 24
5 20 23 39
Geometric mean 17 19 25
21 SD 10 12 17
þ1 SD 29 28 37
AUC, area under the curve.
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simulation with regard to the use of the single-
compartment model for estimating Fe absorption.
First, there is a potential loss of accuracy due to the
underestimation of the true Fe absorption because of the
decrease in the ‘real’ baseline serum Fe concentration
(diurnal effect). In using the model for the pilot study, it
was assumed that the baseline serum Fe concentration
was the same throughout the experiment (i.e. the t ¼ 0
value). This underestimation will become proportionately
larger the lower the dose of Fe and this has implications
for extending the use of the model in situations where
the Fe dose is less than 10 mg.
Second, the effect of the measurement variation in the
Sigma Ferrozine kit leads to an uncertainty of approxi-
mately 1·8 % in a simulated absorption of 20 % from a
10 mg dose. For the purposes of the following statistical
work, it has to be assumed that the diurnal variation in
serum Fe concentration does not vary significantly between
any 2 d. Power calculations estimate that at a 0·05 level of
significance with a power of 80 %, a two-tailed test for an
experiment would require eight volunteers in a crossover
design to guarantee being able to resolve a difference in
absorption of 3 % between two test meals. This rises to six-
teen and fifty-one volunteers for a 2 and 1 % difference in
absorption respectively. The Ferrozine kit therefore
appears to be inadequate for situations where an attempt
is being made to resolve a small difference (,2 %) in Fe
absorption and in these cases the use of inductively
coupled plasma MS or thermal ionisation MS would be
expected to measure total Fe in serum with a precision
(% relative SD) of less than 1 %. This would lead to an
uncertainty in model absorption estimation of approxi-
mately 0·5 % and only six volunteers would be required
to resolve a difference of 1 % in Fe absorption between
two test meals assuming, again, that the diurnal variation
in serum Fe concentration is the same on the two test
meal days. Also, the Ferrozine kit requires 5 ml whole
blood for triplicate analysis but less than 1 ml would be
required for inductivity coupled plasma MS or thermal ion-
isation MS thereby reducing the total blood volume taken
in a study. This would have obvious benefits in studies
where the same volunteer is required to participate in
more than one intervention.
The use of a single-compartment model to estimate
unlabelled Fe absorption requires a larger study, with smal-
ler doses of Fe, both haem and non-haem, to be undertaken.
The 10 mg dose is higher than the quantity consumed in
most meals, thus the technique must be shown to work
with doses of 5 mg or less. However, the results of the
present pilot study demonstrate that the estimation of
the absorption of total Fe from an unlabelled source has
promise and highlight the potential of mathematical model-
ling in nutritional studies.
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Single oral doses of 13C forms of pteroylmonoglutamic acid
and 5-formyltetrahydrofolic acid elicit differences in short-term
kinetics of labelled and unlabelled folates in plasma: potential
problems in interpretation of folate bioavailability studies
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J. F. Gregory2
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Single 13C6-labelled doses of pteroylmonoglutamic acid (PteGlu; 634 nmol) or 5-formyltetrahydrofolic acid (431–569 nmol) were given to
fasted adult volunteers, and the rise in total and 13C-labelled plasma 5-methyltetrahydrofolic acid metabolite monitored over 8 h by HPLC
and liquid chromatography–MS. The dose-adjusted area under the curve (AUC) for total (labelled plus unlabelled) plasma 5-methyltetra-
hydrofolic acid following a 5-formyltetrahydrofolic acid test dose was 155 % that obtained following a PteGlu test dose. Surprisingly, an
average 60 and 40 % of the total plasma 5-methyltetrahydrofolic acid response to [13C6]PteGlu and [
13C6]5-formyltetrahydrofolic acid,
respectively, was unlabelled; an observation never before reported. Short-term kinetics of plasma [13C6]5-methyltetrahydrofolic acid
showed a slower initial rate of increase in plasma concentration and longer time to peak following an oral dose of [13C6]PteGlu compared
with that for an oral dose of [13C6]5-formyltetrahydrofolic acid, while the [
13C6]5-methyltetrahydrofolic acid AUC for [
13C6]5-formyl-
tetrahydrofolic acid was 221 % that for [13C6]PteGlu. These data indicate that PteGlu and 5-formyltetrahydrofolic acid, which are thought
to be well absorbed (about 90 %) at physiological doses, exhibit dramatically different rates and patterns of plasma response. A limitation
in the rate of reduction of PteGlu before methylation could result in slower mucosal transfer of [13C6]5-methyltetrahydrofolic acid derived
from [13C6]PteGlu into the plasma. This, when coupled with an observed similar plasma clearance rate for [
13C6]5-methyltetrahydrofolic
acid metabolite derived from either folate test dose, would yield a comparatively smaller AUC. These findings suggest potential problems
in interpretation of absorption studies using unlabelled or labelled folates where the rate of increase, the maximum increase, or the AUC, of
plasma folate is employed for test foods (mainly reduced folates) v. a ‘reference dose’ of PteGlu.
Pteroylmonoglutamic acid: Folate: Absorption: Plasma: Stable isotopes
Folate is a generic term for B-group vitamins found widely
in foodstuffs, mainly reduced methyl and formyl folates
(Perry, 1971), that have nutritional properties and chemical
structures similar to those of pteroylmonoglutamic acid
(PteGlu) (Scott & Weir, 1976). PteGlu is the synthetic
form of the vitamin that is used extensively for food forti-
fication purposes and supplements, but which does not
occur naturally in significant amounts. Folates are crucial
for methionine and nucleotide biosynthesis (Shane,
1995). Periconceptual supplementation of women with
PteGlu has been shown to significantly reduce the inci-
dence and recurrence of neural tube defects, such as
spina bifida (Anonymous, 1991; Czeizel & Dudas, 1992).
Marginal folate deficiency is also associated with elevated
plasma homocysteine, an emerging risk factor for vascular
diseases (Bousey et al. 1995), epigenetic factors such as
cytosine-phosphate-guanosine dinucleotide methylation-
associated transcription factor-binding (Nephew &
Huang, 2003) and uracil-induced genomic instability
(Blount et al. 1997). Either manipulation of the diet or for-
tification of food with physiological levels of PteGlu may
be expected to reduce the prevalence of these folate-related
diseases. However, the bioavailability of different folate
vitamers is not well understood. Is folate status increased
best by the intake of folate supplements, fortified foods
or natural food folates? Is optimal folate status easily
achievable in countries that do not permit the PteGlu forti-
fication of foodstuffs?
Methods for the assessment of folate bioavailability in
human subjects include the comparison of the serum or
* Corresponding author: P. M. Finglas, fax þ44 1603 507723, email paul.finglas@bbsrc.ac.uk
Abbreviations: AUC, area under the curve; 5-CH3H4PteGlu, 5-methyltetrahydrofolic acid; 5-CHOH4PteGlu, 5-formyltetrahydrofolic acid; 5MTHF,
5-methyltetrahydrofolic acid; PteGlu, pteroylmonoglutamic acid.
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plasma response to a single oral dose relative to that of a
PteGlu reference dose (Gregory, 1997, 2001). This may
entail either measurement of the rate of increase, or the
maximum increase, in plasma folate concentration over
2 to 3 h (Perry & Chanarin, 1970, 1972; Brown et al.
1973; Lucock et al. 1989; Bower et al. 1993; Kelly et al.
1997), or measurement of the rise in plasma folate concen-
tration (the area under the curve (AUC) of the increase in
plasma folate concentration above fasting baseline level)
over 6 h or more (Markkanen, 1968, 6 h AUC; Bailey
et al. 1988, 8 h AUC; Fenech et al. 1999, 7 h AUC;
Prinz-Langenohl et al. 1999, 10 h AUC). In respect of
methodological aspects in vitamin bioavailability testing,
the AUC is accepted as a valuable indicator of bioavailabil-
ity provided the post-dosing plasma measurement test
period is long enough to capture $80 % of the whole
AUC (Pietrzik et al. 1990).
Because of the potential benefits of sensitivity and speci-
ficity, it is increasingly common to study the absorption
and metabolism of folates in human subjects by using
stable-isotope-labelled folates (Wolfe et al. 2001). Our
group has used such an approach to assess the relative
absorption of two different folate vitamers; PteGlu and
5-formyltetrahydrofolic acid (5-CHOH4PteGlu). This
way, folate can be followed and differentiated from the
natural store of folate already present in the body. Thus,
more accurate estimates of ‘relative absorption’ should
be able to be calculated as a result.
During the course of these studies it became apparent
that there are a number of problems in interpreting com-
parative folate absorption based on short-term plasma
folate responses, even when folate test doses are labelled.
The present paper presents the evidence for this statement,
which emerged in a human volunteer study. Human plasma
5-methyltetrahydrofolic acid (5-CH3H4PteGlu) AUC excur-
sion profiles were followed over a period of 8 h following
ingestion of single oral physiological doses of 13C6-labelled
PteGlu or (6S-) 13C6-labelled 5-CHOH4PteGlu. Folate-
binding affinity columns were used to isolate extracted
plasma folate and, following HPLC analysis of folate con-
centrations, a newly developed liquid chromatography–MS
analytical method was used to determine the proportions of
13C-labelled and unlabelled 5-CH3H4PteGlu (Hart et al.
2002).
Materials and methods
Materials
Purified [2H2]PteGlu was synthesised using a previously
published procedure (Gregory, 1990), stored frozen at
2188C, and used as the internal standard. Proton NMR,
HPLC and mass spectrometric results gave a purity of
.99 % and an isotopic enrichment of .95 %. Purified
[13C6]PteGlu with an isotope enrichment of 96 % was syn-
thesised by the method of Maunder et al. (1999), and then
encapsulated in gelatin capsules (‘softgels’) and stored at
þ48C (Finglas et al. 2002b). These capsules release their
contents rapidly once in contact with acid stomach contents
and the bioavailability of encapsulated water- and acid-
soluble compounds (such as folates), as measured by
plasma appearance, has been shown to be indistinguishable
from oral aqueous solutions (Seager et al. 1988). Purified
(6S-) [13C6]5-CHOH4PteGlu was synthesised using a pre-
viously published enzymic–chemical procedure (Moran
et al. 1986), and stored frozen, as a solid, at 2188C. The
purified [13C6]5-CHOH4PteGlu was checked by HPLC
analysis, u.v. spectrum and MS. The mass spectrum gave
an isotopic enrichment of .94 %. There were no detect-
able impurities and contaminants from the HPLC chroma-
togram, and u.v. spectra gave an estimated purity .98 %.
Intermittently, as required, a batch of oral doses of [13C6]5-
CHOH4PteGlu were prepared. Approximately 10mmol
solid was weighed out and dissolved in 0·5 ml NaOH sol-
ution (0·1 mol NaOH/l). High-grade water was then
added to obtain a solution of about 1·2mmol/ml. This
was then dispensed, in doses of 0·5 ml (about 600 nmol),
into 2·0 ml plastic screw-capped microfuge tubes. One
dose was retained for spectroscopic analysis, with folate
concentration being calculated after further dilution in
PBS (0·1 mol/l, pH 7·0) using a molar extinction coefficient
(E(mol, 10 mm)) of 37 200 (Blakley, 1969). The residual
doses were temporarily stored frozen at 2188C until
required, and used within 2 weeks.
Human study design
The present work forms part of an ongoing crossover,
within-subject, study comparing the absorption of
13C6-labelled folate isolates or
15N-intrinsically labelled
spinach folates in a group of healthy male and female
adults. The study was approved by the Norwich and Dis-
trict Ethics Committee (Norfolk & Norwich Area Health
Care Trust). After giving written consent, a 12 h fasting
blood sample was taken and analysed at the haematology
department of a local hospital for full-blood-count, blood
glucose, erythrocyte-folate, serum B12, urea and electro-
lytes, and liver function tests. If all results were inside
normal assay ranges, volunteers then attended test days
where, following an overnight fast, a baseline (time zero)
blood sample (10 ml) was taken and where they were
then given a single oral dose of [13C6]PteGlu (634 nmol)
or (6S-) [13C6]5-CHOH4PteGlu (431–569 nmol). The
dose of [13C6]PteGlu was administered in gelatin capsules
washed down with a glass of bottled ‘still’ mineral water.
The thawed dose of (6S-) [13C6]5-CHOH4PteGlu was
added to a glass of 25 ml bottled ‘still’ mineral water and
then drunk by the volunteer. The glass was quickly
rinsed out twice with further water, which was also
drunk. A timer was started after the test doses had been
completely swallowed and rinsed down. Volunteers were
always allowed access to water, and were given a light
lunch only after a 4 h post-dosing venous blood sample
had been obtained. With few exceptions, the sub-set of
volunteers reported in the present paper did not complete
both 13C6-labelled PteGlu and 5-CHOH4PteGlu test days.
The present paper therefore reports essentially independent
results from ten volunteers (age 30·9 (SE 1·3) years; BMI
25·7 (SE 1·3) kg/m2) who had (6S-) [13C6]5-CHOH4PteGlu
as the test dose and twelve volunteers (age 31·1 (SE 1·2)
years; BMI 25·4 (SE 1·3) kg/m2) who had [13C6]PteGlu
as the test dose.
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Blood sampling and storage
Venous blood samples (10 ml) were taken by cannula at
time zero and at eleven further time points over an 8 h
period following each test dose; 0, 0·5, 1, 1·5, 2, 2·5, 3,
3·5, 4, 5, 6 and 8 h. Blood samples were transferred
immediately into tubes containing K2-EDTA (Sarstedt
Ltd, Beaumont Leys, Leics., UK) and mixed gently.
Samples were centrifuged (1500 g, 10 min), plasma
removed and frozen immediately over solid CO2, and
then stored at 2308C until analysis.
Sample preparation, folate extraction and analysis
Following storage, plasma samples were mixed thoroughly
and 5 ml transferred into 50 ml screw-top glass centrifuge
tubes. Extraction buffer (20 ml, 0·1 M-K2HPO4, pH 7·0;
containing 0·05 M-sodium ascorbate and 0·01 M-mercapto-
ethanol as antioxidants) and an internal standard (0·1 ml
[2H2]PteGlu; 2mg/ml) were added. The tubes were then
flushed with N2, capped, and the sample mixed thoroughly
before being placed into a boiling water bath for 10 min for
proteins to precipitate. The samples were cooled over ice,
precipitates agitated, then centrifuged for 10 min (1000 g).
The supernatant fraction was removed and stored in a
clean tube. Extraction buffer (15 ml) was added to the
pellet and thoroughly mixed. The sample was re-centri-
fuged and the wash supernatant fraction removed and com-
bined with the first supernatant fraction. All folate from
each extracted plasma sample was purified on an affinity
column using folate-binding protein and eluted with HCl
(0·1 mol/l) into a 5 ml volumetric flask containing ascorbic
acid solid (10 mg), mixed thoroughly, and transferred in
three roughly equal portions to microfuge tubes (Hart
et al. 2002). These folate isolates were temporarily stored
in liquid N2 (with no loss of potentially labile 5-CH3H4-
PteGlu, even after several months) and subsequently ana-
lysed, utilising a cooled (48C) autoinjector, in negative
ion mode by liquid chromatography–MS as previously
described (Hart et al. 2002). Selected ion monitoring was
conducted on the [M-H]2 ion: m/z 458 for analysing
5-CH3H4PteGlu; m/z 464 [M þ 6-H]2 to determine 5-CH3-
H4PteGlu derived from the label dose; m/z 444 for analysis
of 2H4PteGlu internal standard; m/z 446 and 478 to confirm
there was no evidence of unmetabolised labelled PteGlu or
5-CHOH4PteGlu originating from the oral test doses. Total
plasma 5-CH3H4PteGlu concentrations were analysed
(100ml injection) by HPLC utilising a cooled (78C) autoin-
jector (with no loss of potentially labile 5-CH3H4PteGlu,
even after 30 h). Chromatographic separation was on a
250 mm £ 4·6 mm internal diameter column packed with
LiCrosphere 100 RP C18 (Merck Ltd, Poole, Dorset,
UK), performed isocratically at 1·0 ml/min with a mobile
phase consisting of phosphoric acid (0·05 mol/l)–aceto-
nitrile (9:1, v/v) with fluorescence detection for 5-CH3H4-
PteGlu (excitation at 292 nm and emission at 356 nm)
and u.v. absorbance (288 nm) for both PteGlu and 5-
CHOH4PteGlu. HPLC quantification was against external
standards. Stock folate solutions were made up in borate
buffer (0·05 mol/l, pH 9·3) containing 0·4 % (v/v) mercap-
toethanol, and samples were further diluted in phosphate
buffer (0·1 mol/l, pH 7·0; van den Berg et al. 1994)
before true folate concentrations were established using
appropriate molar extinction coefficients (Blakley, 1969).
When required, sub-samples of stock solutions (that had
been stored in liquid N2) were thawed and diluted to suit-
able concentrations with HCl (0·1 mol HCl/l containing
2 mg/ml ascorbic acid as an antioxidant); the same matrix
as used for isolated plasma samples. Plasma concentrations
of unlabelled and 13C6-labelled 5-CH3H4 PteGlu were cal-
culated using selected ion monitoring ratios (Hart et al.
2002) (see Appendix 1). Step 1 involves calculating the
fraction of each source in the sample. Step 2 involves mul-
tiplying the measured total 5-CH3H4PteGlu concentration
by the derived fraction of each source to give the actual
plasma concentrations of unlabelled and 13C6-labelled
5-CH3H4PteGlu.
Area under the curve calculations of the rise in plasma
folate above initial fasting baseline concentration
The AUC was calculated using the trapezoidal method,
and then adjusted to an oral dose equivalent to 600 nmol
folate. For each test dose, in each volunteer, both the
‘total’ and the ‘unlabelled’ plasma 5-CH3H4PteGlu AUC
(the AUC of the rise in plasma folate concentration)
were calculated after deduction of each individual’s base-
line (time zero) concentration from the concentration
values obtained for each of their post-absorption time
points. The 13C6-labelled 5-CH3H4PteGlu AUC was calcu-
lated without adjustment, since there was no excess label
at baseline (time zero).
Statistics
Originally, our ongoing study (of which the volunteers
reported on in the present paper form a part) had a cross-
over within-subject design. However, partly because of the
intrusive nature of 8 h cannulations, most subjects reported
here did not complete both 13C6-labelled PteGlu and
5-CHOH4PteGlu test days. Hence, for statistical purposes,
the data that are reported in the present paper are treated as
independent observations. For PteGlu and 5-CHOH4
PteGlu test meals, plasma total, labelled and unlabelled
AUC, unlabelled:labelled ratio and total:labelled ratio
were examined by the Kolmogorov–Smirnov one-sample
continuous distribution test. As distributions were not sig-
nificantly different from normal, each parameter for the
two test doses was compared by parametric Student’s
unpaired t test for: (i) total plasma 5-CH3H4PteGlu
AUC; (ii) plasma 13C6-labelled 5-CH3H4PteGlu AUC;
(iii) plasma unlabelled 5-CH3H4PteGlu AUC; (iv) plasma
unlabelled:labelled 5-CH3H4PteGlu AUC ratio; (v) plasma
total:labelled 5-CH3H4PteGlu AUC ratio. Linear regression
analysis was used to assess associations (r 2) with either
fasting plasma baseline folate concentration, or erythro-
cyte-folate concentration. It was also used, within subject,
to assess association between labelled and unlabelled
plasma 5-CH3H4PteGlu AUC response.
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Results
Selected ion monitoring indicated that neither of the test
doses appeared unmetabolised in the plasma as PteGlu or
5-CHOH4PteGlu.
The total plasma response to both labelled PteGlu and
5-CHOH4PteGlu test doses was significantly greater than
their labelled plasma response. This indicates that there
was a significant appearance of unlabelled folate in the
plasma following both test folates (Fig. 1).
The labelled plasma response to PteGlu was slower, and
peaked much later than the response to the 5-CHOH4PteGlu
test dose (Tmax 173 (SE 10) v. 41 (SE 9) min respectively).
Tmax is the time between the administration of the dose
and the occurrence of the peak plasma concentration of
labelled 5MTHF.
Table 1 shows (i) ‘total’, (ii) ‘labelled’, and (iii)
‘unlabelled’ plasma AUC responses, together with the
(iv) unlabelled:labelled and total:labelled AUC ratios to
the PteGlu and 5-CHOH4PteGlu test doses.
On average, the ‘total’ plasma AUC response to
5-CHOH4PteGlu was 155 % of the response to PteGlu; a
significant trend for difference (P¼0·062).
In comparison, the average plasma ‘labelled’ AUC
response to 5-CHOH4PteGlu was 221 % of the response
to PteGlu; a significant difference (P,0·001).
In contrast to the ‘total’ and ‘labelled’ response,
the average plasma ‘unlabelled’ AUC response to
5-CHOH4PteGlu was the same as the response to PteGlu;
no significant difference (P¼0·864).
Plasma ‘unlabelled’ and ‘labelled’ AUC varied greatly
between volunteers but an ‘unlabelled’ plasma response
was always present. Notably, there was no significant
association, within subject, between ‘unlabelled’ and
‘labelled’ plasma AUC responses to either PteGlu
(r 2 0·039; P¼0·541) or 5-CHOH4PteGlu (r 2 0·166;
P¼0·243) test doses.
A comparison of the plasma ‘unlabelled’:‘labelled’ AUC
ratios for the two oral folate test doses indicated that the
mean ratio for PteGlu (1·43) was more than double, and
significantly different (P¼0·012), than the mean ratio for
5-CHOH4PteGlu (0·61).
A comparison of the plasma ‘total’:‘labelled’ AUC
ratios for the two oral folate test doses indicated that the
mean ratio for PteGlu (2·27) was significantly different
(P¼0·027) from the mean ratio for 5-CHOH4PteGlu (1·47).
Table 2 shows the results of linear regression analysis
between both labelled and unlabelled plasma AUC
responses to PteGlu and 5-CHOH4PteGlu test doses with
(a) fasting plasma and (b) erythrocyte-folate concentration.
It also shows that there was no relationship between
fasting plasma and erythrocyte-folate concentrations.
Neither ‘unlabelled’ nor ‘labelled’ plasma AUC responses
were significantly associated (r 2) with volunteer fasting
baseline erythrocyte-folate concentrations. Furthermore,
neither the ‘unlabelled’ plasma AUC response to both
test folates, nor the ‘labelled’ plasma AUC response to
the 5-CHOH4PteGlu test dose, were significantly associ-
ated (r 2) with volunteer fasting baseline plasma concen-
trations. However, interestingly, there was an extremely
high degree of association between the ‘labelled’ plasma
AUC response to the PteGlu test dose, and volunteers’
fasting baseline plasma folate concentration (r 2 0·880;
P,0·001).
Discussion
The size of the oral folate test doses used in the present
study did not exceed any threshold for the reported direct
appearance of unmetabolised PteGlu in the plasma (Kelly
et al. 1997); consequently no evidence of unmetabolised
PteGlu or 5-CHOH4PteGlu appearing in any of the ana-
lysed samples was found.
Results indicated that a significant proportion of the total
plasma AUC response to an oral load of labelled PteGlu or
labelled 5-CHOH4PteGlu did not originate directly from
the oral test doses because it was not labelled (Fig. 1(a)
and (b)). Approximately 40 % (range 7 to 64 %) of the
plasma response to the dose of labelled 5-CHOH4PteGlu,
and approximately 60 % (range 38 to 75 %) of the
plasma response to the dose of labelled PteGlu did not
Fig. 1. (a), Plasma response to (6S-) [13C6]5-formyltetrahydrofolic
acid (5-CHOH4PteGlu). Mean values with their standard errors of
total (B) and 13C6-labelled (V) plasma 5-methyltetrahydrofolic acid
(5-CH3H4PteGlu) areas under the curve (AUC) of the rise in plasma
folate concentration in response to an oral test dose (n 10) of (6S-)
[13C6]CHOH4PteGlu. AUC responses are adjusted to an oral dose
of 600 nmol. The unlabelled response, not of test-dose origin, is
the difference between the two responses shown. (b), Plasma
response to [13C6]pteroylmonoglutamic acid (PteGlu). Mean values
with their standard errors of total (B) and 13C6-labelled (V) plasma
5-CH3H4PteGlu AUC of the rise in plasma folate concentration in
response to an oral test dose (n 12) of [13C6]PteGlu. AUC responses
are adjusted to an oral dose of 600 nmol. The unlabelled
response, not of test-dose origin, is the difference between the two
responses shown.
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originate from the labelled oral test doses (Table 1). This
result has not been demonstrated previously.
The ‘unlabelled’ plasma AUC response cannot be as a
result of metabolic cleavage and loss of label from the
test folates during subsequent metabolism. The underlying
parent structure of all monoglutamate folate compounds
that exhibit a common vitamin activity is based on the
parent structure of PteGlu (pteroyl-L-monoglutamic acid).
The pteroylmonoglutamate molecule consists of an aro-
matic pteridine ring linked through a methylene bridge to
para-amino-benzoic acid, and then to one L-glutamic
acid residue. Cleavage between the pteridine ring and
benzoic-acid ring (generating a pteridine residueþpara-
aminobenzoylglutamic acid), between the benzoic-acid
ring and glutamic acid (generating pteroic acidþglutamic
acid), or between both (generating a pteridine residueþ
para-aminobenzyol residueþglutamic acid), will result in
molecules with no vitamin activity that human metabolism
cannot reassemble. Hence, the classification of folates as
‘vitamins’. It is thus self-evident that the benzene ring of
our labelled test folates that carries the six 13C-carbons
cannot be removed and substituted with a non-labelled
ring without irreversible destruction of the vitamin folate
molecule.
The large, and highly variable, displacement of endogen-
ous folate is problematic in interpreting absorption studies
using ‘unlabelled’ folates because the portion of plasma
response due to oral v. endogenous folate cannot be deter-
mined. There was no relationship between this ‘unlabelled’
folate response and folate status. Furthermore, there does
not appear to be a simple relationship between oral and
endogenous response as there was no significant associ-
ation, within subject, between ‘unlabelled’ and ‘labelled’
plasma AUC response to either ‘labelled’ PteGlu or
‘labelled’ 5-CHOH4PteGlu test doses. It could be specu-
lated that the larger variation in unlabelled plasma folate
response may be due to variable absorptive epithelial cell
exposure to folate intake in the day-or-so immediately pre-
ceding the test days, and a knock-on perturbation effect.
The latter effect would result in the previously absorbed
‘cold’ folate being pushed out of the epithelial cells into
the body-proper to generate an unlabelled folate plasma
response that is completely unpredictable, and unrelated
to the absorption of any labelled test dose. If unlabelled
Table 1. Plasma 5-methyltetrahydrofolic acid (5-CH3H4PteGlu) area under the curve (AUC) responses and unlabelled:labelled and total:la-
belled ratios in fasting healthy adult volunteers following an oral dose of either [13C6]pteroylmonoglutamic acid (PteGlu) or (6S-) [
13C6]5-formyl-
tetrahydrofolic acid (5-CHOH4PteGlu)
(Mean values with their standard errors)
5-CH3H4PteGlu AUC* (pmol £ min/ml per 600 nmol dose)
Oral dose
[13C6]PteGlu (n 12)
Oral dose (6S-)
[13C6]5-CHOH4PteGlu
(n 10)
Statistical significance
of difference between
oral [13C6]PteGlu and
(6S-)[13C6]5-CHOH4PteGlu
Mean SE Mean SE test doses†
Total AUC 2437 300 3771 646 P¼0·062 (trend)
13C6-labelled AUC 1149 128 2542 187 P,0·001
Unlabelled AUC 1497 257 1589 503 P¼0·864 (NS)
Ratio of unlabelled:labelled 1·43 0·23 0·61 0·17 P¼0·012
Ratio of total:labelled 2·27 0·26 1·47 0·20 P¼0·027
*All AUC responses are adjusted to an oral dose of 600 nmol, and are over the post-dosing period from 0 to 480 min.
† Student’s unpaired t test.
Table 2. Linear regression analysis of the association (r 2) between unlabelled or 13C6-labelled plasma 5-methyltetrahydrofolic
acid (5-CH3H4PteGlu) area under the curve (AUC) response in fasting healthy adult volunteers, following an oral dose of either
[13C6]pteroylmonoglutamic acid (PteGlu) or (6S-) [
13C6]5-formyltetrahydrofolic acid (5-CHOH4PteGlu), and fasting plasma
folate concentration or fasting erythrocyte-folate concentration
Oral dose [13C6]PteGlu (n 12) Oral dose (6S-) [
13C6]5-CHOH4PteGlu (n 10)
Test meal. . . Fasting plasma folate Fasting erythrocyte folate Fasting plasma folate Fasting erythrocyte folate
Unlabelled AUC per 600 nmol dose
r 2 0·000 0·007 0·066 0·004
P 0·990 (NS) 0·805 (NS) 0·505 (NS) 0·878 (NS)
13C6-labelled AUC per 600 nmol dose
r 2 0·880 0·022 0·226 0·174
P ,0·001 0·990 (NS) 0·196 (NS) 0·265 (NS)
Fasting plasma (oral dose PteGlu)
r 2 0·032
P 0·600 (NS)
Fasting plasma (oral dose 5-CHOH4PteGlu)
r 2 0·102
P 0·442 (NS)
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folate was mainly a result of hepatic biliary excretion then
one may have expected the ‘unlabelled’ AUC to be related
to the initial fasting plasma folate concentration of volun-
teers, because it too is a function of enterohepatic recircu-
lation (Steinberg et al. 1979). Such a relationship was not
observed.
The oral dose of 5-CHOH4PteGlu induced larger ‘total’
plasma AUC responses than equivalent oral doses of
PteGlu (Table 1). If the AUC of an unlabelled oral test
folate is compared with the AUC of an equivalent
unlabelled dose of PteGlu (i.e. using PteGlu as the ‘refer-
ence’ dose) then this would have indicated that the ‘relative
bioavailability’ of 5-CHOH4PteGlu was 155 % that
of PteGlu. Similarly, the ‘relative bioavailability’ of
5-CHOH4PteGlu calculated when using only the plasma
‘labelled’ AUC responses was 221 % that of PteGlu.
Under the conditions of the present trial in which relatively
small folate test doses (within the physiological range)
were given to fasting volunteers, one would expect that a
high proportion (approximately 90 %) of the dose would
be absorbed (Bhandari & Gregory, 1992; Clifford et al.
1998). Thus, differences in plasma kinetics and AUC as
seen in the present study are almost assuredly due to differ-
ences in rate or extent of conversion to 5-CH3H4PteGlu,
displacement of tissue folates, and release into the circula-
tion. These data suggest that a reduced folate such as (6S-)
5-CH3H4PteGlu or (6S-) 5-CHOH4PteGlu would be a more
appropriate ‘reference’ dose in bioavailability studies of
natural folates, especially comparisons carried out ‘within
volunteer’.
A review by Selhub et al. (1983) concluded that the
intestine is capable of both reduction and one-carbon sub-
stitution (methylation) of physiological doses of folate
before absorbed folate is transported from the mucosal to
the serosal side. It is therefore expected that physiological
oral doses of both PteGlu and 5-CHOH4PteGlu will only
result in the transfer of 5-CH3H4PteGlu into the hepatic
portal vein. Though an extensive hepatic uptake of
absorbed folate has been noted (Gregory, 2001), this, logi-
cally, should be the same in response to both these oral test
folates and calculation of ‘relative absorption’ should still
be valid. However, a comparison of labelled plasma
AUC responses indicated that the ‘initial rate’ and ‘time
to peak’ response to PteGlu test doses was slower and
longer, respectively, than that to 5-CHOH4PteGlu test
doses (Fig. 1(a) and (b)). Arguably, a slower mucosal
transfer of labelled 5-methyltetrahydrofolic metabolite,
derived from labelled PteGlu, to the plasma (possibly due
to a limitation in the rate of initial reduction of PteGlu
to H2-PteGlu, before further reduction to H4-PteGlu,
subsequent 1-carbon addition and re-arrangement to
5-CH3-H4-PteGlu; Mathews & Huennekens, 1963) when
coupled with a similar plasma clearance rate to 5-methylte-
trahydrofolic metabolite derived from 5-CHOH4PteGlu
would result in a comparatively smaller ‘labelled’ plasma
AUC.
The lack of association (Table 2), with one exception,
between labelled or unlabelled plasma AUC responses to
PteGlu or 5-CHOH4PteGlu test doses, and either volunteer
fasting baseline plasma or erythrocyte-folate concen-
trations, indicates that plasma AUC responses cannot be
predicted using either of these criteria. The exceptional
observation of a high degree of association (r 2 0·880;
P,0·001) between the labelled plasma AUC response to
a labelled PteGlu oral test dose and volunteers’ fasting
baseline plasma folate concentration could be real, and
could eventually provide an insight into the specific meta-
bolism of PteGlu. Alternatively, the association could be
an artifact of having undertaken a total of ten statistical
comparisons (i.e. including testing of associations between
‘unlabelled’ and ‘labelled’ plasma response to both test
folates). So, without an experimental ‘a priori’ intention
to make such comparisons, the associations should, strictly
speaking, be left to future examination. However, since
fasting baseline plasma folate concentration is maintained
by enterohepatic recirculation (Steinberg et al. 1979), it
is too tempting to avoid the speculation that this strong
relationship suggests that absorbed PteGlu is reduced and
methylated in the liver, and not the mucosa, as has been
the accepted wisdom for at least the past two decades
(Selhub et al. 1983).
In summary, the present paper reports that after an oral
folate test dose there is a large and unexpected concurrent
displacement of tissue 5-CH3H4PteGlu into the plasma.
This makes comparisons of the relative bioavailability of
unlabelled reduced folates (i.e. from test food doses),
v. unlabelled PteGlu reference doses, ambiguous. It is
also reported that there is a large difference in plasma
‘labelled’ response to a ‘labelled’ naturally occurring
reduced folate compared with ‘labelled’ unreduced
PteGlu. This difference would lead to spurious conclusions
in bioavailability studies based on comparisons of oral
doses of reduced ‘labelled’ folate (for example, labelled
food folate) v. a ‘labelled’ PteGlu reference dose. It
could be speculated that this phenomenon may be due to
a slower rate of mucosal processing of PteGlu compared
with 5-CHOH4PteGlu. This may result in a slower
transfer of 5-CH3H4PteGlu metabolite to the plasma,
which will, when coupled with a similar clearance rate to
that of 5-CH3H4PteGlu metabolite derived from oral
5-CHOH4PteGlu, result in comparatively smaller labelled
plasma AUC. Contrary to current theory, it is suggested
that absorbed physiological doses of PteGlu mainly enter
the hepatic portal vein unmodified with immediate removal
to the liver for biotransformation, with subsequent plasma
5-CH3H4PteGlu AUC response being entirely a function of
enterohepatic recirculation.
Thus, neither comparison of ‘total’ or ‘labelled’ plasma
AUC responses appears to give a reliable index of ‘relative
bioavailability’. It is concluded that currently held views
on the absorption, metabolism and subsequent tissue distri-
bution of folates (which suggest that the bioavailability of
oral test doses can be estimated by contrasting the plasma
response with that from an equivalent ‘reference dose’ of
PteGlu), need re-evaluation.
Two potential solutions to this problem are suggested.
First, an adaptation could be made to the oral and intra-
venous dual-label stable-isotope ‘urinary excretion ratio’
protocol of Gregory et al. (1992), using isotopically
labelled (6S-) 5-CH3H4PteGlu as the intravenous dose,
rather than isotopically labelled PteGlu. This adaptation
to the method may overcome differences in the kinetics
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of urinary excretion of oral and intravenous doses that have
been observed when using labelled PteGlu as the intrave-
nous dose (Gregory et al. 1992; Rogers et al. 1997; Finglas
et al. 2002b). However, this manoeuvre may eventually
prove to be only a partial solution and have to be restricted
to the estimation of the ‘relative absorption’ of oral doses
of ‘natural’ reduced folates and not PteGlu (as either sup-
plement or fortificant). Second, one could mathematically
model plasma-labelled response data (entrance and clear-
ance rates) using a single-compartment model with esti-
mates for the size of pool mass and volume, and
(perhaps) first-pass liver effect. The advantages of this
approach may be at least to obtain an accurate estimate
of ‘relative bioavailability’, if not absolute absorption.
Metabolic models are currently being investigated (Finglas
et al. 2002a).
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Appendix 1
There are two possible sources of 13C in the 5-CH3H4
PteGlu in our plasma samples: the tracer (the 13C6-labelled
5-CH3H4PteGlu; 5MTHF) and the tracee (unlabelled
5-CH3H4PteGlu). The mass spectrometer is set up to
measure the largest fraction of the 5-CH3H4PteGlu
coming from the tracer (mass 464; M þ 6) and the largest
fraction coming from the tracee (mass 458; M þ 0). The
response for either M þ 0 or M þ 6 will depend on the
number of 5-CH3H4PteGlu molecules present in the
sample that have come from the two sources. Examining
each source separately, the number of 5-CH3H4PteGlu
molecules in the sample, measured in the M þ 6
channel, that have come from the tracer (defined as
M þ 6sampletracer) is proportional to the number of mol of
the tracer present in the sample (defined as moltracer) and
the fraction of the tracer that is actually present at mass
464 (defined as M þ 6tracer). Therefore:
M þ 6sampletracer / M þ 6tracer £ moltracer;
and, in a similar fashion, the number of molecules of
5-CH3H4PteGlu in the sample, measured in the M þ 6
channel, that have been derived from the tracee
(unlabelled) source is:
M þ 6sampletracee / M þ 6tracee £ moltracee:
The overall contribution from the two sources to the
total number of 5-CH3H4PteGlu molecules, measured in
the M þ 6 channel, will be a linear combination of the
two equations above and is defined as M þ 6sample. There-
fore, the number of molecules of 5-CH3H4PteGlu in the
sample that have been derived from the tracer (labelled)
and tracee (unlabelled) source is:
M þ 6sample / M þ 6tracer £moltracer þ M
þ 6tracee £ moltracee; ð1Þ
and, similarly for M þ 0sample,
M þ 0sample / M þ 0tracer £ moltracer þ M þ 0tracee
£ moltracee: ð2Þ
On dividing (2) by (1):
M þ 6sample
M þ 0sample ¼
M þ 6tracer £ moltracer þ M þ 6tracee £ moltracee
M þ 0tracer £ moltracer þ M þ 0tracee £ moltracee : ð3Þ
The ratio M þ 6sample/M þ 0sample is defined as Mþ6/Mþ0R.
Therefore:
Mþ6=Mþ0R ¼
M þ 6tracer £ moltracer þ M þ 6tracee £ moltracee
M þ 0tracer £ moltracer þ M þ 0tracee £ moltracee : ð4Þ
Similarly for the M þ 0sample/M þ 0sample ratio:
Mþ0=Mþ0R ¼
M þ 0tracer £ moltracer þ M þ 0tracee £ moltracee
M þ 0tracer £ moltracer þ M þ 0tracee £ moltracee : ð5Þ
If the denominator in equations 4 and 5 is set to be a constant,
k, then:
1=k ¼ M þ 0tracer £ moltracer þ M þ 0tracee
£ moltracee: ð6Þ
Equations 4 and 5 can now be rewritten:
Mþ6=Mþ0R ¼ M þ 6tracer £ k £ moltracer þ M þ 6tracee
£ k £ moltracee;
ð7Þ
Mþ0=Mþ0R ¼ M þ 0tracer £ k £ moltracer þ M þ 0tracee
£ k £ moltracee: ð8Þ
Equations 7 and 8 can be represented in matrix notation:
Mþ6=Mþ0R
Mþ0=Mþ0R
" #
¼
M þ 6tracer M þ 6tracee
M þ 0tracer M þ 0tracee
" #
£
k £moltracer
k £ moltracee
" #
; ð9Þ
or,
R ¼ A £ x: ð10Þ
Solving for x:
x ¼ A £ R; ð11Þ
where
x ¼
k £ moltracer
k £ moltracee
" #
:
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In terms of mol fractions:
mole fraction of tracer ði:e: 5MTHFfractiontracerÞ
¼ k £moltracer
k £moltracer þ k £moltracee ; ð12Þ
mole fraction of tracee ði:e: 5MTHFfractiontraceeÞ
¼ k £ moltracee
k £ moltracer þ k £ moltracee : ð13Þ
It is now a simple task to calculate the quantity of the
5-CH3H4PteGlu that has come from the tracer or tracee
in any plasma sample because the total 5-CH3H4PteGlu
(defined as 5MTHFtotal) in the sample is known from an
HPLC measurement.
Quantity of tracer ¼
5MTHFfractiontracer £ 5MTHFtotal
5MTHFfractiontracer þ 5MTHFfractiontracee ; ð14Þ
Quantity of tracee ¼
5MTHFfractiontracee £ 5MTHFtotal
5MTHFfractiontracer þ 5MTHFfractiontracee : ð15Þ
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Adaptive responses in men fed low- and high-copper diets
Linda J. Harvey1*, Gosia Majsak-Newman1, Jack R. Dainty1, D. John Lewis2,
Nicola J. Langford2, Helen M. Crews2 and Susan J. Fairweather-Tait1
1Nutrition and Consumer Science Division, Institute of Food Research, Norwich Research Park, Colney,
Norwich NR4 7UA, UK
2Central Science Laboratory, Sand Hutton, York YO41 1LZ, UK
(Received 11 March 2002 – Revised 11 February 2003 – Accepted 3 March 2003)
The study of Cu metabolism is hampered by a lack of sensitive and specific biomarkers of status and suitable isotopic labels, but limited
information suggests that Cu homeostasis is maintained through changes in absorption and endogenous loss. The aim of the present study
was to employ stable-isotope techniques to measure Cu absorption and endogenous losses in adult men adapted to low, moderate and high
Cu-supplemented diets. Twelve healthy men, aged 20–59 years, were given diets containing 0·7, 1·6 and 6·0 mg Cu/d for 8 weeks, with at
least 4 weeks intervening washout periods. After 6 weeks adaptation, apparent and true absorption of Cu were determined by measuring
luminal loss and endogenous excretion of Cu following oral administration of 3 mg highly enriched 65Cu stable-isotope label. Apparent
and true absorption (41 and 48 % respectively) on the low-Cu diet were not significantly different from the high-Cu diet (45 and 48 %
respectively). Endogenous losses were significantly reduced on the low- (0·45 mg/d; P,0·001) and medium- (0·81 mg/d; P¼0·001) com-
pared with the high-Cu diet (2·46 mg/d). No biochemical changes resulting from the dietary intervention were observed. Cu homeostasis
was maintained over a wide range of intake and more rapidly at the lower intake, mainly through changes in endogenous excretion.
Copper: Fructose: Stable isotopes: Copper absorption: Copper endogenous losses
Whole-body Cu balance (homeostasis) is maintained by a
combination of changes in absorptive efficiency of the
intestinal mucosal cells and quantity of endogenous Cu
excreted via the gastrointestinal tract. At low and high
intakes the efficiency of absorption is up and down
regulated respectively, but adaptation is more rapid with
a low Cu intake (Turnlund et al. 1989). The extent to
which this endogenously excreted Cu is reabsorbed from
the gut is not known (Linder, 1991).
Cu absorption decreases with malnutrition and in
various disease states with malabsorption syndromes, for
example, coeliac disease (Cordano et al. 1964; Goyens
et al. 1985), and several dietary factors reduce absorption,
for example, antacids, infant cows’ milk formulas (Dorner
et al. 1989), Zn (Turnlund et al. 1988; August et al. 1989)
and fructose. The Cu–fructose interaction is potentially the
most important due to the increasing consumption of
fructose in the Western diet. However, the mechanisms
are uncertain because the results of human studies have
proved difficult to interpret. Fructose has been found to
impair Cu status, whilst Cu balance appears to be increased
(Reiser et al. 1985).
Cu absorption has been measured in human volunteers
using a highly enriched 65Cu stable isotope, with doses
corresponding to 50–200 % of typical daily intakes
(August et al. 1989; Turnlund et al. 1991). In these studies,
the unabsorbed Cu isotope is excreted in the faeces within
5–7 d, followed by smaller amounts of isotope that have
been absorbed and then re-excreted (endogenous loss).
Thus the period of time over which the faecal collections
are made is critical; if it is too short then the apparent
absorption (intake minus luminal loss) will be over-
estimated, as not all of the unabsorbed Cu will have been
excreted. In addition, it is only possible to calculate true
absorption if endogenous excretion has been estimated
from the appearance of absorbed isotope in the later
faecal collections.
The aim of the present study was to determine Cu
absorption, retention and endogenous losses following
equilibration at different levels of intake of Cu, from that
found in diets low in Cu to a level generally only attainable
with Cu supplements. In the absence of a sensitive and
specific index of Cu status, this was believed to be the
best approach for generating information needed to assess
the public health significance of low and high Cu intakes.
A range of biochemical assays was undertaken at the
beginning and end of each dietary intervention in order
to underpin the metabolic measurements.
* Corresponding author: Dr Linda Harvey, fax +44 1603 507723, email linda.harvey@bbsrc.ac.uk
Abbreviations: GPx, glutathione peroxidase; ICP–MS, inductively coupled plasma–mass spectrometry; IFR, Institute of Food Research; SOD,
Cu,Zn-superoxide dismutase.
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Methods
Subjects
Twelve healthy men were recruited to a residential,
longitudinal intervention study (subject characteristics are
given in Table 1). A screening blood sample (10 ml) was
taken to exclude volunteers whose biochemical and
haematological indices lay outside the normal range. Other
exclusion criteria included chronic illness, taking medication
or nutritional supplements, and smoking. The aims and pro-
cedures of the study were explained to the volunteers during a
visit to the Human Nutrition Unit at the Institute of Food
Research (IFR) and written informed consent was obtained.
The IFR Human Research Ethics Committee approved the
protocol and the study was conducted in accord with the
Helsinki Declaration of 1975 as revised in 1983.
Study design
The subjects were resident in the Human Nutrition Unit for
three periods of 8 weeks with a minimum washout of
4 weeks between study periods. A diet low in Cu was fed
throughout the study using a 7 d rotating menu consisting
of three meals per d and snacks. Additional Cu was added
to the diets in the form of copper sulfate with each meal,
such that the total daily intake was 1·6 and 6·0 mg during
the first and third dietary periods respectively. The diets
were regularly analysed to ensure that the Cu content
remained constant from batch to batch. During each study
period, the energy intakes of the subjects were adjusted as
necessary in order to maintain body weight by the addition
of either a commercially available dextrose drink or
yoghurt. The mean Cu content of the diet analysed by
atomic absorption spectroscopy was 0·69 (SD 0·02) mg/d.
All other dietary variables were within customary UK
limits. The diet had a mean daily energy intake of
10·78 MJ (2577 kcal), of which 12 % was from protein,
52 % from carbohydrate and 36 % from fat. The mean calcu-
lated daily mineral content of the diet was 2845 mg K,
2234 mg Na, 1299 mg Ca, 2918 mg Mg, 7·7 mg Fe and
7·6 mg Zn. The habitual dietary Cu intake of each volunteer
was assessed before the residential part of the study. Each
volunteer kept a 7 d weighed food intake diary, which was
analysed for Cu content using food composition tables
(Royal Society of Chemistry, 1991). Subjects also collected
24 h duplicate diets during this period. The daily collections
were homogenised and analysed for Cu content using
the inductively coupled plasma–mass spectrometry (ICP–
MS) facility at the Central Science Laboratory.
On day 42 of each dietary period, following a 12 h
overnight fast, each volunteer received a 3 mg oral dose of
the highly enriched 65Cu stable isotope in 130 g of a diet
cola drink together with a low-Cu meal consisting of 70 g
white bread and 17 g butter. The cola drink also
contained 1 mg of the rare earth element Ho, which acted
as a non-absorbable faecal marker (Harvey et al. 2002). Six
of the volunteers (randomly assigned) also received 25 g
fructose dissolved in the cola drink. The effect of the fructose
was not evaluated. The volunteers refrained from eating and
drinking (except demineralised water) for 4 h following the
test meal. Complete faecal collections were made for a
period of approximately 14 d post-dosing and each subject
also collected a baseline faecal sample before the test meal.
Fasting blood samples were taken on days 1 and 42 of
each dietary period for a range of biochemical assays
(see p. 163).
Dose preparation
Isotopically enriched copper chloride (65CuCl2) was
prepared from elemental 65Cu (Europa Scientific Ltd,
Crewe, UK) by dissolving the metal in 10 ml concentrated
HNO3 (BDH, Poole, UK) (Aristar grade) and evaporating
to virtual dryness. The sample was then taken up in
0·1 M-HCl (25 ml; BDH, Aristar grade) and again evapor-
ated to almost dryness; this stage was then repeated twice
more and finally the sample was taken up in an appropriate
volume of 0·1 M-HCl to give an approximate concentration
of 1 mg/ml. The concentration was accurately determined
by ICP–MS. The solution was divided into individual
doses and stored in plastic vials at 2208C until required.
The Ho oral doses were prepared by dissolving holmium
chloride (Avocado Research Chemicals Ltd, Heysham,
UK) in demineralised, purified water (Elga, Cambridge)
to concentrations of approximately 0·5 mg/ml. The solution
was divided into individual 1 mg doses and stored in plastic
vials at 2208C until required and the concentration
accurately determined by ICP–MS.
Sample preparation and analysis
Faecal samples were autoclaved, freeze-dried, ground to a
fine powder using a mortar and pestle, and sub-sampled.
Before analysis by ICP–MS, portions of faecal samples
(0·5 g) were digested in concentrated nitric acid (5 ml)
using a high temperature–pressure microwave digestion
system and the digest fluid diluted 50-fold with distilled
water containing Ga (50 ng/ml) as an internal standard.
The total levels of Cu and the 63Cu:65Cu isotope value in
the solutions were measured using a VG Plasmaquad
Turbo II Plus ICP–MS (VG Elemental, Winsford, UK)
(Baxter et al. 1997). The quality of the analytical data was
assessed in two ways; first, by the use of a certified reference
material (BCR 422 cod muscle), and second, by the recov-
ery of a known amount of added analyte. Ho concentrations
were also quantified by ICP–MS (Baxter et al. 1997).
Biochemical assays
Blood samples collected on days 1 and 42 were prepared
for various analyses performed either at the IFR or at
the Chemical Pathology Department of the Norfolk and
Table 1. Subject characteristics
(Mean values and standard deviations for twelve subjects)
Mean SD Range
Age (years) 32 11 20–59
Height (m) 1·79 0·06 1·70–1·94
Weight (kg) 78·4 9·3 67·8–100·3
BMI (kg/m2) 24 2 20–28
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Norwich Hospital (Norwich, UK). Analyses performed by
the Chemical Pathology Department included serum Cu,
caeruloplasmin, C-reactive protein and a full lipid
screen. Serum Cu was measured by atomic absorption
spectroscopy (Phillips model no. PU9200; Phillips,
Cambridge, UK) and total caeruloplasmin by an immuno-
turbidimetry assay (Dako, High Wycombe, UK). The
inter-assay CV were 6·4 and 10 % for the Cu and caerulo-
plasmin respectively. Serum samples were also analysed
for triacylglycerols and total, LDL- and HDL-cholesterol;
LDL-cholesterol was calculated using the Friedewald
equation (Friedewald et al. 1972). Apolipoprotein A1 and
B concentrations were determined using immunoturbidi-
metry assays (IMMUNO, Ltd., Sevenoaks, Kent, UK)
automated on a Cobas Fara centrifugal analyser (Roche,
Welwyn Garden City, UK). In order to eliminate raised
caeruloplasmin or ferritin concentrations that resulted
from an inflammatory response or infection, C-reactive
protein concentrations were determined using an immuno-
turbidimetry assay (Dako). Caeruloplasmin activity was
determined at the Northern Ireland Centre for Diet and
Health using a modified method of Henry et al. (1960)
on an autoanalyser (Cobas Fara; Roche).
The remaining assays were performed at the IFR using
an autoanalyser (Cobas Mira; Roche). Control serum
(Serum N; Roche) and quality control samples prepared
in-house were used for each assay as appropriate:
(a) Cu,Zn-superoxide dismutase (SOD) was measured in
erythrocytes using a commercial kit (Ransod kit;
Randox Laboratories, Crumlin, UK) based on a
modified method of Jones & Suttle (1981). SOD
activity was expressed in terms of SOD units/g
haemoglobin measured by Drabkin’s method
(Drabkins & Austin, 1932) standardised with cyano-
methaemoglobin (BDH standard).
(b) Glutathione peroxidase (GPx) activity was deter-
mined in plasma, platelets and erythrocytes using a
commercially available kit (Ransel test kit; Randox
Laboratories) based on a modified method of Paglia
& Valentine (1967). Gpx activity was expressed in
terms of protein concentration (Unimate 7 Total
protein kit; Roche) in plasma and platelets (GPx
activity/g protein) and haemoglobin concentration
in erythrocytes (Gpx activity/g haemoglobin).
(c) Plasma ferritin was determined by an in-house ELISA
assay using A133-rabbit anti-human ferritin coating
anti-body and P145-rabbit anti-human ferritin detec-
tor antibody, peroxidase conjugated (Dako). The
assay was standardised using the 3rd International
Standard for Ferritin (National Institute for Biological
Standards and Control, Potters Bar, UK).
(d) Platelet aggregation was determined as a response to
ADP at a final concentration of 2 £ 1025 mol/l in
citrated blood using a platelet aggregation profiler
(model PAP-4; Bio/Data Corporation, Horsham,
PA) (Williams et al. 1977).
(e) Other haematological indices including haemoglobin,
packed cell volume and mean cell haemoglobin
concentration were measured using an MD8 Coulter
Counter (Coulter Electronics Ltd, Hialeah, FL, USA).
Mathematical analysis
Quantities of labelled and unlabelled Cu were calculated
according to the method described in Harvey et al.
(2002); this paper also details the calculation of
endogenous losses from the labelled Cu dose. Fig. 1
shows an overview of the labelled and unlabelled Cu
absorption and excretion that was measured and calculated
in the present study. The following equations were used to
generate the results shown in Tables 2 and 6.
Labelled copper absorption and excretion.
Apparent absorption ¼ ðDL 2 RLÞ=DL;
True absorption ¼ ðDL 2 RL þ ELÞ=DL
¼ AL=DL ¼ AU=DU; ð1Þ
where DL is the labelled Cu dose, RL is the labelled Cu
recovered in faeces, AL is the absorbed labelled Cu, AU
is the absorbed unlabelled Cu and DU is the unlabelled
Cu in the diet. Endogenous loss ðEL; mgÞ ¼ FL þ SL
where FL (mg) is the loss of labelled Cu from a ‘fast’
pool and SL (mg) is the loss of labelled Cu from a
‘slow’ pool. Labelled Cu from the fast pool is defined to
be Cu that was absorbed from the dose and then excreted
within 14 d. Labelled Cu from the slow pool is defined to
be Cu that was absorbed from the dose and excreted
more than 14 d after the dose. Since the study period is
only 14 d, labelled Cu from the slow pool is not measured
and SL¼0. Therefore all the endogenous losses of labelled
Cu are from the fast pool, i.e. EL¼FL.
Endogenous loss ðas a fraction of doseÞ
¼ EL=DL ¼ FL=DL ¼ FU=DU; ð2Þ
where FU is the rate of loss of unlabelled Cu from the ‘fast’
pool in mg/d.
Fig. 1. Overview of labelled and unlabelled copper absorption and
excretion.
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Unlabelled copper balance and excretion. In an analo-
gous way to the labelled Cu, unlabelled Cu from the fast
pool is defined as Cu that was absorbed from a meal and
then excreted within 14 d. Unlabelled Cu from the slow
pool is defined to be Cu that was absorbed from a meal
and excreted more than 14 d after the meal.
Balance ðmg=dÞ ¼ DU 2 RU;
where RU is the unlabelled Cu recovered in faeces.
Endogenous loss ðEU; mg=dÞ ¼ RU 2 DU þ AU ¼
RU 2 DU þ ðDU £ ALÞ=DL (from equation (1)).
Unlabelled Cu from the ‘fast’ pool (FU; mg/d) ¼ EL £ DU/
DL (from equation (2)).
Since EL, DU and DL are all known or measured, FU can
be calculated. These results are shown in Table 2 in the
‘fast pool’ section.
Unlabelled Cu from the ‘slow’ pool (SU; mg/d) ¼
EU 2 FU.
Therefore, on substitution and rearrangement,
SU ¼ ððRU £ DLÞ2 ðRL £ DUÞÞ=DL: ð3Þ
Since RU, RL, DU and DL are all known or measured, SU
can be calculated. These results are shown in Table 2 in the
‘slow pool’ section.
Statistical analysis
All data are expressed as means and standard deviations.
ANOVA with repeated measures was used to determine
the effect of dietary Cu intake on the efficiency of Cu
absorption and excretion. If a significant difference was
found, the least squares difference test was used to deter-
mine which treatment means differed. Student’s t test
was used to determine the difference between measured
and calculated habitual dietary Cu intakes. A significance
level of P,0·05 was used for all statistical tests.
Results
The biochemical data are shown in Table 3. In every case,
none of the parameters measured on day 42 was signifi-
cantly different from those measured on day 1 and there
was also no significant difference between the values
measured on day 1 of each dietary period; thus only the
day 42 results are presented. All erythrocyte SOD, serum
Cu, serum total caeruloplasmin and plasma caeruloplasmin
activity measurements fell within normal ranges; statistical
evaluation of the data demonstrated that none of the par-
ameters was affected by dietary Cu intake. Equilibration
for 6 weeks at each Cu intake level was also found to
have no significant effect on various risk factors related
to cardiovascular disease, including ADP-stimulated plate-
let aggregation, plasma lipoproteins (total, HDL-, LDL-
cholesterol), triacylglycerols, apolipoproteins A1 and B
and GPx (Table 4). Other haematological factors were
also unaffected by dietary Cu intake including haemo-
globin, mean cell haemoglobin concentration and packed
cell volume (Table 5).
All data for efficiency of Cu absorption for the low
(0·7 mg/d), medium (1·6 mg/d) and high (6·0 mg/d) Cu
intake levels are presented in Table 6. Apparent absorption
data for eleven of the twelve volunteers are presented due
Table 2. Unlabelled copper endogenous losses and balance data†
(Mean values and standard deviations)
6·0 1·6 0·7
Dietary Cu intake (mg/d). . . n Mean SD Mean SD Mean SD
Cu recovered in faeces‡ (mg/d) 12 5·25 1·05 1·60* 0·31 0·83* 0·32
Balance (mg/d) 6 0·75 1·05 0·00* 0·31 20·13* 0·32
Slow pool§ (mg/d) 6 1·33 1·15 0·58 0·15 0·35* 0·25
Fast poolk (mg/d) 6 1·14 0·29 0·23* 0·09 0·10* 0·02
Total (slow poolþ fast pool) (mg/d) 6 2·46 1·11 0·81* 0·16 0·45* 0·25
* Mean value was significantly different (P,0·05) from the value on the high Cu diet.
† For details of subjects and procedures, see Table 1 and p. 162.
‡ Based on the unlabelled Cu recovered 14 d after label administration.
§ Cu absorbed from a meal and excreted at least 14 d after the meal.
kCu absorbed from the meal and excreted within 14 d of the meal.
Table 3. Putative indices of copper status after 6 weeks of each dietary period*
(Mean values and standard deviations for twelve subjects)
6·0 1·6 0·7
Dietary Cu intake (mg/d). . . Mean SD Mean SD Mean SD
Erythrocyte superoxide dismutase activity (U/g haemoglobin) 1016 79 1070 120 1009 113
Serum Cu (mmol/l) 15·5 2·2 13·9 1·7 14·4 2·1
Serum caeruloplasmin (g/l) 0·28 0·14 0·23 0·07 0·21 0·04
Plasma caeruloplasmin activity (U/mg) 2·62 0·48 2·29 0·39 2·60 0·64
* For details of subjects and procedures, see Table 1 and p. 162.
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to incomplete stool collection for one of the volunteers.
Data for true absorption are reduced to six data sets
because the method used to calculate true absorption
failed on five other volunteers due to slow transit times
of these subjects. This resulted in an inadequate number
of stools being available in the later stages of the faecal
collection period containing only 65Cu stable isotope
dose resulting from endogenous losses. The mean apparent
absorption of the 3 mg label for eleven of the volunteers on
the low Cu intake was not significantly different from the
apparent absorption of the dose at the high dietary intake
level. There was no significant difference in apparent
absorption between the medium and high or medium and
low Cu intakes.
Table 5. Haematological and haemostatic measurements after 6 weeks at each level of copper intake*
(Mean values and standard deviations)
6·0 1·6 0·7
Dietary Cu intake (mg/d). . . n Mean SD Mean SD Mean SD
Packed cell volume (%) 11 45·7 4·0 44·5 3·3 44·1 1·3
Haemoglobin (g/l) 12 151 13 150† 7 148 5
MCHC (g/l) 11 331 8 336 13 335 6
Ferritin‡ (ng/ml) 12 29·3 14·9, 57·8 47·3 18·7, 119·3 30·6 12·5, 74·9
MCHC, mean cell haemoglobin concentration.
* For details of subjects and procedures, see Table 1 and p. 162.
† Values for eleven subjects.
‡ Values are geometric means (21 SD, þ1 SD).
Table 6. Copper absorption and endogenous losses (from an oral dose of 3 mg copper label)
measured after 6 weeks of each dietary period*
(Mean values and standard deviations)
6·0 1·6 0·7
Dietary Cu intake (mg/d). . . n Mean SD Mean SD Mean SD
Apparent absorption
% 11 45 13 42 15 41 12
mg 1·34 0·38 1·27 0·44 1·23 0·35
True absorption
% 6 48 11 45 14 48 13
mg 1·45 0·33 1·36 0·41 1·45 0·39
Endogenous loss of label†
% 6 40 11 38 20 30 15
mg 0·58 0·17 0·48 0·22 0·40 0·10
* For details of subjects and procedures, see Table 1 and p. 162.
† Absorbed label excreted within 14 d of dose administration.
Table 4. Biochemical indices denoting increased risk of cardiovascular disease measured after 6 weeks
at each level of copper intake*
(Mean values and standard deviations for twelve subjects)
6·0 1·6 0·7
Dietary Cu intake (mg/d). . . Mean SD Mean SD Mean SD
Platelet aggregation (%) 80 10 80 7 82 5
Plasma lipoproteins (mmol/l)
Total cholesterol 5·0 0·9 5·2 1·1 5·1 1·1
LDL-cholesterol 3·3 0·9 3·4 1·0 3·5 1·0
HDL-cholesterol 1·1 0·2 1·0 0·2 1·1 0·2
Triacylglycerols (mmol/l) 1·24 0·43 1·51 0·94 1·19 0·53
Apolipoprotein A1 (g/l) 1·14 0·04 1·10 0·04 1·19 0·04
Apolipoprotein B (g/l) 1·08 0·1 0·96 0·80 0·93 0·09
Glutathione peroxidase
Erythrocyte (U/g haemoglobin) 45 9 47 10 47 9
Plasma (U/g protein) 9 1 9 2 9 2
Platelets (U/g protein) 265 120 225 101 347 252
* For details of subjects and procedures, see Table 1 and p. 162.
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Generally, the non-absorbed label was excreted in the
faeces within 6 d of administration of the dose. This was
validated by the simultaneous and complete recovery of
the Ho dose (mean recovery was 98 (SEM 5) %).
Labelled Cu appearing in the faeces after this time was
attributed to endogenous losses. Labelled endogenous
losses were calculated using the method of Harvey et al.
(2002) and were significantly lower on the low- and
medium-Cu diets compared with the high-Cu diet (Table 6).
True absorption was estimated by adjusting the apparent
absorption, as determined from faecal monitoring, with the
endogenous loss measurements of the recovered label in
these subjects (Table 6). True absorption was found to
follow the same pattern as apparent absorption; absorption
on the low-Cu diet was not significantly different from the
high-Cu diet. There was no significant difference in the
absorption between the medium and either the high or
low Cu intakes.
Balance is measured as the difference between dietary
intake of unlabelled Cu and unlabelled Cu recovered in
the faeces. It can be seen from Table 2 that, on average,
the volunteers are in negative balance on the low-Cu diet
and positive balance on the medium- and high-Cu diets.
Balance on the high-Cu diet was significantly greater
than for both the medium- and low-Cu diets. However,
the difference between the medium- and low-Cu diets
was not significant. For the labelled Cu, volunteers on
the low-Cu diet retained 1·05 (SD 0·40) mg of the label
14 d after administration compared with 0·88 (SD 0·44)
mg on the medium-Cu diet and 0·87 (SD 0·26) mg on the
high-Cu diet. The difference between the low- and
high-Cu diet values was not significant.
In the present experiment, total endogenous losses can
be divided into two parts: fast and slow loss. The ‘fast’
loss is Cu that has been absorbed from a meal and then
excreted within 14 d. The ‘slow’ loss is absorbed Cu that
is excreted in the faeces more than 14 d after the meal
was consumed. The total daily endogenous loss is
calculated from the quantity of absorbed Cu per d plus
the difference between dietary intake and recovered
faecal Cu. This assumes that the quantity of Cu lost via
other routes (for example, urine) is small. These data are
presented in Table 2 for the unlabelled Cu. The total
endogenous loss on the high-Cu diet was significantly
different from both the medium- (P¼0·001) and low-Cu
diets (P,0·001). A similar significant difference was
observed for the rate of endogenous loss from the fast
pool on the high-Cu diet compared with the medium-
(P,0·001) and low-Cu diets (P,0·001). The rate of
endogenous loss from the slow pool was calculated as
the difference between the total and the fast rates of
loss (Table 2). The rate of loss was significantly greater
on the high- than on the low-Cu diet (P¼0·023). No
significant difference was observed between the high-
and medium-Cu diets.
The habitual dietary Cu intake of each of the volunteers
was determined from both calculated and direct measure-
ments. The mean analysed daily intake was 1·8 (SD 0·5)
mg with a range of 0·8–2·8 mg/d and was significantly
higher (P¼0·021) than the calculated value of 1·4
(SD 0·5) mg with a range of 0·7–2·5 mg/d.
Discussion
From the results presented it appears that Cu homeostasis
is maintained through control of only endogenous
excretion and not absorption. Although the present study
does not include data on urinary output, it has been
reported that this form of excretion is minimal (Ishihara
& Matsushiro, 1986) and is not dependent on dietary Cu
intake. Turnlund et al. (1989, 1998) have performed two
dietary intervention studies with male volunteers, feeding
Cu levels similar to those used in the present study.
Stable-isotope methodology was used to determine appar-
ent absorptions of 56 and 54 % following equilibration at
Cu intake levels of 0·785 and 0·66 mg/d respectively,
higher than the mean apparent absorption of 41 % found
on the low-Cu diet (0·7 mg/d) in the present study. Daily
intakes of 7·53 and 1·68 mg Cu were found to result
in apparent absorptions of 12 and 36 % respectively
(Turnlund et al. 1989). These values are, however, lower
than the values found in the present study, which may be
the result of differences in experimental protocol. First,
the present study measured absorption from a single test
meal, which has been reported to over-estimate absorption
compared with measurement over several meals as used by
Turnlund et al. (1989). Second, in the present study, in
order to be able to calculate endogenous losses, 3 mg
labelled Cu was given in a single test meal on each of
the high-, medium- and low-Cu diets, whereas in the
study by Turnlund et al. (1998) Cu in the study meals
was replaced with the same quantity of Cu label.
The study by Turnlund et al. (1998) estimated
endogenous losses by measuring the faecal appearance of
intravenous doses of highly enriched 65Cu stable isotope.
In agreement with our data, endogenous losses were
found to be reduced with low dietary Cu intake when
compared with higher intake levels. A Cu metabolism
model based on the disappearance of both infused and
oral 65Cu dose has suggested that tissue uptake of oral
and intravenous Cu is different, with flow between the
plasma and liver compartment from the intravenous dose
only being 80 % of the oral dose (Scott & Turnlund,
1994). The intravenous technique gives a general
indication of the relative changes in endogenous losses
resulting from different dietary Cu intakes, whereas the
technique used in the present study has the advantage of
reflecting the metabolism of the absorbed oral dose in the
same volunteer during the same time period as the
absorption efficiency is assessed.
Within 14 d, 38 (SD 20) % of the absorbed oral dose had
been excreted when the volunteers were on the medium-Cu
diet. From the retention data of the unlabelled Cu it is
known that the volunteers were in balance (Table 2).
This indicates that the other 76 % of the absorbed label
will be excreted at a future indeterminate time from a
slowly exchangeable pool in the body. When the
volunteers were on the high-Cu diet, 40 (SD 11) % of the
absorbed dose was excreted 14 d after the dose was
given. The volunteers were not, however, in balance
(0·75 mg/d was retained). It is not clear from our study
or others (Turnlund et al. 1989; 1998) how long, if at all,
it would take to restore Cu balance on such a high-Cu
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diet. Losses from the rapidly exchanging (fast) pool alter
significantly between the diets (Table 2). There is a five-
fold increase between the medium- and high-Cu diets in
this fast pool but only a two-fold increase in the slow
pool loss between the same two diets. This fast pool can
clearly respond to changes in dietary conditions much
more readily than the slow pool and indicates that the
physical locations of the fast pool are a series of rapidly
turning over spaces that certainly include the liver in
some capacity.
Linder et al. (1986) and Owen (1971) have shown in rats
that the loss of Cu from the body can be represented by a
biphasic equation. Our model of endogenous loss assumed
that the labelled Cu was lost according to a linear equation
(of the form y ¼ mx þ c) since this is all that can be justi-
fied from the data. Fig. 2 and Table 7 show an attempt to
estimate the endogenous loss in one volunteer on the high-
Cu diet by applying three different mathematical models to
the data. In all three models, estimates of endogenous loss
are made beyond the time that measurements were taken
(14 d). After 30 d of the mono- and bi-exponential simu-
lations and 19 d of the linear one, there is still at least
1 mg absorbed Cu that has not been excreted. The interven-
tion periods were 6 weeks and the volunteers on the
medium- and low-Cu diets were in balance at the end of
them. This suggests that a complex excretory system
exists for Cu and that our attempts at simple models are
not adequate to describe it. The division of endogenous
losses into two pools (slow and fast) is an over simplifica-
tion but is all that can be attempted with a study of this
type. Single meal stable-isotope studies with physiological
doses cannot, at present, measure the return of labelled Cu
from slow turnover pools because their half-life is too long.
The physical nature of the slow pool (or pools) is a matter
for conjecture but the most probable candidates are muscle
and bone. Whatever the nature of the pool, it appears to be
under homeostatic control, as evidenced by a doubling of
Cu flowing from it between the low- to medium- and
medium- to high-Cu diets, although it had not changed
sufficiently over the 6 weeks of the high-Cu diet to achieve
Cu balance.
The results of the present study indicate that homeostasis
is more strongly controlled by endogenous excretion.
Absorption did not change in response to variations in Cu
intake. A four-fold dietary increase in Cu (medium- to
high-Cu diet) would necessitate a four-fold reduction in
absorption (60 to 15 %) if this were the body’s only
homeostatic mechanism. Similarly, the change in
absorption between the medium- and the low-Cu diet was
45 to 48 %, whereas the reduction in dietary Cu between
the two periods was approximately a factor of two.
An attempt has been made in the present paper to use the
data from the re-excreted oral dose to calculate endogenous
losses. This allows quantification of the so-called fast pool
of endogenous loss. Although a linear model has been used
to calculate these losses, other researchers, using radioiso-
tope data, have shown that a biphasic curve represents the
endogenous loss in the best way. Using physiological doses
of stable isotope, measurements of enrichment in faeces are
possible up to about 14 d post-dose. After this length of
time, the precision is not sufficient to use the data. This
limits the complexity of any models derived from stable-
isotope data to only the simplest kind, i.e. linear regression
models. Although the modelling is simple, it still generates
useful information and allows the calculation of two Cu
loss pools (fast and slow) through direct and indirect
means. Overall, the data suggest that adaptive responses
to a high dietary intake take longer to achieve than at
lower intakes. The fact that none of the biochemical
measurements changed as a result of altered Cu intake
lends support to our hypothesis that adult men faced with
quite large variations in Cu intake are able to maintain
Cu homeostasis predominantly by up and down regulation
of Cu secretions into the gastrointestinal tract.
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We describe a liquid chromatography (LC) tandem mass spectrometry (MS-MS) method for the determination of 5-methyl-
tetrahydrofolic acid (5-methylTHF) and folic acid concentrations and enrichments in human plasma. It was used to study
absorption and initial metabolism in ﬁve volunteers with two simultaneously administered oral test doses ([13C6]folic acid in capsules
and [2H2]folic acid in a drink). [
13C5]5-methylTHF and [
2H4]folic acid were used as internal standards. Plasma samples (2ml) were
puriﬁed using folate binding protein aﬃnity columns, followed by a concentration step. After LC separation, folates were detected
using positive electrospray ionization MS-MS under multiple reaction monitoring conditions. Calibrations were linear for
5-methylTHF over the range 1.2 1011 (¼limit of detection) to 3.2 107 mol/L and for folic acid over the range 5 1010 (¼limit
of detection) to 4.5 108 mol/L. For 5-methylTHF concentration in plasma, intraassay coeﬃcient of variation was within 8.6%
(and for unlabeled 5-methylTHF it was within 2.8%) and interassay coeﬃcient of variation was within 9.0%. For folic acid con-
centrations these coeﬃcient of variations were within 7.5% and within 6.5%, respectively. The [13C6] and [
2H2] isotopomers of folic
acid and 5-methylTHF were measured in the plasma of each volunteer for 8 h. After accounting for the time delay due to capsule
opening, the modeling results showed no signiﬁcant diﬀerences in absorption time, ﬁrst pass eﬀect, and elimination rate in the folic
acid test doses in capsule or drink. We conclude that LC-MS-MS oﬀers increased sensitivity for quantiﬁcation of plasma con-
centrations and enrichments of 5-methylTHF and folic acid and is applicable to stable-isotope studies in humans.
 2004 Elsevier Inc. All rights reserved.
Keywords: Folate; Liquid chromatography tandem mass spectrometry; Bioavailability1 Abbreviations used: 5-methylTHF, 5-methyltetrahydrofolate glu-Folates are a group of compounds derived from food
stuﬀs. They belong to the B vitamin group and are an
essential element in the diet. In human pathology, folate
deﬁciency causes anemia and neurological disturbances.
Diminished folate status is associated with hyperhom-
ocysteinemia, an independent risk factor for vascular
disease [1]. Folic acid, a synthetic product not appearing
in nature, is used as an oral supplement by patients with
these disorders and is recommended to women of
childbearing age to reduce the risk of neural tube defects* Corresponding author. Fax: +31-20-4440305.
E-mail address: novosilski@hotmail.com (K. de Meer).
0003-2697/$ - see front matter  2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.ab.2003.12.003in oﬀspring. In some countries, folic acid is also used as
a food fortiﬁcant in cereals and dairy products.
Folic acid is absorbed in the small intestine and is
converted in the body through several steps into the
methylated derivative of tetrahydrofolic acid, 5-methyl-
tetrahydrofolic acid (5-methylTHF).1 5-MethylTHF
either is then stored in tissues or appears in plasma.
If folic acid is consumed in amounts exceedingtamate; LC, liquid chromatography; MS, mass spectrometry; MS-MS,
tandem mass spectrometry; tlag, time that 5-methylTHF enrichment
remains at baseline; TTR, tracer to tracee ratio; CV, coeﬃcient of
variation.
130 R.M. Kok et al. / Analytical Biochemistry 326 (2004) 129–138
PAPER 55.7 107 mol (250 lg) in a single dose or as fortiﬁcant
in a meal, its free form can also appear in plasma [2]. To
study the in vivo absorption and metabolism of these
folate forms, several stable isotopes are available. In
stable isotope studies, mass spectrometry (MS) is used
for the measurement of enrichment in folic acid deriv-
atives, in particular 5-methylTHF in plasma. With the
use of isotope dilution techniques, MS can also be used
to measure the plasma 5-methylTHF and folic acid
concentrations. For that purpose, blood samples of
5-methylTHF must be protected against degradation
because the compound is sensitive to heat, UV light, and
oxidation.
For assessment of 5-methylTHF isotopic enrichment,
several methods using LC-MS have been described.
These methods used folate binding protein aﬃnity col-
umns to purify the folate from the plasma samples. The
time-consuming steps required in extraction and deriv-
atization inherent in previous approaches using gas
chromatography-mass spectrometry [3,4] can thus be
overcome. In recent years, LC-MS has been applied to
quantify folate monoglutamates [5–8]. In a study ap-
plied to human folate bioavailability, Hart et al. [9]
described good linearity for 5-methylTHF using LC-MS
with ‘‘negative ion’’ electrospray ionization; using
[2H2]folic acid as internal standard, limits of detection
were 2–5.5 1010 mol/L (coeﬃcient of variation (CV)
7.4%). After ingestion of [13C6]folic acid and [
13C6]5-
HCOH4folic acid by volunteers, this method allowed the
measurement of tracer (mass+6) enrichment in plasma
5-methylTHF samples.
In the present study, we developed a LC tandem MS
(LC-MS-MS) technique to measure 5-methylTHF and
folic acid enrichments in human plasma. The method is
applied in a human stable isotope study in which folic
acid was administered orally in two forms, i.e., [2H2]folic
acid dissolved in water and [13C6]folic acid in capsules.
Both forms were administered in a single bolus, and this
was followed by measurements of plasma 5-methylTHF
isotopomer enrichments. Absorption and initial metab-
olism of both folate tracers was studied with short-term
kinetic modeling, and characteristics for both adminis-
tration forms were compared.Methods
Materials
Folic acid (purity 98%) and 5-methylTHF (6R/S;
purity 90%) were obtained (Sigma, Deiselhofen, Ger-
many), and aqueous stock solutions were prepared
(1.6 104 mol/L folic acid and 5-methylTHF, with 0.1
w/v% ascorbic acid added as antioxidant). (6S)5-meth-
ylTHF was obtained from Eprova AG (Schaﬀhausen,
Switzerland) and aqueous stock solutions were prepared(1.6 104 mol/L 5-methylTHF, with 0.1 w/v% ascorbic
acid added as antioxidant). The labeled folates [2H2]folic
acid, [2H4]folic acid, and gelatin capsules containing
[13C6]folic acid were obtained from the Institute of Food
Research (Norwich, UK), and [13C5]5-methylTHF was
obtained from Eprova AG. Aqueous solutions were
prepared (3.6 106 mol/L [2H4]folic acid and [13C5]
5-methylTHF, with 0.1 w/v% ascorbic acid added as
antioxidant) for use as internal standards. One dose
of the stock solutions and internal standard solutions
was diluted (with 0.1M K2HPO4 buﬀer, pH 7.0) and
folate concentration measured with spectroscopic anal-
ysis using molar extinction coeﬃcients (E[mmol1,
cm1]) of 31,700 for 5-methylTHF and 27,600 for folic
acid [10]. The residual doses were stored at )80 C in the
dark.
For the in vivo experiments, [13C6]folic acid in gelatin
capsules and [2H2]folic acid in water were used as test
doses. The capsules (containing 1.27 107 mol
[13C6]folic acid, with isotopic purity 96% [11,12]), and
glass vials with [2H2]folic acid in pyrogen-free water
(concentration 1.18 104 mol/L with isotopic purity
99%, determined using LC-MS-MS as described below)
were stored in the dark at 4 C.
Human study protocol
Five nonsmoking healthy volunteers (one female and
four males, mean age 27 years, mean body weight 72 kg)
were studied. The volunteers did not use medication or
vitamin supplements and were asked to avoid excessive
consumption of folate-rich food during the week pre-
ceding the experiment (systematic food fortiﬁcation with
folic acid is not practiced in The Netherlands). The
study protocol was approved by the ethics committee of
the VU University Medical Center (Amsterdam, The
Netherlands), and informed consent was obtained from
each subject.
The subjects reported to the VU University Medical
Center at 0800 h, following an overnight fast. An in-
travenous catheter was placed in a dorsal hand vein for
blood sampling. After baseline blood sampling, the
volunteers were given simultaneously two kinds of la-
beled folic acid (i.e., [13C6]folic acid in capsules and
[2H2]folic acid as a drink). First, four gelatin capsules
(total tracer dose 5.1 107 mol (¼ 224 lg) [13C6]folic
acid) were swallowed, followed immediately by a 4-ml
solution (total tracer dose 4.7 107 mol (¼ 207 lg)
[2H2]folic acid) dissolved in water. Volunteers were gi-
ven only a light lunch after a 4-h postdosing blood
sample had been obtained. Venous blood was drawn at
t ¼ 0 (baseline), 20, 40, 60, 90, 120, 150, 180, 240, 300,
360, and 480min, collected in EDTA vacutainers (Bec-
ton–Dickinson, Plymouth, UK), and immediately cen-
trifuged (at 4 C; 2000g, 10min); the plasma was stored
at )80 C.
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Folate aﬃnity columns were prepared overnight by
binding folate binding protein (Scripps Laboratories,
San Diego, USA) to Aﬃgel 10 (Bio-Rad, Hemel
Hempstead, UK) in 0.1M sodium bicarbonate at 4 C,
stored in 0.1M K2HPO4, buﬀer pH 7 (containing 0.2m/
v% sodium azide), and kept at 4 C. The aﬃnity columns
were checked regularly and found to be stable over a
period of 6 months.
5-MethylTHF extraction from plasma was based on
the method described by Hart et al. [9], with minor
modiﬁcations. Plasma (2ml) was transferred into 50-ml
propylene tubes and 20 ll of an internal standard solu-
tion (containing 3.6 106 mol/L [13C5]5-methylTHF
and [2H4]folic acid) was added. Protein was precipitated
and folates were protected against oxidation by adding
10ml extraction buﬀer (0.1M K2HPO4, pH 7), con-
taining 50mM ascorbic acid and 10mM mercap-
toethanol). To further protect the folates against
oxidation the tubes were ﬂushed with nitrogen prior to
placing them in a boiling waterbath for 20min. Samples
were placed on ice and centrifuged (2000g, 10min). The
supernatant was collected and the pellet was extracted
with an additional 10ml extraction buﬀer. Folate aﬃn-
ity columns were used for sample cleanup; they were
preconditioned by rinsing three times with 5ml of 0.1M
K2HPO4 (pH 7). Both supernatant fractions were in-
troduced onto the column and the columns were washed
with 5ml of 0.1M K2HPO4, 1M NaCl buﬀer (pH 7),
5ml of 0.05M K2HPO4 (pH 7), and 5ml of 0.025M
K2HPO4 (pH 7). The eluate was collected in tubes
(containing 5mg ascorbic acid), and 5.5ml of 0.1M HCl
was added. After this the aﬃnity columns were condi-
tioned by rinsing three times with 5ml of 0.1M K2HPO4
(pH 7) and stored at 4 C in 5ml of 0.1M K2HPO4
(pH 7) (containing 0.2% sodium azide) until further use.
To concentrate the sample, Oasis columns (Waters,
Millford, USA) were used. The columns were precon-
ditioned with 1ml methanol and 1ml water. The 0.1M
HCl fraction was then introduced onto the column. The
columns were washed with 2ml of water and eluted with
500 ll of methanol into vials (containing 2mg ascorbic
acid). Subsequently, the methanol fraction was evapo-
rated under nitrogen at 40 C and redissolved in 500 llTable 1
Transition settings in MS-MS of labeled and unlabeled folic acid and 5-met
Folic acid Precursor ion (m=z) Fragment ion (m=z)
Unlabeled compound 442.2 295.1
Labeled site: glutamic acid
[2H4]folic acid 446.2 295.1
Labeled site: benzoyl ring
[2H2]folic acid 444.2 297.1
[13C6]folic acid 448.2 301.1of eluent (10mM formic acid, 10% acetonitrile). The
samples were stored at )20 C. A volume of 50 ll was
used for LC-MS-MS analysis.
Liquid chromatography tandem mass spectrometry
All analyses were performed on an API 3000 triple
quadrupole tandem mass spectrometer (Applied Bio-
systems, Foster City, USA). Side instrumentation con-
sisted of a Perkin–Elmer Series 200 HPLC pump, a
Perkin–Elmer Series 200 auto sampler (operated at
4 C), and a Harvard Apparatus Pump 11 infusion
pump. Liquid chromatography was performed on a
Xterra MS C18 analytical column (4.6 250mm; 5-lm
beadsize) (Waters) using 10mM formic acid:acetonitrile
(90:10), pH 2.3, as mobile phase at a ﬂow rate of 1ml/
min. The column was connected to the turbo ion elec-
trospray source by a splitter (1:20), MS was performed
in the ‘‘positive ion’’ mode, with temperature of the
turbo ion electrospray set to 450 C, and nitrogen was
used as turbo ion gas (ﬂow rate 8L/min, ion spray
5000V). The mass spectrometer was optimized under
computer control by constant infusion of the target
analytes. For each precursor fragment transition a dwell
time of 0.150 s was applied. The optimization included
collision-induced dissociation, which was performed in
the second quadrupole using nitrogen as the collision
gas (at 0.06 kPa).
The mass spectrometer was operated under unit res-
olution. The selected precursor and fragment ions used
for the measurement of the labeled and unlabeled folate
vitamers are summarized in Table 1. The LC-MS-MS
data were acquired and processed using Analyst for
Windows NT software (Applied Biosystems). Diluted
folate standards within the linear range of the calibra-
tion curves (see Results) were measured before and after
human plasma samples in all measurement series for
calibration veriﬁcation. Duplicate injections were per-
formed for plasma samples and standards.
Calculations and statistics
Calibration curves were constructed and concentra-
tions of sample enrichments and concentrations were
calculated using linear regression analyses (leasthylTHF
5-MethylTHF Precursor ion (m=z) Fragment ion (m=z)
Unlabeled compound 460.2 313.1
[13C5]5-methylTHF 465.2 313.1
[2H2]5-methylTHF 462.2 315.1
[13C6]5-methylTHF 466.2 319.1
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tracer to tracee ratio,
TTRð%Þ ¼ ðRs  RbÞ  100%;
where Rs and Rb are the ratios of the areas at the m=z
values of the labeled and unlabeled compounds for the
enriched sample and a sample of natural abundance,
respectively.
In vivo folate absorption was estimated from the data
sets of the labeled and unlabeled 5-methylTHF concen-
trations. Multiple folate pools exist in the human body
and can be characterized as either fast or slow turnover
pools. Prediction of whole-body folate turnover and
metabolism require characterization of the slow-turnover
pools in long-term studies [13]. Short-term protocols do
not allow assessment of slow-turnover pools which in-
clude intracellular folate polyglutamates but can be ap-
plied to study the short-term distribution of absorbed
(monoglutamate) folate.During ameasurement period of
>6 h after an orally administered labeled folic acid dose,
changes in plasma concentration of 5-methylTHF iso-
topomers can be approximated as a single-compartment
model of the fast monoglutamate pools [14,15]. In this
model, the time after ingestion during which the plasma
5-methylTHF isotopomer enrichment remains at baseline
(tlag), the absorption time (i.e., the time between the ﬁrst
rise in enrichment and the peak (tmax)), the ﬁrst pass eﬀect
(i.e., the removal of part of the absorbeddose, presumably
by the liver), and the rate of elimination (k) can be esti-
mated. The model, assumptions, and calculations are
described in the Appendix.
Data from each in vivo experiment were analyzed in
the single-pool model with SAAM II software (version
1.1.1, Saam Inc., Seattle, USA), and parameters for ﬁrst
pass eﬀect and rate of elimination were estimated with
SAAM II using standard goodness of ﬁt criteria.
Students t tests for paired samples were performed to
compare test folates (SPSS 9.0, SPSS Inc., Chicago,
USA). Values are presented as means SD, unless
otherwise stated. Diﬀerences were considered signiﬁcant
if p < 0:05 (two-tailed).Results
LC tandem mass spectrometry of folic acid and
5-methylTHF in plasma
The LC-MS-MS spectra with collision-induced de-
composition of folic acid and 5-methylTHF isotopomers
(depicted in Fig. 1) showed intense fragment ions. Due
to the loss of the glutamic acid residue from the pro-
tonated molecular ion, fragments m=z 295 and 313 (and
additional isotopomers for benzoyl-ring-labeled com-
pounds) were found for folic acid and 5-methylTHF,
respectively. These fragments were used for multiple
reaction monitoring (Fig. 2).The calibration curves for 5-methylTHF were linear
over a concentration range of 4.5 1011 to 3.2
107 mol/L (correlation coeﬃcients for intraassay and
interassay analyses: 0.9976 0.0016 (n ¼ 6) and
0.9993 0.0016 (n ¼ 14), respectively). Linearity for
calibration curves of folic acid also existed over a con-
centration range of 1.5 109 to 4.5 108 mol/L (cor-
relation coeﬃcients for intraassay and interassay
analyses: 0.9942 0.0043 (n ¼ 6) and 0.9971 0.0017
(n ¼ 5), respectively).
Limits of detection were derived by analyzing diluted
folate standards for 5-methylTHF and diluted plasma
for folic acid. The limit of detection for 5-methylTHF
was 1.2 1011 mol/L (¼6.1 1016 mol on column) and
that for folic acid was 5.0 1010 mol/L (¼2.5
1015 mol on column). The limits of quantiﬁcation (with
signal-to-noise ratio >10) were 4.5 1011 mol/L for 5-
methylTHF and 1.5 109 mol/L for folic acid. Results
of reproducibility studies are shown in Table 2. The mean
intraassay and interassay CVs for plasma folic acid con-
centration measurements were 7.5 and  6.5%, respec-
tively. For plasma 5-methylTHF themean intraassay and
interassay CVs were, respectively, 8.6% (and for unla-
beled 5-methylTHF2.8%) and9.0% for concentration
values and 6.5 and 1.3% for enrichment values.
The method was further tested by adding known
amounts of (6S)5-methylTHF and folic acid (and the la-
beled internal standards) to human plasma samples,
which then went through the folate extraction and LC-
MS-MS procedure. After addition of 40, 80, and
120 109 mol/L 5-methylTHF and 6, 11, and 17 109
mol/L folic acid to human plasma, the increase in con-
centration over baseline values ranged between 98.7 and
102.5% of the added amount for 5-methylTHF and be-
tween 96.6 and 104.7% of the added amount for folic acid.
In vivo folate absorption and comparison of test doses
Plasma concentrations of [2H2] and [
13C6]folic acid
and [2H2] and [
13C6]5-methylTHF were simultaneously
quantiﬁed for each volunteer experiment. The data set
from one experiment is shown in Fig. 3. Table 3 shows
the results of the absorption modeling. The tlag for the
capsule opening was approximately 40min; there was no
delay for the drink. Absorption time for [2H2]folic acid
from the drink was 122 21min and that for [13C6]folic
acid from the capsules was 146 38min (p ¼ 0:11). For
unmetabolized [2H2] and [
13C6]folic acid, peak plasma
concentrations were reached within 60min after inges-
tion of the test doses. Thereafter, the plasma concen-
tration of the folic acid isotopomers rapidly diminished
to values below the detection limit. For [2H2] and
[13C6]5-methylTHF, plasma peak concentrations were
reached later than for the folic acid isotopomers, and
concentrations declined slowly and remained markedly
higher than the baseline values during the 8-h
Fig. 1. Tandem mass spectrum with collision-induced dissociation of the protonated molecular ion for (A) folic acid (m=z 442) and (B) 5-methylTHF
(m=z 460). Results were obtained with ‘‘positive ion’’ electrospray.
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means for ﬁrst pass eﬀect and rate of elimination in the
study volunteers. Parameter estimation for the elimina-
tion rate constant was less accurate than for ﬁrst pass
eﬀect (as shown by the individual CV values in Table 3).Discussion
We have presented a LC-MS-MS method for the
measurement of 5-methylTHF and folic acid in plasmaand showed its applicability to the study of initial me-
tabolism of folic acid in humans.
Our LC-MS-MS method includes a concentration
step of the folate binding protein column eluent and
combines the use of an acidic mobile phase with a re-
verse-phase column for separation with ‘‘positive ion’’
electrospray MS-MS. We modiﬁed the LC-MS method
described by Hart et al. [9], with the aim to reduce
plasma volume (at present 2ml) and to improve sensi-
tivity for the measurement of concentrations and en-
richments of 5-methylTHF and folic acid. The use of an
Fig. 2. LC-MS-MS multiple reaction monitoring of folates extracted from human plasma. Oral test doses of [2H2]folic acid and [
13C6]folic acid were
administered at t ¼ 0, and a blood sample was obtained at t ¼ 60min. The 5-methylTHF isotopomers elute at approximately 3.3min: (A) unlabeled
5-methylTHF, (B) [2H2]5-methylTHF; (C) [
13C6]5-methylTHF; and (D) [
13C5]5-methylTHF (used as internal standard). The folic acid isotopomers
elute at approximately 9min; (E) unlabeled folic acid; (F) [2H2]folic acid; (G) [
13C6]folic acid; (H) [
2H4]folic acid (used as internal standard). All
traces are normalized to full-scale deﬂection.
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highly polar folates (especially for 5-methylTHF), with
longer retention on reversed-phase-type columns, facil-itating their separation from signal-suppressing impuri-
ties eluting at or near the void volume of the LC column.
For MS determination of folates, ‘‘negative ion’’ elec-
Table 2
Intraassay and interassay precision of LC/MS/MS for folic acid and 5-methylTHF measurements in human plasma
Unlabeled [2H2]-labeled [
13C6]-labeled
Intraassay Interassay Intraassay Interassay Intraassay Interassay
Concentration
[109mol/LSD]
Folic acid —a —a 4.95 0.57 2.68 0.18 2.82 0.22 7.80 0.10
(11.5%) (6.5%) (7.7%) (1.3%)
4.66 0.16
(3.4%)
Mean CV(%)b 7.5%
5-MethylTHF 12.62 0.48 10.16 0.02 0.035 0.00 0.10 0.02 2.96 0.34 0.36 0.02
(3.8%) (0.2%) (8.6%) (16.6%) (11.6%) (5.7%)
16.57 0.15 16.84 0.29 1.55 0.09 0.50 0.04 3.73 0.17 0.94 0.05
(0.9%) (1.7%) (5.9%) (7.6%) (4.5%) (4.8%)
45.26 1.63 47.07 0.27 3.53 0.23 2.59 0.08 5.35 0.52 3.21 0.12
(3.6%) (0.6%) (6.5%) (3.0%) (9.7%) (3.8%)
Mean CV(%)b 2.8% 0.8% 7.0% 9.0% 8.6% 4.8%
Enrichment
[TTR (%) SD]
5-MethylTHF 7.09 0.52 8.77 0.09 9.77 0.41 4.19 0.08
(7.3%) (1.1%) (4.2%) (1.2%)
10.74 .079 11.24 0.18 21.56 0.77 13.43 0.08
(7.4%) (1.6%) (3.6%) (0.6%)
18.24 0.89 14.74 0.17 46.14 1.34 41.22 0.87
(4.9%) (1.1%) (2.9%) (2.1%)
Mean CV(%)b 6.5% 1.3% 3.6% 1.3%
Samples were selected from human volunteers to obtain values for unlabeled and labeled vitamers. TTR, tracer-to-tracee ratio.
aNot available.
bCV denotes coeﬃcient of variation (n ¼ 6; CV between parentheses).
Fig. 3. Sample set of data from a human volunteer for plasma concentrations of (A) [2H2] and [
13C6]folic acid isotopomers and (B) [
2H2] and [
13C6]5-
methylTHF isotopomers. Two oral test doses ([13C6]folic acid in capsules and [
2H2]folic acid in a drink) were administered at t ¼ 0. m, [2H2] Iso-
topomer;j, [13C6] isotopomer. Peak plasma concentration for folic acid ranged 1.8–2.9 109 mol/L for [2H2]folic acid and 3.1–5.0 109 mol/L for
[13C6]folic acid (n ¼ 5 volunteers). Note that folic acid levels were below the limit of quantiﬁcation at t ¼ 20 min and t  120min.
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ions [8,9]. Satellite ions (mainly sodium and potassium
adducts) are observed when ‘‘positive ion’’ electrospray
MS-MS is used and lower the protonated molecular ion.
However, in contrast to its use in combination with
‘‘positive ion’’ electrospray, acidic mobile phases com-
promise the signal in ‘‘negative ion’’ electrosprayMS-MS, requiring in the latter case the use of post-
column addition of organic bases (such as triethylamine
[8]). The combination of ‘‘positive ion’’ electrospray
with an acidic mobile phase precludes such complica-
tions. Therefore we applied positive electrospray despite
the drawback of this technique with respect to the
formation of satellite ions. Recently, ‘‘positive ion’’
Table 3
Bioavailability of folic acid in ﬁve human volunteers after oral ingestion of two test doses: [13C6]folic acid in capsules and [
2H2]folic acid in drink
Sex/BW tlag (min) Absorption time (min) First pass eﬀect [% dose]
(CV in %)
Rate constant of elimination [h1]
(CV in %)
Capsule Drink Capsule Drink Capsule Drink Capsule Drink
F/62 20 0 100 105 66 (6%) 76 (7%) 0.054 (37%) 0.072 (20%)
M/91 60 0 160 135 76 (5%) 81 (4%) 0.096 (21%) 0.120 (10%)
M/64 40 0 150 100 52 (23%) 82 (13%) 0.174 (68%) 0.120 (68%)
M/75 40 0 200 150 59 (15%) 76 (12%) 0.078 (80%) 0.072 (54%)
M/67 20 0 120 120 74 (30%) 75 (10%) 0.150 (45%) 0.138 (22%)
Mean SD 146 38 122 2 65 10 78 3 0.108 0.048 0.102 0.030
p value 0.111 0.069 0.686
Data are derived from plasma 5-methylTHF enrichment data sets, as described under Methods and Appendix.
F, female; M, male; BW, body weight (kg); %dose, percentage of doseoral; tlag, time that 5-methylTHF enrichment remains at the baseline value; p
value, result of paired t test for diﬀerence between the test folates in capsules and in drink. Parameters (and their coeﬃcients of variation; CV) for ﬁrst
pass eﬀect and rate of elimination were obtained with Saam II software.
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was also used by Nelson et al. [16].
Limits of detection and quantiﬁcation for 5-meth-
ylTHFwithourLC-MS-MSmethod are comparablewith
those of another (hydrophilic interaction chromatogra-
phy) LC-MS-MS method [8] and at least one order of
magnitude lower than those obtained for LC-MS [9,16].
Although LC with electrochemical detection has higher
sensitivity for the measurement of 5-methylTHF con-
centrations [17], it lacks the advantage of LC-MS-MS for
application to in vitro or in vivo studies with stable-iso-
tope-labeled folates. Our LC-MS-MS method showed
linearity for quantiﬁcation over approximately four or-
ders of magnitude for plasma 5-methylTHF concentra-
tions, validating its use in human (patho)physiology.
Folic acid is not naturally present in plasma, but after
ingestion it can be present in unmetabolized form at low
concentrations. Limits of detection and quantiﬁcation
for folic acid in plasma of our LC-MS-MS method were
close to the results of HPLC combined with a microbi-
ological assay procedure [18]. Our LC-MS-MS method
showed folic acid isotopomers present in plasma after
[2H2] and [
13C6]folic acid was orally ingested by the
human volunteers. The unmetabolized folic acid con-
centrations could be accurately quantiﬁed near the
plasma peak concentration, but due to the limit of
quantiﬁcation folic acid could not be followed during
the full 8-h time course of the study.
The LC-MS-MS method was applied to measure in
vivo absorption and bioavailability using two test
folates and a single-pool model for 5-methylTHF plas-
ma-enrichment data sets. The data showed a delay in
capsule opening in the human volunteer bioavailability
study but no diﬀerences in absorption time and kinetics
of ﬁrst pass eﬀect and elimination in both test folates.
With the use of absorption time (which corrects for tlag),
modeling of folate bioavalilability is similar for test fo-
lates administered in capsules or in a drink.
The assumptions of the in vivo model and the results
with the volunteers need to be discussed. First, ourshort-term protocol does not allow assessment of slow-
turnover pools in the body and is limited to the
absorbed and metabolized folic acid as 5-methylTHF
monoglutamate in the plasma pool. Second, folate ab-
sorption is assumed to be 90%. This value for absorp-
tion was obtained in 1 healthy human volunteer after an
oral dose of 0.8 107 mol (¼35 lg) monoglutamate-
[14C]folic acid [19]. A similar absorption (92%) was
found in a patient in remission with Hodgkins disease
after ingestion of 7.25 107 mol [14C]folic acid [20],
which is close to the dose ingested by our study subjects
(total for [2H2] and [
13C6]folic acid: 9.8 107 mol).
Absorption characteristics of both folic acid isotopo-
mers were also very similar to those measured with the
same model in 27 human volunteers who received an
oral dose of 4.5 107 mol (¼ 200 lg) [2H2]folic acid
[13]. Third, the model does not allow the simultaneous
estimation of both absorption fraction and ﬁrst pass
eﬀect. Assumption of one of these parameters is needed
to estimate the other. In the present study, we focused
on ﬁrst pass eﬀect of the labeled folic acid doses. Fourth,
using the enrichment in plasma 5-methylTHF over an
8-h time course, the model estimates the rate constant of
elimination in each individual with considerable error. A
longer sampling protocol (e.g., 10 or 12 h) would reduce
this.
The rate constants of elimination (k) from the single
pool in the present study were very similar for both test
folates (k ¼ 0:105 h1). These results can be compared
with the literature, reporting results of a radioactive folic
acid experiment in one volunteer using 48-h collection of
urine samples to follow elimination [20]. Biphasic
elimination kinetics, with an initial rapid decline
(k¼0:022h1) followed by a long decline (k¼0:0069h1),
were found [20]. Our study results indicate an even
higher initial elimination from the fast pool in humans.
A possible explanation for the diﬀerence in initial k-
value between our study and the work of Krumdieck
et al. [20] is the diﬀerence in sampling method (plasma
versus urine) and sampling frequency. Whether the
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found in our study reﬂects a higher biological catabo-
lism and metabolism from the central compartment than
previously thought requires further study, preferably
also in a larger group of subjects.
In conclusion, the study with dual orally administered
folic acid stable isotopes demonstrates the potential of
LC-MS-MS for application in human bioavailability
studies of folate vitamers. High sensitivity of LC-MS-
MS for measuring 5-methylTHF enrichments might be
useful for research in the in vivo absorption and kinetics
of folates and interactions with one-carbon metabolism.
Also, experiments to further develop the single-pool
model for folate absorption into two-compound, mul-
tiple-pool models including unmetabolized folic acid can
be designed. The accurate and simultaneous measure-
ment of concentrations and enrichments of 5-meth-
ylTHF and folic acid using 2-ml plasma samples can
now be achieved with LC tandem MS.Acknowledgments
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Norwich, UK) for comments.Appendix. Estimation of in vivo folate absorption and
elimination
Changes in 5-methylTHF isotopomer plasma con-
centrations are approximated in a single-compartment
model (see Fig. 4). Following an oral dose of [13C6]folic
acid or [2H2]folic acid in a measurement protocol of
>6 h, which allows for the completion of the absorptiveFig. 4. Schematic overview of single-compartment model for folate
absorption after orally administered labeled folic acid test dose.process and characterization of the decay of the plasma
concentration, the plasma appearance of labeled folic
acid is assumed to approximate that of an infusion of
rate (R), over the absorption time period. The absorp-
tion time period (T ) is deﬁned as the time from the ﬁrst
rise (tlag) of 5-methylTHF isotopomer enrichment in the
plasma to the peak (tmax).
The deﬁnition of R is
R ¼ mass of dose that is absorbed
time period for absorption
¼ M
T
: ðA:1Þ
If V is the apparent volume of distribution for folate,
k is the rate constant of elimination from the compart-
ment (the decay slope of loge plasma labeled folate when
t > tmax), and t is time after ingestion of the test dose
(doseoral), then the labeled 5-methylTHF concentration
in the compartment (C) can be approximated as
C ¼ M
V :T :k
: ð1 ek:ðttlagÞÞ ð0 < t < tmaxÞ and ðA:2Þ
C ¼ M
V :T :k
: ð1 ek:T Þ: ekððttlagÞT Þ ðt > tmaxÞ: ðA:3Þ
The time during which the plasma enrichment re-
mains at baseline (tlag) and the value of T (i.e., tmax mi-
nus tlag) are established from the plasma 5-methylTHF
enrichment curve, and V is estimated as 389ml/kg ac-
cording to Loew et al. [21]. By ﬁtting Eqs. (A.2) and
(A.3) to the labeled 5-methylTHF plasma concentration
data over time, M can be calculated. The apparent
absorption can then be calculated according to the
equation
Apparent absorption ¼ M
doseoral
: ðA:4Þ
A ﬁrst pass eﬀect is present when folate is absorbed
from a meal [22]. By assuming that the absorption
fraction of a folic acid test dose in humans is approxi-
mately 0.90 [19], the ﬁrst pass eﬀect (as % of doseoral) can
be estimated:
First pass effect ¼ 1

 M
0:9  doseoral

 100%: ðA:5ÞReferences
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modelling of triglyceride-rich
lipoprotein plasma fraction (TRL)
response. Method Whole or
chopped-leaf cooked spinach was
fed to volunteers (n = 7, paired)
with vegetable oil (40 g) in yoghurt.
Blood and ileal effluent samples
were collected for up to 24 h. Efflu-
ent and TRL samples were analysed
for lutein and β-carotene by HPLC.
A digesta transit model was used to
describe meal transit and a single
compartment model used to pre-
dict percentage absorption from
the plasma TRL response. Results
Mass balance showed 25 % of lutein
and β-carotene were absorbed from
chopped spinach, compared with
25 % β-carotene and 40 % lutein
from whole-leaf spinach. Increased
lutein absorption correlated to
slower gastrointestinal (GI) transit
for the whole-leaf meal.An area un-
der the curve (AUC) response for
the TRL fraction, found in 50 % of
cases, was not confined to those
with the greatest percentage ab-
sorption.Absorption by mass bal-
ance and TRL AUC indicate a half-
life of newly absorbed carotenoid
around 11 min Conclusion GI resi-
dence time appears to have an effect
on the absorption of lutein but not
β-carotene. Rapid clearance is
probably the main reason for ab-
sence of measurable plasma con-
centration excursions. Lack of
plasma response cannot be inter-
preted as lack of carotenoid absorp-
tion without knowledge of the ab-
sorption and disposal kinetics.
■ Key words Lutein – β-carotene –
absorption – ileostomy – model
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Abbreviations
AUC Area under the curve
BMI Body mass index
GI Gastro-intestinal
HDL High-density lipoproteins
HPLC High performance liquid chromatography
LDL Low-density lipoproteins
SD Standard deviation
SI Small intestine
TGWM Total gastrointestinal washout method
TRL Triglyceride rich lipoproteins
VLDL Very low density lipoproteins
IV Intravenous
Introduction
The absorption of carotenoids from test meals is re-
ported to range between 2–90 % depending upon the
test material, the model used to assess absorption and
interpretation of data obtained [1]. Reports of low ab-
sorption values [2, 3], obtained using changes in plasma
concentration have undermined the hypothesis that the
carotenoids are one of the active protective constituents
of diets high in vegetables and fruits, and that supple-
mental green vegetable feeding may be ineffective in re-
lieving retinol deficiency [4]. Plasma concentrations of
the carotenoids may be elevated significantly in chronic
dosing studies [5, 6] but the absolute amount absorbed
cannot be quantified by this approach.
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■ Summary Background Reports
of low carotenoid absorption from
food sources has undermined their
postulated ‘protective’ role as one of
the active agents in diets rich in
vegetable matter. Aims of the study
This study quantified β-carotene
and lutein absorption from a repre-
sentative green vegetable with dif-
ferent degrees of processing, using
both mass balance and metabolic
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The absorption of carotenoids has been attempted in
human volunteers by a number of methods. Oral-faecal
mass balance [7], whole plasma response after chronic
[3, 8–10,] or acute [11, 12] dosing, triglyceride-rich
lipoprotein (TRL) response after an acute dose [2, 13],
radioactive tracers [14, 15], stable isotope tracers
[16–18], total gastrointestinal washout, mass balance
method (TGWM) [19] and the ileostomy mass balance
model [20].
Of the mass balance methods, the oral-faecal ap-
proach has been the most commonly used. However, the
method is prone to losses of carotenoid through their
exposure to the microflora of the large intestine and pre-
cise faecal collection may be a problem. Estimates of ab-
sorption by this method are therefore predicted to be
high and variable.
A second, frequently used approach is measuring
carotenoid concentration in whole plasma following an
acute (single meal), or chronic, dose (multiple meals
over several days/weeks). Plasma response after a single
meal has identified many individuals who do not appear
to ‘respond’, i. e. no measurable change in plasma con-
centration; sometimes interpreted as no, or low,
carotenoid absorption. This interpretation has been
challenged following consideration of plasma clearance
kinetics and the likelihood, or not, of observing a per-
turbation in the plasma pool after a single meal [20]. In
chronic feeding studies, plasma concentrations of
carotenoids are more likely to be significantly elevated,
but the amount absorbed still cannot be quantified
without a knowledge of the clearance kinetics from all
appropriate plasma pools and re-exportation kinetics
from liver and other tissues. Furthermore, changes in
plasma concentration after feeding a ‘standard’ isolated
compound vs. a food are usually assumed to follow a lin-
ear dose response.At best, absorption from the food can
only be expressed as a percentage of the absorption
from the ‘standard’ dose.
In the present study the ileostomy approach has been
selected as the preferred mass balance method for ob-
taining quantitative data on the absorption of
carotenoids from an important food source (green leafy
vegetable). Whilst there may be some microbial activity
in the SI through colonisation of the terminal ileum, ap-
propriate collection and storage of effluent minimises
the potential confounding influence of microbial action,
and variable residence time in the large bowel.
As an alternative to mass balance measurements, the
study described here also included carotenoid analysis
of whole plasma and the triglyceride-rich lipoproteins
to produce comparative data between loss of carotenoid
from ileal effluent and appearance of carotenoids in
blood. Newly absorbed carotenoids, from a meal given
after an overnight fast, appear in the TRL. The AUC for
the TRL-carotenoid response is measured, clearance
rate assumed to be the same as for chylomicrons and
carotenoid absorption quantified [13]. However, the ac-
tual clearance kinetics for chylomicron remnant half life
[21–23], or chylomicron triacylglycerol half life are not
known for the individual volunteers, and have to be as-
sumed from limited published information [24], gives
rise to large differences in carotenoid absorption values,
depending on the half life value selected. By quantifying
the amount of carotenoid lost in ileal effluent, together
with the size of the TRL excursion, calculation of the
carotenoid half-life was possible and assumptions relat-
ing to chylomicron remnant half-life tested.
In summary, the objectives of the study were to quan-
tify β-carotene and lutein absorption from a representa-
tive green vegetable with different degrees of process-
ing; using both mass balance and metabolic modelling
of TRL response. This dual approach allowed compari-
son of the data sets obtained and testing of assumptions
relating to clearance kinetics of carotenoids from the
TRL fraction.
Experimental
A group of seven ileostomy volunteers who had minimal
ileal resection (< 15 cm) for ulcerative colitis (5 women
and 2 men), mean (SD) age 51 (7.6) y, weight 80.1 (16.4)
kg gave informed written consent to the study which was
approved by the Norwich District Ethics Committee.
Volunteers had BMI values of 19–27, fasting plasma cho-
lesterol ≤ 6.5 mmol/l, fasting plasma triglycerides
≤ 2.3 mmol/l, plasma β-carotene 0.1–1.0 µmol/l and
plasma retinol ≥ 0.1 µmol/l, were non-smokers, not tak-
ing medication or dietary supplements. All but one con-
sented to provide serial blood samples over the duration
of the 2 study periods. Volunteers attended the Human
Nutrition Unit on two occasions, at least 6 weeks apart,
having avoided excessive carotenoid intake (a list of
foods was provided) for 24 h before the study day. They
arrived at 08.00 h having fasted from 19.00 h the previ-
ous evening and having performed their usual morning
routines.
Volunteers were cannulated (antecubital/cephalic),
provided a baseline fasting blood sample (20 ml), emp-
tied their appliances (baseline effluent collection) and
were then given approximately 150 g of either cooked
whole, or cooked finely chopped, leaf spinach prepared
from the same harvest. The spinach meal contained ap-
proximately 15 mg lutein and 10 mg β-carotene. The
spinach, which had been blanched, drained, frozen and
stored at –40 °C in heat sealed foil laminate pouches, was
reheated in boiling water to a core temperature in excess
of 72 °C for 3 min.A sub-sample of the spinach meal was
retained at –70 °C for analysis. The spinach meal was fol-
lowed by 400 g of skimmed milk yoghurt containing 40 g
of low vitamin E sunflower oil, 20 g of sucrose and
chocolate flavouring. The study was timed from when
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the spinach was consumed (t = 0). Defined carotenoid-
free midday (t = 4.5h) and evening (t = 10 h) meals were
provided and carotenoid free drinks were freely avai-
lable at all times. The midday meal provided 20 g of fat
(25 % of energy) and the evening meal 42 g of fat (28 %
of energy).
Volunteers remained seated in an armchair for the
duration of the study except for toilet visits. This proce-
dure was adopted to harmonise physical activity in all
volunteers although it is recognised that it may have had
an impact on gut motility. Blood samples (20 ml) were
drawn every 2 h from t = 0 up to 12 h, into lithium he-
parin blood tubes, centrifuged, the plasma separated
and frozen at –70 °C before further treatment. Total ileal
effluent was collected every 2 h up to 12 h and then as
discrete timed samples up to 24 h at the volunteers’ own
convenience. All effluent samples and retained food
samples, collected into polythene bags, were spread into
thin sheets within the bag, frozen on solid CO2, weighed
and stored at –70 °C. Plasma (5 ml) was density adjusted
with potassium bromide, layered into saline (1.006 sg)
and ultracentrifuged for 4 h at 64,000 g [25] to separate
the lipoproteins into TRL, LDL, and HDL fractions. The
fractions were then aspirated from the centrifuge tube
and stored at –70 °C.
Plasma and plasma fractions were extracted using
hexane and the carotenoid content assayed by HPLC [6]
with a limit of quantification < 1 ng. Effluent and
spinach samples (ca. 8 g) were broken from the frozen
sheets, placed in 50 ml screw top glass centrifuge tubes
and 20 ml of acetone added. The effluent was thoroughly
dispersed using a small homogeniser (Ultra Turrax), the
mixture centrifuged for 10 min at 2000 g to pellet the
solids and the supernatant transferred to a 100 ml volu-
metric flask. The pellet was re-suspended in 20 ml ace-
tone and the process repeated 3 more times. The acetone
extract was made up to 100 ml, thoroughly mixed and a
filtered (No.1 paper. Whatman) sub-sample (20 ml)
stored at –20 °C. A sub-sample (1 ml) of the filtered ace-
tone extract was dried under N2, made up in HPLC mo-
bile phase, diluted if needed, and assayed by HPLC as
above.
■ Statistics
One tailed Student’s paired t-test was used to determine
whether carotenoid absorption (within subject) was sig-
nificantly different (p < 0.10, because of the low value of
n) between the whole leaf and finely chopped leaf
spinach test meals. A one-tailed test was used because it
was believed that absorption from the chopped spinach
would be greater than from whole leaf spinach because
of the more extensive tissue disruption. A ‘within sub-
ject’ correlation of the absorption of β-carotene from
whole leaf and chopped leaf spinach was undertaken to
test if the magnitude of absorption was volunteer con-
sistent, i. e. whether a higher absorption from whole leaf
spinach predicted a higher absorption from chopped
leaf spinach, and vice versa. Likewise, a correlation for
lutein absorption was also undertaken. Fasting plasma
concentrations of β-carotene and lutein were correlated
with percentage absorption to test if there was a rela-
tionship between habitual plasma concentration and
absorption from the test meal. Regression analysis was
used to assess if physical performance of the meal in the
GI tract (lag phase, rate, t1/2) was related to absorption.
■ Data treatment
To characterise the appearance of the spinach meal in
the ileal effluent, lutein was used as a marker. The per-
centage of the original spinach meal collected at each
time point was calculated from the total recovered lutein
and the amount of lutein found in each collection. Nor-
malised cumulative collection (percentage) of the
spinach meals were plotted against time to provide a
transit profile of the spinach and the data fitted using a
logistic model to calculate the t1/2 of the gastrointesti-
nal residence time. The portion of the curve that ap-
peared to be steeply increasing with time was fitted with
a regression model. The slope is equivalent to the efflu-
ent production rate, the intercept (x at y = 0 %) the lag
time and time for complete passage of the meal (x at
y = 100 %).
The total loss of lutein and β-carotene to the effluent
and the amount in the spinach meal were calculated and
expressed as percentage absorption of the carotenoid
content of the meal.
■ Digesta transit model
The normalised cumulative effluent loss (y) vs. Time (t)
data was fitted using the following 2-parameter equa-
tion:
y = 100 · 
[
e–a+b·t
1+e–a+b·t
]
The time taken to reach 50 % loss is given by:
t1/2 = a/b
The slope and y-intercept were found from the linear re-
gression of the data points in the central (linear) section
of the normalised cumulative effluent loss vs. time plot.
The regression model can be summarised as:
y = mt + c
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where (m) is the slope and is equivalent to the effluent
production rate and (c) is the y-intercept. The x-inter-
cept of this line is the lag time and is calculated from:
lag time = – c/m
100 % transit time (y = 100) can be calculated from:
t = 100 – c
m
■ TRL area under the curve model.
The areas under the curve (AUCoral) of these plots were
calculated using the Altman trapezoidal approximation
method [26]. The integrated area under the curves for
the TRL response in two of the volunteers who gave
complete TRL curves within the 12 h blood sampling pe-
riod were calculated and compared to the theoretical
TRL AUC that would have been obtained if the
carotenoids had been given as an intravenous bolus. The
half life of the carotenoids in the TRL is not known, thus
the theoretical TRL AUC from the bolus was calculated
at a number of time points between 2 and 11 min to em-
brace the chylomicron triacylglycerol t1/2 of 2–5 min, up
to the chylomicron remnant t1/2 of 11 min.
After correcting for the background TRL concentra-
tion of carotenoid (lutein and β-carotene), a plot of TRL
concentration against time was constructed which rep-
resents the TRL response to the oral dose. A single com-
partment model (Fig. 1) can be assumed with only dis-
posal (k1) from the TRL fraction, because TRL was the
only pool to have an input exclusively (theoretical or
real) of newly absorbed carotenoid.
By assuming that a single compartment model
(Fig. 1) will approximate chylomicron clearance from
the plasma, various plasma half-lives (t1/2) were simu-
lated using the SAAM II modelling package [27] to in-
vestigate the absorption of an oral dose of carotenoid.
For each t1/2, the plasma response to an intravenous
(IV) dose was simulated using the above model. The
plasma volume of each volunteer was estimated [28] and
given as an input parameter in the model. The IV dose
was adjusted until the simulated area under the curve
(AUCiv) was the same as that found experimentally from
the oral dose (AUCoral). Under these conditions, the sim-
ulated IV dose was the same as the amount of carotenoid
actually absorbed from the oral test meal.
Results
■ Meal behaviour in the GI tract
Figs. 2a and 2b show the normalised appearance of
spinach meal in the ileal effluent.
The calculated mean lag phase of the initial appear-
ance of the effluent from the chopped leaf spinach meal
(2.6 h,range 0.1–4.5 h) was shorter (p = 0.078,n = 7) than
that from the whole leaf spinach meal (3.6 h, range
0–6 h). The mean half-life of the chopped spinach meal
in the stomach and small intestinal (SI) tract (6.5 h,
range 3.4–10 h) was shorter (p = 0.08, n = 7) than that for
the whole leaf meal (7.4 h, range 4–11.3 h). The mean
rate of mass transit through the SI tract as estimated
from the slope of the cumulative collection of spinach in
the ileal effluent was the same with both meals. The
chopped spinach meal passed the whole SI (12.6 h, range
8–16 h) more rapidly (p = 0.099, n = 7) than the whole
leaf spinach meal (13.4 h, range 10–18 h). The transit
Fig. 1 Single compartment model. k1 represents the clearance rate of the
carotenoids entering the plasma pool as a theoretical intravenous (IV) dose. The
half-life (t1/2) of the carotenoid in the plasma pool is given by the equation
Fig. 2 The normalised appearance of the spinach meals in the ileal effluent of 7
volunteers fed chopped leaf spinach (a) or whole leaf spinach (b)
a)
b)
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time of the whole leaf spinach meal at all time points was
about 1 h longer than that of the chopped leaf meal.
■ Absorption of lutein and β-carotene by mass balance
All the meals contained approximately 15 mg lutein and
10 mg β-carotene, the exact amount being measured by
weighed intake and assay of a retained portion of the
meal. The mean ratio of lutein: β-carotene was 3:2 in the
whole leaf and chopped spinach.Chopping and drip loss
from the prepared spinach meals did not affect this ra-
tio.
The percentage absorption of lutein and β-carotene
from leaf and chopped spinach is shown in Table 1.
Lutein absorption from whole leaf spinach (mean
44 %, range 28–58 %) was greater (p = 0.01, n = 7) than
from chopped leaf spinach (mean 26 %, range 8–58 %)
whereas the mean absorption of β-carotene from both
meals was similar (chopped 23 %, range 4–41 %, whole
leaf 26 %, range 9–58 %). Percentage lutein absorption
from all meals was weakly correlated (R2 = 0.27, p = 0.05,
n = 13) with lag phase of initial appearance of spinach in
ileal effluent by the equation: percentage absorp-
tion = 4.6 x lag phase (h) + 20.4. This indicated about
20 % lutein absorption with the shortest (> 2 h) lag
phase and up to 55 % absorption with the longest (6 h)
lag phase. Residence time in the SI tract altered the ratio
of β-carotene: lutein absorbed. There was equal mass
absorption of both carotenoids for short lag phase ris-
ing to 3:2 lutein:β-carotene at longer residence times.
Absorption of β-carotene and lutein were also weakly
correlated (R2 = 0.43, p = 0.01, n = 14); percentage β-
carotene absorbed = 0.49 x percentage lutein ab-
sorbed + 7.7.
There was no relationship between fasting plasma
concentration of lutein or β-carotene and the amount
absorbed measured by mass balance.
■ Plasma and lipoprotein β-carotene and lutein
response
Fasting plasma β-carotene (mean ± SD) was 216 ±171
ng/ml and lutein 135 ±72 ng/ml.
None of the volunteers (n = 6) showed a plasma re-
sponse for β-carotene or lutein with either chopped or
whole leaf spinach, probably because the amounts ab-
sorbed over the time taken for the spinach to pass
through the SI tract were too low (β-carotene, 2.5 mg;
lutein 3.75–7.5 mg). There was also no measurable
carotenoid response in either LDL or HDL fractions.
However, there was a measurable TRL fraction response
in 50 % of the volunteers (n = 3) for both β-carotene and
lutein from chopped and whole leaf spinach, but com-
plete curves were obtained for only 2 volunteers within
the 12 h period of blood sampling. The absorption, mea-
sured by mass balance in these 2 volunteers, was com-
pared to that predicted at various half life (t1/2) values
(Table 2).
Table 1 Percentage absorption lutein and β-carotene from spinach (whole leaf
and chopped leaf) meals by mass balance in ileostomy volunteers
Lutein % absorbed β-Carotene % absorbed
Volunteer Whole Chopped Whole Chopped
A 33.6 28.0 22.4 30.0
B 28.0 16.0 23.0 20.6
C 51.0 26.7 32.0 21.0
D 52.7 7.3 8.7 4.3
E 29.6 14.9 13.0 14.7
F 57.0 57.9 52.1 40.9
G 58.5 33.2 33.7 32.5
Mean 44.3* 26.3 26.4 23.4
(SD) (13.4) (16.6) (14.5) (12.2)
* Whole leaf lutein is significantly greater (p < 0.05) than chopped leaf lutein
Lutein β-Carotene
Volunteer B B G G B B G G
Meal Type WL CL WL CL WL CL WL CL
t1/2 (min) Predicted Absorption % Predicted Absorption %
2 17 68 36 44 18 87 141 58
3 11 45 24 29 12 58 94 38
4 8 34 18 22 9 43 71 29
5 7 27 14 18 7 35 57 23
8 4 17 9 11 5 22 35 14
11 3 12 7 8 3 16 26 10
Measured
Absorption% 28 16 58 33 23 21 34 33
WL Whole leaf spinach. CL Chopped leaf spinach
Table 2 Predicted and measured absorption of
carotenoids from spinach meals by TRL response.
Lutein and β-carotene TRL absorption kinetics from
spinach meals: Predicted percentage absorption
from a single compartment model with various val-
ues of t1/2 and absorption measured by mass balance
in two volunteers
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In most cases, the measured absorption falls within
the range predicted from t1/2 values in the range
2–11 min. The exception was the measured absorption
of lutein from whole leaf spinach, which was greater
than could be accounted for by even the most rapid
plasma clearance.
Discussion
Understanding the concept of bioavailability is essential
to all involved in food production, nutritional assess-
ment and determination of diet:health relationships.
However, the absorption and post-absorptive metabo-
lism of many of the bioactive organic components of
foods is complex and not fully understood. The
carotenoids provide an excellent example of where too
little understanding of the complexity of the behaviour
of a food component within the food matrix, during di-
gestion,absorption and clearance and within human tis-
sues, can lead to naïve interpretation of study results.
Faecal mass balance studies are constrained by (a) di-
etary modification,(b) prolonged sample collection,and
(c) the assumption that loss is the same as absorption.
Some of these criticisms can be overcome by using mod-
ified mass balance methods such as the ileostomy model
[20] and TGWM [19].
Interpretation of plasma or plasma fraction
carotenoid excursions can only be undertaken with a
clear knowledge of the absorption and clearance mech-
anisms and by sampling the most appropriate ‘pool’.
Even so, there are inevitably assumptions that need to be
invoked and justified when using plasma response mod-
els.
Particular care must be taken with chronic dosing
when comparing ‘relative bioavailability’ for four main
reasons, (a) the absence of a knowledge of dose re-
sponse, (b) change in plasma concentration induced by
a test food relative to the free compound does not pro-
vide an absolute absorption,(c) change or rate of change
of plasma carotenoid concentration can be constrained
if the doses exceed the capacity of the gut to absorb or
the plasma to carry, thus all excessive doses will provoke
the same plasma response, (d) at what point during the
supplementation period are the relative plasma re-
sponses to be measured?
Acute studies also present specific problems. These
relate to (a) observing small changes in plasma concen-
tration against a high endogenous background, (b)
avoiding the confounding influence of sequestration
from and re-export to the plasma pool, (c) lack of
knowledge of absorption and clearance kinetics,(d) lack
of knowledge of dose response relationship curves.
Newly absorbed carotenoids appear in the plasma
chylomicron fraction (TRL), which is virtually free of
carotenoids in the fasting state; thus measurement of the
TRL response avoids both the problems of quantifying
small changes against a high endogenous background
and the problems arising from carotenoid trading be-
tween other body pools.
The present study sought to quantify β-carotene and
lutein absorption from a representative green vegetable,
using two experimental systems (together with meta-
bolic modelling) to allow comparison, and more rigor-
ous examination and interpretation, of the data sets ob-
tained.
■ Mass balance: effects of food structure
Most nutrients have specific absorption mechanisms
but many minor lipophilic components are passively ab-
sorbed from the gut as an integral part of lipid absorp-
tion. Such components, if present in foods of plant ori-
gin, must be extracted from their native environment
and dissolved in appropriate lipid carriers. Intuitively,
breaking up the cellular structure of the food, the pres-
ence of lipid, bile salts, lipases and the correct pH should
increase the probability of achieving maximum absorp-
tion. Absorption from cooked processed foods may be
very different by comparison with that from raw; how-
ever, disruption of plant cell architecture, beyond that
occurring during the relatively mild processing used
here, did not influence the proportion of β-carotene ab-
sorbed from spinach in vivo (Table 1).
The increased absorption of lutein from the whole
leaf spinach was unexpected, since it was assumed that
the larger particle size would slow down mass transfer
to absorbable lipid structures in the stomach and ileum.
However, recent studies of carotenoid mass transfer in
an in vitro gastric and duodenal environment (using
samples taken from spinach as fed to human volunteers)
demonstrate that whilst the rate and limit of mass trans-
fer are the major controlling factors of transfer to the
lipid phase, time is much more crucial for the transfer of
lutein [polar] than β-carotene (apolar) (Fillery-
Travis. A.Personal Communication).This would explain
the enhanced absorption of lutein from the whole leaf
spinach and the lack of self-consistency of lutein ab-
sorption (Table 1), which might be confounded by un-
quantified transit rate fluctuations or changes in lumi-
nal conditions which affect lutein, but not β-carotene,
absorption.
■ Mass balance: inter- and intra-individual response
Inter-individual β-carotene absorption response to the
same food was highly variable but intra-individual re-
sponse was consistent (R = 0.887, n = 7, p = 0.01) be-
tween different forms of the same food (Table 1). A self-
consistency of plasma response has also been seen in
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chronic supplementation studies [6]. This could be due
to two mechanisms: those individuals who exhibit low
plasma concentrations of β-carotene (a) absorb less β-
carotene, or (b) the β-carotene is absorbed to the same
extent but is not retained in the plasma pool. The con-
verse would be true for those showing high plasma β-
carotene concentrations.
The data show wide variation between individuals
with regard to lutein absorption but, unlike β-carotene,
there was no self-consistency between the different
forms of spinach meal despite there being a weak corre-
lation between lag phase and amount absorbed
(R2 = 0.27, p = 0.05, n = 13), with the longer residence
time doubling the absorption.
■ Modelling of TRL response
Those individuals that showed a TRL response to β-
carotene and lutein, from both chopped and whole leaf
spinach, were the same in both cases but were not the in-
dividuals that gave the greatest absorption. The fact that
there is a measurable TRL response at all levels of ab-
sorption (depending on the individual) is a reflection of
clearance from the plasma rather than absorption (con-
firmed by mass balance). Although all the volunteers
had ‘normal’ plasma lipids, turnover was not measured.
It would be expected that individuals with rapid clear-
ance of chylomicrons would show the smallest change in
TRL concentration of carotenoids because they would
not accumulate in the plasma to any measurable extent.
Those volunteers with slower lipid turnover may be
those that exhibit measurable TRL carotenoid excur-
sions. This might be the reason why the volunteers fell
into consistent groups of TRL ‘responders’ and ‘non-re-
sponders’despite the fact that carotenoid absorption oc-
curred in all cases.
Two individuals gave complete TRL AUCs for both
lutein and β-carotene, over the 12 h of blood sampling,
for both whole and chopped spinach meals (Table 2).Us-
ing the kinetic model described in this paper, the mea-
sured absorption of lutein from the whole leaf meal ex-
ceeded that which is predicted from the model, whereas
for the chopped leaf meal the measured absorption falls
within the range of acceptable t1/2 (2–11 min). This indi-
cates that GI transit rate of whole leaf spinach is posi-
tively associated with loss of lutein in the GI tract, which
contributes to an increased loss (elevated measured ab-
sorption) but which is not seen in the TRL response. Al-
ternatively, TRL is not an appropriate measure for newly
absorbed lutein,which,because of its more polar nature,
may be partially transported in portal blood by a mech-
anism un-associated with the chylomicrons and thus it
was not detected. For the TRL lutein response to
chopped spinach the percentage absorption can be pre-
dicted if the TRL t1/2 is in the range 2–11 min. The range
of t1/2 does not allow any decision as to whether the
lutein is cleared from the TRL in the extrahepatic capil-
lary bed along with the triacylglycerols (t1/2 ≈ 2–5 min),
or remains with the chylomicron remnants (mean t1/2 ≈
11.5 min).
For β-carotene the measured absorption exceeds that
which would be predicted from a TRL t1/2 of 11 min
(Table 2). This is not surprising because some of the ab-
sorbed β-carotene will be converted to retinol in the en-
terocytes and it will therefore not appear in the plasma
as β-carotene. However, if conversion is low (≈10 %) it
will not significantly reduce the TRL β-carotene con-
centration and could still indicate that some of the β-
carotene is absorbed in the extrahepatic capillary bed
and the remainder being cleared by the liver along with
the chylomicron remnants indicating a shorter t1/2.
Carotenoid losses, here interpreted as absorption be-
cause it is assumed that there are no microbial or oxida-
tive losses, may in fact have occurred. If this is the case
then absorption by mass balance in the ileostomy model
(and oral-faecal model) is an overestimate and t1/2 would
be longer than that indicated.
Conclusion
Whole leaf spinach has approximately a 1 h longer GI
transit time than chopped leaf spinach and this doubles
the loss of lutein (25 % → 40 %) but has no effect on β-
carotene (25 %). The attenuated delivery of the small
amounts of both lutein and β-carotene from the spinach
meals did not cause a measurable plasma AUC or re-
sponses in LDL and HDL fractions. TRL carotenoid re-
sponses were seen in 50 % of the volunteers but in only
2 cases were the whole curves within the 12 h blood sam-
pling window. Future studies with foods should be run
for at least 16 h to ensure the complete curves needed for
modelling. In both volunteers, the measured absorption
of lutein and β-carotene exceeds that predicted from a
theoretical TRL t1/2 of 11.5 min and this could be a result
of luminal losses that are taken as absorption in the
mass balance model but which do not appear in the TRL
fraction. In the specific case of β-carotene some of the
‘loss’ will be accounted for by conversion to retinol.
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Nutritional Models
Differential Kinetic Behavior and Distribution for Pteroylglutamic Acid and
Reduced Folates: a Revised Hypothesis of the Primary Site of PteGlu
Metabolism in Humans1
Anthony J. A. Wright,2 Paul M. Finglas, Jack R. Dainty, Caroline A. Wolfe, David J. Hart,
Dawn M. Wright, and Jesse F. Gregory*
Nutrition Department, Institute of Food Research, Norwich NR4 7UA, United Kingdom; and *Food Science
and Human Nutrition Department, University of Florida, Gainesville, FL 32611-0370
ABSTRACT Single 13C6-labeled doses of pteroylmonoglutamic acid (PteGlu: 634 nmol; n  14), (6S-)5-formyltet-
rahydrofolic acid (431–569 nmol; n  16), or [15N1–7]-intrinsically labeled spinach (mainly 5-methyltetrahydrofolate)
(588 nmol; n  14) were fed to fasting adult volunteers. Plasma-labeled 5-methyltetrahydrofolic acid responses
were monitored for 8 h. There was a slower rate of increase in plasma-labeled 5-methyltetrahydrofolic acid and
longer time to peak (171  9 min; mean  SEM) following an oral dose of [13C6]PteGlu than either [
13C6]5-
formyltetrahydrofolic acid (54  10 min) or [15N1–7]spinach folate (60  13 min) suggesting saturated metabolic
capacity for the biotransformation of PteGlu. Mathematical modeling generated a significantly higher mean
“apparent absorption” for 5-formyltetrahydrofolic acid (38%) and spinach folate (44%) than for PteGlu (24%). The
high “relative absorption” of reduced folates to PteGlu was unexpected given that PteGlu itself, from 14C-tracer
mass balance experiments, is almost completely absorbed. Although it is ubiquitously accepted that a physiolog-
ical dose of PteGlu is reduced and methylated in the epithelial cells of the small intestine, and that essentially only
5-methyltetrahydrofolic acid is exported into the hepatic portal vein (HPV), as is the case for absorbed reduced
1-carbon-substituted folates, modeling indicated greater liver sequestration when PteGlu was used as the test
dose, suggesting that PteGlu enters the HPV unaltered and that the liver is the primary site of initial metabolism.
Because of the observed differential plasma response and the hypothesized difference in the site of initial
metabolism, the historical use of PteGlu as a “reference folate” in studies of folate bioavailability is seriously
questioned. J. Nutr. 135: 619–623, 2005.
KEY WORDS: ● pteroylmonoglutamic acid ● folate ● absorption ● isotopes ● modeling
Because there is an extensive hepatic uptake (liver “first-
pass”) of newly absorbed folate (1–4), which prevents direct
estimation of the degree of folate absorption from any plasma
response, the vast majority of work over the past 35 or more
years attempting to assess folate absorption in humans has
centered on methods comparing the serum/plasma response to
a single unlabeled oral test-dose relative to that of an equal
“reference” dose of pteroylmonoglutamic acid (PteGlu)3 (4,5)
and the subsequent computation of “relative absorption.” This
may entail either measurement of the rate of increase, or the
maximum increase, in plasma folate concentration over 2 to
3 h (6–11) or measurement of the dose-normalized rise in
plasma folate concentration area under the curve (AUC) over
6 h or more (12–19).
Comparison of AUC between test and reference folate has
been accepted as a valuable indicator of absorption, provided
that the postdosing plasma measurement test period is long
enough to capture 80% of the whole AUC (20). This
approach also requires experimental conditions that satisfy the
following 3 principles: Assumption 1 states that PteGlu is
absorbed by the same mechanism as reduced folates and in a
similar manner. PteGlu and reduced folates are absorbed
mainly in the proximal small intestine by a saturable, carrier-
mediated, pH- and energy-dependent transport mechanism,
which, unlike other epithelial tissues, appears to be unique in
its lack of hierarchy of transport, having a similar affinity for
both PteGlu and reduced folate forms (21,22). Assumption 2
states that physiological doses of PteGlu are initially reduced
and then methylated in the epithelial cells of the small intes-
tine and that only 5-methyltetrahydrofolic acid is exported
from the mucosa to the hepatic portal vein. Without excep-
tion, review articles from 1983 onward agree that the small
intestine efficiently reduces and methylates physiological doses
of PteGlu and, as with absorbed naturally occurring reduced
and 1-carbon-substituted folates, subsequently transfers only
5-methyltetrahydrofolic acid (5-CH3H4PteGlu) to the hepatic
portal vein (e.g., 2,22,23). Thus, logically, one would expect
1 Supported by UK Food Standards Agency, the UK Biotechnology & Biolog-
ical Sciences Research Council, and EU project “Folate: From Food to Function-
ality and Optimal Health,” QLK1-CT-1999–00576.
2 To whom correspondence should be addressed.
E-mail: tony.wright@bbsrc.ac.uk.
3 Abbreviations used: 5-CH3H4PteGlu, 5-methyltetrahydrofolic acid;
5-HCOH4PteGlu, 5-formyltetrahydrofolic acid; AUC, area under the curve; Pte-
Glu, pteroylmonoglutamic acid; m/z, mass-to-charge ratio; spinach folate, mainly
5-methyltetrahydrofolate polyglutamate.
0022-3166/05 $8.00 © 2005 American Society for Nutritional Sciences.
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no differential in hepatic uptake in response to oral doses of
PteGlu compared to other test folates, and the calculation of
relative absorption from the comparative plasma AUC re-
sponse of a test-dose to that for PteGlu is a valid “pragmatic”
maneuver. Assumption 3 states that the kinetics of the plasma
response to PteGlu is the same as that for reduced 1-carbon-
substituted naturally occurring folates. Until recently, no sys-
tematic difference has been reported between the plasma
5-methyltetrahydrofolic acid response to test folates and Pte-
Glu.
Controversy has arisen recently because it has been shown
that much of the plasma AUC response to oral folate doses is
induced by, but is not actually derived from, the dose itself
(18), a phenomenon recently reported to also affect vitamin C
(24). We interpreted our reported large, variable, and unpre-
dictable displacement of tissue 5-methyltetrahydrofolic acid
into the plasma pool as making a comparison of the relative
absorption of folate from an unlabeled test dose (food or sup-
plement) versus an unlabeled PteGlu reference dose untenable.
Also, concurrent examination of the plasma 13C-labeled
5-methyltetrahydrofolic acid response to 13C-labeled [6S]5-
formyltetrahydrofolic acid (5-HCOH4PteGlu) and a “refer-
ence dose” of 13C-labeled PteGlu unmasked an underlying
serious discrepancy in plasma response that completely vio-
lated Assumption 3, rendering direct estimates of relative
absorption using even labeled AUCs potentially invalid.
Fortunately, the violation of Assumption 3 need not nec-
essarily be fatal to the overall methodologic approach. The
application of suitable mathematical modeling (25), which
makes allowance for any differences in the kinetics of plasma-
labeled 5-methyltetrahydrofolic acid response, can be used to
estimate important parameters. We have applied such an
approach to the current study where, in fasting human volun-
teers, plasma response profiles for labeled 5-CH3H4PteGlu are
followed over a period of 8 h after ingestion of single oral doses
of [13C6] PteGlu, (6S-) [
13C6]5-HCOH4PteGlu, or intrinsi-
cally labeled [15N1–7]spinach folate. Folate binding affinity
columns were used to isolate extracted plasma folate and,
following HPLC analysis of folate concentrations, a re-
cently developed LC-MS analytical method (26) was used
to determine the proportions of labeled and unlabeled
5-CH3H4PteGlu in the plasma samples.
MATERIALS AND METHODS
Materials. With the exception of intrinsically labeled spinach
folate, a description of materials was given previously (18). A hydro-
ponics system was used for the production of [15N]-intrinsically la-
beled spinach, which leads to intrinsic labeling of some or all of the
7 nitrogen atoms in the folate molecule. In brief, spinach seeds were
grown under glass and, once seed leaves opened, were watered daily
with a growing medium containing 50% of its nitrogen as [15N]-
nitrates. Plants were harvested after 8 wk. Woody stems and outer
leaves were removed and the remaining leaves were washed in lightly
salted cold water, rinsed in cold water, shaken dry, and shredded and
a composite was made. Portions (200 g) were then weighed into bowls
and blanched in a microwave oven (750 W) for 3 min. After the
bowls were cooled in cold water, the contents (leaf and liquid) were
transferred to sealable bags, frozen over solid CO2, and stored at
20°C. Total spinach folate, 2.94 ( 0.38) mol/kg, predominantly
5-CH3H4PteGlu but with some 5-HCOH4PteGlu, was determined
using liquid chromatography-microbiologic assay (27) after polyglu-
tamates were deconjugated to the monoglutamate form with hog
kidney deconjugase (28). Isotopic enrichment of spinach [15N]5-
CH3H4PteGlu isolated on folate binding affinity columns, compared
to natural abundance 5-CH3H4PteGlu, was measured using negative
ion [M-H]- electrospray LC-MS (m/z 458–465) (26). Isotopic spectra
revealed that spinach [15N]5-CH3H4PteGlu had measurable ions at
m/z 458–465 (i.e., M to M  7), with 18% of all the naturally
occurring 14N atoms being replaced by 15N atoms.
Human study design. The study was approved by the Norwich
Local Research Ethics Committee (Norfolk & Norwich University
Hospital NHS Trust). After written consent was obtained, a blood
sample was taken from healthy adult volunteers who had fasted for
12 h and analyzed at the hematology department of the Norfolk &
Norwich University Hospital for full blood count, blood glucose,
erythrocyte folate, serum vitamin B-12, urea and electrolytes, and
liver function tests. If all results were within normal assay ranges,
volunteers were then invited to attend 3 test days. Following an
overnight fast and the measurement of blood pressure, a baseline
blood sample (10 mL) was taken via cannula. Volunteers were then
given a single oral dose of [13C6]PteGlu (634 nmol), (6S-)[
13C6]5-
HCOH4PteGlu (431–569 nmol), or a portion of [
15N1–7]-labeled
spinach (588 nmol folate). The dose of [13C6]PteGlu or (6S-)[
13C6]5-
HCOH4PteGlu was administered as previously described (18). Spin-
ach portions were thawed, homogenized, reheated by microwave, and
then served and consumed within 10 min. A timer was started only
after the spinach had been completely consumed. Volunteers were
always allowed access to water, and were given a light lunch (a
sandwich with a only slice of either processed chicken breast or
processed cream cheese spread and cucumber) only after the 4-h
postdosing venous blood sample had been obtained. Few volunteers
completed all 3 test days.
Blood sampling and storage. Venous blood samples (10 mL)
were taken by cannula: a baseline “time zero” prior to test dose and
11 time points over an 8-h period following each test dose; 0.5, 1, 1.5,
2, 2.5, 3, 3.5, 4, 5, 6, and 8 h. Blood samples were transferred
immediately into tubes containing K2-EDTA and mixed gently. Sam-
ples were centrifuged (1500  g, 10 min), and plasma was removed
and frozen immediately over solid CO2 and then stored at 30°C
until analysis.
Sample preparation, folate extraction, and analysis. The ex-
traction of folate from plasma samples, purification on affinity col-
umns using folate binding protein, and subsequent analysis by HPLC
(total plasma 5-CH3H4PteGlu) or LC-MS (labeled and unlabeled
plasma 5-CH3H4PteGlu) was conducted as described previously (18)
with the exception that selected ion monitoring was conducted
additionally on the [M-H]- ion over the range of m/z 458–465 to
determine 5-CH3H4PteGlu derived from the [
15N1–7]-labeled spin-
ach.
Mathematical modeling of the labeled plasma response. We
started with the application of a simple one-compartment model (Fig.
1), which is designed specifically to elicit an understanding of the
kinetics of initial absorption, metabolism, and transport of absorbed
folates. Mathematical modeling was derived from pharmacokinetic
principles (29); all formulas were executable within cells of standard
operating Microsoft Excel spreadsheet software. Following an oral
dose of labeled folate, the plasma appearance of labeled
5-CH3H4PteGlu is assumed to approximate that of an infusion of rate
R over an absorption time period. The absorption time period (T) is
defined as the time to peak plasma labeled 5-CH3H4PteGlu concen-
tration (tmax) minus the time during which the plasma-labeled en-
richment initially remains at baseline (tlag).
FIGURE 1 Simple 1-compartment model for folate absorption.
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The definition of R is
R 
mass of dose that is absorbed
time period for absorption

M
T
. (1)
If t is time after ingestion of the test dose (doseoral), k is the rate
constant of elimination from the plasma compartment to body tissues
and/or excretion, and V is the apparent volume of distribution for
folate in the sampled plasma compartment, then plasma concentra-
tion (C) of labeled 5-CH3H4PteGlu can be approximated as
C 
M
V  T  k
 1 ektt lag 0 t tmax. (2)
C 
M
V  T  k
 1 ekT  ekttmax t tmax. (3)
The time during which the plasma enrichment remains at baseline
(tlag), the time to peak plasma concentration (tmax), the value of T
(tmax  tlag), and the rate constant of elimination (k) are established
from the plasma-labeled 5-CH3H4PteGlu enrichment curve. The
volume (V) of distribution in the sampled compartment is large and
estimated to be 387 mL/kg body wt in humans (30).
By fitting the pair of simultaneous equations (Eqs. [2] and [3]) to
the plasma concentration of labeled 5-CH3H4PteGlu over time (t),
M can be calculated. The apparent absorption can then be calculated
according to
Apparent absorption
M
doseoral
. (4)
A liver first-pass effect occurs when folate is absorbed from a meal
(12–15). By assuming that the absorption, at least of PteGlu, in the
present study is 90% (31–34), the first pass effect can be estimated:
First pass effect 1 M0.9  doseoral 100% (5)
Statistics. Originally, our study had a crossover within-subject
design. However, because of the intrusive nature of 8-h cannulations,
most subjects did not complete all 3 test days and data are treated as
independent observations. Because distributions were not signifi-
cantly different from normal (Kolmogorov-Shapiro test), data (means
 SEM) were compared using ANOVA. When the ANOVA was
significant (P  0.05), means for reduced-folate test doses were
compared to that for the PteGlu reference folate test dose by t test.
Linear regression analysis was used to assess the correlation (r) of
mathematically modeled “apparent absorption,” “first-pass effect,”
and “plasma 5-CH3H4PteGlu elimination rate constant” (k) to fast-
ing baseline plasma or erythrocyte folate concentration.
RESULTS
Age, BMI, erythrocyte, and plasma (at t  0 h) folate
concentrations of volunteers did not differ in each of the 3
folate test groups (Table 1).
Selected ion monitoring indicated that neither PteGlu nor
5-formyltetrahydrofolic acid from the respective test doses
appeared in the plasma in its unmetabolized form.
Plasma-labeled 5-methyltetrahydrofolic acid response to
the 3 test folates is depicted in Figure 2.
The labeled plasma response to PteGlu was slower and
peaked much later (tmax  171  9 min) than the response to
either of the reduced-folate test doses; tmax  54  10 min in
response to 5-formyltetrahydrofolic acid test dose and tmax 
60  13 min in response to spinach-folate test dose (Table 1).
The mean modeled apparent absorption (an estimate of
folate absorption that takes no account of the fact that a
fraction of newly absorbed folate is sequestered by the liver) for
reduced folates (38% for 5-formyltetrahydrofolic acid and 44%
for spinach-folate) was significantly higher than for the PteGlu
(24%) reference dose (Table 1). Calculation of relative ab-
sorptions (i.e., response for test dose divided by response for
PteGlu reference dose) yields 158 and 183% for 5-formyltet-
rahydrofolic acid and spinach-folate, respectively.
By assuming that the actual absorption of the test folate
dose is 90%, the mean calculated first-pass-effect, where a
percentage of absorbed labeled folate is sequestered (presum-
ably to the liver), was significantly greater for PteGlu (73%)
than for either 5-formyltetrahydrofolic acid (58%) or spinach-
folate (52%) (Table 1).
The rate constant of elimination (k) of plasma-labeled
5-CH3H4PteGlu response was not associated with fasting base-
line plasma or erythrocyte folate concentration (Table 2).
Apparent absorption and the first-pass effect were not cor-
related to fasting erythrocyte folate concentration, but they
did significantly correlate with fasting baseline plasma folate
concentration (Table 2).
DISCUSSION
Most previous work over the past 4 decades attempting to
assess relative folate absorption in humans in studies of folate
bioavailability has centered on methods comparing the serum/
plasma AUC response toward a single oral test dose (food or
supplement) to that of an equal reference dose of PteGlu. This
TABLE 1
[13C6]- or [15N1–7]-labeled plasma 5-methyltetrahydrofolic acid-response in fasting healthy adult volunteers following oral test
doses of [13C6]PteGlu (634 nmol), (6S)[13C6]5-HCOH4PteGlu (431–569 nmol), and [15N1–7]spinach folate (588 nmol)1
PteGlu 5-HCOH4PteGlu Spinach ANOVA
P-value
Age, y 31.4  1.2 30.3  0.9 33  2 0.204
BMI, kg/m2 25.2  1.1 24.9  0.9 25  1 0.943
Erythrocyte folate, nmol/L 958  70 976  70 972  70 0.983
Plasma (at t  0) folate, nmol/L 18.1  3.2 15.4  2.7 12.9  3.4 0.402
tmax,2 min 171  9 54*  10 60*  13 0.001
Apparent absorption,3 % of dose 24  2 38*  6 44*  6 0.05
First-pass effect,4 % of absorbed dose sequestered to liver 73  2 58*  6 52*  6 0.05
1 Data are means  SEM, n  14 (PteGlu and spinach) or 16 (5-HCOH4PteGlu). * Different from mean for PteGlu reference folate test dose, P  0.05.
2 Time to maximum plasma-labeled 5-methyltetrahydrofolic acid response.
3 An estimate of folate absorption that takes no account of the fact that a fraction of newly absorbed folate may be sequestered by the liver.
4 An estimate of the percentage of newly absorbed folate that is sequestered by the liver (assuming true absorption to be 90%).
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approach has been undertaken universally using unlabeled test
and reference folates. We have already demonstrated that a
substantial portion of any total plasma response is elicited by,
but does not originate directly from, an oral test dose itself
(18). Arguably, in all previous studies utilizing unlabeled test
doses, calculations of relative absorption to PteGlu have been
ambiguous and potentially erroneous.
When restricting our current analysis to plasma-labeled
5-methyltetrahydrofolic acid response, we note that the time
to maximum response to a dose of PteGlu is 3 h in compar-
ison to 1 h for reduced folates. This large difference in the
kinetics of plasma response violates Assumption 3 and thus
disqualifies the idea of comparing the plasma AUC response to
an oral test dose of folate with that of an equal reference dose
of PteGlu and the subsequent computation of relative absorp-
tion. We interpret this delay to indicate that the metabolic
capacity for the biotransformation of PteGlu was saturated
when using our dose of 634 nmol, possibly due to a limitation
in the rate of initial reduction of PteGlu to H2-PteGlu (35). A
study published recently (36), using accelerator mass spec-
trometry to quantify the plasma [14C]5-methyltetrahydrofolic
acid response to a small 80 nmol dose of [14C]PteGlu, reports
a similar delayed peak plasma response of 3 h. This evidence
suggests that the metabolic capacity for the biotransformation
of PteGlu in humans may be rate limiting; a conclusion that is
consistent with the lower dihydrofolate reductase activity de-
tected in human tissue compared to corresponding animal
tissue (37–39) and a report that concludes that low levels of
dihydrofolate reductase activity are a feature peculiar to hu-
mans (40).
Fortunately, the violation of Assumption 3 is not fatal
because mathematical modeling of plasma response circum-
vents the issue. Modeling indicates an apparent absorption of
reduced folates that is significantly higher than for the refer-
ence dose of PteGlu. These generate relative absorptions sig-
nificantly in excess of 100%. This is unexpected and biologi-
cally impossible, because the “true absorption” of doses of
[14C]PteGlu in 2 human volunteers by mass balance has been
reported to approximate 90% or more (33,34), and tritiated
forms of PteGlu and reduced folates are almost fully absorbed
in rats (31). It is only when the first-pass effect is estimated
from the current data (Table 1) that it becomes apparent that
more absorbed folate may be sequestered by the liver when
PteGlu is the test dose than when reduced-folates are the test
dose. However, such a differential in distribution to body
tissues should not be so if, as generally assumed, absorbed
folate forms undergo mucosal biotransformation and successive
transfer to the hepatic portal vein primarily as 5-methyltetra-
hydrofolic acid. Therefore, contrary to current theory, it ap-
pears that a substantial fraction of absorbed [13C6]PteGlu may
be entering the hepatic portal vein unchanged, to be more
effectively removed by the liver than would 5-methyltetrahy-
drofolic acid, prior to subsequent biotransformation and partial
enterohepatic recirculation. Although we agree that physio-
logic doses of PteGlu are indeed extensively reduced and
methylated in the mucosal epithelial cells of the small intes-
tine in rats (the historical experimental animal model used in
formulating much of our current understanding of folate ab-
sorption and metabolism), we are not the first to suggest that
this may not take place, or not so extensively, in humans.
High concentrations of untransformed PteGlu were reported
to appear in the hepatic portal vein of humans following oral
administration of both 1.0 mg (2264 nmol) PteGlu (41) and
FIGURE 2 Labeled plasma 5-methyltetrahydrofolic acid (5-MTHF)
response to labeled folate test doses. PteGlu (f), 5-HCOH4PteGlu (),
and spinach folate (Œ). Values are means  SEM, n  14 (PteGlu or
spinach) or 16 (5-HCOH4PteGlu). Neither labeled PteGlu nor
5-HCOH4PteGlu is detected in plasma, only their labeled 5-methyltet-
rahydrofolic acid metabolite. To convert 5-MTFH to nmol/L, multiply
ng/mL by 2.17.
TABLE 2
Correlation among apparent absorption, first-pass effect, or labeled plasma 5-CH3H4PteGlu clearance rate in fasting healthy adult
volunteers following oral labeled-folate test doses and fasting baseline plasma or erythrocyte folate concentration1
PteGlu 5-HCOH4PteGlu Spinach
Plasma
folate
Erythrocyte
folate
Plasma
folate
Erythrocyte
folate
Plasma
folate
Erythrocyte
folate
Apparent absorption, % of dose
r 0.702 0.115 0.735 0.336 0.522 0.258
P 0.005 0.709 	0.001 0.221 0.056 0.373
First-pass effect, % of absorbed dose sequestered
to liver
r 0.703 0.128 0.770 0.312 0.507 0.265
P 0.005 0.676 	0.001 0.257 0.054 0.359
Labeled plasma 5-CH3H4PteGlu clearance rate, k
r 0.051 0.058 0.406 0.103 0.328 0.370
P 0.862 0.851 0.119 0.715 0.252 0.193
1 Data are for n  14 (PteGlu and spinach) or 16 (5-HCOH4PteGlu).
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0.5 mg (1132 nmol) PteGlu (42). Despite criticisms of these
studies, e.g., the use of relatively high doses of PteGlu and the
analysis of folate concentrations by possibly problematic differen-
tial microbiological assay, we think that reports of the almost
complete absence of assayable 5-methyltetrahydrofolic acid in the
hepatic portal vein are remarkable—particularly when a dose of
0.5 mg (1132 nmol) was used (42). This is only twice the dose of
260 g (589 nmol) reported much later (11) to be the threshold
at which PteGlu may start to appear in the plasma.
It is noteworthy that apparent absorption correlates posi-
tively with fasting baseline plasma folate concentration (Table
2). Because a large fraction of newly absorbed labeled folate
undergoes immediate removal to the liver, irrespective of the
form appearing in the hepatic portal vein, much of any sub-
sequent plasma-labeled response may actually be derived from
enterohepatic recirculation. Greater enterohepatic folate re-
circulation would not only result in a higher fasting baseline
plasma folate concentration but also then automatically assist
in generating a greater labeled plasma response to any test
folate by recycling a larger proportion of newly sequestered
folate, mainly as 5-methyltetrahydrofolic acid.
We have serious doubts as to the ubiquitous use of PteGlu
as the reference folate in most nutritional studies conducted in
humans and conclude that currently held views on the absorp-
tion, metabolism, and subsequent tissue distribution of folates
need careful re-evaluation, as does the methodology in current
use for estimating the relative absorption of single folate test
doses. We think it is essential, using labeled folates and sen-
sitive HPLC/MS techniques, to establish whether a substantial
fraction of absorbed PteGlu from even small oral doses enters
the human hepatic portal vein unchanged. If it does, then the
initial primary site of PteGlu metabolism would be the liver,
Assumption 2 would be violated, and the use of PteGlu as a
reference folate in most human folate bioavailability studies
would be fatally undermined.
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Use of mathematical modeling to study copper metabolism in
humans1–3
Linda J Harvey, Jack R Dainty, Wendy J Hollands, Victoria J Bull, John H Beattie, Tony I Venelinov,
Jurian A Hoogewerff, Ian M Davies, and Susan J Fairweather-Tait
ABSTRACT
Background: An improved understanding of copper metabolism is
needed to derive more precise estimates of dietary requirements.
Objectives: The objectives were to validate a method for estimating
endogenous losses of copper, test whether a simple model can pre-
dict true absorption from the plasma appearance of labeled copper,
and develop a compartmental model for copper metabolism by using
stable isotopes.
Design: A stable isotope of copper was intravenously administered
to 6 men, and fecal samples were collected for 14 d. Four weeks later
the study was repeated, but with an oral dose, and blood samples
were collected for 7 d and fecal samples for 14 d.
Results: There was no significant difference (P  0.48) in the
estimated endogenous loss of copper calculated by using either the
excreted intravenous dose (x  SD: 32 5%) or the absorbed and
excreted oral dose (35 2%). A simple mathematical model fitted
to plasma isotope appearance data estimated true absorption to be
8  2% compared with 48–49% measured by fecal monitoring. A
more complicated compartmental model predicted that, when newly
absorbed copper first enters the blood, 74% is removed by the liver
and 99% is bound to ceruloplasmin in the plasma. The exchangeable
pool of copper was estimated to be 43 30 mg. Daily endogenous
losses were predicted to be 2.4 mg.
Conclusions: The results showed that fecal monitoring is the only
method that can reliably measure labeled copper absorption, and it is
not necessary to administer an intravenous dose of copper to estimate
endogenous losses. The compartmental model provides new insights
into human copper metabolism. Am J Clin Nutr 2005;81:
807–13.
KEY WORDS Copper, stable isotopes, men, compartmental
modeling, endogenous losses, true absorption
INTRODUCTION
Copper is an essential nutrient for humans, and stable isotopes
of copper have been used for many years to investigate its me-
tabolism (1). However, because copper has only 2 stable iso-
topes, it is not possible to administer an oral and intravenous
copper label simultaneously. Thus, fecal monitoring has been
used to estimate copper absorption from an oral isotope dose. The
drawback to this technique is that a large unknown quantity of
copper—excreted endogenously via the bile and salivary, gas-
tric, pancreatic, and duodenal routes—appears in the feces,
which will result in an error in the calculation of unabsorbed oral
isotope. Previously, the endogenous loss was quantified by ad-
ministering an intravenous dose of labeled copper either some
weeks before or some weeks after the oral dose and by quanti-
fying its appearance in the feces (2). Recently, Harvey et al (3, 4)
described a new method that only requires an oral isotope dose to
quantify the endogenous loss. The first objective of the present
work was to validate this method by comparing estimates of
endogenous loss from oral and intravenous doses of labeled
copper.
It is generally agreed that the fecal monitoring method is not
ideal in terms of volunteer compliance, ease of sample prepara-
tion, analysis, or cost. An alternative method used for iron ab-
sorption studies (5, 6) involves giving an oral dose and taking
serial blood samples over 6 h. The plasma appearance of iron is
modeled by a simple technique, from which the quantity of iron
absorbed from the oral label can be calculated. The second aim
of the present study was to construct a similar model by measur-
ing the appearance of labeled copper in the plasma and to com-
pare the results with fecal monitoring data to see whether the iron
technique could be used for copper.
Only one compartmental model of copper metabolism has
been developed for humans (7). Although this model incorpo-
rates the main physiologic features, it has some experimental
drawbacks, such as limited sampling of blood, which means that
there is incomplete characterization of the initial metabolism of
absorbed copper. Also, much of the earlier work on copper me-
tabolism has focused on animal models, the results of which are
assumed to mimic human copper metabolism. Some of the as-
sumptions of the animal models have yet to be validated in
humans. Therefore, the third aim of our study was to develop a
comprehensive model of human copper metabolism.
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SUBJECTS AND METHODS
Subjects
Six healthy men aged 34–57 y (x 39 y) were recruited to the
study. A 10 mL screening blood sample was taken to exclude
volunteers whose biochemical and hematologic indexes fell out-
side the normal range. Other exclusion criteria included use of
medications or nutritional supplements and smoking. The aims
and procedures of the study were explained to the subjects during
a visit to the Human Nutrition Unit at the Institute of Food
Research, and written informed consent was obtained. The Nor-
wich District Ethics Committee approved the protocol, and the
study was conducted in accordance with the Helsinki Declaration
of 1975 as revised in 1983.
Study design
Subjects took part in 2 d of experiments at the Human Nutrition
Unit but were otherwise free-living during the course of the
study. On the first experimental day, which followed an over-
night fast (10 h), the subjects received a 0.5-mg intravenous
infusion of a highly enriched copper-65 stable isotope (65Cu 
99.4%). The dose was administered over 60 min via a cannula
inserted into a vein in the forearm. The subjects were given a light
breakfast 1 h after completion of the infusion. Fecal and urine
samples were subsequently collected over the next 14 and 7 d,
respectively. No blood samples were taken.
A minimum of 4 wk later, the subjects attended the Human
Nutrition Unit for a second time. After an overnight fast, the
subjects were given a 3-mg oral dose of highly enriched
copper-65 stable isotope (65Cu  99.7%). Blood samples were
collected over 5 h via a cannula inserted into a vein in the forearm.
After removal of the cannula, the subjects were given lunch
before they returned home. Single blood samples were collected
each morning from fasted subjects for the following 4 consecu-
tive days and 7 d postdosing. Each subject made complete fecal
and 24-h urine collections for 14 and 7 d, respectively, after
dosing. No fecal markers were given but the subjects were made
aware of the importance of compliance and the necessity to report
any missed samples. The subjects kept a record of all food and
beverages consumed for 3 d before and 3 d after the second
experimental day. Diary entries were recorded by using house-
hold measures and coded with the most appropriate food code
selected from UK food-composition tables by using DIET
CRUNCHER (Way Down South Software, Dunedin, New Zea-
land; Internet: www.waydownsouthsoftware.com) nutritional
analysis software. Estimated amounts were calculated from val-
ues derived from average food portion sizes (8).
Dose preparation and administration
The intravenous doses were prepared by Ipswich Hospital
Pharmacy Manufacturing Unit by dissolving 67 mg [65Cu]cop-
per (II) chloride (Trace Sciences International, Richmond Hill,
Canada) in 100-mL sterile saline. The doses were portioned into
2-mL sterile glass ampules and stored at 4 °C until used. The
doses were tested for sterility by Ipswich Pharmacy Quality
Control Department, and copper concentrations were measured
by inductively coupled plasma mass spectrometry (ICP-MS).
The intravenous doses were administered by a qualified nurse
issued with the appropriate approvals by a medical doctor. Be-
fore infusion, the 2-mL copper dose (0.25 mg/mL) was mixed
with 50 mL sterile normal saline and infused with an Omnifuse
pump (Graseby Medical Ltd, Watford, United Kingdom).
Isotopically enriched oral doses of copper chloride were pre-
pared from [65Cu]elemental copper (Chemgas, Boulogne,
France) as previously described (6), and the concentration was
accurately determined by ICP-MS. The solution was divided into
individual doses, which were stored in plastic vials at 20 °C
until required. The oral dose was administered in 50-mL water,
and the subjects were asked to consume the dose as quickly as
possible.
Blood sample collection and analysis
A baseline blood sample (10 mL) was collected on the second
experimental day, 15 min before the oral dose was administered;
subsequent blood samples (10 mL) were collected at 0, 20, 40, 60,
80, 100, 120, 150, 180, 210, 240, and 300 min. Five additional
blood samples were collected 24, 48, 72, 96, and 168 h after
dosing. Blood was collected into trace element–free lithium he-
parin–containing tubes (Sarstedt, Leicester, United Kingdom)
mixed gently by inversion, and centrifuged at 15 000 g for 10
min at room temperature. The supernatant fraction of the plasma
was transferred to acid-washed Nalgene cryogenic vials (Nalge
Company, Rochester, NY), frozen on dry ice, and stored at
80 °C.
The copper that was not bound to ceruloplasmin, known as
directly reacting copper, was extracted from the samples by using
a dialysis-chelex method (9) with the following modifications.
Human plasma (5 mL) was dialyzed against 100 mL of 175 mmol
ammonium phosphate buffer/L (pH 7.0) for 4 h and then 2 100
mL of 175 mmol ammonium phosphate buffer/L (pH 7.0) con-
taining 50 mmol histidine/L for 16 h with the use of Spectrapore
dialysis tubing (10 mm flat-width cellulose ester membrane,
MWCO 5000; Spectrum Europe BV, DG Breda, Netherlands).
Copper in the histidine-containing dialysates was extracted by
using 2 mL Chelex-100 minicolumns, which were prepared ac-
cording to the manufacturer’s instructions (Bio-Rad, Hemel
Hempstead, United Kingdom). The pH of the dialysates was
adjusted to 8.0 with ammonium hydroxide before being applied
to the columns. After washing with 1 mol ammonium acetate/L
and 18.2 Mwater, the divalent metals (including copper) were
eluted with the use of 10 mL of 2.5 mol nitric acid/L. Total plasma
copper and retentate copper were extracted by adding 0.8 mL
water and 0.1 mL concentrated ultrapure nitric acid to a 0.1-mL
sample. Precipitates were removed by centrifugation at 10 000
g for 15 min, and the supernatant fractions were retained. All
solutions were then analyzed for copper by atomic absorption
spectrometry and for copper isotope ratios by ICP-MS. The
methods used to remove the contaminant copper from the re-
agents used throughout the procedure and to quantify the remain-
ing contaminant copper were described previously (9, 10).
Copper isotope ratios were measured with a Perkin-Elmer
(Norwalk, CT) Elan 6100 DRC ICP-MS instrument (10). Instru-
mental performance was checked daily with the use of multiele-
ment standard solutions. The ratio of cerium oxide to cerium
signals was maintained between 2.2% and 3.5% to control the
formation of oxides, and the formation of double-charged ions
was controlled by keeping the signal for Ba2/Ba below 3%.
Isotope ratios were first corrected for fractionation by reference
to the published isotope ratio for 63Cu/65Cu (11). The isotope
ratio for a prepared standard was obtained before each measure-
ment and used to derive an isotope ratio correction factor.
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Fecal sample preparation and analysis
All equipment used during sample processing was acid-
washed before use. Fecal samples were autoclaved, freeze-dried,
ground to a fine powder with the use of a mortar and pestle, and
subsampled. Samples were prepared for ICP-MS analysis by
using a combination of 2 methods (2, 12). Briefly, portions of
fecal samples were ashed at 450 °C for 48 h in a muffle furnace
(Vulcan 3-550; Jencons Scientific Ltd, United Kingdom). Sam-
ples were then prepared for the ion-exchange extraction of cop-
per by taking up 0.2 g fecal ash in a 1:1 mixture of water (Milli-Q;
Millipore, Billerica, MA) and concentrated ultrapure nitric acid
(Merck Ltd, Lutterworth, United Kingdom), drying on a hot-
plate, and reashing overnight at 500 °C. The resultant ash was
taken up in 2 mL of 6 mol hydrochloric acid/L (Aristar grade;
Merck Ltd) and left overnight before being centrifuged at 3000
rpm for 10 min. The supernatant fraction was removed and dried
down under hot lamps until only 1 mL solution remained.
Copper was subsequently extracted from the supernatant frac-
tion by ion-exchange chromatography using analytic-grade
anion-exchange resin (AG1 8, 200-mesh chloride; Biorad Ltd,
Hemel Hempstead, United Kingdom). The resin was soaked in
deionized water for24 h before use, and 2 mL presoaked resin
was packed into acid-washed glass columns (1-mL pipette tips;
Sarstedt, Nu¨mbrecht, Germany). The columns were connected to
a peristaltic pump (Watson Marlow, Falmouth, United King-
dom) via polyethylene tubing (1 mm internal diameter, 2 mm
outside diameter) with a flow rate of 1 mL/min. The ion-
exchange system was purged of any contaminant copper by
washing with 2.5 mol HCl/L (Aristar grade; Merck Ltd) for 10
min. Minerals were eluted from the columns for 1 h with a
solution of 2 mol HNO3/L. The resin was regenerated into the
chloride form by pumping a 6 mol HCl/L solution through the
column for 1 h. Samples were subsequently loaded directly onto
the resin, and the columns were flushed with a 6 mol HCL/L
solution for 15 min. Copper was eluted with a 2.5 mol HCl/
solution into polytetrafluoroethylene vials in 15-mL fractions.
Fractions were dried down under a hot lamp and reconstituted for
MC-ICP-MS analysis in 2% (by vol) ultrapure HNO3. Copper
totals were measured by atomic absorption spectrometry (model
3300; Perkin-Elmer).
Copper stable isotope ratios were determined by using a mul-
ticollector ICP-MS (Micromass “Isoprobe” multicollector in-
ductively coupled plasma mass spectrometer; GVi, Manchester,
United Kingdom) combined with a Cetac “Aridus” desolvator
(Cetac, Omaha, NE). The samples were analyzed (at a concen-
tration of 1 ppm) with bracketing standards and instrument
blanks (13). For correction of instrumental mass bias, a simple
linear correction between samples and bracketing standards was
applied. Standard Reference Material 976 (copper certified for
isotopic composition; National Institutes of Standards and Tech-
nology, Gaithersburg, MD) was used as a reference. The internal
reproducibility of the measurement was not 0.05% for 63Cu/
65Cu ratios. The external reproducibility of the calculated copper
isotopic enrichment, which was based on the isotopic variation in
the baseline fecal samples, was 0.1%.
Urine sample preparation and analysis
Urine samples (20 mL) were weighed into acid-washed cru-
cibles and gently evaporated on a hot plate until the volume was
reduced to 1–3 mL; 1 mL of the concentrated urine was trans-
ferred to a 5-mL acid-washed plastic tube (Sarstedt, Leicester,
United Kingdom) and gently mixed with 1 mL 2% ultrapure
nitric acid. Total copper concentrations were measured by
atomic absorption spectrometry (model 3300; Perkin-Elmer).
Kinetic data analysis
Estimation of endogenous losses
In a previous publication we described a method to estimate
endogenous losses of copper from a labeled oral dose, which
involved the simultaneous administration of the rare earth
marker holmium (3). That article showed that copper and hol-
mium share identical excretory patterns; therefore, it was
deemed unnecessary in the present study to give holimum as a
marker to indicate when all the unabsorbed copper had been
excreted. This point comes when the mole fraction of labeled
copper in the feces falls below 0.02 (2% of the total copper in the
feces). After this time, all of the subsequent stool samples contain
only labeled copper that has been absorbed and then excreted. By
plotting a straight line through these subsequent points in a graph
of mole fraction of labeled copper in feces versus time and ex-
trapolating back to the time of label administration (t  0), the
mole fraction of all labeled copper absorbed and then excreted
can be estimated. The process for converting this into mass of
copper is detailed in the article (3). The procedure for estimating
the loss of the intravenous dose into the feces is simple; it is the
cumulative appearance of the intravenous label over the period of
fecal collection.
Simple model for predicting copper absorption
A previous publication (5) details the mathematical approach
taken for this simple model. In summary, it is assumed that a
certain fraction of the copper from the oral dose is absorbed at a
constant rate over a clearly defined absorptive time and appears
in the plasma, where it is eliminated according to a rate constant.
Compartmental model for investigating copper metabolism
Data from plasma and feces were analyzed by using the
SAAMII (SAAM Institute Inc, Seattle, WA) program (14) and
the compartmental model (Figure 1).
Definitions. The compartments represent discrete amounts of
copper that behave identically. A compartment is a theoretical
construct that may combine material from several different phys-
ical spaces in a system. A model can be viewed as a hypothesis
to be tested against experimental data, and the structure of the
model is then altered until a satisfactory fit to the data occurs. The
accessible compartments in our system were 2 and 5, which
represent the plasma. Transfer of copper between compartments
[ki, j, fraction/time] is defined as the fraction of compartment j
moving into compartment i per unit time.
Data fitting. Two parameters, the apparent volume of distri-
bution of the accessible compartments (V) and the fractional
transfer rate from compartments 1 to 7 (k7,1), were held constant
for all volunteers. Both of these parameters were difficult to
estimate from our data; therefore, V was fixed at 5 L according to
information received from a personal communication (N Lowe,
2003) and k7,1 set to 10.0 d1. The other parameters were given
initial estimates consistent with published data on human copper
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metabolism. During the fitting process, the parameters are al-
lowed to vary until a minimum of the objective function is
reached. The software then returns the mean and the SD of the
parameters. The 3 data sets (plasma copper concentrations from
the oral dose, copper from the oral dose that appeared in the feces,
and copper from the intravenous dose that appeared in the feces)
were combined within SAAMII. The fecal data were entered as
a cumulative total. It is assumed that within the time frame of this
experiment, none of the oral or intravenous isotope would have
been incorporated into bone and subsequently released and re-
turned to the accessible compartment. The final model structure
was arrived at by a process of trial and error but with the guiding
principle that it must contain the fewest compartments to ade-
quately describe the data (Principle of Parsimony). The final
model parameters are nonuniquely identifiable, which means
that they have more than one but a finite number of solutions.
Several compartmental structures were attempted based on
known physiology and metabolism, but the final structure (Fig-
ure 1) was chosen because it seemed to capture most of the known
features of copper metabolism with the minimum SD on the
parameters. The mass of copper in each compartment was esti-
mated by using SAAMII in “system” mode with an exogenous
input into the gut compartment equivalent to the calculated daily
intake from the diet.
Statistics
All data are expressed as means  SDs. Student’s t test was
used to test for differences between parameters of interest. Dif-
ferences were considered significant if the P value was 0.05.
RESULTS
From the dietary assessment, the volunteers habitually con-
sumed 1.4 0.4 mg Cu/d. This value is in good agreement with
the mean unlabeled copper excreted in feces over the course of
the study (1.6  0.2 mg Cu/d; P  0.25) and indicates that the
subjects were in steady state when they consumed their habitual
diets. The analysis of total copper in urine resulted in trace
amounts being detected, and these data are not reported or used
in any of the kinetic modeling.
The oral and intravenous isotope excretion and oral absorption
estimates are summarized in Table 1. The quantity of intrave-
nous copper isotope excreted (32  5%) was not significantly
different (P  0.27) from the estimate of excretion of the ab-
sorbed oral copper label (35 2%). The mean apparent absorp-
tion from the oral dose was 33  3%. When a correction was
made to the apparent absorption for the quantity of oral dose
absorbed and then excreted, the mean true absorption was esti-
mated to be 49 4%. This was not significantly different (P
0.48) from the true absorption (48  5%) when the correction
was made by using the estimation of the quantity of the intrave-
nous dose excreted. True absorption as calculated by the simple
model was 8 2%, which was significantly different (P 0.01)
from that estimated by fecal monitoring.
The results of the compartmental modeling are shown in Table
2. The exchangeable pool size was estimated to be 43 30 mg,
with most of the copper being located in compartment 6 (84%).
True absorption was estimated to be 49 4% [true absorption
(k2,1 k3,1)/(k2,1 k3,1 k7,1)]. Plasma copper was present in 2
compartments, the vast majority (99%) being in compartment 5;
the remaining 1% was found in compartment 2. Most of the rate
constants (ki,j) that were fitted by the model had a CV (CV 100
 SD/ki,j)25%, although k1,3, k1,6, and k5,6 had greater uncer-
tainty (CV:50% on average). Rate constant k6,5 for subjects 4
FIGURE 1. Compartmental model of copper metabolism. The circles
represent compartments, the rectangles represent delays, and the arrows
represent the transfer of copper from one compartment to another.
TABLE 1
Oral and intravenous (IV) isotope excretion in feces and estimated absorption of the oral dose in feces and plasma
Subject
no.
Amount of IV
dose excreted
Amount of oral
dose excreted1
Apparent
absorption
True absorption based
on excretion of IV
dose
True absorption based
on excretion of oral
dose
Model-derived true
absorption2
% % % % % %
1 29 33 39 55 55 9
2 33 35 31 47 51 4
3 27 34 31 42 43 7
4 38 37 32 52 50 8
5 37 32 30 48 47 9
6 28 36 33 46 48 9
x 32 35 33 48 49 8
SD 5 2 3 5 4 2
1 Refers to the percentage of the oral dose that was absorbed and then excreted into the feces as estimated with the method of Harvey et al (3).
2 Refers to the simple model developed by Dainty et al (5).
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and 6 was fixed because of fitting problems and has no uncer-
tainty associated with it. The same applies to k4,3 for subject 5.
The mean model fit to the average of the 6 subjects’ experimental
data is shown in Figure 2. The first peak concentration (Cmax
0.028 0.008 g/mL) in the labeled plasma occurred90 min
after the dose before steadily decaying and then peaking again
(Cmax 0.021 0.005 g/mL) 2–3 d later. An example of the
distribution of labeled copper between components of human
plasma in subject 4 is shown in Figure 3. The directly reacting
copper was the first to peak, at 80 min, followed by the
ceruloplasmin-bound copper3 d later.
DISCUSSION
The recovery of the intravenous labeled copper in the feces
appears to validate our previously published method (3) in which
the appearance of orally labeled copper in feces is used in con-
junction with a linear model as a predictor of endogenous losses.
In a subsequent article (4) we speculated that the linear model
may not be adequate and that a mono- or bi-exponential fit may
be necessary. However, the data presented in this article indicate
that a linear fit is valid under our conditions and can be easily
applied because of its simplicity.
The attempt to quantify copper absorption with the use of a
simple mathematical model (single compartment) was unsuc-
cessful. True absorption estimated from the simple model was
only 8%, whereas it was 48–49% when measured by fecal mon-
itoring. This difference can probably be explained by the large
first-pass effect in the liver that newly absorbed copper under-
goes on passing through the portal vein. This effect is not incor-
porated into our simple model.
The more complicated compartmental model (Figure 1) was
developed by using the well known Principle of Parsimony,
which states that one should not increase, beyond what is nec-
essary, the number of entities required to explain anything.
Therefore, this model had the minimum number of parameters to
produce the observed behavior of the experimental data. The
parameters are nonuniquely identifiable, which means that dif-
ferent starting estimates for the parameters will result in the
program optimizer converging to different estimates for the pa-
rameters. This requires the starting estimates to be based on
sound physiologic principles, otherwise the final estimates will
be meaningless even though the optimizer may converge to what
appears to be a good fit. Convergence also depends on how much
noise or uncertainty is in the data, and, unfortunately, it was
necessary to fix rate constant k (6, 5) for subjects 4 and 6 and k (4,
3) for subject 5 to fit the remaining parameters. This is an indi-
cation that the model suffers from some a posteriori identifiabil-
ity issues when the data are noisy. The uncertainty on most of the
parameters was acceptable for modeling of this type (15). The
experimental data that was simultaneously fitted to the model
was the fecal appearance of the oral and intravenous isotopes and
the plasma appearance of the oral isotope in the form of total
labeled copper concentration. Originally, we planned to use the
ceruloplasmin-bound labeled copper plasma concentration and
the directly reacting labeled copper plasma concentration as
model inputs rather than the total labeled copper plasma concen-
tration. Unfortunately, the labeled ceruloplasmin-bound and di-
rectly reacting copper plasma concentrations proved to be very
noisy data sets (see Figure 3 for an example), so only the total
labeled copper concentration was used.
One of the main findings from our compartmental model (Fig-
ure 1) was the necessity of including a pathway (k3,1) from the gut
to the liver. This so-called first-pass effect accounts for the sur-
prisingly small quantity of newly absorbed copper that appears in
the plasma and explains why the simple model of predicting
TABLE 2
Model parameters for each subject1
Parameter Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6
delay 7 (d) 1.377 0.0532 1.687 0.135 0.985 0.018 1.399 0.043 1.445 0.034 1.409 0.034
k1,3 (d1) 0.175 0.017 0.365 0.055 0.438 0.249 3.659 8.079 0.449 0.055 0.284 0.039
k1,6 (d1) 0.028 0.006 0.006 0.017 0.056 0.005 0.068 0.005 0.047 0.005 0.039 0.004
k2,1 (d1) 3.749 0.895 1.480 0.153 1.942 0.369 3.624 0.605 2.522 0.099 2.266 0.237
k3,1 (d1) 6.570 1.010 11.232 0.824 5.499 0.389 6.839 0.762 7.113 0.381 6.640 0.335
k3,2 (d1) 39.410 10.639 9.012 1.544 18.970 3.860 26.862 6.171 13.447 0.664 12.143 1.409
k5,6 (d1) 0.267 0.137 0.171 0.173 0.188 0.126 2.552 0.179 0.514 0.226 0.207 0.046
k6,5 (d1) 2.491 0.844 4.012 1.623 4.002 1.471 25 (fixed) 4.000 1.528 5 (fixed)
k4,3 (d1) 0.387 0.087 0.337 0.104 3.029 1.893 14.975 33.723 1 (fixed) 1.174 0.238
delay 4 (d) 0.680 0.168 0.889 0.270 2.514 0.437 0.685 0.322 0.985 0.189 1.451 0.197
k8,7 (d1) 1.452 0.056 1.186 0.095 2.031 0.037 1.430 0.044 1.385 0.033 1.419 0.035
k5,4 (d1) 2.943 0.729 2.251 0.685 0.796 0.138 2.920 1.371 2.031 0.390 1.379 0.187
M1 (g) 136 97 187 99 171 148
M2 (g) 13 16 19 13 32 28
M3 (g) 2495 1758 401 56 1137 904
M4 (g) 656 524 3056 570 1120 1540
M5 (g) 4130 4140 1319 1292 3416 1330
M6 (g) 34 892 93 553 21 621 12 330 24 365 26 957
M7 (g) 1873 1638 1842 1384 2470 2086
Total mass (g) 44 197 101 727 28 446 15 745 32 711 32 993
1 Rate constants (ki,j) refer to the fractional transfer of copper from compartment j to compartment i in unit time. Masses (Mi) refer to the quantity of copper
located in compartment i. Delay elements (delay i) refer to the average time that copper spends inside compartment i.
2 x  SD (all such values).
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copper absorption on the basis of plasma appearance data does
not work. The ratio of k3,1 to k3,1 k2,1 would indicate that74%
of absorbed copper is removed by the liver on the first pass before
undergoing a delayed entry into the plasma bound to ceruloplas-
min (80%) or excreted back into the gastrointestinal tract (20%).
The other copper excretory path back into the gut in our model is
via compartment 6, which we speculate as containing muscle and
other soft tissue. This excretory pathway is consistent with
known copper physiology, which suggests that a large flux of
copper (2.0–2.8 mg/d) is excreted via salivary, gastric, duodenal,
and pancreatic routes (16). The estimated copper flux from our
model is 1.4 mg/d via these routes and from biliary excretion
(k1,3  mass of compartment 3) is 1.0 mg/d. which, again, is
lower than the value (ie, 2.5 mg/d) reported by Linder et al (16).
Our estimates of copper pool sizes are also lower than those
previously reported. It is thought that a 70-kg man contains110
mg Cu (17), but our model has estimated this to be43 mg. One
explanation for this low value may be that the time frame of our
blood sampling was a relatively short (7 d) period; therefore, we
would not have seen any exchange of the labeled copper with
skeletal copper. This seems likely because it is known from
calcium kinetic studies that even 14 d of plasma sampling does
not allow detection of exchange or equilibrium of labeled cal-
cium with the native element in bone matrix (18). It is thought
that almost one-half of the copper stored in the body is contained
in the skeleton, so our estimate of total body copper (43 mg)
almost certainly excludes any copper in this region.
The sampled compartments (2 and 5) represent the plasma. It
was decided to fix the volume of distribution of this space to 5000
mL based on unpublished data (N Lowe, 2003). This value was
the mean of 8 subjects who each received an intravenous dose of
labeled copper and then had 12 blood samples taken over 90
min, which allowed an estimate to be made of the apparent
volume of distribution by a standard pharmacokinetic method
(19). The ratio of the volume of distribution to the total copper
contained in compartments 2 and 5 represents the predicted
plasma concentration of copper. The model predicted that the
distribution of copper in the plasma was 99% in compartment 5
(identified as ceruloplasmin-bound copper) and 1% in compart-
ment 2 (identified as directly reacting copper). This compares
with 94% ceruloplasmin-bound copper as measured by Cart-
wright and Wintrobe (20), 97% measured by Buckley et al (21),
and 96% measured by Inagaki et al (22).
The half-life (t1/2) of ceruloplasmin copper in this study was
estimated to be 27 d, which compares well with the value of
20 d that was found in 10 “normal” control subjects in the study
FIGURE 2. Variation in labeled plasma copper concentrations over 14 d
(A) and 7 h (B) postdose and the cumulative fecal excretion of the oral dose
(C) and the intravenous (IV) dose (D) over 14 h postdose. The solid line
represents the model fit, and the filled squares represent the mean experi-
mental data point and its SD.
FIGURE 3. Variation in labeled plasma copper concentrations over 5 h
(A) and 7 d (B) postdose in subject 4. ■, Total labeled copper; , labeled
copper bound to ceruloplasmin; , labeled copper bound to albumin.
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by Lyon et al (23). The t1/2 of the directly reacting copper was
estimated to be 60 min, which is higher than the values reported
by Buckley et al (21) in 2 subjects after an intravenous infusion
(t1/211 min) and estimated indirectly by Scott and Turnlund (7)
in 5 subjects after an oral dose (t1/2 26 min) during a metabolic
period when the subjects were consuming 1.68 mg Cu/d. Given
the small sample size of these studies, there is still some uncer-
tainty as to the true population mean of t1/2 for directly reacting
copper. Interestingly, the indirect estimate from the Scott and
Turnlund model after the intravenous dose of labeled copper
(t1/2  41 min for the directly reacting copper) suggests that it
depends on the route of administration. We cannot comment on
this on the basis of our study because no blood samples were
taken after the administration of the intravenous dose.
In conclusion, the previously published method (3) for esti-
mating endogenous losses of copper from an oral dose has been
shown to be consistent with that from an intravenous dose. The
use of a simple model for estimating the absorption of an oral
dose of copper from its appearance in plasma does not warrant
further investigation. Fecal monitoring remains the only feasible
method for estimating copper absorption. A more complicated
compartmental model showed that newly absorbed copper un-
dergoes a substantial first-pass effect in the liver, where74% of
the copper is initially removed from the circulation. The ex-
changeable pool of copper in the body was estimated to be 43 mg;
this value is well below the total body copper concentration of
110 mg reported from autopsy data but consistent with the fact
that most copper in the body cannot be quantified by using stable
isotopes and compartmental modeling because it is contained in
very slowly exchanging bone.
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ORIGINAL COMMUNICATION
[6S]5-methyltetrahydrofolate or folic acid
supplementation and absorption and initial
elimination of folate in young and middle-aged adults
K de Meer1*, YM Smulders2, JR Dainty3, DEC Smith1, RM Kok1, CDA Stehouwer2, PM Finglas3 and
C Jakobs1
1Department of Clinical Chemistry, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The
Netherlands; 2Department of Internal Medicine, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The
Netherlands; and 3Institute of Food Research, Norwich, UK
Objectives: To assess the effects of supplementation with the diastereoisomer of 5-methyltetrahydrofolate ([6S]5-methylTHF),
as an alternative supplement for folic acid, on folate absorption and elimination, in two age groups.
Design: A randomized, double-blind intervention study.
Subjects: A total of 12 young (o30 y) and 12 middle-aged (Z50 y) healthy volunteers were recruited.
Methods: Volunteers were randomized to receive daily supplementation with 400 mg folic acid or equimolar amounts of [6S]5-
methylTHF during 5 weeks. Before and after supplementation, absorption and initial elimination were calculated following oral
[2H2]folic acid test doses using isotope kinetics in plasma.
Results: Folic acid absorption was lower in the middle-aged as compared to the young adults, both before (P¼ 0.03) and after
(P¼0.05) supplementation. In the young adults, absorption decreased by 22% after [6S]5-methylTHF and increased by 21%
after folic acid (P¼0.02). In the other age group, no such changes were found. The folate rate constant of elimination increased
after folic acid supplementation in the young (þ50%; P¼ 0.05) but not in the middle-aged (þ18%; P¼ 0.5) adults.
Conclusions: Young adults show increased folate turnover after folic acid supplementation relative to the effect of [6S]5-
methylTHF supplementation. Similar differences are not observed in middle-aged adults, in whom folic acid absorption was
found to be lower as compared to the young adults.
Sponsorship: Financial support was received from the European Union 5th Framework Programme (Grant QLRT-1999-00576).
European Journal of Clinical Nutrition (2005) 59, 1409–1416. doi:10.1038/sj.ejcn.1602254; published online 7 September 2005
Keywords: [6S]5-methyltetrahydrofolate; folic acid kinetics; homocysteine; elderly
Introduction
Supplementation with folic acid, the synthetic form of the B
vitamin, has been shown to reduce the incidence of neural
tube defects during pregnancy and to reduce elevated plasma
total homocysteine (tHcy) levels, a risk factor for cardio-
vascular disease and other illnesses (Homocysteine Trialists’
Collaboration, 1998, 2002; Oakley, 1999). Mandatory for-
tification of grain products is in effect in the United States
and elsewhere, and is known to reduce the incidence of
neural tube defects and tHcy levels in the population (Savage
& Lindenbaum, 1995; Jacques et al, 1999; Flynn & Enright,
2000; Halliday & Riley, 2000; Honein et al, 2001). In many
other countries, folic acid fortification has not been imple-
mented, in part because of the concern that high levels of
folic acid intake prevent the timely diagnosis of vitamin B12
deficiency (Dickenson, 1995; Savage & Lindenbaum, 1995;
Flynn & Enright, 2000; Dhar et al, 2003). This is of parti-
cular concern in people over the age of 60 y, in whom
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decreased cobalamin status and associated elevated tHcy
have been documented (Savage & Lindenbaum, 1995;
Stabler et al, 1997; Carmel et al, 1999). Whether gut
absorption and initial metabolism of folic acid changes over
time upon supplementation, and whether this is different
among natural folate monoglutamyl forms are not known.
The most abundant natural folate in human plasma
is the diastereomer ([6S]) of 5-methyltetrahydrofolate
(5-methylTHF). On theoretical grounds, the use of [6S]5-
methylTHF in supplements or as a fortificant is less likely to
mask the anemia of vitamin B12 deficiency, as 5-methylTHF
(and not folic acid) requires the cobalamin-dependent
methionine synthetase reaction for conversion into tetra-
hydrofolate (Shane, 1997). Tetrahydrofolate is the precursor
of folate forms that support hematopoiesis (ie methylenete-
trahydrofolate and formyltetrahydrofolate). In the presence
of cobalamin deficiency, supplemented [6S]5-methylTHF is
unable to stimulate erythropoiesis because vitamin B12 is
necessary for conversion of 5-methylTHF to tetrahydro-
folate. However, folic acid is converted to dihydrofolate
and tetrahydrofolate (Scott & Weir, 1994). Since [6S]5-
methylTHF has become commercially available in recent
years, its effect on folate status in the blood and reduction
of plasma Hcy levels have been studied (Venn et al,
2002, 2003; Lamers et al, 2004). However, data on its
bioavailability and elimination as compared to folic acid
are limited (Prinz-Langenohl et al, 2003; Pentieva et al, 2004).
Bioavailability, the appearance of 5-methylTHF in plasma
after oral folic acid ingestion, may be different between these
compounds.
[6S]5-methylTHF could possibly be used for food fortifica-
tion or in supplements as an alternative for folic acid,
provided [6S]5-methylTHF has beneficial effects equal to
those of folic acid with respect to prevention of neural tube
defects (in offspring of women at the age of reproduction)
and reducing cardiovascular disease risk (in the middle-aged
and elderly). Ageing is associated with changes in gut
function. Age-associated changes (eg in intestinal luminal
pH and microbial flora) could possibly affect absorption of
different folate forms. Whether [6S]5-methylTHF and folic
acid supplementation have different effects on folate
absorption at different ages is at present unknown. The
aim of the study was to compare the effects of supplementa-
tion with [6S]5-methylTHF or folic acid on folic acid
bioavailability in healthy young and middle-aged adults.
Subjects and methods
Subjects
Volunteers were recruited from Amsterdam and suburbs,
through advertisements in public places and local written
media. The respondents were invited to participate in the
study if they were either agedZ18 ando30 y (young adults)
or Z50 y (middle-age adults) and were neither taking
medication nor vitamin supplements. Respondents were
not eligible if they had any type of chronic or acute disease,
consumedZ2 U alcohol/day, had lost body weight (45 kg in
the previous 2 months), were either pregnant or planning a
pregnancy, or were found to have a deficiency of folate
(total serum folate level measured with immunologic assay
o5.9 nmol/l) or vitamin B12 (serum level o150 pmol/l) on
screening. A total of 12 young and 12 middle-aged
volunteers were recruited. The size of these groups was
calculated based on data on folate absorption in women of
childbearing age (Finglas et al, 2002b), assuming that a
clinically relevant difference of 20% in bioavailability would
be detected with power 90% (and type I error 5%). The ethics
committee of the VU University Medical Center approved
the study, and written informed consent was obtained from
all participants.
Study protocol
A 5 weeks, double-blind, randomized trial was conducted
comparing oral supplementation with either folic acid
(400 mg once daily) or [6S]5-methylTHF (454 mg once daily).
Experiments with an oral test dose of [2H2]folic acid were
performed before and at the end of the intervention period.
During preintervention testing, volunteers visited the VU
University Medical Center outpatient clinic. Height, body
weight and blood pressure were measured, and a blood
sample was taken after an overnight fast to determine serum
folate and vitamin B12. For the first experiment (d 1), the
participants reported to the hospital in the morning (at
B0800), after an overnight fast of 11–14 h. An intravenous
catheter was placed in a dorsal hand vein for blood sampling.
Baseline blood samples were drawn for tHcy, vitamins,
methylmalonic acid and 677C-T methylenetetrahydro-
folate reductase (MTHFR) polymorphism. At 0830 (time 0),
an oral test dose of 202 mg (¼454 nmol) [2H2]folic acid ([30
50-2H2]folic (monoglutamic) acid, 98% isotopic purity;
Professor JF Gregory III, University of Florida, Gainesville,
FL, USA) was dissolved in water and administered in a drink
(Kok et al, 2004). Venous blood was drawn at time 0, 20, 40,
60, 90, 120, 150, 180, 240, 300, 360 and 480 min for total
folate and for 5-methylTHF concentrations and enrichments
in plasma. Volunteers had access to water, and used a light
folate-free lunch (after time 240 min). Participants were
assigned to one of two interventions ([6S]5-methylTHF or
folic acid) according to a computer-generated randomization
list, and received a batch of supplements (see below). They
were asked to take, from d 1 to d 34, two capsules in the
morning of each day and to record this on a diary form. The
volunteers were encouraged to continue their customary
diet. The second experiment was performed on d 35, using
the same [2H2]folic acid test dose protocol as described
above. Compliance was checked by inspection of the diary
forms and counting of the number of capsules at the end of
the intervention period.
The supplements were manufactured by Eprova (Schaff-
hausen, Switzerland) as hard gelatin capsules containing a
blend of magnesium stearate and microcrystalline cellulose
[6S]5-methyltetrahydrofolate and folate absorption
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and either 227 mg [6S]5-methylTHF as calcium salt (208 mg
(454 nmol) for the [6S]5-methylTHF moiety) or 200 mg
(454 nmol) folic (monoglutamic) acid. The supplements
were identically packed in coded batches of 70 capsules,
and stored in bags covered with aluminum foil. The
randomization code was kept at the Institute of Food
Research, Norwich, UK (PF). Stability tests of the supple-
ments (microbiological assay; Institute of Food Research)
performed at the beginning, middle and end of the
intervention studies showed a recovery of 98% of both
folate forms.
Analytical methods
Blood samples were placed on ice, and were transferred into
EDTA-containing tubes for determination of the concentra-
tions of total folate, tHcy and methylmalonic acid and
concentration and enrichment of 5-methylTHF, or trans-
ferred into glass tubes for determination of serum vitamin
B12 and pyridoxine. The samples were centrifuged at 41C
within 15 min (1000 g, 10 min) and stored at 801C.
A blood sample was also taken for determination of
the 677C-T polymorphism of MTHFR, transferred into
EDTA-containing tubes and stored at 801C.
Plasma total (ie free and protein bound) Hcy was measured
with a microparticle enzyme immunoassay (IMX analyser;
Abbott, Chicago, IL,USA) (interassay CV 4%). Methylmalo-
nic acid was measured as its dicyclohexanyl ester by
stable isotope dilution capillary gas chromatography–
positive chemical ionization mass spectrometry (interassay
CV 5–8%) (Rasmussen, 1989). Methylmalonic acid and
tHcy samples were tested in a single run to eliminate
day-to-day assay variation. Serum vitamin B12 concentra-
tions were measured with radioassay (ICN, Costa Mesa,
CA, USA) (interassay CV 4%) and serum vitamin B6
(pyridoxal-5-phosphate) with the use of fluorescence
high-performance liquid chromatography (interassay CV
7%) (Ubbink et al, 1985).
Total folate was determined by means of automated
chemiluminescence (ASC:180 Automated Chemilumines-
cence Systems, Chiron Diagnostics, Halstead, UK) (interassay
CV 5%). The concentration and isotopic enrichment of
5-methylTHF were measured as previously described (Kok
et al, 2004). Briefly, [13C5]5-methylTHF (Institute of Food
Research, Norwich, UK) was added to the plasma sample as
internal standard. The samples were deproteinated and
protected against oxidation, and folates were extracted with
folate binding protein affinity columns and a concentration
step. Liquid chromatography tandem mass spectrometry was
performed on a triple quadrupole tandem mass spectrometer
(API 3000, Applied Biosystems, Foster City, CA, USA) in the
positive ion mode following multiple reaction monitoring of
precursor fragment transitions (interassay CVs: for unlabeled
5-methylTHF concentration 3–8% and for [2H2]5-methylTHF
enrichment 1–2%). Enrichment was expressed as tracer-to-
tracer ratio (TTR).
The 677C-T polymorphism of MTHFR was assessed
in DNA obtained from the buffy coat of EDTA blood (Tsai
et al, 2000).
Calculation of folate kinetics
Changes in labeled 5-methylTHF plasma concentrations are
approximated in a single compartment model of the fast
folate pool (Finglas et al, 2002a; Kok et al, 2004). Following
an oral dose of [2H2]folic acid, a measurement protocol of
46 h allows for the completion of the absorptive process and
characterization of the decay of the plasma concentration. In
the model, apparent absorption and true absorption can be
estimated (in the latter, we assume that when folate is
absorbed, a first pass effect in the liver is present at a fraction
of 0.65 of the dose; Finglas et al, 2002a) as well as the rate
constant of elimination (k). The model, assumptions and
calculations are described in Appendix A1.
Statistical analyses
Compartmental modeling was performed with SaamII
(version 1.1.1), obtained from the Saam Institute (Seattle,
USA), and true absorption, apparent absorption (assuming
no first pass effect) and the rate constant of elimination from
the pool were retrieved under goodness of fit conditions.
Differences between the [6S]5-methylTHF and folic acid
supplementation and between age groups were analyzed
with unpaired Student’s t-tests or, when data were skewed,
Mann–Whitney U-tests. For paired observations, paired
Student’s t-tests or Wilcoxon matched pairs rank sum tests
were performed. Correlation analysis was performed with
the Spearman’s rank test. ANOVA was performed to test the
effects of interactions between age groups and folate inter-
vention. To account for potential confounders, in particular
baseline differences in folate status and absorption and
elimination kinetics, multiple regression analyses were
performed. Because MTHFR genotype and folate status
interact with plasma tHcy, these analyses were performed
with and without inclusion of MTHFR genotype. Normality
was assessed by visual inspection of distributions and
Kolmogorov–Smirnov tests. Values are presented as
means7s.d. or median (range). Data were analyzed with
SPSS (version 9.0, SPSS, Chicago, IL, USA). Differences were
considered significant if Po0.05 (two-tailed).
Results
All volunteers completed the study according to the
protocol’s criteria for compliance. There were no signi-
ficant differences in baseline plasma tHcy, 5-methylTHF,
total folate and other characteristics between the volun-
teers receiving [6S]5-methylTHF or folic acid (Tables 1
and 3). Baseline vitamin B6 was slightly lower in the
middle-aged volunteers in the folic acid subgroup, but there
was no significant difference between groups (overall
[6S]5-methyltetrahydrofolate and folate absorption
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ANOVA, P¼0.18, independent t-tests for separate groups:
0.12rPr0.92). Body weight was slightly higher in the
middle-aged as compared to young adults (independent
t-test, P¼0.06).
At baseline, true absorption of folic acid was significantly
lower in the middle-aged as compared to the young adults
(110734 vs 84720%, respectively; independent t-test,
P¼0.03), and tended to be different after supplementation
(107756 vs 80735%, P¼0.05). The rate constant of
elimination was not different between age groups (data not
shown). Results for the intervention studies are presented in
Table 2. In the young adults, folic acid true absorption
increased significantly after folic acid supplementation, as
opposed to a decrease in absorption after [6S]5-methylTHF
supplementation (paired t-test, difference between interven-
tions: 43%, P¼0.02). Absorption in the middle-aged adults
did not change significantly after either supplement. For
both age groups combined, the means of percentage change
in absorption were significantly different between [6S]5-
methylTHF and folic acid supplementation (16 vs þ13%,
respectively; Po0.05). The rate constant of elimination
showed a trend to increase after folic acid supplementation
in the young adults (þ 50%; paired t-test, P¼0.052), and was
unchanged after [6S]5-methylTHF supplementation. In the
middle-aged adults, changes after either supplement were
small. For all volunteers combined, changes in folic acid
absorption were positively associated with changes in the
rate constant of elimination (Spearman’s r¼0.38, P¼0.06).
Multiple regression analyses were performed with ‘absorp-
tion after supplementation’ as the dependent variable and
‘baseline absorption, baseline 5-methylTHF status, age
category and intervention type’ as independent variables.
For both age groups combined, the only positive predictor
of ‘absorption after supplementation’ was intervention
with folic acid (beta-coefficient þ8.9% compared to [6S]5-
methylTHF; P¼0.04). Separate multivariate analyses of the
two predefined age categories reconfirmed that this positive
effect of folic acid supplementation on true absorption was
entirely attributable to the young age group (beta-coefficient
þ13.2%; P¼0.02) and was not present in the elderly
(beta-coefficient 5.0; P¼0.50). Results were identical for
apparent absorption. Additional adjustment for baseline
Table 1 Characteristics of human volunteers in both supplementation groups
Age o30 y Age 450 y
[6S]5-methylTHF (n¼6) Folic acid (n¼6) [6S]5-methylTHF (n¼6) Folic acid (n¼6)
Gender (M/F) 3/3 2/4 3/3 2/4
Age (y) 2674 2473 5373 5577
Body weight (kg) 66710 63710 7278 72712
Vitamin B6 (nmol/l) 50719 55727 72732 38716
Vitamin B12 (pmol/l) 202746 2687108 245750 2557107
Methylmalonic acid (mmol/l) 0.19 (0.14–0.22) 0.23 (0.15–0.69) 0.17 (0.15–0.5) 0.20 (0.15–0.3)
Values are means7s.d. or median (range).
No significant differences were present between age and intervention groups.
Table 2 Folic acid absorption and initial metabolism before and after 5 weeks supplementation with [6S]5-methylTHF or folic acid in young and middle-
aged adultsa
Age o30 y Age 450 y
[6S]5-methylTHF (n¼6) Folic acid (n¼6) [6S]5-methylTHF (n¼6) Folic acid (n¼6)
Apparent absorptionb (% dose)
Before 42710 35714 3178 2776
After 33710 4378 28711 28714
Mean % change 21* þ23 10 þ4
True absorptionc (% dose)
Before 119729 101739 89728 78719
After 93728 122723 80723 80740
Mean % change 22* þ21 10 þ3
Rate constant of elimination (h1)
Before 0.10470.021 0.09470.6 0.10770.043 0.10370.050
After 0.09070.032 0.14570.6 0.09670.043 0.12270.038
Mean % change 9 þ50 6 þ18
aValues are means7s.d. Results were obtained with kinetic modeling of [2H2]5-methylTHF concentrations.
bAssuming no first pass effect.
cAssuming a first pass effect of 65% of tracer dose (Finglas et al, 2002b). Significant difference between folate interventions (for change from baseline): *Po0.05
(Mann–Whitney U-test).
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vitamin B6 levels and MTHFR genotype did not change these
results. In addition, similar multiple regression analyses for
‘rate of elimination’ were also in agreement with the results
of the bivariate analyses presented in Table 2.
Effects of supplementation on blood concentrations of
5-methylTHF and tHcy are shown in Table 3. After supple-
mentation, plasma 5-methylTHF concentration was higher in
all subgroups (Mann–Whitney U-tests, 0.03rPr0.08). Plasma
total folate was also higher after supplementation in all
subgroups (Mann–Whitney U-tests, 0.03rPr0.05), with a
higher increase in the young adults as compared to the
middle-aged adults (Mann–Whitney U-test, P¼0.015). Both
folate interventions resulted in lower tHcy levels, with no
apparent overall differences between the two age groups.
Fasting tHcy showed a more pronounced decrease in [6S]5-
methylTHF-supplemented volunteers (Mann–Whitney
U-test, P¼0.07), which was entirely attributable to the
younger age group (Mann–Whitney U-test, P¼0.03). The
change in plasma 5-methylTHF concentrations did not
correlate with the change in fasting tHcy. There was no
statistical significance present for the interaction between
age and folate intervention with regard to effects on tHcy, 5-
methylTHF and total folate levels.
Discussion
In young adults, but not in the middle-aged, we found a
significant difference in absorption and initial elimination of
a folic acid test dose between supplementation with the
diastereoisomer of 5-methylTHF as compared to folic acid.
Absorption was lower in the middle-aged as compared to the
young adults. These findings suggest different age-depen-
dent mechanisms for these folate forms.
With respect to methodology, we studied initial metabo-
lism of 5-methylTHF following labeled folic acid absorption
after oral loading. As shown by others (Krumdieck et al, 1978;
Clifford et al, 1998), the results indicate that folic acid
bioavailability in the young adults is nearly complete,
but variation of the estimate existed due to small sample
size in each subgroup. The elimination constant in our
study is higher than reported in radioactive folic acid
studies conducted in two healthy adults (Krumdieck
et al, 1978; Clifford et al, 1998). Exchange with hydrogen
of the deuterium in the folic acid tracer may result in
underestimation of the 5-methylTHF enrichment (Gregory
& Quinlivan, 2002). The extent of this isotope effect
under the study conditions is very limited. With our study
model, similar values for k are obtained for [30 50-2H2]folic
acid and [13C6]folic acid ingested as test doses (Kok
et al, 2004). The rate constant of elimination used in
our study represents elimination from the plasma, not
excretion from the body.
In the young adults in the present study, 400 mg folic acid
supplementation elicited an increased initial turnover of
folic acid relative to supplementation with [6S]5-methylTHF.
Previous studies on increasing folate intake and folate
absorption and elimination have not been conclusive. In a
study in two groups of young women at total folate intake
levels of either 450 or 850 mg/day (part of it as folic acid
supplements), a trend to a lower residence time was reported
in women with the higher folate intake (Gregory et al, 2001).
In another study performed in 32 elderly women (60–85 y)
randomized into two groups after experimental depletion
at a folate intake of 118 mg/day, total urinary folate cata-
bolite excretion was significantly increased after 7 weeks of
repletion in women receiving a folate intake of 400 mg/day
but not in those receiving 200 mg/day (Wolfe et al, 2003). It
should be noted that these studies were conducted in
women of different age groups and used different experi-
mental protocols, making comparison of the results hazar-
dous. In the present study, folic acid absorption was 20%
lower in the middle-aged as compared to the young
volunteers. Under these dissimilar baseline conditions, the
middle-aged adults in the present study exhibited no
Table 3 Plasma concentrations before and after 5 weeks supplementation with [6S]5-methylTHF or folic acid in young and middle-aged adultsa
Age o30 y Age 450 y
[6S]5-methylTHF (n¼6) Folic acid (n¼6) [6S]5-methylTHF (n¼6) Folic acid (n¼6)
Fasting tHcy (mmol/l)
Before 9.4 (7.3–12.5) 8.5 (5.6–18.5) 9.7 (6.4–13.9) 10.2 (4.8–46.0)
After 7.6 (5.8–9.4) 7.4 (4.8–20.3) 8.8 (6.3–11.3) 9.2 (5.4–31.6)
Median % change 22* 12 11 9
5-MethylTHF (nmol/l)
Before 15.2 (4.7–25.4) 10.1 (6.2–24.7) 16.7 (10.8–29.7) 13.6 (4.1–30.6)
After 23.4 (12.3–74.8) 29.2 (19.9–37.4) 25.6 (19.2–47) 20.5 (6.4–37.2)
Median % change þ64 þ129 þ57 þ58
Total folate (nmol/l)
Before 9.9 (6.9–20.6) 13.3 (8.9–23.1) 21.0 (13.5–29.0) 16.7 (6.4–20.7)
After 21.6 (11.0–39.7) 23.7 (18.3–30.5) 26.6 (21.2–34.0) 22.1 (10.1–30.0)
Median % change þ102 þ96 þ37 þ53
aValues are medians (range).
Significant difference between folate interventions: *Po0.05 (Mann–Whitney U-test).
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changes in absorption and initial folic acid elimination upon
supplementation with either supplement.
What could be the physiological explanation for these
findings? The intestinal folate transport system has similar
avidity for the monoglutamyl forms of folic acid and
5-methylTHF (Selhub et al, 1984; Mason & Rosenberg,
1994). However, in terms of 5-methylTHF appearance in
plasma, the metabolic routing of orally administered folic
acid is different from that of oral 5-methylTHF. For a [6S]5-
methylTHF supplement, the 5-methylTHF transported over
the brush border of the enterocyte only needs to be
transported to the portal circulation and pass through the
liver to appear in the systemic circulation. In contrast, for
the folic acid supplement, the folic acid appearing in
the enterocyte must undergo reduction and one-carbon
substitution. At low doses, folic acid is excreted into the
systemic circulation mainly as 5-methylTHF. However, even
at an oral dose of 200 mg, part of the folic acid reaches the
liver and systemic circulation in its unmetabolized form
(Sweeney et al, 2002; Kok et al, 2004). Folic acid that reaches
the portal circulation requires reduction and one-carbon
substitution in the liver (or in other tissues). In the liver, folic
acid undergoes these transformations only if unbound to
folate binding protein (Henderson, 1990). From the vantage
point of appearance in the plasma 5-methylTHF pool, there
are now several theoretical options to explain the increased
folate appearance rate after folic acid supplementation
relative to [6S]5-methylTHF supplementation.
The first option is that in the folic acid supplementation
group, exposure of enterocytes and hepatocytes to unmeta-
bolized folic acid during the 5 weeks supplementation
resulted in upregulation of enzyme activity for dihydrofolate
reductase, the rate-limiting enzyme in the conversion of folic
acid into 5-methylTHF. Enzyme induction by folic acid
exposure (Kamen et al, 1985) is a possible mechanism
because dihydrofolate is the product of the first step in folic
acid metabolism and also the endogenous substrate for
dihydrofolate reductase in its conversion to tetrahydrofolate.
In the folic acid supplementation group, this may have
resulted in faster conversion of the labeled folic acid from the
test dose into 5-methylTHF on d 35 as compared to d 0. Since
enzyme induction would not occur in the participants
supplemented with [6S]5-methylTHF, a difference in post-
supplementation as compared to presupplementation
absorption characteristics between both supplementation
groups may be explained. However, to explain the differ-
ences between both age groups with respect to absorption
and initial elimination after supplementation, this option
would require the assumption that the dihydrofolate
reductase upregulation by folic acid supplementation is age
dependent.
The second option follows the observation that folate
binding protein has a higher affinity for folic acid than for
reduced folates (Henderson, 1990). The exposure to folic acid
supplementation may saturate the hepatic folate binding
protein pool with folic acid, so that on the second test day
less unmetabolized labeled folic acid arriving in the hepato-
cytes is able to bind to this protein. Conversely, exposure to
[6S]5-methylTHF supplementation saturates the hepatic
folate binding protein with reduced folates but not with
folic acid. Thus, bioavailability for the second folic acid test
dose could be lower in the volunteers who received [6S]5-
methylTHF supplementation as compared to those with folic
acid supplementation. In order to explain the difference in
absorption between young and middle-aged volunteers, this
explanation would require an age-dependent difference in
the characteristics of the folate binding protein pool or its
interaction or saturation with folates.
The third option follows the reasoning that the explana-
tion for age-related differences in folic acid absorption
derives from changes in the gut that are associated
with age. Ageing in humans is associated with a decrease
in gastric acid production and a rise in pH of the intestinal
lumen content. A mildly acidic luminal environment greatly
enhances folate transport (Smith et al, 1970). Atrophic
gastritis is common in the elderly and results in folic acid
malabsorption, which can be corrected by oral administra-
tion of hydrochloric acid (Russell et al, 1984, 1986; Krasinski
et al, 1986). In a dynamic in vitro model simulating human
gastric passage, folate binding proteins have been shown to
maintain binding of folic acid in the gut lumen whereas
binding of 5-methylTHF diminished, resulting in a high
fraction of unbound 5-methylTHF (Verwei et al, 2004).
Interaction between age, small bowel luminal pH and folate
binding protein affinity to folate forms may thus explain
both the difference in folic acid absorption between young
and middle-aged adults in our study and the differential
effect of supplementation with different folate forms on
folate absorption in these age groups. It should be noted
that in the present study, no further data are available to
test these optional hypotheses, and other explanations
remain possible.
The limitations of the study merit discussion. Firstly, our
measurement protocol has the limitation that, without
sampling of the portal vein or liver, the two components
of folate bioavailability (absorption and first pass effect)
cannot be quantified. No estimations of intracellular or long-
term folate metabolism or excretion in the urine were made
(Sites et al, 1997). The hepatic first pass effect was assumed to
be constant (65% of the dose) in our study, but it should be
noted that it may vary between individuals (between-subject
CV approximately 10%; Kok et al, 2004). At baseline, means
for true absorption ranged between 78 and 101% in three
subgroups but was 119% in the young volunteers in the
[6S]5-methylTHF supplementation group. Since absorption
cannot exceed 100%, the latter finding indicates either
measurement or modeling error. Background plasma folate,
enrichment curves and modeling goodness of fit were not
different in the young volunteers in this subgroup; simula-
tions showed that true absorption of 100% was obtained if
first pass effect in the subgroup was assumed to be 54% of the
dose. Although we have no reason to suspect background
[6S]5-methyltetrahydrofolate and folate absorption
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hepatic folate stores or first pass effect in the young
volunteers receiving [6S]5-methylTHF supplementation to
be different from the other volunteers, we cannot exclude
this possibility. Whether the first pass effect changes with
supplementation and is different between two orally admi-
nistered folate forms is unknown, but if present this would
affect the calculation of true absorption. With the present
knowledge, we cannot further explore these validity issues of
the model. Secondly, as a complication of the study design
(which included two age groups and two interventions,
with six volunteers per subgroup), the possibility to detect
differences within- and between-study groups and to
formally test for interaction effects (which requires many
more subjects than testing for group differences) was
reduced. Changes were observed in folic acid absorption
and rate constant of elimination after supplementation
(range between 20 and þ50% within subgroups; see
Table 2). Wolfe et al (2003) found a significant increase in
urinary folate excretion after supplementation with 400 mg/
day folic acid in folate-depleted elderly women, and this is in
agreement with the trend (þ18%) for higher rate constant
of elimination from plasma in our middle-aged volunteers
supplemented with 400 mg/day folic acid. Nonetheless,
statistical significance was present for lower absorption in
the middle-aged adults and intervention-related differences
in the younger adults.
Thirdly, the measurement of folate forms in plasma
was incomplete. Folic acid ingestion increases not only
5-methylTHF but also other reduced folate concentrations.
We have not measured dihydrofolate and tetrahydrofolate
levels and enrichments, and cannot exclude the possibility
that part of the labeled folic acid is retained in the pools of
these reduced folates. Plasma levels of total folate (measured
by chemiluminescence) levels and of 5-methylTHF (mea-
sured with mass spectrometry) in our study did not show
consistently lower values for 5-methylTHF as compared to
total folates as expected (80–90% of total folate is methyl-
folate; Pfeiffer et al, 2004). Laboratory assays of folate are
notoriously difficult and various methods are known to
agree poorly (Gunter et al, 1996; Pfeiffer et al, 2001).
Fourthly, the study design does not allow inferences to be
made with respect to the mechanism that explains the
observed differences in folate absorption. Exploration of
theoretical options to explain the study findings would
require further data.
In conclusion, the preliminary findings of the present
study, using a novel single pool model for folate absorption
in a limited number of subjects, show that in healthy young
adults, two different folate supplements taken during 5
weeks elicit differential changes in folic acid absorption and
initial elimination. Why the middle-aged adults in our study
do not show changes in folic acid handling after supple-
mentation similar to the young adults is unclear, and should
be the subject of further studies. We also found that folate
bioavailability was lower in middle-aged adults, in whom no
differences in initial folic acid turnover are found between
both supplements. This finding needs to be confirmed in
middle-aged and elderly adults, as decreased folate absorp-
tion in the elderly would have important public health
implications.
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Appendix A1
Estimation of in vivo folate absorption and elimina-
tion
Changes in 5-methylTHF isotopomer plasma concentrations are
approximated in a single-compartment model (Kok et al, 2004).
The appearance of labeled folic acid approximates an infusion
rate (R) over the absorption period T. The definition of R is
R ¼ mass of dose that is absorbed
time period for absorption
¼ M
T
ðA:1Þ
With V the apparent volume of distribution for folate
(B389 ml/kg body weight; Loew et al, 1987), k the rate
constant of elimination from the compartment and t the
time after ingestion of the test dose (doseoral), the labeled
5-methylTHF concentration (C) can be approximated as
C ¼ M
VTk
ð1 ekðttlagÞÞ ð0ototmaxÞ ðA:2Þ
and
C ¼ M
VTk
ð1 ekT Þ ekððttlagÞTÞ ðt4tmaxÞ ðA:3Þ
Here, tlag is the time during which the plasma enrichment
remains at baseline. The value of T (ie tmaxtlag) is
established from the plasma 5-methylTHF enrichment curve.
M can be calculated by fitting equations (A.2) and (A.3) to
the time series of labeled 5-methylTHF concentrations. The
apparent absorption can then be calculated as
apparent absorption ¼ M
doseoral
ðA:4Þ
A first pass effect is present when folate is absorbed.
Assuming that in humans it is a fraction of 0.65 of doseoral
(Finglas et al, 2002b), true absorption can be estimated as
true absorption ¼ M
1  first pass effect ðA:5Þ
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Estimation of iron absorption in humans using
compartmental modelling
B Sarria1, JR Dainty2*, TE Fox2 and SJ Fairweather-Tait2
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Objective: To evaluate whether a compartmental model could estimate iron absorption as accurately as the well-validated
technique of plasma area under the curve using labelled test meals.
Design: The study is a randomised cross-sectional intervention.
Setting: The study was carried out at the Human Nutrition Unit at the Institute of Food Research, Norwich, UK.
Subjects: A total of nine female volunteers, aged 3378 y.
Interventions: Volunteers were given an oral dose (approximately 5 mg) of Fe-57 as iron sulphate in an orange juice test drink
and simultaneously infused Fe-58 (approximately 200 mg) as iron citrate over 90 min. Multiple blood samples were taken for the
following 6 h. The samples were analysed by mass spectrometry and iron absorption was estimated using a mathematical model
based on the appearance of Fe isotopes in plasma and the area under the curve technique.
Results: The geometric mean (1 s.d., þ1 s.d.) absorption of the model estimate is 16% (9, 31) and the area under curve
estimate is 18% (8, 29).
Conclusions: Results indicate that a compartmental model can be used to estimate labelled iron absorption although it is
unlikely that this new method will be used in favour of an existing one. Further studies are now needed with unlabelled iron to
assess whether the technique could have application in the assessment of total (haemþnonhaem) iron absorption from food.
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UK.
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Introduction
The aim of several previous studies investigating iron
absorption methodologies in human volunteers has been
to correlate the peak increase in serum iron concentration
with the absorption of iron from a test meal (Hallberg &
Solvell, 1960; Ekenved et al, 1976). This has failed because
the underlying assumption behind it that the rate of
elimination of iron from serum does not vary markedly
between individuals is false. Where this has been recognised,
an intravenous (i.v.) labelled iron has been given in
conjunction with an oral test dose to calculate iron
absorption (Gonzalez et al, 2001). The drawback to the latter
method is that the oral and i.v. doses must behave in the
same (kinetic) way once in the systemic circulation, but
there is some evidence that this does not always happen
(Winchell, 1968).
Compartmental modelling can overcome these problems
because it can be used to estimate the quantity of iron
absorbed from an oral dose without the need to give a
simultaneous i.v. dose of iron. It is a well-established
technique for estimating fluxes and pool sizes, and does
not require invasive sampling of body tissues (Carson et al,
1983; Green & Green, 1990; Jacquez, 1996). Its use in iron
metabolism is based on radioisotope work, published mainly
in the 1960s, which resulted in the development of complex
multicompartmental models (Pollycove & Mortimer, 1961;
Sharney et al, 1965; Hosain et al, 1967; Najean et al, 1967). A
pilot study (Dainty et al, 2003) has indicated that simple,
Received 23 December 2003; revised 21 May 2004; accepted 11 June
2004; published online 14 July 2004
*Correspondence: JR Dainty, Institute of Food Research, Norwich
Research Park, Colney, Norwich NR4 7UA, UK.
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single compartmental modelling shows promise in estimat-
ing unlabelled iron absorption; however, bias due to
modelling assumptions needs further investigation. The
current paper attempts to address this issue by comparing
the estimate of iron absorption made from the plasma area
under the curve (AUC) method (Barrett et al, 1994) with that
from the compartmental model using labelled test doses.
Subjects and methods
Volunteers were recruited through advertisements placed
around the Norwich Research Park. Nine healthy women
between the ages of 20 and 45 y volunteered for the study.
Their health was assessed through prestudy screening, which
included a blood test and a medical questionnaire. None of
the subjects were taking dietary supplements, was pregnant
or a smoker. The study was approved by the Norwich and
Norfolk District Ethics Committee and all recruits signed
informed consent forms before entering the study. After an
overnight fast, the subjects had an i.v. cannula inserted into
each arm. The experimental protocol and dose preparation
are similar to that described by Dainty et al (2003). In all, 12
serial blood samples were taken at t¼0, 20, 40, 60, 80, 120,
145, 175, 200, 260, 320 and 380 min after the simultaneous
oral and intravenous dose. A single focussing multicollector
inductively coupled plasma mass spectrometer (Isoprobe,
Micromass, UK) with a desolvating sample introduction
system and microconcentric nebulizer (Aridus and T1 H,
both from Cetac) was used for isotope analysis. All samples
were run in duplicate and calibrated against IRMM014
(Rosman & Taylor, 1998).
Model analysis
The majority of the analysis is contained in a recently
published paper (Dainty et al, 2003) and is not reproduced
here. Briefly, the model estimates the quantity of iron that
has been absorbed from a test meal by assuming that it
crosses the gut wall as a constant infusion, appears in the
plasma and is cleared. By fitting equations to the labelled
plasma iron concentration data, it is possible to estimate the
quantity of iron absorbed from the test meal (Moral). By using
the same model for the i.v. infusion, it is possible to validate
some of its assumptions by estimating the ‘i.v. recovery’,
which is defined as the calculated mass coming from the i.v.
dose, Mi.v., divided by the actual mass of labelled iron in the
i.v. dose (dosei.v.). The ratio of these two masses should be an
independent validation of the model’s suitability for pre-
dicting absorption from the oral dose.
i:v: recovery ¼ Mi:v:
dosei:v:
ð1Þ
Statistical analysis
All data are presented as arithmetic mean7s.d. and are based
on nine volunteers (n¼9) unless stated otherwise. A paired,
two-tail, Student’s t-test was carried out to assess the
significance of numerical differences arising from different
routes of isotope administration. Differences were considered
significant if Po0.05. A graphical technique was used to
assess the agreement between estimation of iron absorption
from the AUC method and the model method (Bland &
Altman, 1986). The difference in iron absorption between the
two methods is plotted against the average value of iron
absorption found using both techniques. Two methods for
measuring the same quantity are said to have good agreement
provided (1) variations within the mean of the difference in
iron absorption72 s.d. are not significant and (2) the average
bias of one method relative to the other is small.
Results
Absorption data, plasma half-lives and i.v. recovery data are
shown in Table 1. The geometric mean (1 s.d.,þ1 s.d.)
absorption for the AUC method is 18% (10, 32) and that for
the model is 16% (8, 29). When the model is applied to the
labelled i.v. plasma concentration data, it can be seen that
there is a small underestimation of the true i.v. dose that was
infused into the subjects (i.v. recovery¼95711%). The half-
life (t1/2) of the labelled iron in the plasma from the oral dose is
2.6770.36 h (k¼0.2670.04 h1) and is not significantly diffe-
rent (P¼0.43) from that for the i.v. dose (t1/2¼2.6070.36 h,
k¼0.2770.04h1). Figure 1 is a graphical depiction of the
agreement between the two methods. The mean difference
between the estimation of %Fe absorption is calculated at
1.8% (ie the model method gives a lower estimate) and the
95% confidence interval is estimated as being between 7.5
and 3.9 units of difference (% iron absorption).
Discussion
In the present paper, we have attempted to show that a
single compartment model can be used to estimate the
Table 1 Absorption of labelled oral dose of iron, half-life of labelled iron
in plasma and recovery of i.v. dose as predicted by the model
Oral dose
absorption (%)
Plasma Fe
half-life (h)a
Subject no. AUC Model Oral i.v. i.v. recovery (%)b
1 48 52 3.2 3.3 105
2 28 25 2.3 2.2 97
3 13 9 2.5 2.2 91
4 23 20 2.7 2.6 93
5 13 11 2.9 2.6 104
6 11 11 3.2 2.7 106
7 30 24 2.3 2.3 82
8 12 12 2.7 2.8 104
9 9 7 2.2 2.6 77
Mean 18c 16c 2.7 2.6 95
aHalf-life of labelled iron in plasma (t1/2) ¼ loge 2/elimination rate constant, k.
bi.v. recovery¼mi.v./dosei.v. (Eq. (1) in Subjects and methods section).
cGeometric mean.
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absorption of extrinsically labelled nonhaem iron from a test
drink. For a new measurement technique to be accepted, it
must be shown to perform as well as existing methods and to
offer some advantages. Inspection of the Bland and Altman
analysis (Figure 1) suggests that there is a small bias (mean
difference¼1.8%) between the two methods for calculat-
ing iron absorption. This finding is reinforced by the
geometric mean iron absorption values, 18% for the AUC
method and 16% for the model. The underestimation in i.v.
recovery (Table 1) also supports these observations and the
reasons for this have already been discussed in an earlier
publication (Dainty et al, 2003) and can be summarised as an
oversimplified model structure that does not take account of
labelled iron that disappears and then refluxes back into the
plasma compartment during the experimental period.
Despite these concerns, the model method appears to
compare well with the AUC method although the width of
the 95% confidence interval needs further discussion.
In their original paper (Bland & Altman, 1986), a key
question was posed as to how much disagreement can be
tolerated between ‘old’ and ‘new’ measurement techniques
before a new method is considered to be acceptable. Using
the model method in the present study, we may expect an
estimate of iron absorption to be somewhere between 22 and
10% instead of the ‘true’ value of 18% as estimated by the
AUC technique. In most nutritional studies, this would
clearly be unacceptable and the model method would not be
used. However, agreement between the two techniques
would almost certainly have been improved with a larger
sample size. For this kind of comparative study it is
recommended that 50 data points be collected (Altman,
1991) and this would lead to a much more definitive
statement regarding the agreement of the two methods.
The promising nature of the results from this pilot study
suggests that such an exercise should be undertaken because,
while it is clear that the model method for predicting
labelled iron absorption is not perfect, the method could be
useful for unlabelled iron studies, where there is presently no
method for quantifying the absorption of total iron from
single test meals. Further work is needed to assess the
quantity of unlabelled iron that would be needed in a test
meal to ensure adequate characterisation of the plasma
response curve, and to establish whether the method is
applicable to a range of test meals with differing iron release
properties.
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Folate absorption from folate-fortified and processed foods using a human
ileostomy model
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Data on folate absorption from food from validated human studies using physiological folate doses are still needed to estimate dietary requirements
and to formulate recommendations. The aim of the present work was to study the effects from fortified and processed foods on folate absorption in
ileostomy volunteers (n 9) using the area under the plasma concentration curve (AUC) and kinetic modelling. Using a standardized single-dose
protocol, dairy products fortified with a candidate fortificant (6S)-5-methyltetrahydrofolate ((6S)-5-CH3-H4folate), folic acid-fortified bread and a
dessert cre`me containing natural yeast folate polyglutamates were compared with folate supplements. Absorbed folate was estimated by AUC and
a kinetic model, and non-absorbed folate by ileostomal folate excretion. Median apparent absorption from test foods ranged from 55 to 86 %.
Added folate-binding proteins (FBP) significantly reduced folate absorption from dairy products, as in the absence of FBP, AUC–dose-corrected
ratios were increased and ileal folate excretion decreased. After in vivo gastrointestinal passage of dairy products containing FBP, up to 43 % of the
ingested FBP was found in ileostomal effluent. Folate absorption was similar for (6S)-5-CH3-H4folate fortificant from fermented milk and for folic
acid from fortified bread. Folic acid, ingested as food fortificant in bread, was significantly less absorbed compared with an isolated supplement.
We conclude that all tested foods were suitable matrices for folate fortification. However, dairy products, fortified with the new candidate forti-
ficant (6S)-5-CH3-H4folate, are suitable if no active FBP is present.
(6S)-5-Methyltetrahydrofolate/folic acid: Folate-binding proteins: Fortified foods: Human folate absorption
An optimal folate status is linked to several health-protective
effects, e.g. diminished risk for neural tube defects (Honein
et al. 2001; Liu et al. 2004) and spontaneous abortions
(George et al. 2002), decreased risk of occlusive vascular dis-
eases (Wald et al. 2002) and improved cognitive or mental
functions (Seshadri et al. 2002). These reported health benefits
have led to increased folate intake recommendations in the
USA and some European and Nordic countries (Yates et al.
1998; Becker et al. 2004).
Information about the extent to which certain foods could
contribute to increased folate intake is still incomplete. How-
ever, some in vitro and in vivo trials aimed to determine the
effects of food matrix on folate absorption, e.g. folic acid-for-
tified cereal-based foods (Pfeiffer et al. 1997; Malinow et al.
1998; Johansson et al. 2002) or dairy products which contain
folate-binding proteins (FBP; Arkba˚ge et al. 2003; Verwei
et al. 2003). Different human models have been used to deter-
mine long-term (Malinow et al. 1998; Johansson et al. 2002;
Vahteristo et al. 2002) or short-term (Pfeiffer et al. 1997;
Prinz-Langenohl et al. 1999; Finglas et al. 2002; Konings
et al. 2002; Wittho¨ft et al. 2003) folate bioavailability or
absorption. Long-term protocols are tedious, and also most
short-term protocols have certain requirements and limitations
as reviewed elsewhere (Wittho¨ft et al. 1999; Gregory, 2001),
e.g. lack of sensitivity demanding high test doses or presatura-
tion of volunteers’ body stores as recommended for dual-label
stable-isotope protocols (Pfeiffer et al. 1997; Rogers et al.
1997). The area under the plasma concentration curve
(AUC) technique (Prinz-Langenohl et al. 1999; Konings
et al. 2002) is commonly used to estimate folate absorption
by comparing a single oral dose of test food with a known
dose of a pharmaceutical folate preparation. This concept
was questioned as it was hypothesized that oxidized folic
acid and reduced folates have different sites of initial metab-
olism resulting in a greater liver sequestering of folic acid
(Wright et al. 2003).
*Corresponding author: Dr Cornelia M. Wittho¨ft, fax þ46 18 67 2995, email Cornelia.Witthoft@lmv.slu.se
Abbreviations: AUC, AUC0!600, area under the (plasma concentration) curve, superscript time range (in min); C20, plasma folate concentration, subscript defines
time (in min); FBP, folate-binding proteins; (6S)-5-CH3-H4folate, (6S)-5-methyltetrahydrofolate; t, t20, time (point), subscript defines time (in min) of folate
concentration in plasma.
British Journal of Nutrition (2006), 95, 181–187 DOI: 10.1079/BJN20051620
q The Authors 2006
PAPER 11
The present study was carried out to determine effects from
differently fortified and processed foods on folate absorption
using the AUC technique and a new kinetic modelling
method (Kok et al. 2004; Wright et al. 2005) in human ileost-
omy volunteers and forgoing body store presaturation (Wit-
tho¨ft et al. 2003). Test foods were differently processed
dairy and cereal products, which were fortified with folic
acid or a new candidate fortificant (6S)-5-methyltetrahydrofo-
late ((6S)-5-CH3-H4folate) or natural yeast folate polygluta-
mates. Furthermore, effects from dairy FBP on folate
absorption and the fate of FBP during in vivo gastro-intestinal
passage were studied.
Material and methods
Subjects
Nine subjects were recruited (eight males, one female), appar-
ently healthy based on routine haematological and biochemi-
cal measurements and a physical examination. They had a
mean age of 62 (SD 9·3, range 51–79) years, a mean BMI
of 28·9 (SD 4·3, range 22·6–38·4) kg/m2, were non-smokers,
and did not use any medication or vitamin supplements affect-
ing folate metabolism. They underwent proctocolectomy 12–
37 years earlier as a result of ulcerative colitis with a maximal
resection of 5–10 cm (except one volunteer: 25 cm) of the
distal ileum and possessed a conventional well-established
ileostomy with no signs of inflammation. Volunteers were
screened for fasting serum folate, serum cobalamin and eryth-
rocyte folate concentrations to ensure normal folate and vita-
min B12 status. The protocol was approved by the Ethical
Committee of Umea˚ University Hospital.
Study design
All volunteers underwent nine independent study days each
2–4 weeks apart in random order. They received, after over-
night fast, either a single dose of test food or a pharmaceutical
preparation of the naturally occurring diastereoisomer (6S)-5-
methyltetrahydrofolate ((6S)-5-CH3-H4folate) or folic acid
(Table 1). On one day they received no folate to allow for esti-
mation of baseline folate excretion into stomal effluent.
During the several months’ long trial, volunteers’ folate
status was standardized by presaturation of body stores with
a daily dose of 0·96 mg folic acid from day 9 to day 2 prior
to each study day (Wittho¨ft et al. 2003). A standardized
low-folate and low-fat lunch (Wittho¨ft et al. 2003) was con-
sumed at 4 h 5 min post-dose, providing 2556 kJ, 13·6 g fat
and 18·1mg folate. A snack of 8 g unsalted rice-cake and
15 g pasteurized apple cre`me, providing 163 kJ, 0·2 g fat and
3·4mg folate was consumed at 7 h 5 min post-dose.
Table 1. Pharmaceutical preparations and test foods
Treatment Folate dose/portion* Further details
I Intramuscular
injection
194–266mg (422–579 nmol)†
5-CH3-H4folate
Injection solution (1 ml) prepared from (6S)-Ca-5-CH3-H4
folate (Merck Eprova AG, Schaffhausen, Switzerland)
according to Wittho¨ft et al. (2003).
O Pharmaceutical preparation 192mg (418 nmol) (6S)-5-CH3-H4folate Gelatine capsule by Merck Eprova AG.
C Pharmaceutical preparation 199mg (451 nmol) folic acid Gelatine capsule by Merck Eprova AG.
U Fermented milk 187–234mg (406–509 nmol)
(6S)-5-CH3-H4folate
Commercial fermented milk product (Filmjo¨lkw;
Arla Foods, Stockholm, Sweden; 0·5 % fat), addition
of (6S)-Ca-5-CH3-H4 folate injection solution 30 min
prior to consumption; 400 g/portion.
F Fermented milk with FBP 180–205mg (392–445 nmol)‡
(6S)-5-CH3-H4folate
Commercial fermented milk product
(Filmjo¨lkw; Arla Foods; 0·5 % fat), addition of
(6S)-Ca-5-CH3-H4 folate injection solution and whey
protein concentrate WPC 65 (Arla Foods) 30 min prior
to consumption; providing 156–442 nmol FBP/400 g
portion.
P Pasteurized milk with FBP 249mg (542 nmol) (6S)-5-CH3-H4folate Pasteurized skimmed milk (0·5 % fat) with strawberry
taste, fortified with 262 nmol FBP/portion by addition of
whey protein concentrate, WPC 65 (Arla Foods). Prior
to consumption, the milk was defrosted in a refrigerator
overnight and mixed (400 g/portion).
B Bread 217mg (491 nmol) folic acid Wheat bread, fortified with folic acid (Merck Eprova),
baked by Cerealia (Ja¨rna, Sweden), stored at 2208C.
The bread was thawed in a refrigerator overnight, the
crust removed and portions of 50 g weighed out 20 min
prior to consumption, providing 12mg (26 nmol)
endogenous 5-CH3-H4folic acid/portion.
Y Yeast cre`me 68–75mg (147–162 nmol) yeast
5-CH3-H4folate polyglutamates
Lemon mousse ‘fresta’ (citronfromage; Ekstro¨ms,
Procordia Food, Eslo¨v, Sweden) with yeast flakes
(Edelhefe-Flocken auf Melasse Basis, Tartex þ Dr
Ritter GmbH, Freiburg, Germany); portions (about
170 g) were prepared 30–45 min prior to consumption.
(6S)-5-CH3-H4folate, (6S)-5-methyltetrahydrofolate; FBP, folate-binding proteins.
* Concentrations in mg as free 5-CH3-H4folic acid.
† Range for n 8, another ¼ 433mg/921 nmol.
‡ Range for n 8, another ¼ 111mg/241 nmol.
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Folate absorption was estimated by plasma AUC and a kin-
etic model from venous blood samples collected 10 min pre-
dose and at 20, 40, 60, 90, 120 min and 3, 4, 6, 8 and 10 h
post-dose. Non-absorbed folate was estimated from folate
excretion into stomal effluent samples, collected every
second hour over 10 h post-dose. Urine samples from spon-
taneous bladder emptying during 10 h post-dose were used
to ensure that ingested doses did not exceed the kidney
threshold. Detailed information of sample collection and
storage is given elsewhere (Wittho¨ft et al. 2003).
Sample pretreatment for folate analysis
Procedures for extraction and purification of plasma and ileost-
omy samples by strong anion exchange solid-phase extraction
and urine samples by affinity chromatography using bovine
FBP (Scripps Laboratories, Cincinnati, OH, USA) are
described elsewhere (Wittho¨ft et al. 2003). Individual urine
samples derived from each subject were pooled beforehand
for each test day. Procedures for extraction, deconjugation
using hog kidney acetone powder (Sigma Chemical Co., St
Louis, MO, USA) and strong anion exchange solid-phase
extraction purification of aliquots from food samples (dairy
products 5 g, dessert cre`me with yeast 3·5 g, freeze-dried hom-
ogenized lunch and snack samples 2 g) have been described
earlier (Wittho¨ft et al. 2003). To ensure complete deconjuga-
tion of folate polyglutamates in the yeast dessert cre`me, rat
serum (Scanbur, Sollentuna, Sweden) was used according to
Patring et al. (2005). Freeze-dried bread samples (2 g) were
extracted by a tri-enzyme method using thermostable a-amy-
lase (Megazyme International, Cork, Ireland) and protease
(Sigma Chemical Co.) according to Johansson et al. (2002).
Folate quantification by HPLC
5-CH3-H4folate content in test foods, pharmaceutical folate
preparations and human samples was quantified by reverse-
phase HPLC according to Jastrebova et al. (2003) using a
HP 1100 series system equipped with a multi-wavelength
detector and a fluorescence detector (Agilent Technologies,
Waldbronn, Germany) and a Zorbax SB C8, 150 £ 4·6 mm,
5mm (Agilent Technologies, Palo Alto, CA, USA) column.
External calibration (n 8) was carried out using the standards
(Eprova AG, Schaffhausen, Switzerland) (6S)-H4folate, (6S)-
5-CH3-H4folate, (6S)-5-HCO-H4folate at 290/356 nm (fluor-
escence detector) and folic acid at 290 and 300 nm (multi-
wavelength detector). The limits of quantification were
0·5 ng/ml for H4folate, 0·3 ng/ml for 5-CH3-H4folate, 4 ng/ml
for 5-HCO-H4folate and 4 ng/ml for folic acid. Calibration
was linear over a range of 0·5–100 ng/ml for H4folate, 0·3–
100 ng/ml for 5-CH3-H4folate, 4–200 ng/ml for 5-HCO-
H4folate and 4–200 ng/ml for folic acid. Intra-assay CV and
relative recoveries for 5-CH3-H4folate were: CV of 11·0 %
(n 4), 84–105 % recovery in stomal effluent samples and
CV of 6·9 % (n 4), 86–94 % recovery in plasma samples,
including sample preparation and all analytical steps. An in-
house plasma control sample and a milk sample as control
for stomal effluent samples were carried through all pro-
cedures of sample extraction and purification, resulting in
CV of 6·2 % (n 41, plasma) and 5·5 % (n 35, milk) of
5-CH3-H4folate concentrations. For folic acid in bread a CV
of 0·9 % (n 3) and for 5-CH3-H4folate in yeast cre`me a CV
of 7·5 % (n 3) were obtained. Spiking of urine samples with
5-CH3-H4folate prior to affinity purification resulted in recov-
eries of 92–111 % (Wittho¨ft et al. 2003). The day-to-day
repeatability for affinity procedures and subsequent 5-CH3-
H4folate quantification resulted in CV of 6·8 % (n 3, urine)
and 4·5 % (n 18, standard solution).
Folate-binding protein quantification
FBP concentrations in dairy products and stomal effluent
samples were determined by a two-site ELISA developed
for milk according to Højer-Madsen et al. (1986) with
minor modifications as published by Wigertz et al. (1997)
using rabbit anti-bovine FBP 24 739 (State Serum Institute,
Copenhagen, Denmark), FBP calibrant (Central Hospital Hil-
lerød, Hillerød, Denmark) and the software KinetiCalc 4, ver-
sion 2.5 for Windows (Bio-Tek Instruments, Winooski, VT,
USA). A whey protein concentrate, containing 65 % protein
(WPC 65; Arla Foods, Go¨tene, Sweden), was included as in-
house reference material into every analysis. The CV between
runs did not exceed 15 %.
Kinetic and statistical calculations
Non-absorbed folate from oral doses was estimated by 10 h
post-dose stomal effluent. Absorbed folate was estimated
using plasma folate net increase above baseline concentrations
(pre-dose). When plasma concentration fell below the pre-
dose level, the increment was taken as zero. The (positive)
AUC0!1 from t0 to infinity was calculated for each subject
using linear and logarithmic trapezoidal rules for ascending
and descending plasma concentrations up to the last time-
point. If folate concentrations at the last blood sampling
point (C600) were still above baseline concentrations (C0),
the AUC beyond t600 to infinity (AUC
600!1) was extrapolated
by log-linear regression analysis using the last three to five
plasma concentration data points (choosing the best fit by cor-
relation coefficients).
Relative folate absorption from test foods was compared
using AUC–dose-corrected ratios (AUCTestfood/DoseTestfood
((h ng/ml) per mol)) to normalize for differences in individual
test portions.
Apparent folate absorption was estimated by assuming a
zero-order absorption process in a single compartment
model as described by Kok et al. (2004) using the following
equations for all test foods and doses except bread:
C ¼ M
VTk
12 e2kðt2tlagÞ
  ð0 , t , tmaxÞ ð1Þ
C ¼ M
VTk
12 e2kT
 
e2kððt2tlagÞ2TÞ ðt . tmaxÞ ð2Þ
where M is the mass of dose absorbed, tlag is the time during
which the plasma enrichment remains at baseline, tmax is the
time at which the 5-CH3-H4folate concentration is a maximum
in the plasma, T is the time period for absorption (tmax 2 tmin),
C is the 5-CH3-H4folate concentration in the sampled (plasma)
compartment, V is the distribution volume of 389 ml/kg body
weight as estimated by Loew et al. (1987) and k is the elim-
ination rate constant. By fitting the above equations to the
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5-CH3-H4folate curve (above C0) over time, M can be calcu-
lated. For bread, folate absorption was estimated using the
first-order absorption process using the Bateman function:
C ¼ MKa
VðKa 2 KeÞ e
2Ket 2 e2Kat
  ð3Þ
where C is the concentration in the sampled compartment, M
is the quantity of the dose that is absorbed, V is the distribution
volume (389 ml/kg body weight) and Ka and Ke are rate con-
stants of absorption and elimination, respectively. The appar-
ent folate absorption was calculated according to: apparent
absorption (%) ¼ 100 £ M/Doseoral.
All calculations were made using Office Excel 97.SR or
2003 SP1 (Microsoft, Redmond, WA, USA).
All statistical analyses were made using Minitab release
13.32 (Minitab Ltd, Coventry, UK). Continuous variables
are presented as median and range.
Normal plots of the residuals after fitting linear models
showed that log-transformed response variables: AUC–dose-
corrected ratios, apparent folate absorption and relative
folate excretion with stomal effluent, were approximately nor-
mally distributed. Tukey’s method was used to control the
simultaneous experimental error when performing pair-wise
comparison among the treatments. When comparing the intra-
muscular injection (day I) with the oral treatments Dunnett’s
method was used to control the simultaneous experimental
error. Wilcoxon signed rank test was used to compare effects
of treatments P and F (see Table 1 for treatments) on relative
FBP excretion in ileostomal effluent. A two-sided P value less
than 0·05 was considered significant in all analyses.
Nutrient content in standardized low-folate and low-fat
lunch and snack was calculated using the software MATs
4.05 (2001) (MATs den flexible, version 2.2; Rudans la¨ttdata,
Va¨stera˚s, Sweden).
Results
Effects of ingested doses on folate content in plasma, urine
and ileostomal effluent
After ingestion of test foods and pharmaceutical preparations
containing 5-CH3-H4folate and folic acid, post-dose plasma
5-CH3-H4folate concentrations increased above fasted base-
line levels, but no folic acid was detected. AUC–dose-cor-
rected ratios after intramuscular injection of pharmaceutical
(6S)-5-CH3-H4folate (day I) were greater than AUC on days
B, P, F (P,0·0001) and U (P¼0·0074), borderline greater
than on day C (P¼0·0581) and similar to days O
(P¼0·2898) and Y (P¼0·2360). When no folate dose was
given to volunteers (day N), no clear increase and subsequent
decrease of plasma 5-CH3-H4folate concentrations over time
was observed. Resulting AUC from t0 to t600 had for all vol-
unteers a mean size of below 10 % of the AUC on day I
(data not shown), and were not taken into account for further
calculations. AUC–dose-corrected ratios after ingestion of
fermented milk without FBP (U) and yeast dessert cre`me
(Y) were higher compared to the other foods (Table 2).
This is similar when estimating apparent folate absorption
(Table 3). Apparent absorption from fermented milk without
FBP (U) is similar to yeast cre`me (Y) (P¼0·9891), and both
are significantly larger than from pasteurized milk with FBP
(P) (P¼0·0137 and P¼0·0056, respectively). Apparent folate
absorption from bread (B) tends to be larger than from pas-
teurized milk (P) (P¼0·067).
Only small quantities of intact 5-CH3-H4folate from below
1 to 20mg were excreted into urine during 10 h post-dose (data
not shown). Highest amounts of intact 5-CH3-H4folate
excreted into urine corresponded on three occasions to a maxi-
mum of 8 %, and on all other occasions to below 5 % of the
given dose.
After ingestion of test foods containing 5-CH3-H4folate,
only this folate form was found in stomal effluents and no
other folate forms were detected. On day N (baseline), when
no folate dose was given, only negligible quantities of 5-
CH3-H4folate (1·6–6·0mg/10 h) were excreted, being in the
same magnitude as absolute 5-CH3-H4folate excretion after
intramuscular injection (I) (0·7–11·2mg/10 h) and after inges-
tion of folic acid-fortified bread (B) (1·7–15·4mg/10 h, n 8, for
one volunteer peak masked). Relative 5-CH3-H4folate
excretion increased significantly after ingestion of all test
foods containing 5-CH3-H4folate (F, P, U, Y and O, all
P,0·0001) compared with the intramuscular injection (I),
Table 2. Area under the plasma concentration curve
(AUC)–dose-corrected ratios of plasma 5-methyltetrahy-
drofolate (5-CH3-H4folate) after absorption of 5-CH3-H4-
folate and folic acid from test foods*
(Median values and range for nine subjects)
AUC–dose-corrected ratio
((h ng/ml) per mol)
Treatment Median Range
I 0·099bd 0·034–0·154
O 0·065cd 0·033–0·121
C 0·075cd 0·023–0·094
U 0·055c 0·027–0·087
F 0·030a 0·015–0·078
P 0·020a 0·014–0·035
B 0·039a 0·016–0·052
Y 0·143b 0·056–0·177
* For details of treatments and procedures, see Table 1 and p. 182.
a,b,c,d Median values with unlike superscript letters were signifi-
cantly different (P,0·05) (Tukey pair-wise comparison among
treatments on log-transformed AUC–dose-corrected ratios).
Table 3. Apparent 5-methyltetrahydrofolate (5-CH3-H4-
folate) and folic acid absorption (% of dose) from test
foods using kinetic modelling of plasma concentration
curves*
(Median values and range for nine subjects)
Apparent absorption (%)
Treatment Median Range
U 86a 29–147
F 62ab 37–92
P 55b 27–64
B 74ab 31–159
Y 80a 37–152
* For details of treatments and procedures, see Table 1 and p. 182.
a,b Median values with unlike superscript letters were significantly
different (P,0·05) (Tukey pair-wise comparison among treat-
ments on log-transformed apparent folate absorption).
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being significantly higher on days P and Y compared with day
U (P¼0·0214 and P¼0·0371, respectively) and day O
(P¼0·0058 and P¼0·0111, respectively) (Table 4). After
ingestion of folic acid-fortified bread (B), some folic acid
traces up to approximately 17mg/10 h were excreted in
stomal effluent, and after pharmaceutical folic acid (C) 1–
13mg/10 h were excreted. This is only a rough estimate due
to folate concentrations below the limit of quantification in
some of the ileostomal fractions.
Effects from dairy processing and presence of folate-binding
proteins on folate absorption
The presence of FBP in dairy products affected folate absorp-
tion. AUC–dose-corrected ratios were significantly increased
on day U after ingestion of fermented milk without FBP com-
pared to days F (P¼0·0243) and P (P¼0·0001). Median
AUC–dose-corrected ratios for both dairy products containing
FBP did not differ significantly (P¼0·5877). However, appar-
ent folate absorption on day U was only significantly increased
compared to day P (P¼0·0137), but not to day F (P¼0·6224).
Plasma results were complemented by data on relative ileosto-
mal folate excretion, which increased significantly on day P
(P¼0·0214) compared to day U, but not on day F
(P¼0·7152) (Table 4).
After in vivo gastrointestinal passage of dairy products for-
tified with FBP (P and F), FBP was found in ileostomal efflu-
ents (Table 5), being significantly higher on day P than day F
(P¼0·009). On days without FBP ingestion, e.g. days U and
N, no FBP was detected in post-dose effluents, as controlled
for four volunteers (data not shown).
Effect of ingested folate form on extent of absorption
Folate absorption by means of AUC–dose-corrected ratios did
not differ significantly (P¼0·9940) after oral ingestion of
pharmaceutical preparations of (6S)-5-CH3-H4folate (O) and
folic acid (C). Also total folate excretion after ingestion of
both folate forms was similar. After ingestion of 5-CH3-
H4folate (O), 2–74mg 5-CH3-H4folate were found in stomal
effluent during 10 h post-dose, and after ingestion of folic
acid (C), 3–41mg 5-CH3-H4folate and an additional 1–
13mg of folic acid were excreted.
Absorption of different folate forms as fortificant, (6S)-5-
CH3-H4folate monoglutamate in fermented milk (U) compared
to folic acid in wheat bread (B) compared to yeast 5-CH3-
H4folate polyglutamates as ‘bio-fortificant’ (Y), differed sig-
nificantly when expressed as AUC–dose-corrected ratios. Y
was significantly more absorbed than U (P¼0·0001) and
than B (P,0·0001), and B significantly less than U
(P¼0·0384).
After ingestion of folic acid as fortificant within a bread
matrix (B), AUC–dose-corrected ratios were significantly
smaller (P¼0·0041) compared with a supplement (C). Ileosto-
mal folic acid excretion was estimated to be 4–24mg on day
B and 1–13mg on day C. (6S)-5-CH3-H4folate given as sup-
plement (O) was similarly absorbed as when given as fortifi-
cant in fermented dairy matrix (without FBP, U), based on
AUC–dose-corrected ratios (P¼0·7822).
Discussion
Effects of dairy processing and presence of folate-binding
proteins on folate absorption
New information on effects of presence of FBP on folate
absorption in human subjects was provided by the present
study. Plasma results demonstrated that (6S)-5-CH3-H4folate,
a candidate compound for food fortification and the dominant
native food folate form, is bioavailable from all tested dairy
matrices. Median AUC–dose-corrected ratios are significantly
reduced in the presence of FBP (Table 2). Also apparent 5-
CH3-H4folate absorption from pasteurized milk with FBP
(P) is smaller than from fermented milk without FBP (U)
(Table 3) and conversely relative folate excretion with ileosto-
mal effluent is higher for P than U (Table 4). The present find-
ings suggest that FBP is reducing folate absorption. Folate is
better absorbed from fermented milk than from pasteurized
milk due to the absence of native FBP.
The present study is the first to prove intestinal ‘survival’ of
FBP in man. Using in vitro methods simulating the upper
human intestinal tract, Verwei et al. (2003) and Arkba˚ge
et al. (2003) reported that between 0 and 34 % of FBP from
the dose was recovered after ‘digestion’ of milk and yoghurt
fortified with (6S)-5-CH3-H4folate or folic acid. Interestingly,
this reflects our findings in vivo with FBP survival (Table 5).
Table 4. Relative excretion of 5-methyltetrahydrofolate
(5-CH3-H4folate) (% of dose) with stomal effluent over
10 h post-dose*
(Median values and range for nine subjects)
5-CH3-H4folate excretion (%)
Treatment Median† Range
I 2a 0–5
O 8b 2–39
U 7b 4–25
F 16bc 5–29
P 20c 13–51
Y 23c 13–37
* For details of treatments and procedures, see Table 1 and p. 182.
† Median for Y (n 8) as peak for one volunteer masked, median
for I (n 8) as amount for one volunteer traces only.
a,b,c Median values with unlike superscript letters were significantly
different (P,0·05) (Tukey pair-wise comparison among treat-
ments on log-transformed relative folate excretion in stomal
effluent).
Table 5. Relative excretion of folate-binding proteins (%
of dose) with stomal effluent over 10 h post-dose*
(Median values and range for nine subjects)
FBP excretion (%)
Treatment† Median Range
F 4b 0–32
P 24a 3–43
* For details of treatments and procedures, see Table 1 and p. 182.
† No folate-binding proteins found in ileostomal effluent on other
days (N, U).
a,b Median values with unlike superscript letters were significantly
different (P¼0·009) (Wilcoxon signed rank test).
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Arkba˚ge et al. (2003) reported a significantly decreased bioac-
cessibility, from yoghurt fortified with FBP, of both 5-CH3-
H4folate and folic acid. In agreement, we conclude that
dairy products might be a suitable matrix for folate fortifica-
tion if no active FBP is present.
Folate fortificants and supplements
Folate absorption from pharmaceutical folic acid and (6S)-5-
CH3-H4folate supplements did not differ significantly, but
more folic acid was absorbed as a supplement than from a
bread matrix (Table 2). However, as median apparent absorp-
tion from folic acid-fortified bread was high at 74 % (Table 3),
bread is a suitable matrix for folic acid fortification. Data from
a previous study (Johansson et al. 2002) showed that folic acid
fortification of bread results in a significant improvement of
volunteers’ folate status after just 4 weeks of intervention.
Of interest is the comparison of the already-established folic
acid fortification practice of cereal-based food with alternative
fortificants and matrices, e.g. by using as a new candidate for-
tificant the biologically active form of (6S)-5-CH3-H4folate in
dairy matrices, or natural yeast folate polyglutamates for ‘bio-
fortification’. Folic acid is used as food fortificant because it is
inexpensive and relatively stable, but, in contrast to reduced
folates, a high intake can delay diagnosis of an underlying
vitamin B12 deficiency. Around 80 % of all folate ‘fortifi-
cants’, yeast polyglutamates from dessert cre`me (Y), (6S)-5-
CH3-H4folate from fermented milk without FBP (U) and
folic acid from bread, were absorbed (Table 3). Median appar-
ent absorption of yeast folate from the dessert cre`me in the
present study (86 %) was much higher than the estimate of
folate bioavailability of a yeast drink of 59 % in the interven-
tion study of Hannon-Fletcher et al. (2004). Our HPLC
method, allowing quantification of four different folate
forms, might have led to an underestimation of the total
folate content in that particular test food when other folate
forms were present. In theory, this could result in an overesti-
mation of folate absorption. As high folate-producing yeast
strains could be an alternative for folate enrichment, future
investigation of this interesting matrix is warranted.
Critical appraisal of the ileostomy–area under the curve
model: limitations and advantages
The model enables the direct estimation, by comparison of
AUC–dose-corrected ratios and kinetic models, of the extent
of folate absorption after ingestion of different test foods.
Some noise in plasma folate concentrations was visible in
the form of minor AUC on day N with no test food appli-
cation, which may reflect effects from fasting, enterohepatic
circulation and ingestion of the standardized low-folate, low-
fat meals on plasma folate levels. We decided not to correct
for them when interpreting plasma results due to strict stan-
dardization of the study protocol (regarding sampling, fasting
periods and test food ingestion), as we expect possible con-
founding effects to be similar on all days. Another possible
confounder regarding plasma data is the hepatic first pass
effect (Pfeiffer et al. 1997; Rogers et al. 1997). In line with
their recommendation, we presaturated, and therefore standar-
dized, volunteers’ body stores. Using the plasma AUC
approach (Prinz-Langenohl et al. 1999; Konings et al.
2002), folate absorption from a test food is usually estimated
by comparison with an oral reference dose of folic acid; but
hereby it is not guaranteed that the oral reference dose is com-
pletely absorbed. To overcome this problem, the concept of an
intramuscular reference dose was developed (Wittho¨ft et al.
2003), where relative absorbed folate from an oral test dose
was estimated using a reference dose of (6S)-5-CH3-H4folate
administered by intramuscular injection (day I). Using labelled
folate compounds, Wright et al. (2003, 2005) observed con-
current displacement of endogenous (unlabelled) liver folates
after an oral folate test dose and hypothesized differences in
metabolism of oxidized and reduced folates. It was suggested
earlier that different folate forms (oxidized compared to
reduced) and administration (oral compared to intravenous
injection) could result in different handling in the body (Fin-
glas et al. 2002). This may lead to the conclusion that the
quantification of absorbed folate from a test food by compari-
son with any reference dose might be unsuitable when no
labelled compounds are used. Therefore, we decided to
avoid estimation of relative folate absorption by a reference
dose, but rather determine effects of processed and fortified
food on folate absorption by direct comparison of AUC–
dose-corrected ratios.
Plasma results are complemented by data from ileostomal
folate excretion, and estimated absorbed (by AUC) and non-
absorbed (by stomal excretion) folate should in theory amount
to approximately 100 % (Wittho¨ft et al. 2003). Overestimation
of total recovery could be caused by overestimating plasma
AUC due to a bad curve fit when extrapolating or during kinetic
modelling, when estimating the distribution volume V using the
factor (of 389 ml/kg body weight) from Loew et al. (1987),
which was estimated after a single intravenous dose of oxidized
folic acid of pharmacological magnitude. Underestimation of
the model’s overall recovery can mainly be caused by incom-
plete collection of ileostomal effluent.
The small quantities of 5-CH3-H4folate in 10 h post-dose
urine are in line with earlier findings (Pfeiffer et al. 1997; Wit-
tho¨ft et al. 2003). Thus, the given doses can be considered to
be of physiological size and that the kidney threshold was not
reached.
In conclusion, this new human model was used to compare
folate absorption from differently processed and fortified
foods. As each volunteer was randomly participating in the
nine strictly standardized study days, intra-individual as well
as inter-individual comparison of folate absorption was poss-
ible. The presented model would be strengthened by combi-
nation with stable-isotope techniques, as differentiation of
plasma folate deriving from the exogenous dose and from
endogenous body stores is of importance when studying
folate absorption and elimination kinetics by AUC.
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Quantification of the bioavailability of riboflavin from foods by use of
stable-isotope labels and kinetic modeling1–3
Jack R Dainty, Natalie R Bullock, Dave J Hart, Alan T Hewson, Rufus Turner, Paul M Finglas, and Hilary J Powers
ABSTRACT
Background: Discrepancies have been reported between estimates
of the prevalence of riboflavin deficiency based on intakes of ribo-
flavin and estimates based on measures of riboflavin status. One
reason for this may be an overestimate of the bioavailability of
riboflavin from foods, about which relatively little is known.
Objective: We aimed to quantify the bioavailability of riboflavin
from milk and spinach by using stable-isotope labels and a urinary
monitoring technique and by a plasma appearance method based on
kinetic modeling.
Design: Twenty healthy women aged 18–65 y were recruited for a
randomized crossover study performed with extrinsically labeled
(13C) milk and intrinsically labeled (15N) spinach as sources of
riboflavin. An intravenous bolus of labeled riboflavin was adminis-
tered with each test meal to assess the apparent volume of distribu-
tion of riboflavin in plasma.
Results: No significant differences were noted in riboflavin absorp-
tion from the spinach meal and from the milk meal according to
either the urinary monitoring technique (60 8.0% and 67 5.4%,
respectively; P  0.549) or the plasma appearance method (20 
2.8% and 23 5.3%, respectively; P 0.670).
Conclusions: A large fraction of newly absorbed riboflavin is re-
moved by the liver on “first pass.” The plasma appearance method
therefore underestimates riboflavin bioavailability and should not be
used to estimate riboflavin bioavailability from foodstuffs. Urinary
monitoring suggests that riboflavin from spinach is as bioavailable
as is riboflavin from milk. Am J Clin Nutr 2007;85:1557–64.
KEY WORDS Intrinsic label, stable isotopes, compartmental
models, absorption, riboflavin, riboflavin bioavailability
INTRODUCTION
Recent national surveys of the dietary intake and nutritional
status of various groups in the United Kingdom have reported
some discrepancy between the estimated intake of riboflavin in
the diet and measures of riboflavin status. The National Diet and
Nutrition Survey of British Adults (1) reported biochemical ri-
boflavin deficiency in between 54% and 80% of the population,
depending on age, whereas the National Diet and Nutrition Sur-
vey of Young People aged 4–18 y (2) reported biochemical
riboflavin deficiency in 95% of adolescent girls. In view of the
evident interaction between riboflavin status and iron handling
(3), this may be significant for the 50% of 15–18-y-old girls with
iron intakes less than the lower reference nutrient intake (mean
2 SDs). It has been suggested that a high prevalence of biochem-
ical riboflavin deficiency in the elderly may reflect a less efficient
absorption of riboflavin with increasing age, but this has not been
substantiated (4, 5). In all cases, calculated dietary intakes rela-
tive to dietary reference values gave lower estimates of riboflavin
deficiency than did biochemical data. These discrepancies sug-
gest either an overestimate of bioavailability or an inappropriate
biochemical threshold for deficiency.
Published mechanistic studies of riboflavin absorption have
used the pure free compound in experimental systems in vitro (6,
7). Although these studies provide mechanistic insight into the
absorption of riboflavin, they do not address questions relating to
availability from foods, in which this vitamin occurs predomi-
nantly as the phosphorylated derivatives FMN and FAD. No data
suggest that the nature of the food matrix limits riboflavin ab-
sorption, although milk and eggs contain free riboflavin bound to
specific binding proteins, which is in contrast with most food-
stuffs, which contain predominantly FAD and riboflavin phos-
phate bound tightly to enzymes.
A previous study of riboflavin bioavailability used doses of
riboflavin many times greater than usual dietary intakes (8). In
the present study, we determined the bioavailability of riboflavin
from foods in human subjects by using stable isotopes. Ribofla-
vin was synthesized with different labels (milk: 13C; spinach:
15N), which allowed us to administer physiologic doses (0.5
mg) and trace the absorbed riboflavin in plasma and urine. It is
well known in trace element work that the dual-stable-isotope
approach can estimate the absorption of a labeled dose from
plasma or urine samples (9). This approach can be complemented
by mathematical modeling, as recently applied to folate metab-
olism (10–12), which yields several important kinetic parame-
ters, including the riboflavin pool size, volume of distribution,
rate of elimination, and mean residence time in the plasma.
SUBJECTS AND METHODS
Subjects
Twenty female volunteers (aged 18–65 y) were recruited from
the Sheffield, United Kingdom, area. Exclusion criteria were
1 From the Institute of Food Research, Norwich, United Kingdom (JRD,
DJH, and PMF); the Human Nutrition Unit, University of Sheffield, Shef-
field, United Kingdom (NRB, RT, and HJP); and the Biomedical Research
Centre, Sheffield Hallam University, Sheffield, United Kingdom (ATH).
2 Supported by the Biotechnology and Biological Sciences Research
Council (BBSRC).
3 Reprints not available. Address correspondence to H Powers, Human
Nutrition Unit, University of Sheffield, Sheffield, United Kingdom. E-mail:
h.j.powers@sheffield.ac.uk.
Received October 30, 2006.
Accepted for publication January 19, 2007.
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smoking, history of cardiovascular disease, use of vitamin sup-
plements, use of drugs known to interfere with folate or ribofla-
vin metabolism, and pregnancy. Although all subjects completed
the study, data sets from 3 volunteers were excluded from the
article because of a failure of the mass spectrometer and the loss
of the samples. The subjects did not differ significantly from
those whose data were analyzed, in terms of either demographic
characteristics or indexes of riboflavin status. Partial data sets are
included for 7 of the remaining 17 volunteers for whom sample
analysis problems were encountered. The number of data sets
that were included in any statistical or mathematical analysis is
indicated in the tables, figures, and results.
Ethical considerations
The study protocol was explained in group interviews, and
detailed written information was provided. Each participant was
asked to give written informed consent to both screening proce-
dures as well as study participation. Ethics approval for this study
was obtained from the Sheffield University Ethics Committee.
Study design
Each subject was admitted to the study unit on 2 occasions, 4
wk apart, in a randomized crossover design. Twenty-four–hour
urine samples were collected for 3 d over the study, beginning
24 h before the test dose. Participants received the following test
doses: 400 g 13C-labeled riboflavin in 200 mL semi-skimmed
milk (fat content 1.7 g/100 mL) with a simultaneous intravenous
injection of 200 g 13C-labeled riboflavin or, 308 g labeled
total flavins as 15N-labeled spinach soup with a simultaneous
intravenous injection of 200 g 13C-labeled riboflavin.
Test meal and blood sampling protocol
On the morning of the study, a 10-mL baseline blood sample
was taken (0 h) after the subjects had fasted overnight fast and
immediately before riboflavin administration. The intravenous
vitamin was given as a bolus into a forearm vein within 2 min.
This was followed immediately by oral administration of either
the spinach soup or milk. Next, 10-mL blood samples were
withdrawn from a permanent cannula in the opposite arm at 10,
15, 20, 25, 30, 40, 60, and 80 min and thereafter at 2.0, 2.5, 3.0,
3.5, 4.0, 5.0, 6.0, and 7.0 h.
Blood samples were centrifuged immediately at 2000 g for
5 min at 4 °C. Plasma was removed by aspiration and divided into
aliquots for storage at – 80 °C. The remaining cells were washed
with an equal volume of ice-cold 1 mol phosphate-buffered sa-
line/L (pH 7.0) and centrifuged for 5 min at 2000 g at 4 °C. The
supernatant fluid and the buffy coat and cell debris were dis-
carded. A 100-L volume of cells was added to 100 L sterile,
distilled water, and the tubes were mixed briefly to hemolyse
the cells before storage at – 80 °C for the later measurement of
erythrocyte glutathione reductase activation coefficient
(EGRAC). Between the blood samples at 3.0 and 4.0 h, all sub-
jects were given a low-riboflavin lunch consisting of canned
vegetable soup and 2 slices of white, unfortified bread, with a
total riboflavin content of 0.06 mg.
Dose preparation and administration
Synthesizing the 13C-labeled riboflavin
[2,4,6-13C3]Barbituric acid. This was prepared from [13C]urea
and [1,3-13C2]diethyl malonate according to the literature pro-
cedure (13).
[2,4,10a-13C3]Riboflavin and [1',2,2',3',4,4',5',10a-13C8]riboflavin.
These were prepared from the labeled barbituric acid and either
unlabeled ribose or 13C5-ribose according to the following pro-
cedure, which is essentially that previously described in the lit-
erature (14). The identity and purity of the products was initially
determined by absorbance measurements at 267 nm, 373 nm, and
444 nm and the ratios 373/267 and 444/267. Further analysis of
the products by HPLC with fluorescence detection (15) showed
no measurable contaminants.
The purity of the samples was confirmed by thin-layer chro-
matography on silica gel in 2 solvent systems: 1) chloroform:
acetone:concentrated ammonia, 2:2:1, Rf 0.35, and 2) butanol:
ethanol:water, 7:2:1, Rf 0.30. The purity of the synthetic material
was confirmed by the appearance of a single spot with the same
Rf as authentic riboflavin. Electrospray mass spectrometry
showed a major peak for [MNa] in each case at mass-to-
charge ratios (m/z) of 399 (Na adduct of natural abundance ri-
boflavin), 402 (Na adduct of [13C3]riboflavin), and 407 (Na ad-
duct of [13C8]riboflavin), respectively. Channels (m/z) at 400,
401, 403, 404, 405, 406, and 408 were also monitored, and total
peaks were 2% of the major peak. It was concluded that the
doses were98% of the desired isotopomer.
Preparing the intravenous 13C-labeled dose
13C-Labeled riboflavin prepared in phosphate-buffered saline,
pH 7.4, underwent sterility testing with a British Pharmacopoeia
membrane filtration method and was dispensed in 4.0-mL ali-
quots into dark brown glass vials for intravenous injection. All
procedures were carried out by the Pharmacy Department of the
Royal Hallamshire Hospital, Sheffield, United Kingdom.
Preparing the extrinsically labeled 13C milk dose
A total of 12 mg 13C-labeled riboflavin was added to 6 L
semi-skimmed milk. The mixture was stirred magnetically for
1 h at room temperature to ensure thorough homogenization. The
milk was then frozen at20 °C in 200-mL aliquots (equivalent
to 400g 13C-labeled riboflavin). Samples were defrosted over-
night at 4 °C before use. The unlabeled riboflavin content of the
milk was measured as 1.67 g/mL. FAD and FMN constituted
0.40 g/mL (see “Blood sample flavin analysis” below), and
each test meal consisted of 200 mL milk. Each volunteer there-
fore consumed 334 g unlabeled and 400 g labeled riboflavin
from the milk dose.
Preparing the intrinsically labeled 15N spinach dose
Spinach plants were grown hydroponically. Primed seeds
(var: Ballet) were sown in 9-cm pots, 2 to a pot, in a support of
vermiculite and pearlite (50:50) in a greenhouse. Temperature
was partially controlled by automatic ventilation (opening at
18 °C) and by applying a shade coating to the glass (Coolglass;
PBI Agrochemicals, Waltham Abbey, United Kingdom). Ini-
tially, the pots were placed in the hydroponicum, watered with
unlabeled nutrient solution, and covered with a polythene sheet
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until germination. When the plants had obtained 2 leaves, the
weaker plant in each pot was removed. Labeled (15N) nutrient
was then provided by using a nutrient flow technique. Nutrient
solution flowed through the trays from a header tank to a sump
tank and was returned by a pump. Air was bubbled through the
solution in the header tank by an air pump (Fisher Scientific,
Loughborough, United Kingdom).
The crop was harvested after 56 d (more detail of the procedure
can be found in a previous publication; 16), yielding 4.55 kg of
leaf material. The 15N-labeled spinach was washed, dried, mixed,
and frozen at 20 °C for shipment to Sheffield University for
processing into soup within 7 d. After being defrosted, the spin-
ach leaves were finely chopped with a food processor. To make
the soup, 42.5 g fresh clove garlic (crushed) and 850 g finely
chopped white onions were heated in 175 mL olive oil. All of the
chopped spinach was added to this, along with 850 mL recon-
stituted vegetable stock (from powder). The mixture was heated
briefly for 2 min until warmed (approx 60 °C) throughout and
was then divided into 283-g portions and stored at – 20 °C in
sealed containers. Each portion contained 202 g wet weight spin-
ach. Before the day of the study, the spinach soup was defrosted
overnight. A total of 200 mL semi-skimmed milk was added, to
be comparable with that used in the milk dose. This mixture was
heated briefly to serving temperature (85 °C) immediately be-
fore consumption. A portion of soup thus consisted of 200 g raw
spinach cooked and blended with 200 mL milk.
Spinach flavin analysis
Extraction and enzymic deconjugation of riboflavin in spinach
was carried out, followed by determination of flavin content by
HPLC. The detailed procedure can be found in an earlier publi-
cation (16). The riboflavin content was 0.86 g/g raw spinach,
and the FMN content was 0.68 g/g raw spinach. The riboflavin
content of the milk was measured as 1.67 g/mL. Therefore, for
every portion of soup, each volunteer consumed 334 g unlabeled
riboflavin (200 mL of semi-skimmed milk) and 308g 15N-labeled
total flavins (free riboflavin FMN) from the spinach.
Blood sample flavin analysis
Unlabeled
Plasma flavin concentrations. Plasma samples were analyzed
for flavin content (FAD, FMN, and riboflavin) by HPLC by using
a method modified from a previous publication (15). Briefly,
150 L chilled 10% trichloroacetic acid was added to 300 L
plasma or standards. Precipitated protein was removed by cen-
trifugation at 20 780 g for 5 min. A total of 100 L of the
supernatant fluid was injected onto an HPLC column [PLRP-S,
100A, 5 mol/L, 250  4.6 mm (internal diameter); Polymer
Laboratories, United Kingdom] in accordance with the method
described previously (17).
Red blood cell erythrocyte glutathione reductase activation
coefficient. The EGRAC assay was performed on lysed red blood
cells (18) as a measure of functional riboflavin status. The assay
is a measure of the degree of unsaturation of glutathione reduc-
tase with FAD, such that the greater the value for the activation
coefficient, the less the enzyme is saturated with its cofactor FAD
and the poorer the riboflavin status.
Labeled
Samples were prepared for flavin isotope ratio determination
by HPLC/electrospray ionizationmass spectrometry in batches
of one volunteer day. Frozen plasma samples were thawed and
mixed. An amount of 2 mL (or as much as was available, if less
than this) was placed in a centrifuge tube and was mixed by
vortexing while 1 mL (or one-half the plasma volume) of water
was added, followed by 1 mL (or one-half the plasma volume) of
10% trichloroacetic acid solution, and the tube was mixed thor-
oughly to precipitate proteins. Samples were then centrifuged
and the supernatant fluid was placed into 30 mg/1 mL Strata-X
solid-phase extraction cartridges (Strata-X is a surface-modified
styrene divinylbenzene polymer from Phenomenex UK,
Macclesfield, United Kingdom). Columns were first conditioned
with 2 mL methanol and 2 mL water. The supernatant fluid was then
added, and the columns were washed with 2 2-mL water washes
andsuckeddry.Flavinswereelutedwith2500-Lportionsof1:1
methanol:water and were collected directly into an autosampling
vial. The flow rate was regulated at 500 L/min by drawing the
sample through the columns with a peristaltic pump (Watson Mar-
low Bredel, Falmouth, United Kingdom).
HPLC–mass spectrometry
HPLC separation was carried out by using a Jasco 1500 system
(Jasco UK Ltd, Great Dunmow, United Kingdom) according to
a previously published method (19). Briefly, the mobile phase
consisted of 65:35 water:methanol, and an isocratic flow rate of
0.80 mL/min into a 4  250 mm Chromosphere RP18 column
(VWR International Ltd, Lutterworth, United Kingdom) was
maintained at 30 °C. The flow was split post-column in a 5:1 ratio
by using an ASI 600 fixed ratio splitter (Presearch, Hitchin,
United Kingdom), with the higher flow being monitored by a
fluorescence detector (excitation wavelength  450 nm, emis-
sion wavelength510 nm), and the lower flow going to the mass
spectrometer.
Mass spectra were obtained by using a Micromass Quatro II
(Waters/Micromass, Manchester, United Kingdom) in positive
ion electrospray mode with a Z-spray ion source. Selected ion
monitoring liquid chromatograph–mass spectrometry chromato-
grams were recorded by monitoring the sodium adducts of the
riboflavin isotopomers at m/z 399 (M), 400 (M 1), 401 (M
2 – spinach oral dose), 402 (M 3 – milk oral dose), 403 (M
4), and 407 (M 8 – intravenous dose) with a dwell time of 0.1 s
per mass and a cycle time of 0.03 s. Spectra and chromatograms
were processed with MassLynx software [version 3.4; Micro-
mass Ltd (Waters Group), Manchester, United Kingdom].
Urine sample analysis
Unlabeled
Urinary flavins were measured by use of the HPLC method
described for the plasma samples.
Labeled
Frozen urine samples were thawed and shaken. A 1-mL ali-
quot of urine was applied directly to a preconditioned Strata-X
column, and the same procedure as for plasma was followed
throughout.
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Kinetic data analysis
Urinary monitoring
The definition of the true absorption of a nutrient is that frac-
tion of the ingested nutrient that is absorbed across the gastroin-
testinal tract and not eliminated (eg, via the biliary tract) back into
the gastrointestinal tract for removal as part of fecal waste. For
most minerals and vitamins, there is some elimination via the
bile, and therefore a measure of true absorption needs to take
account of this. By giving a simultaneous intravenous label with
an oral label and measuring the dose-corrected ratio of the ap-
pearance of the 2 labels in urine, true absorption can be quanti-
fied. The main assumption behind this is that the 2 labels are
excreted in urine (and via the bile) at the same rate. Therefore,
riboflavin “true” absorption is estimated from the dose-corrected
ratio of labeled riboflavin from the oral label (13C-milk or 15N-
spinach) to that from the intravenous (IV) label that appears in the
urine in the 48 h after dosing.
True absorption (abstrue) ( 
0
t48h
oral label in urine/dose of
oral label) (dose of IV label/ 
0
t48h
IV label in urine) (1)
Compartmental model
Isotopic data from plasma analysis were analyzed by using the
SAAMII program (SAAM Institute Inc, Seattle, WA; 20) and the
compartmental model (Figure 1).
Definitions. The compartments represent discrete amounts of
riboflavin that behave identically. A compartment is a theoretical
construct that may in fact combine material from several differ-
ent physical spaces in a system. A model can be viewed as a
hypothesis to be tested against experimental data, and the struc-
ture of the model is then altered until a satisfactory fit to the data
occurs. The accessible compartment in our system was compart-
ment 1, which represents the plasma. Transfer of riboflavin be-
tween compartments [k(i, j), fraction/time] is defined as the frac-
tion of compartment j moving into compartment i per unit time.
Data fitting. One parameter, the apparent volume of distribu-
tion of the accessible compartment (V) was proportional to the
volunteers’ body weight and held constant during the fitting
process (see below). The other parameters [k(0,1), k(1,2), and
k(2,1)] were given initial estimates consistent with published
data on human riboflavin metabolism. During the fitting process,
the parameters are allowed to vary until a minimum of the ob-
jective function is reached. The software then returns the mean
and SD of the parameters. Only the labeled riboflavin concen-
tration in the plasma was used in the fitting process. The final
model structure was arrived at by a process of trial and error but
with the guiding principle that it must contain the fewest com-
partments to adequately describe the data (Principle of Parsi-
mony). The final model parameters are uniquely identifiable,
which means that they have one solution only.
Modeling the absorptive process.The appearance of ribofla-
vin from the gut into the plasma is assumed to be zero order and
can be modeled as a constant infusion of rate R over time T. The
rate (R) is defined as M/T, where M is the apparent mass of
riboflavin seen in the plasma from the oral dose. The time (T) is
defined as the time to peak riboflavin concentration from the time
that labeled riboflavin first appears in the plasma. The apparent
mass of riboflavin seen in the plasma from the oral dose (M) is
one of the parameters that is estimated in the fitting process and
therefore allows the apparent absorption of the oral dose to be esti-
mated from the plasma data.
Apparent absorption (absapparent)M/dose of oral label
(2)
First-pass effect. This is defined as the fraction of newly
absorbed riboflavin that is removed by the liver on the “first pass”
before it enters the systemic blood system. From Equations 1 and
2, the first-pass effect can be estimated as
First-pass effect 1 (absapparent /abstrue) (3)
Volume of distribution in the compartment (V). The change in
plasma concentration of the riboflavin from the intravenous dose
was fitted to the compartmental model, and all parameters were
TABLE 1
Subject characteristics1
Age Height Weight BMI
y cm kg kg/m2
Mean 36.5 164.2 59.6 22.1
SEM 3.38 1.91 2.00 0.65
Minimum 21 149 47 19.07
Maximum 60 178 74 25.39
1 n 17 subjects for whom data were available for the kinetic analysis.
“True” mass
absorbed
from gut
“Apparent” mass
M appears in
plasma at rate R
in time T
Liver
Riboflavin
concentration, C
Voume of
distribution, V
1 k2,1
k1,2
k0,1
rate constant of elimination to
other tissues or excretion
Liver “first-pass”
effect, where a
large fraction of
riboflavin is
removed
2
FIGURE 1. Circles represent compartments, and arrows represent transfer of riboflavin from one compartment to another or out of the system. Compartment
1 was the accessible (sampled) compartment and is associated with the volume of distribution (V).
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allowed to vary freely. By pooling the estimates from all the volun-
teers, the volume of distribution in the accessible compartment (V)
was calculated to be 549 284 mL/kg body wt.
Statistics
Statistical analysis was performed by using the statistical
package R (21). Analysis of variance (ANOVA) models in con-
junction with Tukey’s highly significant difference post hoc test
were used to analyze the data. Initial models were set up to
include the potential explanatory variables and all possible two-
way interactions; backwards elimination was then used to reduce
the model to one consisting only of terms with a significant effect
on the response. Model diagnostics were checked and, if neces-
sary, remedial action was taken (outlier exclusion, data transfor-
mation, or nonparametric modeling). Repeated-measures models
were also tried. These were primarily so that the interaction between
food and visit could be examined. When the interaction was not
present, the repeated-measures models are similar to the ANOVA
model and so usually only the ANOVA model is presented.
All data in the text are presented as means SDs. Data points
in figures are meansSEMs unless stated otherwise in the figure
caption. Differences were considered significant at P 0.05.
RESULTS
The 20 subjects recruited were between 21 and 60 y of age.
Descriptive data for the 17 subjects whose data were included in
the analyses are shown in Table 1. Riboflavin status measure-
ments at baseline for volunteers at each of the 2 occasions are
shown in Table 2. Mean EGRAC values were significantly
higher (P  0.05) at visit 2, and plasma FAD values were sig-
nificantly lower, which suggests a moderate decline in riboflavin
status over the 4-wk study even though the subjects received the
test meals in random order and the samples were analyzed ran-
domly. Nevertheless, median EGRAC values at both visits were
close to those reported in the recent National Diet and Nutrition
Survey of UK adults, which suggests that this cohort was repre-
sentative of the population with respect to riboflavin status.
The variation in urinary excretion of total (labeled  unla-
beled) flavins is shown in Table 3. There was no significant
difference for any flavin within or between test meals across the
time periods. In our analyses,70% of total excretion was made
up of free riboflavin, with the remainder being mostly FAD.
The volunteers excreted 30  1.59 g (n  32, data not
tabulated) of the labeled riboflavin from the intravenous dose in
the urine in the first 24 h, which constituted 15% of the original
200-g dose. No trace of labeled riboflavin from the intravenous
dose was found in urine after 24 h. The excretion of labeled
riboflavin from the spinach was 3214 g (10.4%; n  14) and
that from milk was 38  4.90 g (9.5%; n  15) over the 48 h
after dosing. Most (75%) was excreted in the first 24-h period.
The total (labeled  unlabeled) plasma concentrations of
FMN, FAD, and riboflavin are shown in Figure 2. The riboflavin
concentration increased markedly after both milk and spinach
test meals, and the peak plasma concentration occurred at 42
min after the spinach dose and 30 min after the milk dose.
Neither the milk nor the spinach test meal elicited a clear re-
sponse in plasma concentration of FAD or FMN. The small
fluctuations in concentrations of these metabolites over the 420
min after the test meals are also shown in Figure 2.
Absorption and kinetic parameters are shown in Table 4.
There was no significant difference in riboflavin true absorption
(P 0.549) between the spinach meal (60 8.0%) and the milk
meal (675.4%) according to the urinary monitoring technique.
The modeled plasma data also indicated that there was no sig-
nificant difference in riboflavin apparent absorption (P 0.670)
TABLE 2
Biomarkers of riboflavin status (plasma flavin concentrations) at baseline1
Visit 1
(n 17)
Visit 2
(n 17)
EGRAC Riboflavin FAD FMN EGRAC Riboflavin FAD FMN
nmol/L nmol/L
Mean 1.36 10.51 45.59 3.04 1.482 8.90 39.662 3.602
SEM 0.04 1.42 1.78 0.32 0.05 0.99 1.44 0.35
Minimum 1.17 3.73 35.65 0.87 1.03 3.53 32.55 2.30
Maximum 1.59 22.92 60.71 7.08 1.91 18.64 48.81 8.53
1 EGRAC, erythrocyte glutathione reductase activation coefficient.
2 Significantly different from visit 1, P 0.05 (ANOVA).
TABLE 3
Total (labeled unlabeled) flavins in urine1
Test
meal
FAD
(n 17)
FMN
(n 17)
Riboflavin
(n 17)
24 h 0–24 h 24–48 h 24 h 0–24 h 24–48 h 24 h 0–24 h 24–48 h
g g g
Milk 334 29.37 381 40.78 366 37.38 14 1.21 17 2.18 18 3.15 749 182 1019 183 944 192
Spinach 373 35.7 371 31.6 365 26.9 15 1.7 18 1.9 17 4.6 870 185 989 153 760 145
1 All values are x SEM. No significant differences in flavins were found at any time point for any test meal (ANOVA).
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between the spinach meal (20 2.8%) and the milk meal (23
5.3%). The peak concentration of labeled riboflavin in the plasma
(Cmax) was not significantly different (P 0.536) after the milk
(1.5  0.2 ng/mL) and spinach (1.3  0.2 ng/mL) meals.
Furthermore, there was no significant difference (P0.497; data
not tabulated) in the fraction (first-pass effect) of newly absorbed
riboflavin from the milk meal (0.66 0.06) or the spinach meal
(0.57  0.08) that was removed by the liver on the first pass
before entering the systemic blood system. The time to maximum
plasma concentration (Tmax) was significantly longer (P 
0.026) after the spinach meal (34 2.3 min) than after the milk
(24  2.5 min), but there was no significant difference (P 
0.435) in the time taken (delay) for labeled riboflavin to first
appear in the plasma (spinach: 111.3 min; milk: 101.3 min).
The predicted plasma riboflavin concentrations with use of the
2-compartment model are shown in Figure 3 for the intravenous
data. There was a rapid decline in riboflavin concentration from
the intravenous dose over the first 20 min, and after 3 h the label
was barely measurable. Rate constants from the 2-compartment
model (data not tabulated) were k(0,1): 234.7 71.4 d1; k(1,2):
54.5 8.6 d1; and k(2,1): 102.4 17.3 d1.
The predicted plasma riboflavin concentrations from the
2-compartment model are shown in Figure 4 for the test meal
data. Rate constants from the 2-compartment model differed
between test meals (spinach versus milk) as k(0,1): 18.5  3.6
compared with 36.7 8.4 d1 (P 0.076); k(1,2): 40.7 22.9
compared with 25.3 8.4 d1 (P 0.959); and k(2,1): 20.0
5.4 compared with 55.3 14.3 d1 (P 0.041). The volume of
distribution (V) of riboflavin in the sampled (plasma) compart-
ment was estimated to be 549  71 mL/kg body wt, which is
equivalent to35 L for a subject with a body mass 64 kg.
DISCUSSION
The kinetics of riboflavin have been investigated before, but
the present study is unique for several reasons. This was the first
study to use stable-isotope labels, which allows small, physio-
logic doses to be administered. A recently published study used
very high, nonphysiologic doses of riboflavin, up to 60 times
what is usually found in meals (8). The use of unlabeled ribofla-
vin necessitated correction for baseline plasma and urinary ribo-
flavin, which introduces uncertainty, especially because ribofla-
vin is prone to changes in plasma concentration as the result of
circadian rhythms. The use of foods is also unique, and the
labeling of the spinach and milk meant that the labeled riboflavin
from these meals would be handled identically to the unlabeled
vitamin. This is important when it comes to interpreting the
results and extrapolating them to other foodstuffs.
Milk represents an important source of riboflavin in Western
diets. In the United Kingdom, for example, milk and milk prod-
ucts are estimated to provide about one-third of the dietary ribo-
flavin in the adult population (1, 2). Because the riboflavin in
milk is present predominantly in the free form, it could be as-
sumed that riboflavin in milk would be highly bioavailable. The
results from this study suggest that riboflavin from spinach is
absorbed to the same extent, and this could have important im-
plications for public health messages for good sources of ribo-
flavin in the diet. The urinary monitoring technique is a gold
standard method in mineral research for measuring bioavailabil-
ity (22) and gives an estimate of so-called true absorption (see Eq
1). The method works from the premise that the route of admin-
istration of riboflavin (oral or intravenous) is immaterial because
the body does not discriminate between riboflavin administered
by either route, in terms of excretion via the urine, as long as there
are no differences in the chemical form in which the vitamin is
transported in the plasma. This is generally true for most
FIGURE 2. The mean (SEM) change (n 17) in plasma concentration
of total (labeled unlabeled) riboflavin, FMN, and FAD after the milk (Œ)
and spinach () test meals. The lines between the data points are interpola-
tions and are shown to aid in interpretation.
1562 DAINTY ET AL
 at TO
C Library on June 8, 2007 
w
w
w
.ajcn.org
D
ow
nloaded from
 
PAPER 12
minerals, but some evidence suggests that more care is needed for
certain vitamins. For example, the form of folate that appears in
the plasma after an oral dose is 5-methyltetrahydrofolate and not
folic acid, which is the form that was used as the intravenous dose
in some previous studies (23, 24). We were careful to ensure that
our intravenous dose contained only free riboflavin, because this
is the predominant form that appears in the plasma from an oral
dose immediately after absorption (8). This was also confirmed
in our study from inspection of the change in concentration of
total riboflavin, FMN, and FAD in Figure 2 and the lack of any
labeled FMN and FAD in the plasma after the milk and spinach test
meals (data not shown). In this study, most of the flavins excreted in
the urine occurred as riboflavin, the remainder being mainly FAD.
Other flavin metabolites have been characterized in urine, and var-
ious estimates have been made of the contribution they make to
urinary flavins (25, 26), but uncertainty still exists as to the relative
concentrations of such metabolites that are not of microbial origin,
especially under conditions of physiologic intakes of riboflavin.
The apparent riboflavin absorption was estimated from the
plasma appearance of the oral dose by using the model shown in
Figure 1 and Eq 2. The principles behind this approach are similar
to previous work in folate (10, 11, 27) and iron (28, 29) modeling.
The apparent absorption of the riboflavin test doses is lower than
the true absorption estimated by the urinary monitoring method
and the reasons for this will be discussed later. The apparent
absorption of riboflavin from spinach and milk is not statistically
different, which supports the conclusions drawn from the urinary
monitoring method.
Only some of the absorbed riboflavin appears in the plasma,
and it is likely that the remainder is sequestered by the liver on the
first pass through the portal vein from the gut (see Eq 3). This
first-pass effect has also been seen in human studies of folate
(11), vitamin C (30), and vitamin B-6 (31) and in an animal study
of biotin (32). This suggests that it is a common feature of water-
soluble vitamins and plays some important role in homeostasis
and metabolism. Interestingly, the folate and vitamin C articles
(11, 30) also reported a large release of unlabeled folate and
vitamin C (respectively) into the plasma after a labeled test dose.
This has implications for those studies that try to interpret the
plasma response from large unlabeled doses of water-soluble
vitamins to make predictions about absorption. Our study design
does not allow us to test whether riboflavin follows the same
pattern, but because we are quantifying absorption by using la-
beled test doses, it does not detract from our conclusions.
The delay in first appearance in plasma was not significantly
different between the milk (10 1.3 min) and the spinach (11
1.3 min), but the time to peak plasma concentration was different,
with the riboflavin from the milk peaking earlier (24 12.5 min)
than that from the spinach (35 12.3 min). This was despite the
fact that more riboflavin from the milk (93 21 mg) than from
the spinach (63  8.5 mg) entered the plasma pool. The impli-
cation from this is that the riboflavin from the milk was absorbed
faster across the gut wall than that from the spinach, but this was
FIGURE 4. The mean change in plasma concentration of labeled ribo-
flavin after the milk (n  16) and the spinach (n  15) test meals. The line
represents the model fit.
TABLE 4
Kinetic parameters of interest derived from the analysis of the labeled riboflavin data1
Test meal Cmax Tmax Delay k(0,1) k(1,2) k(2,1)
Apparent
absorption
True
absorption
ng/mL min min d1 d1 d1 % %
Milk 1.5 0.2 [16] 24 2.5 [16] 10 1.3 [16] 36.7 8.4 [16] 25.3 8.4 [16] 55.3 14.3 [16] 23 5.3 [16] 67 5.4 [15]
Spinach 1.3 0.2 [15] 34 2.32 [15] 11 1.3 [15] 18.5 3.6 [15] 40.7 22.9 [15] 20.0 5.42 [15] 20 2.8 [15] 60 8.0 [14]
1 All values are x SEM; n in brackets. Cmax is the peak plasma concentration of labeled riboflavin after dosing; Tmax is the time to maximum plasma
concentration after dosing; delay is the time taken for labeled riboflavin to first appear in the plasma after dosing; rate constants [k(0,1), k(1,2), and k(2,1)] are
defined in Figure 1 and in the “Kinetic data analysis” section of Subjects and Methods; apparent absorption was calculated by fitting the change in plasma
concentration of labeled riboflavin to the 2-compartment model shown in Figure 1 (see Eq 2); true absorption was calculated from the urinary recovery of labeled
oral and intravenous riboflavin collected 48 h after dosing (see Eq 1).
2 Significantly different from the milk dose, P 0.05 (ANOVA).
FIGURE 3. The mean (SEM) change in plasma concentration of labeled
riboflavin after the intravenous (IV) bolus. The line represents the model fit.
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unlikely to have been due to the more complicated food matrix
present in the soup because it was thoroughly homogenized and
of the same consistency as the milk. Instead, the greater delay in
peak time was likely due to the need for the gut wall to convert the
large fraction of FMN in the spinach into free riboflavin for
transport in the plasma.
Although it is unlikely that the conversion of spinach FMN to
riboflavin happened in any place other than the gut wall, it is
possible that some conversion occurs in the liver. Differences in
rate constants between the milk and spinach data indicate that
riboflavin from milk and spinach are handled differently after
being absorbed. This could just be due to the time delay in
conversion at the gut wall, but it is impossible to be certain
without taking blood samples from the hepatic portal vein shortly
after consumption of the test doses. However, the first-pass ef-
fects were no different after the spinach and milk meals, which
indicates that the liver receives the same form of riboflavin after
each meal, thereby providing further support for the gut wall
being the major site of FMN conversion to riboflavin.
Thus, the results of the present study suggest that an average of
60–65% of flavins are absorbed from milk or spinach, that no
significant differences exists in the handling of flavins from
either of these food sources, and that because of an evident first-pass
effect in the liver, the plasma appearance method is an inappropriate
tool for estimating thebioavailabilityof riboflavin.Estimatesof true
absorption suggested that some individuals may be poor absorbers,
but generally absorption was good and it is unlikely that an overes-
timation of the bioavailability of riboflavin explains the apparently
lower prevalence of riboflavin deficiency when estimated from di-
etary intakes than by biochemical status indexes. It is more likely
that the biochemical threshold for deficiency has been set too low
and needs to be reevaluated.
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Review Article
Folic acid metabolism in human subjects revisited: potential implications
for proposed mandatory folic acid fortification in the UK
Anthony J. A. Wright*, Jack R. Dainty and Paul M. Finglas
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Following an introduction of the importance of folates and the rationale for seeking to estimate fractional folate absorption from foods (especially
for countries not having a mandatory folic acid fortification policy), scientific papers covering the mechanisms of folate absorption and initial
biotransformation are discussed. There appears (post-1983) to be a consensus that physiological doses of folic acid undergo biotransformation
in the absorptive cells of the upper small intestine to 5-methyltetrahydrofolic acid (as happens for all naturally-occurring reduced 1-carbon-sub-
stituted folates). This ‘validates’ short-term experimental protocols assessing ‘relative’ folate absorption in human subjects that use folic acid as the
‘reference’ dose. The underlying scientific premise on which this consensus is based is challenged on three grounds: (i) the apparent absence of a
5-methyltetrahydrofolic acid response in the human hepatic portal vein following absorption of folic acid, (ii) the low dihydrofolate reductase
activity peculiar to man and (iii) the implications derived from recent stable-isotope studies of folate absorption. It is concluded that the historically
accepted case for folic acid being a suitable ‘reference folate’ for studies of the ‘relative absorption’ of reduced folates in human subjects is invalid.
It is hypothesised that the liver, and not the absorptive cells of the upper small intestine, is the initial site of folic acid metabolism in man and that
this may have important implications for its use as a supplement or fortificant since human liver’s low capacity for reduction may eventually give
rise to saturation, resulting in significant (and potentially deleterious) unmetabolised folic acid entering the systemic circulation.
Pteroylmonoglutamic acid: Folic acid: Folate: Absorption: Metabolism: Human subjects: Supplementation: Fortification
Introduction
Folic acid (pteroylmonoglutamic acid), though occurring
rarely in nature, is the most oxidised and stable form of a vita-
min used extensively for supplements and food fortification
purposes. Folate is a generic term for the related family of
water-soluble B-group vitamins found widely in foodstuffs,
mainly reduced methyl and formyl folylpolyglutamates1, that
have similar nutritional properties and chemical structures to
those of folic acid2,3. Reduced tetrahydrofolates, carrying 1-
carbon substitutions at positions 5 and/or 10, are crucial for
methionine and nucleotide biosynthesis4,5. A significant
reduction in the incidence and recurrence of neural tube
defects, such as spina bifida, has been shown when women
undertake periconceptual supplementation with folic acid6,7.
Low folate status is associated with elevated plasma homocys-
teine, a risk factor for CVD and stroke8,9, and has been linked
to dementia and Alzheimer’s disease10. Low folate status is
additionally associated with altered methylation of DNA
that may affect gene expression and uracil induced genomic
instability, both of which may increase cancer risk11,12.
Fortification of food with physiological levels of folic acid
may be expected to reduce the prevalence of folate-related dis-
eases. Some countries have mandatory folic acid fortification
of flour programmes (USA 1·4mg/kg from 1998; Canada
1·5mg/kg from 1998; Chile 2·2mg/kg from 2000), but many
European countries do not permit the fortification of food-
stuffs with folic acid at all. Only a thorough knowledge of
the fractional absorption of folate from a variety of folate sup-
plements, fortified foods and natural food folates would allow
us to answer the question of whether optimal folate status is
easily achievable in countries that do not have a mandatory
folic acid fortification policy. An international workshop con-
cluded that the absorption of different folate vitamers from
foods and isolates is not well understood13.
Mechanism of folate absorption
In human subjects, dietary folate polyglutamates are de-
conjugated at the mucosal epithelial cell brush border by folyl-
poly-glutamate carboxypeptidase (EC 3.4.17.21) to the
corresponding monoglutamate forms14. Folic acid and reduced
monoglutamyl folates are absorbed mainly in the proximal
*Corresponding author: Mr A. J. A. Wright, fax þ44 1603 507723, email tony.wright@bbsrc.ac.uk
Abbreviations: AUC, area under the curve; DHF, dihydrofolic acid; DHFR, dihydrofolic acid reductase.
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small intestine (jejunum) by a saturable, carrier-mediated, pH
and energy-dependent transport mechanism which, unlike
other epithelial tissues, appears to be unique in its lack of hier-
archy of transport, having a similar affinity for both oxidised
(e.g. folic acid) and reduced folate forms15,16. Oral doses of
folic acid in excess of about 260–280mg (589–634 nmol)
have been reported to lead to the direct appearance of untrans-
formed folic acid in the systemic circulation of man17.
This indicates a saturation point, is evidence that intestinal
conversion is not a prerequisite for transport, and is arguably
indicative of the dividing line between physiological and non-
physiological oral doses of folate. Absorbed folate, which may
undergo biotransformation in the absorptive mucosa (see next
section), is subsequently transferred via the mesenteric veins
to the hepatic portal vein and carried to the liver where an
extensive amount (liver ‘first-pass’) is removed18,19. The
liver has a high affinity for the removal of folic acid20, but a
lower one for the removal of 5-methyltetrahydrofolic acid
which allows a reasonable fraction of this folate form to pro-
ceed uninterrupted into the systemic circulation where it
usually appears, under fasting conditions, as the predominant
plasma folate form for passage to tissues. Folates removed
by the liver, some of which may have undergone further bio-
transformation, are partially released into the bile allowing
significant re-absorption of folate from the small intestine
and subsequent delivery of 5-methylterahydrofolic acid, via
systemic circulating plasma, to tissues21. This process of
‘enterohepatic recirculation’ is responsible for maintaining
baseline plasma folate levels20. Physiological doses of pure
folate compounds seem to be well absorbed ($90%) in
both man22,23 and rats24.
Site of biotransformation of newly absorbed folates, and
folate transport into the hepatic portal vein
A high-quality study, with catheterisation of the hepatic portal
vein of three human adult volunteer patients, indicated that the
absorptive mucosa simply rearranges the 1-carbon substitution
of physiological doses of 5-formyltetrahydrofolic acid to
5-methyltetrahydrofolic acid before transport to the serosal
side25, and transports 5-methyltetrahydrofolic acid unchanged.
Using everted sacs of rat small intestine, one group
reported no reduction (potentially via dihydrofolate reductase
to H2-folic acid and then to H4-folic acid) and subsequent
methylation of physiological doses of folic acid to 5-methylte-
trahydrofolic acid26. In contrast, others not only reported sig-
nificant degrees of mucosal bioconversion but also reported
concurrently that folic acid above the physiological range
was passively transported, appearing in circulating plasma in
an untransformed state (i.e. that the mechanism of absorption
was ‘saturable’)15,27,28. An explanation for the inability of
some investigators to demonstrate the intestinal conversion
of folic acid to 5-methyltetrahydrofolic in an alkaline
medium was given by Strum15. He suggested that this may
reflect that the enzyme dihydrofolic acid reductase (DHFR)
has an acidic pH optimum for reducing folic acid to H2-
folic acid (in contrast to the much wider acid-to-slightly-alka-
line pH range for the reduction of H2-folic acid to H4-folic
acid) and that whilst the intestinal conversion of folic acid
to 5-methyltetrahydrofolic acid is extensive at pH 6·0 it is neg-
ligible at pH 7·5. Any previous argument and doubts over the
degree to which physiological doses of folic acid could be
reduced and methylated in mucosal epithelial cells appeared
to be mitigated following publication of the high quality
study of Tani & Iwai29. These authors reported on their
in situ investigation of absorption and conversion of folic
acid in the small intestine of the rat in vivo, with mesenteric
vein sampling after jejunal loops were injected directly with
a solution of [3H]folic acid, and HPLC investigation of
[3H]compounds being transferred into the portal blood. They
argued compellingly that their in vivo technique was much
more useful for studying intestinal functions because more
physiological conditions were maintained compared to other
techniques in vitro. They also commented that the correct
ratio of conversion of folic acid was not reported in previous
papers since, for low concentrations of [3H]folic acid injected
into jejunal loops, as high as about 90% of [3H]compounds
that they identified unequivocally by HPLC in portal blood
was [3H]5-methyltetrahydrofolic acid.
The paper of Tani & Iwai29 appeared to be a watershed.
Whilst pre-1983 there was already a reasonable degree of
agreement that a significant portion of physiological doses
of folic acid would undergo conversion to reduced forms in
the intestine30, it was being accepted post-1983 as the norm,
with any lingering doubts muted. In particular, specifically
those doubts generated some years earlier by the reported
appearance of high concentrations of untransformed folic
acid in the hepatic portal vein of human subjects following
oral administration of doses of folic acid that were, arguably,
non-physiological31,32. This watershed was reflected in the
consensus of subsequent scientific ‘Review Articles’ which
invariably either overtly stated or implied that when the muco-
sal extracellular folic acid concentration is low (physiological)
the small intestine efficiently reduces and methylates folic acid
and, as with absorbed naturally-occurring reduced and
1-carbon-substituted folates, subsequently transfers essentially
only 5-methyltetrahydrofolic acid to the hepatic portal
vein16,21,33,34. Thus, from 1983, short-term experimental pro-
tocols assessing ‘relative’ folate absorption in human subjects,
which centred on methods comparing the serum/plasma
response to a single oral test-dose relative to that of an
equal ‘reference’ dose of folic acid, appeared to have been
‘validated’ since all consumed folates would broadly enter
the hepatic portal vein as 5-methyltetrahydrofolic acid.
Short-term protocols for the estimation of ‘relative’ folate
absorption
Short-term experimental protocols, which do not allow assess-
ment of slow-turnover folate pools in the body, are specifically
designed to elicit an understanding of the kinetics of initial
absorption, metabolism and transport of absorbed folates.
They cannot predict whole-body folate turnover33. A short-
term protocol involves monitoring the appearance and sub-
sequent clearance of the 5-methyltetrahydrofolic acid response
in the fast-turnover plasma pool arising from absorbed and
biotransformed oral test folates. However, since there is exten-
sive but unquantified removal of newly absorbed folate from
the hepatic portal vein (liver ‘first-pass’), ‘absolute absorption’
cannot be estimated from plasma response18,19. Instead, in an
attempt to circumvent this problem, these protocols estimate
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‘relative absorption’ comparative to a similar ‘reference’ dose
of folic acid.
Work with radiolabelled folates has been confined mainly
to animal models (usually the rat) that may not be comparable
to human subjects. Application of pioneering work with
stable-isotope folates in human subjects has generally lacked
analytical sensitivity when used in single-dose protocols,
especially when administered in the physiological range33.
To date, the vast majority of short-term protocols attempting
to assess ‘relative’ folate absorption in human subjects have
centred on methods comparing the serum/plasma response to
a single unlabelled oral test-dose relative to that of an equal
unlabelled ‘reference’ dose of folic acid19,35. This may entail
either measurement of the rate of increase, or the maximum
increase, in plasma folate concentration over 2–3 h17,36–40,
or measurement of the dose-normalised rise in plasma folate
concentration AUC (the area under the curve of the increase
in plasma 5-methyltetrahydrofolic acid concentration above
fasting baseline level) over 6 h or more 41–47. Short-term
protocols using unlabelled test folates have not just been
confined to the field of nutrition and have also been used in
pharmacokinetic studies48.
Comparison of the dose-normalised AUC between test
(food folate or isolate) and ‘reference’ folic acid has been
accepted as a valuable indicator of absorption, provided the
post-dosing plasma measurement test period is long enough
to capture $80% of the whole AUC49. However, it is depen-
dent on the premise that the initial absorption and metabolism
of folic acid satisfies the following four conditions: Con-
dition-1, that physiological doses of folic acid are absorbed
by the same mechanism as reduced folates, and with a similar
affinity;
Condition-2, that physiological doses of folic acid are
initially reduced and then methylated in the epithelial cells
of the small intestine and that essentially only 5-methyltetra-
hydrofolic acid is exported from the mucosa to the hepatic
portal vein, as is the case for absorbed physiological doses
of all naturally-occurring reduced folates; Condition-3, that
the kinetics of plasma 5-methyltetrahydrofolic acid response
to folic acid is similar, if not equal, to that elicited for reduced
1-carbon-substituted naturally-occurring folates; Condition-4,
that plasma 5-methyltetrahydrofolic acid response derives
entirely from (biotransformed) newly absorbed folate.
Until recently, no systematic difference had been reported
in the kinetics of plasma 5-methyltetrahydrofolic acid
response to physiological concentrations of test folates and
folic acid. However, new findings have recently shown that
much of the plasma AUC response to oral folate doses is
induced by, but is not actually derived from, the dose
itself50. This phenomenon was reported later to also affect
plasma vitamin C response to test doses of vitamin C51,52.
This raises the interesting question of whether this phenom-
enon will also be found to affect the plasma response to oral
test doses of many other water-soluble vitamins. We inter-
preted our reported large, variable and unpredictable displace-
ment of tissue 5-methyltetrahydrofolic acid into the plasma
pool as contrary to Condition-4 above, thus making compari-
son of the relative absorption of folate from an unlabelled
test dose (food or supplement) to an unlabelled folic
acid ‘reference’ dose unusable50. Concurrent examination
of the plasma 13C-labelled 5-methyltetrahydrofolic acid
response to 13C-labelled (6S)-5-formyltetrahydrofolic acid
and 13C-labelled folic acid also unmasked an underlying
serious discrepancy in plasma responses to these two folates
50. This was possibly due to a limitation in the rate of initial
mucosal reduction of folic acid to H2-folic acid, prior to
further reduction to H4-folic acid and subsequent methylation,
which may result in a slower transport of absorbed folate to
the serosal side53. This is in complete contrast to Condition-
3 above and thus renders direct estimates of ‘relative absorp-
tion’ using even labelled-AUC, which are derived definitively
from the oral test-doses, invalid.
To overcome this, the application of suitable mathematical
modelling54,55, which makes complete allowance for any differ-
ences in the kinetics of plasma labelled 5-methyltetrahydrofolic
acid response, can be used to estimate ‘apparent absorption’.
Apart from unlabelled 5-methyltetrahydrofolic acid (the lone
folate form we detected in the baseline fasted plasma samples
of our unfortified and unsupplemented volunteers), it is import-
ant to note that the only enriched folates appearing in plasma
after ingestion of physiological doses of labelled 13C6 or
15N(1–7) folates were
13C6 or
15N(1–7) 5-methyltetrahydrofolic
acid. This was confirmed by liquid chromatography–MS selec-
tive ionmonitoring for folatemonoglutamate forms on the nega-
tive [M-H]2 ion folate masses: fromm/z 440 (folic acid,M þ 0;
having the smallest folate monoglutamate mass) to m/z 479
(5-formyltetrahydrofolic acid, M þ 7; having the largest folate
monoglutamate mass)50,55.
Absorption and site of initial metabolism of folic acid in
human subjects
The underlying scientific basis on which the post-1983 con-
sensus is based (that physiological doses of folic acid undergo
biotransformation to 5-methyltetrahydrofolic acid in the
absorptive mucosal cells of the small intestine) is now chal-
lenged on three grounds: the apparent absence of a plasma
5-methyltetrahydrofolic acid response in blood sampled
directly from the human hepatic portal vein following the
mucosal absorption of folic acid; the evidence of an extremely
low dihydrofolate reductase activity that seems peculiar to
man; the implications derived from mathematical modelling
of plasma labelled 5-methyltetrahydrofolic acid responses in
human subjects to oral physiological doses of isotopically-
labelled folates.
Absence of a 5-methyltetrahydrofolic acid response in the
hepatic portal veins of human subjects following an oral dose
of folic acid
Whitehead & Cooper31, who gave an oral dose of 1000mg
(2266 nmol) folic acid, and Meilikian et al.32, who gave a
lower oral dose of 500mg (1132 nmol) folic acid, both
reported that human subjects transport folic acid unaltered
into the hepatic portal vein. Both groups took blood samples
from the hepatic portal vein, the hepatic vein and the sys-
temic blood system for at least 2 h post-dosing. They con-
cluded that folic acid was absorbed unaltered and removed
by the liver which they proposed as the initial site of sub-
sequent reduction and methylation. Critics would point to a
number of perceived problems with this work: (i) the dose
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of folic acid used was non-physiological; (ii) the studies
were carried out in patients with either liver disease (cirrho-
sis) or cancer; (iii) analysis of folate concentrations were
undertaken by differential microbiological assay (L. casei
and S. faecalis) in order to distinguish non-methyl folate
from total folate. Nevertheless, it cannot be overemphasised
that it is not the presence of copious amounts of untrans-
formed folic acid in the hepatic portal vein that is note-
worthy, since that would be an inevitable consequence of
using a non-physiological dose. On the contrary, it is the
almost complete absence of an assayable 5-methyltetrahydro-
folic acid response in the hepatic portal vein that is remark-
able, particularly when a dose of 500mg (1132 nmol) was
used32. This is only twice the dose of 260–280mg
(589–634 nmol) reported much later to be the threshold at
which folic acid may even start to appear in the plasma17.
Hence, at the very least, one may have expected at least
half of the dose used by Melikian et al.32 to have appeared
as 5-methyltetrahydrofolic acid.
Heterogeneity in the dihydrofolate reductase activity between
animals and human subjects
Though initial work with crude enzyme preparations of
DHFR had taken place earlier, it was perhaps the work of
Zakrzewski & Nichol with highly purified chicken liver
DHFR that first provided evidence for a single enzyme redu-
cing folic acid and dihydrofolic acid (DHF; H2-folic acid)
56.
These authors reported that this enzyme reduced folic acid
significantly slower than DHF with a more acidic optimum
pH (4·4–4·8 v. 5·2–5·6, respectively), and that there was
unmeasurable activity above pH 7·0 for folic acid but still
reasonable activity for DHF. These conclusions, which indi-
cate the initial reduction of folic acid to DHF to be the rate
limiting step in the biotranformation of folic acid, were con-
firmed by Mathews & Huennekens53. Human placental
DHFR also showed two pH optima (with unmeasurable
activity for folic acid above pH 7·0) with the activity for
reducing folic acid seventy-five times lower than DHF at
pH 6·257. Nylen et al.58 reported a distinct lack of dihydro-
folate reductase activity in human biopsy and autopsy
samples compared to cultured cells. Kamen et al.59 noted
dihydrofolate reductase activity in normal human tissue and
human tumour and leukaemia cells in vivo that was sev-
eral-hundred times lower than present in human cell lines
grown in vitro, or normal animal liver tissue. One hypothesis
put forward for the discrepancy was that the higher level of
DHFR activity with in vitro cell lines could be due to the
high levels of folic acid used historically in culture
medium. The apparent heterogeneity in the dihydrofolate
reductase activity between animals and human subjects was
confirmed in a later paper which concluded that low levels
of DHFR activity are a feature peculiar to man, shared in
part only by closely related primates (the great apes),
which distinguishes him from most animals and birds60.
The implications of these differences, particularly between
rat (the historical experimental animal model used in
formulating most of the current understanding of folate-
monoglutamate absorption and initial metabolism) and man,
have perhaps not been fully appreciated. In comparison to
5-formyltetrahydrofolic acid, the lower effectiveness of
folic acid to correct deoxyuridine suppression in megaloblas-
tic marrows (a consequence of folate deficiency) was partly
attributed to a delay in reduction of folic acid to tetrahydro-
folic acid inside cells61. Modern HPLC analytical techniques,
capable of accurately measuring DHFR in crude extracts,
have indicated that DHFR activity in human liver is about
seventy times or more lower than in rat liver62,63. Of
course a simple comparison of enzyme activity ex vivo
does not necessarily reflect quantitative differences in the
ability to metabolise folic acid, particularly since enzyme
activity is pH-dependent and may be compartmentalised
within the cell. However, the fact that the clearance of
unmetabolised folic acid from the human systemic circula-
tory system was noted by these authors to be quite slow,
and that 78% of 105 American postmenopausal women
have been observed to have measurable concentrations of
unmetabolised folic acid in samples of their fasting
plasma64, strongly suggests that DHFR activity in the
human mucosa, as well as the liver, must also be quite
low. Our reasoning is as follows. A portion of the human
systemic blood flow is continuously diverted via the splenic
and mesenteric arteries where it eventually arrives at the
hepatic portal vein (formed from the superior mesenteric
and splenic veins) thus allowing the potential for clearance
(and subsequent reduction and then methylation) of any sys-
temically circulating folic acid by the human liver, which we
now know to have a limited DHFR capacity. When systemi-
cally circulating folic acid is presented to the human liver
some of it can reappear in bile as unchanged folic acid65.
The process of enterohepatic re-circulation will allow for
the significant re-absorption of biliary folic acid from the
small intestine20,21; a recent multi-compartment kinetic
model indicating a 24-fold higher flux of bile folate than
that previously thought66. Though human liver is known to
have a limited DHFR capacity in comparison to the rat, it
cannot be argued that it is still theoretically possible for
human subjects to have a good mucosal DHFR activity
because enterohepatic re-circulation works in tandem with
continuous partial systemic blood flow via the hepatic
portal vein through the liver. If mucosal DHFR activity in
human subjects was much better than that seen in human
liver, then the clearance of excess folic acid from the sys-
temic system would not be observed to be quite slow, as it
could then be processed alternatively by the mucosal cells
of the upper small intestine. The overall implication is
that, in comparison to the rat, man is not likely to have
the capacity to significantly reduce folic acid in the absorp-
tive mucosa. Thus, most of a physiological dose of folic acid
may inevitably be transported by the absorptive mucosa into
the hepatic portal vein in an untransformed state to be
sequentially removed by the liver for processing (with a
much higher affinity than the 5-methyltetrahydrofolic acid
usually presented20. This would result in a delayed release
(via entero-hepatic re-circulation) into the systemic blood
system of 5-methyltetrahydrofolic acid, its biotransformed
metabolite31. A delayed plasma response to folic acid com-
pared to a reduced folate was confirmed by the use of isoto-
pically labelled folates50, though whether this was due to a
delay in mucosal or liver biotransformation could not be
concluded.
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Mathematical modelling of plasma labelled 5-
methyltetrahydrofolic acid responses to oral physiological
doses of isotopically-labelled folates
The advent of stable-isotope-labelled folates allows folate
absorption to be tracked not only with sensitivity but, more
importantly, with specificity. This way, folate can be followed
and differentiated from the natural store of folate already pre-
sent in the body. The recent use of mathematical modelling55,
which bypasses the need for adherence to Condition-3 because
it completely takes into account differences in the kinetics of
plasma response, infers that sequestration of physiological
doses of folic acid to the liver is the main cause of a delayed
plasma response. This conclusion is incompatible with current
theory that only 5-methyltetrahydrofolic acid enters the hepa-
tic portal vein after oral ingestion of physiological doses of
any folate form. Mathematical modelling of stable-isotope-
labelled plasma 5-methyltetrahydrofolic acid response was
used to estimate the ‘apparent absorption’ of single oral phys-
iological doses of [13C6]folic acid, (6S)-[
13C6]5-formyltetrahy-
drofolic acid and [15N1–7]intrinsically-labelled spinach folates
in fasting human adults55. The ‘apparent absorption’ of
reduced folates was significantly higher than for the ‘refer-
ence’ dose of folic acid; generating ‘relative absorptions’ sig-
nificantly in excess of 100% for both 5-formyltetrahydrofolic
acid (158%) and spinach-folate (183%). This was unex-
pected, and biologically impossible, since the ‘true absorption’
of physiological doses of [14C]folic acid in human subjects has
been reported to approximate 90% or more22,23. It was con-
cluded, contrary to current theory, that a significant fraction
of absorbed [13C6]folic acid may be entering the hepatic
portal vein unchanged in contrast to Condition-2, to be more
effectively removed by the liver than reduced 5-methyltetra-
hydrofolic acid, prior to subsequent biotransformation and
(limited) enterohepatic recirculation.
Implications for the use of folic acid as a ‘reference folate’
The essential absence of a plasma 5-methyltetrahydrofolic
acid response in human blood sampled directly from the hepa-
tic portal vein following a dose of folic acid31,32, the extre-
mely low dihydrofolate reductase activity that now seems
peculiar to man60,62,63, the recent implications derived from
mathematically-modelled ‘apparent absorption’ of isotopi-
cally-labelled folates55, and the observation of unmetabolised
folic acid in plasma of fasted American females64 are key
observations. Collectively, they arguably justify the prop-
osition that, unlike the rat (the chief historical experimental
animal model), absorbed physiological doses of folic acid
are essentially transferred to the hepatic portal of man in an
unmetabolised state to be subsequently removed and metab-
olised by the liver. The main implication of this is that the cur-
rently accepted case for folic acid being a suitable ‘reference
folate’ for studies of the ‘relative absorption’ of reduced
folates in man, particularly in short-term experimental proto-
cols, is invalid.
If subsequent experimentation, using sensitive liquid chro-
matography–tandem MS techniques67,68, confirms that phys-
iological doses of stable-isotope-labelled folic acid mainly
enter the hepatic portal vein of man in an unmetabolised
state, then folic acid should be avoided as the ‘reference’
folate in ‘short-term’ studies of the absorption of reduced
folates. We suggest that it could be replaced by (6S)-5-methyl-
tetrahydrofolic acid (the natural folate form found in circulat-
ing blood plasma). Furthermore, it is questionable whether
folic acid should be used as the ‘reference’ folate in longer-
term dietary intervention studies where surrogate biological
markers of nutritional status or metabolic wellbeing are used
as arguments to the relative absorption of folate from basal
diets supplemented with natural ‘high-folate’ foods versus
those supplemented with an equal amount of folic acid (sup-
plied in either supplemental form or as folic acid-fortified
foods). This is because changes in surrogate markers may be
influenced by differential tissue distribution of supplemented
naturally-occurring reduced folates and folic acid between
the liver and other body tissues. This may explain the recent
observation that erythrocyte folate concentrations increase
more after supplementation with (6S)-5-methyltetrahydrofolic
acid than with folic acid69.
Implications for the use of folic acid as a fortificant or
supplement
If the initial primary site of folic acid metabolism in human
subjects is actually the liver then, because of liver’s apparent
poor dihydrofolate reductase activity, it would seem entirely
logical to hypothesise that regular daily intake of physiologi-
cal doses of folic acid may eventually result in its chronic
appearance in plasma of the systemic circulatory blood
system. This may even happen at quite modest physiological
doses since poor liver dihydrofolate reductase activity could
give rise to eventual saturation of the liver folate-monogluta-
mate pool with regular intake of doses well below that of the
acute threshold dose (260–280mg; 589–634 nmol) that has
been noted to result in its subsequent appearance in
plasma17. Such an hypothesis could go a long way to explain-
ing observations of the systemic appearance of unmetabolised
folic acid observed in both fasting and non-fasting American
subjects exposed to what is debatably quite a modest policy
of mandatory folic acid fortification64,70.
Though there have been a variety of concerns expressed
regarding the potential negatives of mandatory fortification
policies, some of these may arguably result from the general-
ity of an inappropriate exposure to high concentrations of
folate per se, rather than specifically to folic acid (pteroylmo-
noglutamic acid); the current exclusive fortificant folate form.
The following discussions are solely restricted to potential
concerns in human subjects for which there is either metabolic
or direct observational arguments that derive uniquely from a
systemic exposure to unmetabolised folic acid.
Potential masking of the anaemia of B12 deficiency
Effects on cognitive function. Concern that the US policy of
mandatory fortification may to a significant degree may
‘mask’ the anaemia of vitamin B12 deficiency, primarily in
the elderly population, appears to have been unwarranted as
there is no evidence of an increase in the proportion of sub-
jects with low vitamin B12 concentration but without anae-
mia71. Whether fortification at 280mg/100 g flour (double
that of the US), as proposed for the UK, would have an
impact is unknown. A review on folic acid and cognition in
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older persons, which recognised that there may be positive
benefits derived from folic acid fortification, concluded that
the potential harm is the greater concern72.
A high intake of folate (mainly as a result of the intake of
folic acid) has been associated with accelerated cognitive
decline in older persons, with the hypothesis that this may
be related to low vitamin B12 status
73. In contrast, results
from the Folic Acid and Carotid Intima-media Thickness
(FACIT) Trial on B12 replete adults aged 50–70 years
suggested that folic acid supplementation may improve
domains of cognitive function that tend to decline with
age74. A contemporary paper75, examining American seniors
exposed to mandatory folic acid fortification, confirmed that
when vitamin B12 status is normal, high serum folate is associ-
ated with protection against cognitive impairment. However,
in seniors with low vitamin B12 status it also confirmed the
hypothesis that high serum folate is associated with cognitive
impairment; with the suggestion that this effect may be due to
unmetabolised folic acid in the circulation. Thus folic acid
supplementation/fortification may be a ‘double-edged sword’
capable of exhibiting polar ‘Jekyll and Hyde’ characteristics,
depending on vitamin B12 status. An accompanying editorial
succinctly listed some of the challenging research questions
that may need to be addressed if this dichotomous interaction
between folic acid and B12 is confirmed
76.
Effect on cancer. Arguably, it is important here to dis-
tinguish between the relationship between (naturally-occur-
ring) folate and cancer and the potential effects of
appreciable concentrations of systemically-circulating unmeta-
bolised folic acid and cancer. Low folate status may be a risk
factor for cancer, possibly through uracil induced genomic
instability11 and/or altered methylation of DNA12, and
having an adequate folate status (achievable through sufficient
intake of folate, including folic acid) may thus be beneficial.
As compared to the activity in fresh human cells ex vivo, simi-
lar cells cultured in vitro with folic acid as the source of folate
can have their DHFR activity increased 100-fold or more59. If
an up-regulation of DHFR activity can be also induced in vivo
this may be accompanied by increased thymidylate synthase
activity since the transcription of both these genes is co-regu-
lated by the same E2F-1 transcription factor77,78. Mathematical
modelling indicates that this would increase pyrimidine pro-
duction (the rate-limiting step for DNA synthesis) without sig-
nificantly affecting the rest of folate metabolism79. It could
thus be hypothesised that, in contrast to an increased exposure
to the naturally circulating folate (6S)-5-methyltetrahydrofolic
acid, exposure to unmetabolised folic acid may increase cells’
capacity for division, thus predisposing to an ‘accelerating’
effect which may be detrimental in the context of cancer. Of
course if, with prolonged exposure to folic acid, DHFR is indu-
cible in small intestinemucosa and liver then it could potentially
somewhat mitigate systemic exposure to unmetabolised folic
acid. However, direct evidence of the appearance of folic acid
in serum of both fasting 64 and non-fasting70 American adults
many years after the 1998 introduction of mandatory folic acid
fortification indicates that any such alleviation must be of lim-
ited consequence.
Recent research findings, in human subjects, suggest that folic
acid supplements may increase the risk of multiple colorectal
adenomas (Asprin–Folate Polyp Prevention Trial)80 and that
plasma folate concentrations are associated with colorectal
cancer in a U-shaped manner such that high, as well as low,
folate concentrations may increase colorectal cancer risk81.
Additionally, a recent paper, reporting on a prospective study
of US subjects, suggests that a high intake of folate ‘generally
attributable to supplemental folic acid’ may increase the inci-
dence of breast cancer in postmenopausal women82.
In respect of hyperplasia, supplementation with folic acid at
only 1mg/d adversely increases the risk and rate of in-stent
restenosis in men, and the need for target-vessel revascularisa-
tion83. For the vast majority of patients undergoing coronary
intervention, stenting (as opposed to balloon angioplasty) was
reported as the current method of choice; for which prolifer-
ation of smooth-muscle cells is one of the most important
mechanisms leading to restenosis. It was concluded that pre-
viously reported positive effects of folic acid on coronary rest-
enosis appeared to be predominantly in patients who were
treated with balloon angioplasty alone, where thrombus for-
mation within the intimal cracks and vascular remodelling are
of predominant importance to the process of restenosis; these
changes being potentially more susceptible to the folate-
induced effects of homocysteine lowering.
Effect on anti-folate chemotherapy. A further area of con-
cern is the potential for negative effects on chemotherapy
using the anti-folate drug, methotrexate. Its mode of action
is to limit folate availability to cells by reducing (by substrate
competition) the activity of dihydrofolate reductase, an
enzyme whose gene could also conceivably be up-regulated
through exposure to high concentrations of folic acid. Post-
hoc analysis from two randomised, controlled studies has indi-
cated that folic acid reduces the degree of improvement of
methotrexate-treated rheumatoid arthritis patients84. Addition-
ally, a recent study in a US population has indicated that high
serum folate levels above about 50 nmol/litre (approximately
22 ng/ml), a similar concentration above which unmetabolised
folic acid makes up about 15% of total folate70, significantly
increases the failure of ectopic pregnancy treatment with
single-dose methotrexate85.
Effect on multiple births. We accept the conclusions of Li
et al., that previous claims, from European studies, that folic
acid supplementation may increase the risk of multiple births
may have been affected by the use of ovarian stimulation86.
However, more and more individuals (currently about 14% in
Europe) seek medical advice for infertility, of which about
half undergo in vitro fertilisation. It has recently been reported
that high folate status (attributable to folic acid supplementation)
increases the likelihood of multiple births after in vitro fertilisa-
tion, with its associated increased risks of maternal and infant
mortality and morbidity, at a rate similar to that seen in the
USA after mandatory folic acid fortification87.
Effect on immune function. New research has indicated
that the concentration of unmetabolised folic acid (but not
the concentration of natural circulating folate, (6S)-5-methyl-
tetrahydrofolic acid) correlates to a reduction in the cytotox-
icity of natural killer cells.64. Since experimental and
clinical evidence supports a role of natural killer cells in
tumour cell destruction88, and that they may be considered a
first line of host defence against carcinogenesis, it was
hypothesised that this would suggest another way in which
excess folic acid (but not circulating high concentrations of
‘natural’ 5-methyltetrahydrofolic acid) might promote existing
premalignant and malignant lesions.
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Conclusions
Our recent results from stable-isotope-folate absorption
studies and a re-appraisal of historical literature, strongly
suggests that the initial site of folic acid biotransformation
in human subjects is the liver, and not the mucosal absorptive
cells of the upper small intestine. Such a conclusion invali-
dates the historical use of folic acid as a ‘reference dose’ in
studies of the ‘relative absorption’ of reduced folates in
man. It can be concluded that previous attempts to gauge
the absorption of synthetically-produced ‘nature-identical’
(6S)-5-methyltetrahydrofolic acid (the natural circulating
folate form, which arguably should be the form generally
used as the ‘reference folate’ in most future acute and long-
term folate-absorption studies), by expressing the plasma
response ‘relative’ to that from an equal dose of folic acid,
are untenable. This is not only because unlabelled folate test
doses have been used, but because even the use of labelled
folates and mathematical modelling cannot overcome the
inherent flaw of using folic acid as the ‘reference’ folate, as
we currently argue in this paper. It is suggested that the absol-
ute absorption of oral physiological doses of (6S)-5-methylte-
trahydrofolic acid in human subjects can only be estimated
using 14C-label protocols and accelerator MS, as it has for
folic acid23.
Additionally, since human subjects uniquely amongst mam-
mals and birds have a reduced dihydrofolate reductase activity
(and a poor ability to reduce folic acid), it is hypothesised that
even a modest regular daily intake of physiological doses of
folic acid could eventually saturate the preliminary liver
folate-monoglutamate pool. This would result in the sub-
sequent chronic appearance of unmetabolised folic acid in
the systemic circulatory blood system which arguably, accord-
ing to circumstance, increasingly looks as though it can induce
polar ‘Jekyll and Hyde’ health effects. Before mandatory folic
acid fortification is introduced to the UK, it is suggested that a
thorough appraisal of all potential concerns that derive
uniquely from the systemic circulation of unmetabolised
folic acid should be addressed methodically to ascertain a
true picture of risk/benefit of fortification.
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Sodium and Bone Health: Impact of Moderately High and Low Salt
Intakes on Calcium Metabolism in Postmenopausal Women
Birgit Teucher,1,2 Jack R Dainty,2 Caroline A Spinks,2 Gosia Majsak-Newman,  David J Berry,2 Jurian A Hoogewerff,2,3
Robert J Foxall,4 Jette Jakobsen,4 Kevin D Cashman,5 Albert Flynn,5 and Susan J Fairweather-Tait2,3
ABSTRACT: High salt intake is a well-recognized risk factor for osteoporosis because it induces calciuria, but
the effects of salt on calcium metabolism and the potential impact on bone health in postmenopausal women
have not been fully characterized. This study investigated adaptive mechanisms in response to changes in salt
and calcium intake in postmenopausal women. Eleven women completed a randomized cross-over trial
consisting of four successive 5-wk periods of controlled dietary intervention, each separated by a minimum
4-wk washout. Moderately low and high calcium (518 versus 1284 mg) and salt (3.9 versus 11.2 g) diets,
reflecting lower and upper intakes in postmenopausal women consuming a Western-style diet, were provided.
Stable isotope labeling techniques were used to measure calcium absorption and excretion, compartmental
modeling was undertaken to estimate bone calcium balance, and biomarkers of bone formation and resorption
were measured in blood and urine. Moderately high salt intake (11.2 g/d) elicited a significant increase in
urinary calcium excretion (p 0.0008) and significantly affected bone calcium balance with the high calcium
diet (p 0.024). Efficiency of calcium absorption was higher after a period of moderately low calcium intake
(p < 0.05) but was unaffected by salt intake. Salt was responsible for a significant change in bone calcium
balance, from positive to negative, when consumed as part of a high calcium diet, but with a low calcium
intake, the bone calcium balance was negative on both high and low salt diets.
J Bone Miner Res 2008;23:1477–1485. Published online on April 14, 2008; doi: 10.1359/JBMR.080408
Key words: salt, calcium absorption, calcium metabolism, bone biomarkers, postmenopausal women
INTRODUCTION
DIETS HIGH IN sodium alter calcium metabolism by in-creasing urinary calcium excretion (calciuria), and a
high salt intake is therefore assumed to be a risk factor for
osteoporosis. However, the evidence is mainly based on
acute salt-loading studies, which have little relevance to
long-term diets, and the results of bone turnover studies are
inconsistent.(1) There is therefore a need to clarify the ef-
fects of salt and calcium on calcium metabolism at dietary
levels that are commonly consumed. The published litera-
ture on sodium and calcium metabolism indicates that the
average loss of calcium is 1 mmol Ca (40 mg) per 100 mmol
(2290 mg) of sodium, and without any adaptive compensa-
tory mechanisms, a daily loss of 40 mg calcium would de-
plete 10% of the skeleton within a decade.(2) Interindivid-
ual variation in sodium-induced calciuria in cross-sectional
and some salt-loading studies are explained by differences
in intake of other dietary factors known to affect urinary
calcium excretion, such as protein(3) and potassium.(4,5)
Differences in sodium-induced calciuria in short-term con-
trolled dietary interventions (7–14 days) suggest that geno-
type-related salt-sensitivity may also play a role.(6)
To maintain homeostasis, urinary calcium losses may be
compensated for by an increase in the efficiency of calcium
absorption and/or an increase in the rate of bone resorp-
tion. The conclusion from a 2-yr longitudinal study in post-
menopausal women was that high sodium intakes were as-
sociated with increased bone loss at hip but not spine(7) and
from the regression analysis, it was estimated that reducing
the daily urinary sodium excretion from 3450 (8.8 g salt) to
1725 mg (4.4 g salt) would have an effect on BMD equiva-
lent to an increase in daily calcium intake of 891 mg, indi-
cating a potentially powerful effect of sodium on bone loss
at the hip. However, the overall evidence from cross-
sectional and prospective studies on salt reduction and
BMD is inconsistent, and there seems to be no published
data on the relationship between sodium intake and frac-
ture risk.(1) With regard to calcium balance, it has not yet
been conclusively showed that upregulation of calcium ab-
sorption compensates (partially or fully) for sodium-
induced calciuria. The null hypothesis for our study was
that the level of dietary intake (moderately high or low) of
sodium or calcium would not affect the efficiency of calcium
absorption or bone calcium metabolism. State-of-the-art
stable isotope labeling techniques were used to determine
calcium absorption and excretion in a controlled cross-over
metabolic study in postmenopausal women.The authors state that they have no conflicts of interest.
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MATERIALS AND METHODS
Subjects
Sixteen female subjects, at least 5 yr postmenopausal and
<75 yr of age, were recruited. Study exclusion criteria in-
cluded current use of hormone replacement therapy (HRT)
or <2 yr since the use of HRT, osteoporosis or other diag-
nosed bone disease, rheumatoid arthritis, osteoarthritis,
chronic illness, renal, gastrointestinal or hormonal disor-
ders, hypertension, regular use of diuretics or antacids,
smoking, and unwillingness to stop taking vitamin/mineral
supplements for the study duration. Blood pressure was
measured at the prestudy stage to ensure subjects were not
hypertensive. Following British Heart Foundation recom-
mendations, systolic blood pressure of 140 mm Hg and di-
astolic blood pressure of 90 mm Hg were the thresholds
above which subjects were excluded. Eleven of the volun-
teers completed all four dietary interventions.
Ethical considerations
Ethical approval for the study was obtained from the
Norwich Research Ethics Committee. Each participant
gave written informed consent.
Study design
The study was a randomized, repeat cross-over trial of
the effect of moderately high or low salt intake (11.2 g salt
[4.4 g/d sodium] and 3.9 g salt [1.6 g/d sodium], respectively)
on calcium and bone metabolism in postmenopausal
women, consuming either a moderately high or low or high
calcium diet (1284 and 518 mg/d, respectively); there were
four successive 40-d dietary intervention periods, each
separated by a minimum 4-wk washout period when sub-
jects consumed their habitual diet. An identical basal diet
low in calcium and sodium was consumed during all four
interventions, to which appropriate amounts of calcium (as
calcium carbonate supplements) and sodium (in prepre-
pared meals and as supplements) were added to increase
the intake. The four diets were −Ca−Na (low calcium, low
sodium), +Ca−Na (high calcium, low sodium), −Ca+Na
(low calcium, high sodium), and +Ca+Na (high calcium,
high sodium).
A dual-tracer stable isotope technique (oral 42Ca and IV
43Ca) was used to measure calcium absorption after 30 days
on each of the four dietary interventions. Kinetic measure-
ments were made to undertake compartmental modeling to
estimate bone resorption and balance. On the morning of
day 30, after an overnight fast of at least 10 h, subjects
attended the Human Nutrition Unit (HNU) and were given
a standard breakfast (containing 183 mg calcium) of toast,
butter, jam, and 100 ml of semiskimmed milk, extrinsically
labeled with 20 mg 42Ca (as CaCl2). The glass was rinsed
several times with deionized water, and the washings were
consumed to make sure the full dose of oral isotope was
ingested. Approximately 30 min later a solution of 43Ca (4.5
mg 43Ca as CaCl2) was infused over 20 min through a can-
nula inserted into the antecubital vein of the other arm.
During this period, volunteers were only allowed to con-
sume deionized water (MilliQ; Millipore, Watford, Herts,
UK). After removal of the cannula, volunteers were given
a standard light meal, and further 10-ml fasting blood
samples were collected on days 31, 34, and 38, and a final
blood sample (40 ml) was collected on day 40. Calcium
absorption was measured from isotope ratios in fasting se-
rum samples obtained on days 31, 34, 38, and 40. Subjects
collected 24-h urine samples on 2 consecutive days before
each intervention, on day 16 (midintervention) and days
30–40 after the isotope administration. Urine samples be-
fore each intervention were analyzed for calcium, sodium,
phosphorus, and potassium. Urines collected on days 16
and 30–40 were analyzed for calcium and sodium and those
collected on days 39 and 40 were analyzed for potassium
and phosphorus. Individual fecal samples were collected
into autoclavable bags from day 30 through to day 40 and
analyzed for total calcium and isotopic enrichment.
Venous blood on days 1 and 40 was analyzed for markers
of bone formation (bone alkaline phosphatase [B-ALP]
and osteocalcin [OC]) and calciotropic hormones {PTH,
1,25-dihydroxyvitamin D [1,25(OH)2D], and 25-
hydroxyvitamin D [25(OH)D]}. Volunteers collected 24-h
urine samples in preweighed acid-washed 2.5-liter bottles 2
days before each intervention and during the 10 days after
isotope administration. Aliquots of the urine collected be-
fore each intervention and during the last 2 days of inter-
vention were pooled and analyzed for markers of bone re-
sorption (N-terminal telopeptide [NTX], pyridinoline [Pyr],
deoxypyridinoline [Dpyr]) and sodium, calcium, potassium,
and phosphorus.
Blood pressure was determined on three different occa-
sions before acceptance onto the study and monitored on a
weekly basis during each of the four dietary interventions.
All measurements were carried out by trained investigators
using a fully automated blood pressure monitor (Omron
711; Omron Matsusaka).
Experimental diets
The diet was comprised of a 7-day rotating menu, calcu-
lated to be low in sodium (1.5 g/d) and calcium (500 mg/d).
Volunteers selected 7 menus from a total of 12 available
menus. All meals (breakfast, lunch, dinner, and snacks)
during each intervention period were prepared in the Hu-
man Nutrition Unit (HNU) and delivered to subjects’
homes three times a week. A low calcium intake was
achieved by preparing all bakery products with white flour
without the UK legislative addition of calcium, and the milk
intake was restricted to 90 g/d. To make the diets palatable
and hence ensure compliance up to eight portions of fruits
and vegetables were provided each day. A low calcium wa-
ter supply was obtained by providing volunteers with a wa-
ter filter, a supply of replacement filter cartridges and a
kettle. During the high sodium intervention, additional so-
dium (0.7 g/d) was provided from high salt bread. Salt was
also added to some of the cooked meals during batch cook-
ing for the high salt diet. A total of 13 batches of the menu
selections on offer were prepared. Of these, four were ana-
lyzed by AAS to confirm the sodium and calcium content of
the low and high salt diets. The intake of other nutrients
was calculated with “Diet Cruncher” (Way Down South
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Software, Dunedin, New Zealand) using the McCance and
Widdowson’s food composition tables.(8) No additional
food was allowed and subjects completed a food intake
diary each day to monitor dietary and fluid intake.
Supplements
Calcium (125 mg calcium as CaCO3) and sodium supple-
ments (333 mg sodium as NaCl) were provided by Penn
Pharmaceutical Services (Tredegar, Gwent, UK). Vitamin
D supplements (10 g cholecalciferol) were provided by
Solgar Vitamins UK (Newcastle, Staffordshire, UK). For
the high calcium and/or sodium diets, subjects were re-
quested to take two calcium and/or sodium capsules with
each main meal (i.e., three times a day, providing a total of
750 mg calcium/d or 2.0 g sodium/d from supplements) for
the full 40-day intervention period. Vitamin D supplements
were taken once every day, at breakfast, starting 4 wk be-
fore each intervention period and supplementation was
continued until the end of each 40-day intervention period.
A daily guide for supplement intake was included in the
food intake diary and compliance was monitored by written
self-reported intake.
Preparation of isotope labels
The 43Ca tracer for intravenous infusion (52.1% enrich-
ment) was prepared by the Ipswich Hospital Pharmacy
(Ipswich, UK) as follows: an accurately weighed amount of
43Ca-enriched CaCO3 was dissolved in concentrated HCl
(molar ratio of 3:1), the solution adjusted to pH 6, and
made up to volume with sterile water to give a final con-
centration of 0.75 mg/ml. Individual subsamples of the so-
lution were transferred to glass ampoules, sealed, and heat
sterilized, and the sterility of the solution was verified. For
oral administration, 42Ca-enriched CaCO3 (90.8% enrich-
ment) was converted to CaCl2 by adding 6 M HCl in a 2:1
molar ratio. The pH was similar to that of milk (pH 6.7).
For each subject, an aliquot of the extrinsic label containing
20 mg CaCO3 was added to 200 g semiskimmed milk and
allowed to equilibrate overnight at 4°C.
Dietary analysis
All meals and snacks that formed part of the 7-day ro-
tating menu cycle were homogenized (Ultra-Turrax T-50
homogenizer; IKA) and freeze-dried. Aliquots were ashed
in a muffle furnace for 48 h at 450°C (Vulcan, 3–550; NEY
Dental International, Bloomfield, CT, USA), dissolved in 5
ml of a 5% HCl solution, and analyzed for calcium by
atomic absorption spectroscopy (AAS; model 3300; Perkin-
Elmer, Norwalk, CT, USA) after further dilution with 0.1%
lanthanum chloride. For the determination of sodium by
atomic emission spectroscopy (AES; model 3300; Perkin-
Elmer) further dilutions were carried out using 18- water.
All samples were analyzed in duplicate, and a certified typi-
cal diet reference material (Typical Diet 1548a; NIST, Gai-
thersburg, MD, USA) was analyzed with each batch of
samples.
Urine analysis
On receipt, all urines were weighed, mixed, and aliquots
stored. Sodium and potassium were measured by AES and
AAS, after appropriate dilution, respectively (model 3300;
Perkin-Elmer). All samples were analyzed in duplicate to-
gether with certified urine controls with each batch (Lypho-
chek, Quantitative Urine Control; Bio-Rad). Calcium iso-
topes and total calcium were measured by ICP-MS
(IsoProbe; GV Instruments, Manchester UK) using the iso-
tope dilution technique (48Ca spike), UV digestion (Model
707; Metrohm), and oxalate precipitation. Phosphorus was
measured using the ABX Diagnostics Phosphorous Kit
(Shefford, Bedfordshire, UK) on a COBAS MIRA auto-
mated analyzer. All samples were analyzed in triplicate, and
ABX Diagnostics Human Control N was run for quality
control purposes. The intra-assay variation was 3.7%. In-
terassay variation was avoided by analyzing all samples
from each individual in the same run.
Fecal analysis
Individual fecal samples collected for 10 days after dosing
were weighed, autoclaved, freeze-dried, thoroughly homog-
enized, and ashed in a muffle furnace. When more than one
fecal sample was collected on the same day, the individual’s
collection was pooled for that day and processed as de-
scribed above. Again the samples were spiked with Ca-48
isotope solution, but this time were digested with 0.1 M
HNO3 at 80°C. After centrifugation of the digest, the su-
pernatant was subjected to the oxalate precipitation
method as used for urine and serum samples.
Biochemical markers of bone metabolism
Urinary Pyr and Dpyr were measured in triplicate using
a three-step procedure. Urine was first hydrolyzed with an
equal volume of 12 M HCl at 110°C for 18 h, and the
cross-links were extracted by CF1 cellulose chromatogra-
phy with the use of an internal standard (acetylated pyridi-
noline; MetraBiosystems, Wheatley, Oxon, UK) and mea-
sured using a reverse-phase HPLC method with fluorescent
detection.(9) The acetylated pyridinoline was used in accor-
dance with the method described by Calabresi et al.(10) and
Robins et al.(11) The cross-links content of urine was quan-
tified by external standardization using a commercially
available pyridinoline/deoxypyridinoline HPLC calibrator
(MetraBiosystems). The intra-assay CVs for Pyr and Dpyr,
measured as the variation between 10 chromatograms ob-
tained between column regenerations,(9) were 6% and 7%,
respectively. Interassay variation was avoided by analyzing
all samples from each individual in the same run.
Urinary NTX was measured in urine samples by an
ELISA (Osteomark; Ostex International). The intra-assay
CV was 1.6%. Interassay variation was avoided by analyz-
ing all samples from each individual in the same run.
Blood analysis
Total calcium and calcium stable isotopes were quanti-
fied in serum. After an overnight fast, blood was collected
into sterile trace element free tubes (Vacutainer; Becton
Dickinson, Rutherford, NJ, USA) and allowed to clot for a
minimum of 30 min. The serum was removed after centrifu-
gation at 1500g for 10 min and stored at −18°C before
analysis. After UV digestion (Model 707; Metrohm) and
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oxalate precipitation, calcium isotopes were determined by
inductively coupled plasma mass spectrometry (ICP-MS;
IsoProbe, GV Instruments, Manchester, UK).(12) Total cal-
cium was determined by isotope dilution.
PTH was measured in plasma from blood collected in
EDTA tubes, the plasma having been removed after
centrifugation and stored at −18°C. Intact PTH was mea-
sured using a chemiluminescent immunometric assay
(IMMULITE; Diagnostic Products, Los Angeles, CA,
USA). Quality control was monitored through participation
in an External Quality Assessment Scheme (DEQAS).
1,25(OH)2D and 25(OH)D was measured in serum.
25(OH)D was identified and quantified using HPLC
equipped with a PDA-detector, and a radioimmunoassay
(65100E; DiaSorin, Stillwater, MN, USA) was used for the
quantification of 1,25(OH)2D as described elsewhere.
(13)
The accuracy of the analysis was monitored by participation
in the Vitamin D External Quality Assessment Scheme
(DEQAS, Charing Cross Hospital, London, UK).
Serum OC and B-ALP were measured by an ELISA
(BRI-Diagnostics, Dublin, Ireland and MetraBiosystems,
respectively). The intra-assay CVs were 11% and 4.5%,
respectively. All samples from each individual were ana-
lyzed in the same run.
Kinetic modeling
A compartmental model, developed in SAAMII (SAAM
Institute, Seattle, WA, USA), was used to fit the experi-
mental data and estimate parameters of interest (Fig. 1),
similar to that published by Neer et al.(14) and Wastney et
al.(15) but containing just a single soft tissue/bone compart-
ment. The main calcium fluxes were from bone (V0−), to
bone (V0+), to urine (Vu), to feces (Vf), and calcium ab-
sorption from the diet (Va). Several of these fluxes were
used to estimate bone calcium balance, Vbal  Va – Vu –
Vf. The process of bone absorption of calcium is repre-
sented by the calcium flux (V0+). Because this occurs during
the experimental period, it is directly measurable, but this is
not the case with bone calcium resorption (V0−). Any stable
isotope label that is taken up into the bone will not be
reused during the measurement period, and therefore, V0−
is estimated by “difference” because V0−  V0+ − Va +
Vu + Vf.
Statistical analysis
Statistical analyses were performed using the R data
analysis software.(16) Linear models (ANOVA) and paired
t-tests were used to determine effects of the different diets
on a range of physiological responses. Because the four
intervention diets were characterized by combinations of
“low” and “high” dietary intake of sodium and calcium, the
input variables to the linear models were two-level factors
describing sodium and calcium intake and the interaction of
these factors. Where appropriate, these factors had a third
level, corresponding to the baseline intakes. Volunteer
identification was included as a factor variable in all models
so that each volunteer could act as her own control. The
appropriateness of all final models was checked for outliers
(including leverage and influence) and normal errors.
Where necessary, outliers were excluded and/or data trans-
formations performed, and the models were refitted. Sta-
tistical analysis of the effect of diet on bone biomarkers at
the end of each intervention was performed on the calcu-
lated percent change from baseline. At no point was it nec-
essary to use nonparametric models. Tukey’s honest signif-
icant differences were calculated to determine the
differences in the levels of sodium or calcium in the linear
models. All results were considered significant if p < 0.05.
The kinetic data from the low and high calcium dietary
intervention periods was separated and analyzed indepen-
dently. Within these two treatments, the effect of low versus
high salt intake was assessed by paired t-tests. All results
were considered significant if p < 0.05.
For some of the outcome measures, baseline values were
obtained before each of the four diets. The assumption that
all the baseline values were identically distributed could be
tested in these cases. Where this assumption was not met,
the data were tested to see whether the sequence of the
diets was significant. The possibility that sequence of diet
may affect outcome was also investigated for calcitropic
hormones and bone biomarkers.
RESULTS
Characteristics of the subjects
The mean age was 64 yr (range, 59–73 yr), and the mean
body mass index (BMI) was 24.7 kg/m2 (range, 20.9–32.1
kg/m2). According to the WHO definition, 4 of the 11 vol-
unteers were overweight (BMI > 25 kg/m2). Menopause
was defined as at least 12 mo since the last menstrual cycle.
All participating women reported to be at least 5 yr post-
menopausal. The average systolic and diastolic blood pres-
sure for all four intervention periods was 115 and 72 mm
Hg, respectively (data not shown). There was no significant
difference in blood pressure when consuming the high and
low salt diets.
FIG. 1. Compartmental model for calcium metabolism. Circles
represent compartments; arrows represent movement of calcium
in and out of compartments. Vi is the rate of calcium intake, Va is
the rate of calcium absorbed from the diet, Vu is the rate of
urinary calcium excretion, Vf is the rate of endogenous calcium
loss in feces, VF is the rate of dietary calcium loss in feces, V0+ is
the rate of calcium deposited in the bone, and V0− is the rate of
calcium resorbed from bone.
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Intervention diet
The calculated mean energy intake was 1979 kcal, and
the percentage of food energy from fat, carbohydrates, and
protein was 34%, 54%, and 15%, respectively. The diet met
the UK recommended nutrient intake (RNI)(17) for all vi-
tamins except retinol (intake 384 g/d; RNI 600 g/d)
and vitamin D (intake  2.1 g/d; RNI for women <60 yr
 0 g/d and >60 yr 10 g/d); the mean intake of these
two nutrients was also less than the RNI in women 50–64 yr
of age in the latest National Diet and Nutrition Survey in
Great Britain (retinol  449 g/d and vitamin D  3.5
g/d).(18) The mean analyzed calcium content of the 12
menus devised for the low calcium diet was 518 ± 49 (SD)
mg and for the moderately high calcium diet the intake was
increased to 1284 mg/d by the addition of calcium supple-
ments. The mean sodium content of the menus offered for
the low and high salt diets was 1557 ± 237 and 4422 ± 253
mg sodium, respectively. The low salt diets provided a
mean of 3.9 g salt (1.6 g sodium) and the high salt diets a
mean of 11.2 g salt (4.422 g sodium) per day. The high salt
interventions required the ingestion of additional salt in six
capsules per day, each capsule containing 342.3 mg sodium,
and several subjects complained of nausea and vomiting
during the first 2 days of the high salt intervention. In re-
sponse, advice was given on methods of supplement inges-
tion that would avoid any adverse reactions (e.g., mixing of
the salt supplement into the food and dissolving the cap-
sules in hot drinks before consumption). Once adopted,
these guidelines prevented further episodes of nausea, and
none of the subjects withdrew from the study because of
persisting intolerance to the salt supplements. Following
Good Clinical Practice (GCP) guidelines, all adverse events
were reported to the local Ethics Committee.
Calcitropic hormones
Because this cross-over trial spanned a minimum of 36
wk, vitamin D supplementation of the subjects was essential
to avoid any effect of seasonal variation that might have
masked changes in intraindividual absorption efficiency.
The mean serum 25(OH)D3 concentration was 69.6 ± 11.5
nM (range, 47.8–92.5 nM; data not shown). There were no
significant differences in 25(OH)D3 levels at the start and
end of each intervention and no differences in 1,25(OH)2D3
at the end of each intervention period. Differences in these
parameters were also nonsignificant when analyzed accord-
ing to sequence of diet consumed. Although subjects re-
ceived identical vitamin D supplements, the 25(OH)D3
concentration ranged from 48–93 nM, which suggests that
interindividual differences in absorption may have been af-
fected by differences in vitamin D status; however, because
each subject acted as her own control, this would have had
no bearing on the overall findings from the study.
The overall mean serum PTH concentration was 3.5 ± 1.4
pM, which compared well with that reported by others for
this age group.(19,20) In response to sodium, average PTH
levels (3.9 pM) in subjects consuming the high sodium diets
were statistically significantly different (p 0.007; data not
shown).
Urinary sodium, calcium, potassium, and
phosphorus excretion
Results for all four controlled dietary interventions and
for the habitual diet are summarized in Table 1. Urinary
sodium excretion was significantly higher on the high so-
dium diets compared with the low sodium diets (p < 0.0001)
and the habitual diet (p < 0.0001). The difference in sodium
excretion between the low and high salt diet was key to the
success of the study and reflects compliance. There was no
significant difference in sodium excretion between the two
low sodium diets (p > 0.05) and the two high sodium diets
(p > 0.05). The average sodium excretion from the low
(−Ca−Na and +Ca−Na combined) and high (−Ca+Na and
+Ca+Na combined) sodium diets was 1402 ± 161 (equiva-
lent to 3.6 g salt) and 3778 ± 460 mg/d (equivalent to 9.6 g
salt), respectively, which represents a 2.7-fold difference
between the low and high salt diets.
The mean calcium urinary excretion in subjects consum-
ing their habitual diet was 164 ± 91 mg/d (Table 1). Two of
11 subjects excreted calcium in excess of 250 mg/d (>4 mg/
kg/d; data not shown). The average calcium excretion for
diets −Ca−Na, +Ca−Na, −Ca+Na, and +Ca+Na was 123,
159, 141, and 192 mg/d, respectively (Table 1). Both high
sodium and high calcium intake independently provoked a
significant increase in urinary calcium excretion (p <
TABLE 1. MEAN (±SD) URINARY EXCRETION OF SODIUM, CALCIUM, PHOSPHORUS, AND POTASSIUM ACCORDING TO
DIETARY INTERVENTION
Sodium (mg/d) Calcium (mg/d) Phosphorus (mg/d) Potassium (mg/d)
Habitual diet 2686 (818)* 164 (91)* 721 (171)* 2830 (889)*
−Ca−Na diet 1388 (205)a 123 (80)† 678 (100)‡ 2898 (551)
+Ca−Na diet 1415 (109)a 159 (87) 585 (131) 2944 (537)
−Ca+Na diet 3728 (618)b 141 (79)†§ 698 (116)‡ 2969 (618)
+Ca+Na diet 3828 (241)b 192 (102)§ 607 (124) 2982 (430)
* These values are descriptive only and were not included in the statistical analysis; habitual diet was not controlled and can therefore not be compared
with the controlled intervention diet.
† Calcium is the model variable responsible for the significantly different calcium excretion on low compared with high calcium diets (p < 0.0001).
‡ Calcium is the model variable responsible for the significantly higher phosphorus excretion during low compared with high calcium diets (p < 0.001).
§ Sodium is the model variable responsible for the significantly different calcium excretion on high sodium diets compared with low calcium diets (p <
0.0001).
a,b Sodium is the model variable responsible for differences in sodium excretion; values with different superscripts are significantly different from each
other; in all cases (p < 0.0001).
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0.0001). The mean increase in urinary calcium excretion of
36 mg/d on the two low salt diets (low versus high calcium)
and 51 mg/d on high salt diets (low versus high calcium)
presumably reflects an increase in the quantity of calcium
absorbed. The mean increase in urinary calcium excretion
in response to a high salt intake was 18 and 33 mg/d in
subjects consuming the low (−Ca−Na versus −Ca+Na) and
high calcium diets (+Ca−Na versus +Ca+Na), respectively.
A quarter of the volunteers did not respond to the sodium
challenge by increasing their urinary calcium output.
There was no significant difference in potassium excre-
tion between the four dietary treatments, but there was a
significant effect of calcium on phosphorus excretion (Table
1). Both low calcium diets were associated with a signifi-
cantly higher phosphorus excretion; the mean difference
between low and high calcium diets was 92 mg.
True calcium absorption and kinetics
Mean calcium absorption after 30 days adaptation to the
−Ca−Na, +Ca−Na, −Ca+Na, and +Ca+Na diets was 26 ±
6%, 22 ± 3%, 24 ± 5%, and 23 ± 6%, respectively. The
efficiency of absorption from the standard test meal con-
taining 183 mg calcium was higher after a period of adap-
tation to the moderately low calcium diet (low Ca: 25 ± 5%,
high Ca: 23 ± 5%; p < 0.05), but the level of salt in the diet
had no effect on calcium absorption (low Na: 23 ± 5%, high
Na: 24 ± 5%; p  not significant).
When the data generated from the two low calcium in-
terventions were compared, there was no significant differ-
ence between the low and high salt diets for any of the
kinetic parameters (Table 2), but there were some apparent
trends. Urinary calcium excretion (Vu) was slightly higher
as a result of the high salt diet (low Na: 102 ± 71 mg/d; high
Na: 123 ± 81 mg/d), and the resulting bone calcium balance
(Vbal) was more negative (low Na: −71 ± 93 mg/d; high Na:
−115 ± 70 mg/d), but these differences were not statistically
significant. There was no effect on bone calcium uptake,
V0+ (low Na: 455 ± 129 mg/d; high Na: 469 ± 155 mg/d),
bone calcium resorption, V0− (low Na: 565 ± 156 mg/d; high
Na: 585 ± 185 mg/d), and endogenous calcium loss in feces,
Vf (low Na: 112 ± 133 mg/d; high Na: 115 ± 57 mg/d).
In comparison, the data from the two high calcium inter-
ventions showed significant differences in some of the ki-
netic parameters in response to changes in dietary salt in-
take (Table 2). Urinary calcium excretion was significantly
higher (p < 0.001) as a result of the change from a low salt
(Vu 112 ± 143 mg/d) to a high salt diet (Vu 153 ± 149
mg/d). The bone calcium balance was significantly impaired
(p < 0.05), going from a positive balance on the low salt diet
(Vbal 90 ± 46 mg/d) to a negative balance on the high salt
diet (Vbal  −12 ± 46 mg/d). There were nonsignificant
changes in V0+ (low Na: 437 ± 139 mg/d; high Na: 361 ± 144
mg/d), V0− (low Na: 346 ± 88 mg/d; high Na: 372 ± 121
mg/d), and Vf (low Na: 82 ± 168 mg/d; high Na: 146 ± 111
mg/d).
Biochemical markers of bone turnover
The average level of biochemical markers of bone re-
sorption measured in 48-h urine pools at the end of each
dietary intervention is given in Table 3. Statistical analysis
TABLE 3. BIOCHEMICAL MARKERS OF BONE RESORPTION (NTX, DPYR, PYR) AND BONE FORMATION (OC, B-ALP) AFTER EACH
DIETARY INTERVENTION [MEAN (±SD)]
NTX (nM BCE/d) Dpyr (nmol/d) Pyr (nmol/d) OC (ng/ml) B-ALP (U/liter)
−Ca−Na diet 578 (185)*† 193 (46)§ 350 (115)†† 32.8 (12.5) 28.3 (8.9)
+Ca−Na diet 378 (152)† 144 (46)¶ 295 (103)‡‡ 30.8 (11.5) 25.5 (7.5)
−Ca+Na diet 550 (260)‡ 199 (51)** 358 (138)§§ 31.1 (14.7) 27.6 (10.4)
+Ca+Na diet 445 (234) 171 (35) 341 (102)¶¶ 30.7 (15.7) 28.8 (12.6)
*† p  0.0017; †‡p  0.0077; all others NS.
§¶ p  0.0009; ¶**p  0.002; all others NS.
††‡‡ p  0.0001; ‡‡§§p  0.0039; §§¶¶p  0.001; all others NS.
NTX, urinary type 1 collagen cross-linked-N-telopeptides (marker of bone resorption); Dpyr, urinary deoxypyridinoline (marker of bone resorption);
Pyr, urinary pyridinoline (marker of bone resorption); OC, serum osteocalcin (marker or bone formation); B-ALP, bone alkaline phosphatase (marker of
bone formation).
TABLE 2. SUMMARY OF CALCIUM KINETIC DATA FOR THE LOW AND HIGH CA DIETS
Diet Va Vu Vf VF VO+ VO- Vbal
Low Ca diet
Low salt 140 (31) 102 (71) 112 (133) 542 (125) 455 (129) 565 (156) −71 (93)
High salt 122 (24) 123 (81) 115 (57) 501 (38) 469 (155) 585 (185) −115 (70)
High Ca diet
Low salt 284 (41) 112 (143)* 82 (168) 1078 (83) 437 (139) 346 (88) 90 (46)†
High salt 287 (78) 153 (139)* 146 (111) 1110 (72) 361 (144) 372 (121) −12 (84)†
All data are mean (SD) in units of milligrams calcium per day. Va is the rate of calcium absorbed from the diet, Vu is the rate of urinary calcium excretion,
Vf is the rate of endogenous calcium loss in feces, VF is the rate of dietary calcium loss in feces, VO+ is the rate of calcium deposited in the bone, and VO−
is the rate of calcium resorbed from bone.
* Significant difference (p  0.0008) in urinary Ca excretion.
† Significant difference (p  0.0240) in Ca bone balance.
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of percentage change from baseline of Pyr and Dpyr mea-
sured at the end of each dietary intervention showed a
significant increase after the low calcium interventions (Fig.
2). There was a (nonsignificant) decrease in NTX with the
high calcium diet, whereas Pyr and Dpyr excretion in-
creased with the low calcium diets. The resorption markers
differed in their sensitivity to the changes in sodium intake.
There was a significant change in levels of NTX in response
to the high compared with the low sodium diets (p 
0.031), but this was not observed for Dpy or Pyr.
Although there was no effect of diet on the bone forma-
tion marker OC, there was a significant increase in percent
change from baseline for B-ALP on the −Ca+Na diet (+14
± 12%, p  0.011), suggesting an increase in bone forma-
tion activity and overall bone turnover after the increase in
salt and decrease in calcium intake.
DISCUSSION
A marginally negative bone balance is observed in post-
menopausal women because of the dominance of bone re-
sorption over bone formation, but large interindividual dif-
ferences have been reported in women adapted to low and
high calcium intakes.(21) The particular strength of the data
presented here is the randomized cross-over study design
that used four very-well-controlled diets that provided dif-
ferent intakes of calcium and sodium within the range that
is commonly observed in Western-style diets. This study
investigated the effect of sodium on calcium excretion at
two levels of calcium intake in the same individuals using a
cross-over design, thereby eliminating the confounding ef-
fect of genotype. The calcium and salt levels reflect those
consumed by a significant proportion of the UK postmeno-
pausal population. This is an important feature of the study
design because many others have used higher salt loads that
were likely to elicit a response that would only be seen at
the extremes of intake.
The responses to sodium-induced calciuria are similar to
those reported by others and summarized by Cohen and
Roe,(22) but we observed a significantly more pronounced
calciuria on the moderately high (an increase of 33 mg/d)
compared with the moderately low calcium diet (an in-
crease of 18 mg/d; p < 0.001), which shows greater conser-
vation on the lower calcium diet. One previously published
study based on a parallel group design also reported a trend
toward higher calcium excretion on a high calcium diet, but
it was not statistically significant.(23)
A significantly positive association between urinary cal-
cium and sodium at baseline (habitual diet) was observed
(p < 0.05), which supports observations from cross-sectional
and cohort studies.(24–26) However, one quarter of the vol-
unteers did not respond to the sodium challenge by increas-
ing their urinary calcium output. Shortt et al.(27) reported
that some individuals do not respond to a sodium challenge
by increasing urinary calcium excretion and suggested that
interindividual differences may be related to salt sensitivity.
Furthermore, it is well documented that the magnitude of
the estimated increase in calcium excretion per 100-mmol
rise in urinary sodium can vary considerably; 2-fold differ-
ences in sodium-induced calciuria at low(24,28) and high cal-
cium intakes(29) are common.
The low calcium diets also induced a significantly higher
excretion of phosphorus (mean difference, 92 mg; p <
0.001), which is indicative of increased bone turnover be-
cause bone resorption is associated with a loss of both cal-
cium and phosphorus in the urine. Potassium can modify
the renal handling of calcium and sodium, and therefore it
is an important covariate in metabolic studies on calcium.
The average potassium excretion in this study was similar to
that obtained by the Dietary Approaches to Stop Hyper-
tension (DASH) trial(30) (i.e., ∼3000 mg/d). The DASH
trial observed no effect on sodium-induced calciuria (∼8 g
salt/d) between diets low in potassium (1700 mg/d) and
calcium (450 mg/d) compared with diets high in potassium
(4700 mg/d) and calcium (1250 mg/d). This contradicts re-
sults obtained by Sellmeyer et al.,(5) who found that a dou-
bling of potassium excretion from 2720 to 5500 mg/d was
effective in reducing the sodium-induced calciuria in post-
menopausal women consuming a rather high mean intake
of 12 g salt/d. The basal diet in our study contained up to
eight portions of fruits and vegetables (range: 6.9–9.1),
which are a good dietary source of potassium, but the lim-
ited intake of dairy products (another good source of po-
tassium) during the intervention meant that the total po-
tassium excretion (2957 mg/d) was only on average 100 mg
higher than that estimated for the habitual diet (2860 mg/d).
This explains why potassium can be excluded as a modula-
tor of calciuria in this study.
In this study, we chose to administer the same calcium
test dose after each of the 4-wk adaptation periods to avoid
the well-documented dose–response effects that could
mask any response to the dietary intervention. However, it
could be argued that the calcium test loads should have
represented the calcium content of the intervention diets.
FIG. 2. Mean percent change in bone resorption markers after 4
wk of diets low (−Ca) or high (+Ca) in calcium and low (−Na) or
high (+Na) in sodium. *Pyr and Dpyr were significantly increased
on low calcium diets (p < 0.05). All other changes were not sig-
nificant.
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This would mean that our test dose of 183 mg was appro-
priate for the low calcium diet but that 450 mg calcium
should have been given as the test dose for the high calcium
diet. According to work by Heaney et al.,(31) calcium ab-
sorption from a diet containing 1250 mg/d of calcium (our
high calcium intervention diet) should be ∼20%, rather than
the 23% that we observed with our test dose of 183 mg.
Taking the 20% absorption figure obtained from the work
of Heaney et al. and applying it to our model would, the-
oretically, cause minor reductions in the calcium fluxes
shown in Table 2 (high calcium diet). Given this possibly
lower absorption on the high calcium diet and the subse-
quent effect on the calcium fluxes, it would be inappropri-
ate to examine the changes in the kinetic parameters that
may be caused by calcium intake between the low and high
calcium diets. Therefore, resulting kinetic data were sepa-
rated into the two dietary calcium groups (Table 2) and
analyzed separately to determine the effect of the salt in-
tervention. This is a valid comparison because the differ-
ence in salt intake did not significantly alter calcium absorp-
tion (low Na: 23 ± 5%, high Na: 24 ± 5%; p  not
significant), and therefore the only variable that changes
within either the low or high calcium intervention groups is
salt intake, which must be responsible for any changes in
the kinetic parameters.
Our kinetic data suggest that salt has a significant effect
on calcium urinary excretion (p < 0.001) and bone calcium
balance (p < 0.05) only on the high calcium diets. More
calcium is excreted in the urine as a result of the increased
salt intake, and bone calcium balance changes from being
positive on the low salt diet to negative on the high salt diet.
There was a trend for more endogenous calcium to be ex-
creted into the feces, but this was not significant (p 
0.082). The low calcium diets show similar trends, but they
are not significant; more calcium is excreted in the urine as
a result of the increased salt intake (p  0.057), and bone
calcium balance becomes more negative when moving from
a low to high salt diet (p 0.196). Extended periods of low
calcium intake, as used in this study, have been shown to
maximize mechanisms to conserve calcium, which may ex-
plain why the salt challenge on the low calcium diet seems
to be less pronounced and did not reach significance in
terms of calcium kinetics.
An earlier study in postmenopausal women consuming a
moderate intake of calcium (816 mg/d) showed no detect-
able effect of high or low salt diets on the rate of bone
resorption, but this is not surprising given the fact that the
study was only an 8-day duration.(29) Longer-term studies
are needed to evaluate effects on bone turnover in response
to diet(30) as well as drug therapy(32) when assessed by bone
biomarkers. Notwithstanding this requirement, the bone
calcium balance predicted by our kinetic model is sup-
ported by the findings of reduced levels of markers of bone
resorption in response to the high calcium diets. For each of
the three markers of bone resorption, the observed signif-
icant changes from baseline in response to calcium were
associated with a power of >90%. If we assume a minimum
10% difference from baseline in response to sodium to be
significant, the power of identifying such a difference in our
sample was 20% for NTX, 80% for Pyr, and 57% for Dpyr.
The observed percent change for NTX in response to so-
dium was actually 19%, with an associated power of 57%.
In a longer-term study (6 mo) of postmenopausal black
women, a low sodium diet (2 g/d) reduced bone turnover, as
indicated by lower serum concentrations of aminoterminal
propeptide of type 1 collagen.(33) This was accompanied by
a lower urinary excretion of both sodium and calcium, but
there were no changes in calcitropic hormones. Conversely,
in younger men and women (21–39 yr of age) given a low
salt diet for 7 wk, there were no detectable changes in
markers of bone metabolism.(34) However, this was a par-
allel design study, which is not as robust as the cross-over
design used in this study.
In conclusion, it seems that both dietary calcium and so-
dium play a major role in the maintenance of bone health in
postmenopausal women. Low calcium intake (518 mg/d)
was associated with negative bone calcium balance with
both high and low salt diets, but with a moderately high
calcium intake (1284 mg/d), the bone balance was positive
when the salt intake was low (3.9 g/d) but not when it was
moderately high (11.2 g/d).
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